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Abstract 
Background. Stage B Heart Failure (SBHF) is an early stage with no symptoms but 
evidence of cardiac impairment. It is difficult to diagnose and manage without 
echocardiography (Echo, ultrasound of the heart), and the availability of this test in 
primary care and in rural areas is very limited. To date, there is no effective screening 
strategy for the identification of non-ischemic SBHF. There is also no evidence 
available on the efficacy of treatment of this condition to reduce outcome events.  
Aims. This research aimed to study the following: 1) how to assess heart failure (HF) 
risks clinically (before echocardiogram); 2) what screening tools to use; 3) how to 
develop a community screening program combining cardio-protective therapy in at-
risk elderly individuals; 4) to define the best strategies in community screening, 
including the role of electrocardiogram (ECG) versus Echo; 5) to identify the best echo 
predictors (advanced versus conventional echo markers) for outcome at 1 year follow 
up; 6) to investigate the benefits of an intervention response based on imaging guided 
care versus usual care - randomized controlled trial; 7) to investigate the benefit of 
community screening in a young population and association with childhood adiposity. 
Methods. A systematic review and meta-analysis was performed to identify possible 
clinical markers to be used to select subjects at high risk of HF for echo in the 
community. A method validation study was performed on comparing strain 
measurement variabilities between and among vendors as well as software versions. 
Data from CDAH3 pilot trial (Childhood Determinants of Adult Health) was used to 
assess the association of childhood adiposity and evidence of SBHF in a young 
population. An important study platform for this research was the Tasmanian Study of 
Echocardiographic Detection of Left Ventricular Dysfunction (TasELF). Between 
9/2013 and 11/2015, a total of 1026 community individuals responded to our study 
advertisement. Of these, 618 stage A HF individuals met inclusion criteria and were 
eligible (mostly hypertension, diabetes and obesity). At baseline, participants 
underwent standard clinical evaluation, anthropometry, blood pressure, functional 
capacity using 6-minute walk test, 12-lead ECG and comprehensive echo assessment. 
Four ECG markers were assessed including Cornell Product (Cornell-P), P wave 
terminal force in lead V1 (PTFV1), ST depression in lead V5 V6 (minSTmV5V6) and 
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increased heart rate. Four echo markers were used to define the presence of SBHF, 
including left ventricular hypertrophy (LVH), left atrial enlargement (LAE), impaired 
E/e’ or impaired global longitudinal strain (GLS). Participants were then randomized 
into two arms: imaging guided care using advanced echocardiography (AE arm, 
including myocardial deformation and detailed diastolic function examination) or 
usual care (UC arm). The presence of abnormal findings was used to justify subsequent 
cardio-protective treatment. A process evaluation was conducted at 3 months, and 
adherence to therapy was assessed. Patients were followed for 1 year for outcome. The 
primary composite end point was new HF and death from cardiovascular causes. 
Results. First, prediction of incident HF can be calculated from 7 common clinical 
variables (age, gender, BMI, smoking, hypertension, diabetes and coronary artery 
disease). Second, the strain measurement variability has improved after the joint 
standardization task force, is analogous to that of ejection fraction and can be used 
widely. Third, cardiac impairment was present in otherwise healthy but overweight 
and obese young adults. Cardiac impairment was associated with adult body adiposity 
but not with childhood adiposity. Fourth, comparing with patients with hypertension, 
patients with diabetes had more impaired global longitudinal strain (GLS) and reduced 
6-minute walk test distance. Hypertensive patients had more impaired diastolic
function. Fifth, abnormal ECG markers showed low sensitivity for SBHF but were 
associated with poor outcome in those with early cardiac impairment. Sixth, the 
overall annualized incident rate for new HF was 10% in these elderly individuals at 
risk of HF. The initial clinical risk assessment combing functional assessment 
facilitated effective HF screening by identifying the high and intermediate risk groups 
for echocardiographic screening. Seventh, the prevalence of SBHF was 62% defined 
by the presence of ≥ 1 of the four echo markers (LVH, LAE, impaired GLS and 
abnormal E/e’). These markers were associated with outcome. The presence of ≥ 1 of 
any of four SBHF markers was associated with more than 3-fold higher risk. Impaired 
GLS was a more sensitive marker and provided incremental value over clinical 
information for prediction. Eighth, imaging guided cardio-protective therapy was 
ineffective with only 43% having treatment up-titration and 9% reaching target dose. 
At 1 year follow-up, the incidence of HF was no different between two arms. Among 
subjects needing therapy on the basis of imaging and adherence to therapy, imaging 
guided care showed a 77% lower hazard for outcome. Participant non-adherence to 
treatment was a potential obstacle in HF prevention in patients with SBHF. Attitude to 
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additional therapy seemed the main barrier to success of cardio-protection of SBHF. 
At 1 year follow-up, the trial was stopped for futility.  
Conclusions:  
Screening for SBHF in the community using echocardiography was feasible. Given 
the high annualized incident rate of new HF and the recognized adverse outcome of 
SBHF, the identification of those at higher risk was important. However, the adherence 
to preventive therapy was low. In order to reduce the burden of heart failure, effort 
needs to be made not only to identify but also to initiate effective preventive treatment.  
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List of abbreviations 
2D:  two-dimensional 
6MW:  Six-minute walk test 
A: peak trans-mitral A velocity, reflects the pressure gradient during atrial 
contraction 
ACEi:  Angiotensin-Converting Enzyme 
AF:  atrial fibrillation 
AIC:  Akaike’s Information Criterion 
ANP:  atrial natriuretic peptide 
BB:  beta-blocker 
BMI:  body mass index 
BNP:  brain natriuretic peptide 
CAD:  coronary artery disease 
CV:  cardio-vascular walk 
CART: classification and regression tree 
Cornell-P: Cornell Product 
CRP:  C reactive protein 
DecT:  deceleration time 
DD:  diastolic dysfunction 
E:  peak trans-mitral E velocity, correlates with early rapid filling gradient 
e’:  peak early mitral annular tissue Doppler velocity 
ECG:  electrocardiogram 
Echo:  echocardiogram 
E/e’ mitral inflow peak early diastolic velocity/tissue Doppler early diastolic 
velocity 
EF:  ejection fraction 
ESC:  European Society of cardiology 
GLS:  global longitudinal strain 
GCS:  global circumferential strain 
HF:  heart failure 
HFpEF: heart failure with preserved ejection fraction 
HFrEF: heart failure with reduced ejection fraction 
HHE:  hand held echocardiography 
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Chapter 1. Introduction 
1.1 The Magnitude of Heart Failure 
1.1.1 Worldwide  
The incidence and prevalence of heart failure are growing and assuming epidemic 
proportions, affecting an estimated 23 million people worldwide20 21 and 5.7 million 
new cases each year20. In the United States, 5 million people suffer from heart failure, 
with a rate of 550,000 new cases diagnosed each year22. Heart failure is predominantly 
a problem of old age; 80% of patients with incident heart failure are older than 65 years 
and 50% are older than 80 years23.  
Heart failure is major burden to the health care system and to the community due to 
the cost of care and poor quality of life. The total direct and indirect cost of heart failure 
in US exceeds $30 billion 24, where it accounts for 12-15 million office visits and 6.5 
million hospital days each year 25. In the United States, approximately $2.9 billion 
annually is spent on drugs for the treatment of heart failure25. 
1.1.2 Australia 
In Australia, the overall prevalence of heart failure is estimated to be 2-3%. The 
prevalence is 23% in those aged over 65 years; 570,000 people are living with heart 
failure and 30,000 Australians receive a new diagnosis of heart failure each year26. 
More than 45,000 Australians were hospitalized due to heart failure in 2009-2010, 
equating to over 360,000 bed days.  
The cost of chronic heart failure in Australia has been estimated at over $ 1 billion per 
year27. 
1.1.3 Challenges 
With the magnitude of the disease, the question is whether the burden of clinical heart 
failure can be prevented or delayed at an early stage. If yes, how can we identify patient 
who need to be targeted for heart failure prevention and what are the effective tools 
for early detection? Besides treating and controlling heart failure risk factors, what is 
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the current evidence on pharmacological treatment of cardiac dysfunction to improve 
outcome? This chapter will mainly summarize the current evidence and evidence gaps 
to address these challenges. 
1.2 Heart Failure Definition Diagnosis and Classification 
1.2.1 Definition 
Heart failure is a complex clinical syndrome that is frequently, but not exclusively, 
characterised by an underlying structural abnormality or cardiac dysfunction that 
impairs the ability of the left ventricle (LV) to pump or to fill blood, particularly during 
physical activity. Symptoms of heart failure (e.g. dyspnoea and fatigue) can occur at 
rest but are more common during physical activity28.  
1.2.2 Diagnosis  
Heart failure is a clinical diagnosis. In hospital setting, this involves an initial 
evaluation including a history and physical examination, chest radiography, 
electrocardiography, and laboratory assessment to identify causes or precipitating 
factors. No single item on clinical history, sign, or symptom has been proven or can 
be used to diagnose heart failure.  
The recognition of heart failure in a primary care level can be more difficult. Because 
of comorbidity and atypical clinical manifestations, the diagnosis is particularly 
challenging in older persons. There are several diagnostic instruments including 
Framingham29, Boston30, Gothenburg criteria 31and the European Society of 
Cardiology (ESC) principles32. Among these, the Framingham criteria are widely 
accepted33. It included the components of the initial evaluation mentioned above. The 
Framingham heart failure diagnostic criteria are displayed in Table 1.1. 
 
 
Chapter 1 Introduction  35 
 
Table 1.1 Framingham clinical diagnostic congestive heart failure 
Major criteria:  
 Paroxysmal nocturnal dyspnoea or orthopnoea 
 Neck vein distension 
 Rales 
 Cardiomegaly 
 Acute pulmonary oedema 
 S3 gallop 
 Hepatojugular reflex 
Minor criteria: 
 Ankle oedema 
 Nocturnal cough 
 Dyspnoea on exertion 
 Hepatomegaly 
 Pleural effusion 
 Tachycardia (>120 beat per minute) 
 
1.2.3 Classification  
The diagnosis of overt heart failure (HF) requires clinical symptoms. With the hope 
that early recognition and treatment may prevent the progression of disease, two early 
asymptomatic stages have been classified in the “Guidelines for the Diagnosis and 
Management of HF in Adults” by the American College of Cardiology (ACC) and the 
American Heart Association (AHA) 25. Stage A heart failure (SAHF) is identified in 
patients who are asymptomatic but with HF risk factors including hypertension, 
atherosclerotic disease, diabetes mellitus, obesity, metabolic syndrome (MS), previous 
exposure to cardiotoxins or with a family history of cardiomyopathy. Stage B heart 
failure (SBHF) is identified in patients who have evidence of structural heart disease, 
but remain asymptomatic. This includes patients with previous myocardial infarction, 
left ventricular remodelling including hypertrophy and reduced ejection fraction and 
valvular diseases. Stages C and D include patients in clinically overt heart failure with 
marked symptoms and require medical intervention and/or with frequent hospital 
admission and readmissions25. 
Once the diagnosis is established, HF can be subdivided according to the type of left 
ventricular dysfunction. Echocardiography is the most useful test for this purpose. 
Systolic heart failure refers to a weakened ability of the heart to contract. Diastolic 
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heart failure refers to impaired filling of the LV in response to a volume load, despite 
normal ventricular contraction and is classified as “diastolic heart failure”. Systolic 
and diastolic heart failure can occur together but the distinction between them is 
relevant to the therapeutic approach.  
1.2.4 Preclinical heart failure 
Stage A and stage B are precursor stages of clinical heart failure. The distinction of 
stages A and B is important as their treatment strategy and therapeutic implications are 
different. The therapeutic strategy of stage A HF (SAHF) is mainly the control of 
underlying risk factors, i.e. hypertension and diabetes and metabolic syndrome, 
although specific therapy using ACEi or ARB is only indicated in those patients on 
the basis of T2DM or vascular disease.  
 
Figure 1.1 Treatment efficacy of stage B heart failure (SOLVD) 
Adopted from SOLVD investigators N England Journal of Medicine, 1991; 325(5) 
 
The main recommendation for treating SBHF is the use of angiotensin converting 
enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB) and beta-blockers25. 
These agents have been proven to be beneficial in clinical randomized contrail trials 
(RCT) and widely accepted for outcome benefit in general 34. In the trials of Study of 
Left Ventricular Dysfunction (SOLVD)35,36 and Survival and Ventricular Enlargement 
(SAVE)37,38 of patients with asymptomatic LV dysfunction, ACEi or ARB and beta 
blockers were beneficial in all stage B patients, with mortality and morbidity decreased 
by 20-30%37-42 (Figure 1.1).  
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1.2.5 Evidence gaps (the non-ischaemic population) 
Ischaemic SBHF refers to patients with previous coronary artery disease or the 
presence of echocardiographic evidence of scar or regional wall motion abnormalities. 
Clinically, ischaemic SBHF may progress to heart failure with reduced ejection 
fraction (HFrEF).  
Non-ischaemic SBHF may occur in patients with hypertension, diabetes, obesity, 
metabolic syndrome and previous exposure to cardio-toxic agents and patients with 
familial history of cardiomyopathy, without a known history of coronary artery 
disease. They often have normal left ventricular systolic contraction and progress to 
clinical heart failure with preserved ejection fraction (HFpEF). Thus, while, SBHF is 
readily defined in patient after myocardial infarction with reduced left ventricular 
ejection fraction, its recognition in non-ischaemic disease is more challenging. 
Previous efforts in screening and management of early HF have been largely devoted 
to patients with coronary artery disease. However, the epidemiology of heart failure is 
changing, with increasing numbers of patients with normal left ventricular ejection 
fraction.  
In the community, non-ischaemic SBHF is highly prevalent in the elderly and largely 
undetected. It needs to be noted that these individuals with cardiac dysfunction in the 
community would not have been eligible for the clinical trials like SOLVD and SAVE, 
in which middle-aged subjects with coronary artery disease and moderate to severely 
reduced LV ejection fraction (LVEF<40%) dominated. There are currently few 
clinical data focusing on benefit of early recognition and intervention in non-ischaemic 
population with relatively preserved LV ejection fraction34. 
Thus, there are evidence gaps in the early recognition and intervention of non-
ischaemic SBHF in the population. The implications of treating these common forms 
of SBHF (identified by abnormal geometry or diastolic dysfunction25 but not by 
standard criteria by ejection fraction) for the entire health care system are have not 
been defined. 
The approach to community screening and early intervention of non-ischaemic SBHF 
is the focus of this thesis.  
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1.3 Stage B heart failure 
1.3.1 Prevalence and natural history  
SBHF is a preclinical stage. Patients may be detected coincidently, when they present 
with other problems, or screening in the community. This is the target population that 
will potentially be benefit from early intervention. Although highly prevalent, the 
prevalence in the community is dependent on how closely we look –i.e. the imaging 
modality or imaging markers. The conventional markers of SBHF are impaired left 
ventricular ejection fraction (LVEF), left ventricular hypertrophy (LVH) and diastolic 
dysfunction. Community studies using echocardiographic assessment have provided 
the prevalence and natural history of SBHF2,43-50. The prevalence of asymptomatic left 
ventricular systolic dysfunction by ejection fraction (LVEF≤50%) was 3-7% and 
higher in the elderly (>65 years) 43,49. The incident rate of new heart failure in these 
patients was reported to be 5.7-5.8 per 100 person-years as compared with 2.4 per 100 
person-year years in those with normal LVEF51,52.  
The prevalence of LVH was reported to be 16-30%53,54. Patients in the highest left 
ventricular mass quintile showed a relative risk of 2.8 for incident heart failure over 
5.5 years follow up54. The regression of LVH was reported to be associated with 
reduced events54 independent of ischaemic process55 and independent of the initial 
measurement of left ventricular mass 50.  
Patients with diastolic dysfunction (DD) are a complex group. The prevalence of DD 
varies with DD grade and among patients with different risk groups. In elderly (>65 
years) with a diagnosis of hypertension or coronary disease, mild diastolic dysfunction 
was reported 36% and more severe forms of DD in 16%56. This prevalence was 
reported to be 20-30% in patients with obesity and diabetes 57-59. The nature history of 
DD depends on disease stage. From et al. reported that five year incident heart failure 
was 36.9% in moderate DD (using mitral E/e’>13) compared with those normal 
diastolic function57 Figure 1.2. The overall mortality of stages of diastolic dysfunction 
is reported by Redfield 43from the Framingham cohort and displayed in Figure 1.3.  
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Figure 1.2 Kaplan-Meier analysis of diastolic dysfunction  
Diastolic dysfunction and subsequent heart failure in diabetic patients 
Adopted from From et al. JACC 2010; Jan 26; 55(4): 300-5                                              
             
 
 
Figure 1.3 Natural history of diastolic dysfunction 
Kaplan-Meier mortality curves for participants with normal diastolic function versus mild,  
moderate and severe diastolic dysfunction. 
Adopted from Redfield et al. JAMA 2003; 289 (194-202) 
 
The overall prevalence of heart failure stages in the community was studied and 
reported by Ammar (Figure 1.4)44. The corresponding outcome and survival status 
relating to each stage is also shown in Figure 1.4.  
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Figure 1.4 Prevalence of heart failure stages 
Prevalence of heart failure stages and related outcome in the community 
Tables and figures adopted from Ammar et al. Circulation; (115):1563-70, 2007. 
 
1.3.2 Identification of Stage B heart failure  
Identification and diagnosis of SBHF requires imaging – usually echocardiography. 
SBHF is relatively easy to identify in the ischaemic population as echocardiography is 
clinically indicted in this population. Echocardiographic markers are evidence of 
myocardial scar after infarction or reduced left ventricular ejection fraction or the 
presence of both. The identification and diagnosis of non-ischaemic SBHF patients 
can be difficult. Left ventricular ejection fraction is often preserved and is unsuitable 
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for this population. Approximately half of heart failure patients have preserved LVEF 
(HFpEF) 60. Diastolic dysfunction is an early marker of myocardial relaxation and 
filling status, especially in the non-ischaemic population due to the high prevalence of 
hypertension and diabetes. However, conventional assessment of diastolic dysfunction 
needs assessment of several parameters including colour Doppler, pulsed Doppler of 
mitral inflow, pulmonary and myocardial tissue velocity and the size of left atrium. 
Cardiac rhythm and loading issues are other factors complicating the grading. 
Therefore, the integrated diastolic functional grading can be indeterminate as these 
assessments are often discordant61. 
Speckle tracking echocardiography (STE) for the measurement of myocardial 
deformation and strain is a relatively advanced imaging modality. It is a semi-
automated and quantitative technique for the measurement of left ventricular long-
axis, circumferential and radial function62,63. The details of STE technology will be 
discussed in Chapter 3 (Methods). 
Among the STE markers, global longitudinal strain (GLS) has been adopted in routine 
clinical practice and is increasingly accepted as a feasible and useful marker. GLS has 
shown to be a sensitive marker over left ventricular ejection fraction for early 
myocardial impairment and a better marker of prognostic value64-67, especially with 
preserved left ventricular ejection fraction and without wall motion abnormalities. 
Furthermore, GLS corresponds to a variety of parameters that reflect the presence of 
fibrosis68,69. These changes are linked to the underlying metabolic disturbances 
associated with stage A heart failure risks68. 
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Figure 1.5 Improved GLS after intervention  
Left ventricular function improve after intervention. 
Figure adopted from Kosmala et al. JACC Cardiovascular imaging 2011; 4 (12):1239-49. 
 
Because of the prognostic value of DD and GLS, there have been proposal to extend 
the definition of SBHF from conventional markers including LVEF and LVH to 
impaired myocardial deformation and (GLS) diastolic dysfunction based on functional 
assessment70. As a potential modifiable marker, GLS has been reported to be 
associated with treatment response in various settings71-73. These studies showed 
evidence that left ventricular myocardial impairment may be reversible at this early 
stage (Figure 1.5). 
Other means of identification of SBHF are non-echocardiographic approaches. The 
concept of non-echocardiographic detection and screening of left ventricular systolic 
dysfunction is largely based on feasibility of the test and cost-effectiveness strategy74. 
This includes a variety of cardio-specific biomarkers, electrocardiography, and hand-
held echocardiography. The implication of non-echocardiographic approaches to 
assessment of SBHF will be discussed in Chapter 2 (Clinical Prediction of Incident 
Heart Failure Risk). 
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1.4 Community Screening for Stage B heart failure 
Community screening for SBHF is based on the belief that early identification and 
early intervention may delay or prevent its progression to overt heart failure. SBHF is 
known to be highly prevalent in the community. Screening in the community seeks to 
detect disorders in seemingly healthy persons. The key research question is “Will 
screening in the seemingly normal individuals do more good than harm?”  
1.4.1 Guidelines to determine community screening effectiveness 
In order to assess the value of community screening programs, seven criteria should 
be satisfied75. Such criteria are informative in the approval of screening programs by 
organizations such as the US Preventative Services Task Force (USPSTF). They 
evaluate and make recommendations regarding screening services in the community76. 
The seven criteria are as following: 
1. Has the effectiveness of the program been demonstrated in a randomized trial? 
(If an effectiveness trial with a positive result has not been carried out, then the 
following are pertinent): 
2. Are efficacious treatments available? 
3. Does the burden of suffering warrant screening? 
4. Is there a good screening test? 
5. Does the program reach those who could benefit from it? 
6. Can the health system cope with the screening program? 
7. Will those who had a positive screening comply with subsequent advice and 
interventions? 
To date, there have been no randomized trials evaluating the impact of a strategy to 
screen and treat for SBHF77. There is also insufficient evidence on: 1) what is a good 
screening test/or screening strategy for detection of non-ischaemic SBHF; 2) whether 
a screening program can reach those individuals at high risk of heart failure and who 
may be benefit from early intervention; 3) most importantly, whether those who had a 
positive screening will comply with subsequent advice on interventions; 4) Lastly, it 
is unknown whether the health system can cope with the screening program of SBHF.  
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This thesis seeks to explore, evaluate and gather evidence to address the criteria 1, 2, 
4, 5 and 7. 
1.4.2 Who to screen 
The recognition of SBHF needs echocardiography. One of the main concerns is the 
cost of the test and its feasibility in the community settings. Rather than screen the 
whole population at large, screening may be most feasible and effective if applied to 
selected individuals of higher risk. “Who to screen” and whether a “screening program 
can effectively reach those who could benefit” are the important first steps.  
Clinical risk factor-based screening would identify people at higher risk. There have 
been a few heart failure risk scores derived from population studies. They are the 
Atherosclerosis Risk in Communities (ARIC) heart failure risk score78; the Health 
ABC heart failure risk score79 and the Framingham heart failure risk scores with and 
without the consideration of biomarkers80,81. However, these scores were developed in 
selected study populations and some require the use of bio-markers, which are 
potential limitations in the community setting. Readily available clinical information 
could be combined into a possible risk algorithm tool to facilitate selection of “who to 
screen” in the community. 
The clinical prediction of incident heart failure risk is summarized in Chapter 2 (the 
following chapter). The feasibility and performance of these risk scores will be further 
explored in Chapter 8 (Screening strategy- role of HF scores ECG and 6MW). 
1.4.3 How to screen 
After selection of the “at risk” individuals, comprehensive echocardiography is 
considered the single most useful diagnostic test in patients with suspected HF. This 
test evaluates and determines whether abnormalities of myocardium, heart valves, or 
pericardium are present and which chambers are involved25. In asymptomatic 
community individuals, unselective screening using echocardiography was not 
justified due to the cost of the test and relative low prevalence of the conditions 47,82. 
In these studies, the main echocardiographic marker for SBHF was reduced LVEF. 
LVEF is not a suitable marker to detect non-ischaemic SBHF, and the prevalence of 
reduced LVEF in the community was low82. Screening of non-ischaemic SBHF 
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requires more sensitive tools and has been facilitated by the use of speckle tracking 
echocardiography (STE) of myocardial deformation (strain) and diastolic functional 
assessment70. The implications of STE and GLS as sensitive markers to identify SBHF 
has been discussed in the previous section.  
In the community setting, measurement of segmental and global longitudinal strain 
(GLS) has been reported in healthy individuals83. Although, the normal ranges for 
global longitudinal strain (GLS) has been defined and widely used 84,85, its value in the 
community in improving outcome is predicated on the ability to combine modified 
therapy and has not been proven.  
Another main concern of using GLS for community screening and subsequent 
intervention is its measurement variability86. The measurement variability between 
vendors and software versions is often cited as a limitation to the clinical application. 
To achieve a consensus on methodology for the quantitative evaluation of cardiac 
mechanics, the European Association of Cardiovascular Imaging and the American 
Society of Echocardiography (ASE) has implemented a standardization initiative to 
improve and reduce inter-vendor variability.  Whether there has been improvement in 
this aspect ensure this new imaging modality robust enough to be used for screening 
will be discussed in Chapter 4 (Use of Strain for Screening – is it Robust Enough?) 
1.4.4 Implication of treatment 
The evidence of pharmacological treatment benefit for asymptomatic left ventricular 
dysfunction has been document in a few important clinical trials. These trial are: the 
Study of Left Ventricular Dysfunction (SOLVD); the Survival And Ventricular 
Enlargement (SAVE) trial; the Carvedilol Post-infarct Survival Control in LV 
Dysfunction (CAPRICORN) trial; the Australia/New Zealand (ANZ) trial; the 
Reversal of Ventricular Remodelling with Toprol-XL (REVERT) trial; the Optimal 
Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan 
(OPTIMAAL); the TRAndolapril Cardiac Evaluation (TRACE) trial; and the 
Valsartan in Acute Myocardial Infarction Trial (VALIANT)37,38,40,87-94.  
Most of these studies used reduced LVEF (<35-40%) as marker of SBHF and the use 
of ACEi or ARB and beta blocker showed outcome benefit40,91. The number needed to 
treat (NTT) ranged from 8-4834. Based on evidences summarized in a systematic 
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review, it was suggested that ACE inhibitors (or ARBs in those with a history of 
intolerance to ACE inhibitors) should be administered to all patients with 
asymptomatic LV dysfunction in the absence of contraindications. Beta blockers 
should also be considered in the vast majority of patients, although evidence to support 
their use is less robust34. 
Given that the benefit of treatment in left ventricular systolic dysfunction has been 
established and accepted in the ischaemic SBHF, there are uncertainties: 1) whether 
those with mild LVSD would benefit similarly from treatment as they would not have 
been eligible for the trials like SOLVD or SAVE; 2) treatment of non-ischaemic forms 
of SBHF (LVH or diastolic dysfunction) is not well defined; 3) How these cardio-
protective therapies should be up-titrated in those who are already on these agents for 
their primary risk factors or combined with other treatments; 4) treatment adherence 
in these asymptomatic populations, whether they will comply with subsequent 
interventions in the case of abnormal screening.  
The intervention response to screening result will be evaluated and discussed in 
Chapter 10 (Therapeutic Guidance from Screening). 
1.4.5 Potential Issues of community screening for stage B heart failure 
Screening in asymptomatic adults causes concerns that “disease labelling” and 
“medicalization”, which may cause psychological distress and anxiety. However, 
these effects may be minimal. The spectre of cardiovascular disease is familiar in these 
individuals with conditions like diabetes, metabolic syndrome and hypertension. Since 
the risk of false positives will lead to over-treatment; while the risk of limited test 
sensitivity may lead to false negative, resulting in delayed treatment. However, we 
lack evidence on whether the detection of SBHF changes management or outcome76.  
To date, screening for heart failure has not been recommended by the US Preventive 
Services Task Force (USPSTF) 76 and few screening tests for cardiovascular disease 
have been endorsed by the USPSTF (http://www.uspreventiveservicestaskforce.org).  
Some of these issues will be discussed in the subsequent chapters. 
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1.5 Aims of this thesis 
The Aims of the thesis are based on the following established facts: 1) Heart failure is 
an increasing health care burden in Australia – being among the most frequent causes 
of hospital admissions95. 2) Elderly subjects with diabetes, hypertension, obesity, past 
cancer therapy or known cardiac disease are at particularly higher risk of developing 
non-ischaemic heart failure25. 3) If identified early, treatment of non-ischaemic SBHF 
is hoped to prevent or delay its progression to overt HF34,37,38. 4) Echocardiography is 
the most important test to identify non-ischaemic SBHF96. Advanced 
echocardiographic imaging modalities are able to identify early myocardial damage 
and show excellent prognostic values73,84,97.  
Therefore, the main aims are to determine the value of echocardiographic screening in 
the community to identify non-ischemic SBHF and to guide subsequent 
cardioprotective therapy. We also sought to understand the benefit of imaging 
surveillance to reduce the progression of cardiac dysfunction to overt heart failure with 
pharmacological treatment. In order to achieve that, the studies presented in this thesis 
aim to address the following. This list is in similar order of thesis chapters and is aimed 
to address the following two main aspects: 1) issues related to screening: who to 
screen, how to screen, what tools to use and what is the best tool; 2) issues related to 
randomized controlled trial: what is the intervention response to screening results. 
 Who to screen – how to assess heart failure risk clinically to select patient for 
echocardiography 
 What screening tools to use – validation of echo strain as a robust marker  
 Community screening in a younger age group – association of childhood 
adiposity and adult subclinical cardiac function (This chapter seeks to assess 
whether childhood adiposity be used as risk factor in community screening) 
 To develop a community screening program combined with cardio-protective 
therapy  
 What is the best screening tool to use – is a combined imaging-marker 
approach (strain and diastolic functional measures) more appropriate? Are 
there any association of HF aetiology with echocardiographic features? 
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 Screening strategy – role of ECG techniques and association with 
echocardiographic markers and outcome 
 Screening strategy – role of risk scores, ECG and baseline function capacity 
to justify a good pre-screening approach before echocardiographic screening  
 Community screening using echocardiography – what are the best echo 
predictors for outcome  
 Community screening and intervention – intervention response to imaging 
guided care (randomized controlled trial) 
 
1.6 Structure of this thesis 
Chapter 1: Introduction – review of current literature on evidence and evidence-
gaps 
Chapter 2: Prediction of incident heart failure – systematic review of clinical 
risks for incident HF and role of biomarkers 
Chapter 3: Methods – TasELF study protocol and echocardiographic outreach 
screening clinics; standard Echo; ECG; questionnaires; 6MW test 
protocols 
Chapter 4: Use of strain for screening – Is it robust enough for screening 
Chapter 5: Community screening in a younger age group – Importance of 
childhood and adult obesity and associated early cardiac impairment 
Chapter 6: Using combination of screening tools – Association of etiology and 
pathophysiology  
Chapter 7: Screening strategy in the community – Role of ECG in initial 
screening, association with echo features of SBHF and outcome  
Chapter 8: Screening strategy in the community – Role of clinical risk scores, 
ECG and functional assessment (6MW) 
Chapter 9: Community screening using echo – Echocardiographic predictors for 
outcome (comparison of echo markers) 
Chapter 10: Randomized controlled trial – Interventional response to screening 
results 
Chapter 11:  Summary and conclusions 
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1.7 Sources of data used in this thesis 
Data used for analyses in most Chapters (except for chapter 4 and chapter 5) were from 
the on-going Tasmania Study of Echocardiographic Detection of Left Ventricular 
Dysfunction (TasELF). The research protocol was approved by the Tasmanian Human 
Research Ethics Committee (HREC: H0013333), and registered with the Australian 
and New Zealand Clinical Trials Registry (http://www.anzctr.org.au/ ; 
ACTRN12614000080628). 
Chapter 4 used 82 patients and healthy adults, data were from the following: 1) 
outpatient from Royal Hobart Hospital echocardiographic laboratory (n=45), Hobart 
Australia. 2) Inpatient and outpatient (n=21) and health volunteers (n=16) from 
Takasaki General Medical Centre, Japan. Data were prospectively collected. Both 
institutional review boards approved the study protocol. 
Chapter 5 used data from the Childhood Determinants of Adult Health (CDAH3) pilot 
trial. The CDAH3 pilot trial is a 29-year follow up of Australian Schools Health and 
Fitness Survey (ASHFS) of 8498 Australian Schoolchildren aged 7-15 years in 1985. 
A sub group of 205 health adults completed a pilot follow trial in 2014. Among these, 
159 individuals with both baseline and follow-up were included for analysis. The State 
Director General of Education approved the ASHFS in 1985 and the Southern 
Tasmania Health and Medical Research Ethics Committee approved CDAH3 follow-
up trial. 
1.8 Concluding remarks 
This chapter provides an overview of burden of heart failure and the recognition of 
preclinical stage of heart failure – SBHF. In summary, the findings suggest the 
following: 1) to reduce the burden of heart failure, a preventive strategy could be 
targeted to the preclinical SBHF; 2) a variety of risk factors are known to be associated 
with heart failure. Knowing the relative magnitude of each risk factor and their 
combined risk can facilitate the identification of highest individuals for further 
echocardiographic screening; 3) active screening in the community with an effective 
screening strategy will improve effectiveness of screening; 4) no evidence is available 
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to define the benefit of pharmacological treatment for patients with non-ischemic 
SBHF. 
This thesis aims to evaluate the benefit of cardiac imaging surveillance in the 
community of non-ischaemic SBHF followed by imaging guided cardio-protective 
treatment. Findings of this research are to fill the current evidence gaps. 
Postscript 
The next chapter aimed to perform a systematic review and meta-analysis to identify 
a series of clinical risk factors and to assess the relative magnitude of common risk 
factors of incident heart failure.  
Other non-imaging tools including biochemical markers, electrocardiogram and hand-
held ultrasound devices potentially suitable for screening are also to be summarized in 
the next chapter. 
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Clinical Prediction of Incident Heart 
Failure Risk 
 
 
The Systematic Review from this chapter  
“Clinical Prediction of Incident Heart Failure Risk: a systematic Review 
and meta-analysis” was published in 
Open Heart 2015;2(1): e000222 
Hong Yang, Kazuaki Negishi, Petr Otahal, Thomas H Marwick 
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Chapter 2. Clinical Prediction of Incident Heart 
Failure Risk 
Introduction 
The prediction of incident heart failure using non-imaging markers includes clinical 
prediction (often risk scores), biochemical markers, electrocardiogram and hand-held 
ultrasound devices. This chapter will summarize and give an overview of evidence in 
the literature on these non-imaging tools. The purpose is to seek an initial screening 
strategy using readily available information to optimize the feasibility and 
effectiveness of a screening program. A systematic review was performed to evaluate 
the clinical prediction of incident heart failure. Other non-imaging markers are also 
summarized in this chapter including biochemical markers, Electrocardiogram and 
Handheld ultrasound devices. 
The available heart failure risk scores were either derived from selected populations 
or contain biomarkers limiting the use in community setting. The following section 
aims to perform a systematic review of the common heart failure risk factors from 
community unselected populational studies. We intended to quantify the relative 
magnitude of these risk factors and their combined effects. This systematic review was 
to prepare and exercise the argument about “who to screen” for a community screening 
and interventional study. 
The following text in this section has been published in Open Heart Open Heart 2015; 
2(1): e000222 
2.1 Clinical Prediction of Incident Heart Failure Risk – A 
systematic review and Meta-analysis 
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Abstract 
Background. Early treatment may alter progression to overt heart failure (HF) in 
asymptomatic individuals with stage B heart failure (SBHF). However, the 
identification of patients with SBHF is difficult. This systematic review sought to 
examine the strength of association of clinical factors with incident HF, with the 
intention of facilitating selection for HF screening.  
Methods. Electronic databases were systematically searched for studies reporting risk 
factors for incident HF. Effect sizes; typically hazard ratios (HR) of each risk variable 
were extracted. Pooled crude and adjusted hazard ratios with 95% confidence intervals 
(CIs) were computed for each risk variable using a random-effects model weighted by 
inverse variance.  
Results. Twenty-seven clinical factors were identified to be associated with risk of 
incident HF in 15 observational studies in unselected community populations which 
followed 456,850 subjects over 4-29 years. The strongest independent associations for 
incident HF were coronary artery disease (CAD; HR=2.94; 95% CI 1.36-6.33), 
diabetes mellitus (DM; HR=2.00; 95% CI 1.68-2.38), age (HR [per 10 years] =1.80; 
95% CI 1.13-2.87) followed by hypertension (HTN; HR=1.61; 95% CI 1.33-1.96), 
smoking (HR=1.60; 95% CI 1.45-1.77), male gender (HR=1.52; 95% CI 1.24-1.87) 
and body mass index (BMI; HR [per 5 kg/m2] =1.15; 95% CI 1.06-1.25). Atrial 
fibrillation (HR=1.88; 95% CI 1.60-2.21), left ventricular hypertrophy (HR=2.46; 95% 
CI 1.71-3.53) and valvular heart disease (HR=1.74; 95% CI 1.07-2.84) were also 
strongly associated with incident heart failure but were not examined in sufficient 
papers to provide pooled hazard estimates.  
Conclusion. Prediction of incident HF can be calculated from 7 common clinical 
variables. The risk associated with these may guide strategies for the identification of 
high-risk people who may benefit from further evaluation and intervention. 
2.1.1 Background 
What is already known about this subject? A variety of risk factors are known to 
be associated with heart failure - ranging from social determinants of health, to lifestyle 
characteristics (smoking, physical inactivity, increased salt intake) and common 
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comorbidities (hypertension, type 2 diabetes mellitus (T2DM), coronary artery disease 
(CAD), obesity and metabolic syndrome (MS) and precursors of myocardial disease 
including a history of chemotherapy or a family history of cardiomyopathy. 
What does this study add? The relative magnitude of these risk factors, and their 
combined effects, are not well known. This systematic review sought to examine the 
strength of association of clinical factors with incident HF, with the intention of 
creating a practical clinical score to facilitate selection for HF screening. The strongest 
associations for incident HF (adjusted HR ≥2) were coronary artery disease (CAD; 
HR=2.94; 95%CI 1.36-6.33) and diabetes mellitus (DM; HR = 2.00; 95%CI 1.68-
2.38). Adjusted HR ≥1 were age (HR [per 10 years] = 1.80; 95%CI 1.13-2.87), 
hypertension (HTN; HR = 1.61; 95%CI 1.33-1.96), smoking (HR = 1.60; 95%CI 1.45-
1.77), male gender (HR = 1.42; 1.27-1.59) and body mass index (BMI; HR [per 5 
kg/m2] = 1.15; 95% CI 1.06-1.25). Thus, incident HF could be predicted from 7 
common clinical variables. 
How might this impact on clinical practice? The early detection of asymptomatic 
patients with LV dysfunction is now possible with a variety of sensitive biochemical 
and imaging techniques, and should lead to the use of cardioprotective strategies to 
prevent progression of disease. The estimation of HF risk is a critical step in 
appropriate selection of patients for imaging. 
The incidence and prevalence of heart failure (HF) are growing and assuming epidemic 
proportions, affecting an estimated 23 million people worldwide 21. In the United 
States, 5 million people suffer from HF with a rate of 550,000 new cases diagnosed 
each year 25. HF is predominantly a problem of old age, the most frequent cause of 
hospitalization in the elderly and a major burden on the community due to the cost of 
care and poor quality of life. The total direct and indirect cost of heart failure in US 
exceeds $30 billion 24, where it accounts for 12-15 million office visits and 6.5 million 
hospital days each year 25.  
The morbidity and cost of late-stage HF may be delayed or even prevented by 
pharmacologic interventions, once evidence of structural heart disease (stage B HF) 
has been defined37-42. Subclinical cardiac impairment is most readily identifiable in 
patients with prior myocardial infarction. Identification of stage B HF in the 
approximately 50% of HF patients who are non-ischaemic might be possible with 
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echocardiographic or biochemical screening 44, but this would be most feasible if there 
was a means of identifying risk on clinical grounds. Various risk factors have been 
associated with HF, ranging from lifestyle characteristics such as smoking, physical 
inactivity, increased salt intake and lower socioeconomic status to common 
comorbidities including hypertension, type 2 diabetes mellitus (T2DM), coronary 
artery disease (CAD), obesity and metabolic syndrome (MS). Risk factors also include 
a history of chemotherapy or a family history of cardiomyopathy 98,99. We undertook 
a systematic review and meta-analysis of studies reporting risk factors relating to 
incident heart failure in unselected community-based populations.  
2.1.2 Aims and Hypothesis 
The goal of this was to identify a series of clinical markers which could be used to 
identify subjects from a community-based population in whom further evaluation and 
intervention might be warranted. 
2.1.3 Methods 
Search Strategy. The research strategy, study selection and analysis method used in 
the study followed the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses statement (PRISMA)100. Electronic databases (MEDLINE, EMBASE) were 
systematically searched for published studies reporting risk factors related to incident 
HF. Search key terms were: "incident heart failure" and "risk factors", "risk 
assessment", "risk impact", "risk prediction", "risk score", “risk prevention”. To ensure 
the identification of all relevant articles and publications, the reference lists of these 
articles were also reviewed to identify additional studies. The last search was 
performed on 7 October 2013. 
Study inclusion. From these lists, studies were included if they met each of the 
following criteria: (1) studies of a full-length publication in a peer-reviewed English 
language journal; (2) studies done in human adults >18 years of age; (3) studies done 
in an unselected community population; (4) studies reporting risk factors relating to 
incident heart failure; (5) studies using Cox Proportional hazard models reporting risk 
effect sizes in Hazard Ratio (HR) with 95% confidence intervals (CIs) and/or 
associated p value. This review incorporated mainly observational cohort studies.  
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Outcomes. The primary outcome of interest was incident HF. The criteria for 
identification of incident HF were described as one or more of the following: (i) 
medical diagnosis from physician’s records; (ii) evidence of treatment for HF (i.e. 
diuretics and either digitalis or a vasodilator); (iii) hospital or nursing home stays in 
which the participant had a discharge diagnosis with a code of International Statistical 
Classification of Diseases and related health problems (ICD-9 code) of 428.0 to 428.9; 
(iv) death certificate report in which the underlying cause of death was recorded using 
an ICD-9 code of 428.0 to 428.9. 
Data extraction. Data was extracted independently by reviewers (HY, KN and PO). 
All discrepancies were reviewed and resolved by consensus. For the systematic 
review, the following data concerning the individual study populations was extracted: 
demographic and clinical characteristics and associated risk prevalence at baseline; 
study design; years of follow-up; statistical models; statistic models; risk effect sizes 
and their associated 95% confidence intervals (CIs) with p values; covariates included 
in the risk assessment models in relation to outcome. In situations in which multiple 
articles were published from a single cohort, data were included only if different risk 
variables were analysed and reported. 
Statistical analysis. Reported risk effect sizes and the statistical models used in each 
study were reviewed. Crude measures of effect with 95% CIs were extracted for each 
risk variable. Multiple within-study effects stratified in subgroups were combined by 
weighting each group by its number of participants. Study risk estimates reported per 
categorical change were re-calculated as continuous variables for BMI 101. Risk 
estimates from the majority of studies were estimated using Cox proportional hazard 
models and were pooled as Hazard Ratios (although some incorrectly labelled these as 
Relative Risk/Rate) 102,103. Risk estimates reported as “Relative Risk” using Mantel-
Haenszel 104 or linear regression model 105 or Odds Ratio using logistic regression 
model106 were excluded for further analysis. Consequently, pooled risk estimates were 
all from studies using Cox proportional hazard models and were suitable for providing 
summary risk estimates. Both unadjusted and maximally adjusted risk effects were 
pooled using random effect models weighted by inverse variance 107. Further a subset 
of studies reporting seven mutually adjusted risk effects (age, male gender, BMI, 
smoking, HTN, DM, CAD) were also pooled. When confidence intervals were not 
Chapter 2- Clinical Prediction of Incident HF risk 58 
 
reported, their associated p values were used to estimate variance of the risk estimate 
108. 
The Cochrane Q statistic and I2 values index were used to assess the degree of 
heterogeneity across studies. Funnel plots were constructed and Egger’s test was used 
to assess potential publication bias. Duval and Tweedie’s Trim and Fill method was 
used to assess the potential effects of publication bias on risk estimates. Meta-
regression was also performed for each risk factor to examine possible study factors 
associated with heterogeneity. The assessment of study quality was performed using 
the Newcastle-Ottawa Scale (NOS) for non-randomized studies in meta-analyses 109. 
Statistical analysis was performed using statistics package R version. 3.1.1. 
2.1.4 Results 
Study selection. The process of article selection based on PRISMA guidelines is 
presented in Figure 2.6.  
 
Figure 2.6 The process of article selection based on PRISMA guidelines 
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After exclusion of duplicates, the initial search revealed a total of 1974 original articles 
published from 1967-2013. After exclusion of inappropriate papers, or studies without 
relevant risk analysis, there were 15 studies eligible for inclusion, from which 4 studies 
had more than one eligible article either from the same data set or from a pilot study 
set. Therefore, a total of 20 articles were systematically reviewed and eligible for 
quantitative synthesis (Figure 2.6)60,78-80,102-104,108,110-121. Risk estimates from two 
articles 80,110 were not included in the meta-analysis since they duplicated estimates 
from the same cohort, and estimates from Kalogeropoulos 104 and Mujib 108 were only 
included where they were absent from the corresponding articles on the same cohorts; 
Butler 79 and Gottdiener 103, respectively. The included articles were published 
between 1993 and 2013. 
Baseline characteristics. The baseline demographic characteristics of included 
studies (15 prospective cohort studies) are summarized in Table 2.2.  
The geographic distribution of the studies was predominantly in North America and 
Europe (11 studies in US, 4 in Europe). There were a total of 456,850 subjects – the 
reported mean age of participants was 24-81 years (weighted mean 42±13 years), the 
proportion of male participants ranged from 32%-100% (weighted mean 49±9%), and 
the majority of the participants were Caucasian 39%-100% (weighted mean 64±6%). 
Over an average follow-up time of 4-29 years, there were 11467 incident HF cases, 
giving an average cumulative incident HF rate of 0.97±0.11% (Table 2.2).  
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Table 2.2 Baseline population demographic characteristics and risk prevalence 
 Author(s) 
Publish 
(year) 
Trial  
(study name) 
Total  
(n) 
Follow Up 
(year) 
Incident 
HF (n) 
Cumu * 
Incidenc
e  
Age 
(years) 
% 
male 
Risk 
ratio 
Stats 
Mode
l used 
% 
Smok
e 
BMI 
% 
DM 
% 
CAD 
% 
LVH 
% 
HTN 
% 
VHD 
1 
Ho KK et al 110 1993 
Framingham and 
offspring (US) 
9405 ǂ 40ǂ 652ǂ    RR CPH        
Kannel et al80 1999 15267 pe* ǂ 38ǂ 486ǂ    OR PLR        
Ho J et al60 2013 6340 8  512 8.1% 60±12 46% HR CPH 22% 27±4 7% 8% 8% 46% 1% 
2 
Butler et al79 
Kalogeropoulos et 
al104 
2008 
2009 
Health ABC study 
(US) 
2934 7  258 8.8% 74±2.9 48% 
HR 
RR 
CPH  
MH 
56% 27.3±4.8 15% 17% 12% 43%   
3 He et al102 2001 NHANES (US) 13643 19  1382 10.1% 50±15 41% RR § CPH 35% 25.6±5 4% 5% 
 28% 5% 
4 Agarwal et al78 2012 ARIC (US) 13555 16  1487 11.0% 54±5.8 45% HR   CPH 25% 27.6±5.2 10% 4% 2%   1% 
5 Goyal et al111 2010 Million P-Yr* (US) 359947 5  4001 1.1% 38±14 47% HR CPH 
  3% 1%  12% 1% 
6 
Bahrami et al112 
Bahrami et al113 
2008 
2008 
MESA (US) 6814 4  79 1.2% 65±0.7 47% HR CPH 49% 28.4±0.1 14%   10% 48%   
7 
Gottdiener et al103 
Mujib et al 108 
2000 
2010 
Cardio Vascular 
Health (US) 
5625 12  597 10.6% 73±4.5 42% 
RR 
HR 
CPH 
CPH 
54%  17%   58%  
8 Chen et al114 1999 EPESE (US) 1749 8  173 9.9% 74±6.8 41% HR CPH 78%   11%     54%   
9 Bibbins-D et al115 2009 CARDIA (US) 5115 20  27 0.5% 24±3.5 45% HR CPH 31% 24.5±4.8 2% 
 6% 3%  
10 Ingelsson et al116 2005 ULSAM (Sweden) 2321 29  259 11.2% 50±0.0 100% HR CPH 51% 25±3.2 6% 0% 2% 43%   
11 Wang et al117 2010 Kuopio (Finland) 1032 21  303 29.4% 69±2.8 38% HR CPH 29% 27.2±4.0 17% 7% 31% 26% 
 
12 Aronow et al118 1999 Mt Sinai (US) 2902 4  794 27.4% 81±8.0 32% HR CPH     25% 44%   46%   
13 Smith et al119 2010 MDCS (Sweden) 5187 14  112 2.2% 58±5.9 41% HR CPH 27% 25.7±3.9 8% 2% 
 17%  
14 Kenchaiah et al120 2009 
Physician’s heart 
(US) 
21094 21  1109 5.3% 53±9.4 100% HR CPH 48% 24.8±1.4 3% 9%   24%   
15 Brouwers et al121 2013 
Prevend 
(Netherlands) 
8592 12  374 4.4% 49±12 50% HR CPH 38% 26±4.0 4% 6%  32%  
 Sum 
1993 - 
2013 
15 studies 456850 198  11467                         
 Mean (Weighted)     30457 7  3323 0.97% 42 49%     39% 26 4% 2.23% 6% 16% 1% 
 SD (Weighted)       1.0 811 0.11% 12.6 9%     2.70% 3  1% 0.23% 1% 3% 0.2% 
 Maximum     359947 29  4001 29.36% 81 100%     78% 28  25% 44% 31% 58% 5% 
 Minimum     1032 4  27 0.53% 24 32%     22% 25  2% 0.3% 1.5% 3.0% 0.5% 
* pe (person exam); Cum incidence (Cumulative incident rate); P-Yr (person year); ǂ duplicated counts from a single study, not included in total and cumulated incidence; BMI (Body mass Index); DM (Diabetes mellitus); CAD (Coronary Artery 
Disease); LVH (Left Ventricular Hypertrophy); HTN (Hypertension); VHD (Valvular Heart Disease); RR (Relative Risk); OR (Odds Ratio); HR Hazard Ratio); CPH (Cox Proportional Hazard); PLR (Pooled Logistic Regression); MH (Mantal Haenszel); § RR 
(Risk Ratio); 
FHS (Framingham Heart Study); HABC (Health Aging and Body Composite Study); NHANES (National Health Nutrition Examination Survey); ARIC (The Atherosclerosis Risk in Communities); Million P-Y (One Million Person-Year study); 
MESA (Multi-Ethnic Study of Atherosclerosis); CVH (Cardio Vascular Health study); EPESE (Established Population for Epidemiologic Studies of the Elderly program); CARDIA (Coronary Artery Risk Development in Young Adults); ULSAM 
(Uppsala Longitudinal Study of Adult men); Kuopio (Kuopio Finland study); Mt Sinai (Study at Mt Sinai); MDCS (the Malmo diet and Cancer Study in Swedish people); Physician Heart (the Physician heart study); Prevend (Prevention of Renal 
and Vascular End-stage Disease) 
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The detailed baseline prevalence of cardiovascular and non-cardiovascular 
comorbidities is summarized in Table appendix 2.5 and Table appendix 2.6. The 
BMI was 25-28 kg/m2 (weighted mean 26±3kg/m2). The prevalence of DM varied 
from 2%-25% (weighted mean 4±1%), CAD varied from 0.3-44% (weighted mean 
2.2±0.2%), HTN 3%-58% (weighted mean 16±2%) and left ventricular 
hypertrophy (LVH) 1.5-31% (weighted mean 6±1%). In the study populations, 
22%-78% were either current or past smokers.  
Clinical factors associated with incident HF. Twenty-seven variables were 
reported to be associated with incident HF, including twenty clinical variables, six 
biomarkers and one echocardiographic marker. These variables were age, male 
gender, black race, family history of cardiac disease, excessive use of alcohol, 
smoking, physically inactive, obesity, education level, DM, CAD, LVH by ECG, 
HTN, chronic obstructive pulmonary disease (COPD), valvular heart disease 
(VHD), chronic kidney disease (CKD), stroke, resting heart rate, atrial fibrillation 
(AF), abnormal ECG which includes bundle brunch block, ST-T and QRS changes, 
and echocardiographic left ventricular ejection fraction (LVEF). Biomarkers were 
fasting glucose, C - reactive protein (CRP), creatinine, albumin, dyslipidaemia and 
NT-proBNP.  
Crude and adjusted risk ratios were extracted. The reporting details of each risk 
variable and overall reporting frequency are summarized in Table appendix 2.7. We 
selected variables only if they were reported in four or more of the included studies 
for quantitative synthesis. Thirteen variables meet this requirement. We excluded 
abnormal ECG due to heterogeneous criteria based on the presence of QRS changes 
78; ST-T changes 103 and bundle bunch block 60. We also excluded dyslipidaemia 
and fasting glucose, due to inconsistency in categorical 102,113,117,121 as well as 
continuous cut-offs of these two biomarkers 60,78,79,116 in risk calculation between 
studies. Therefore, a total of 11 risk variables (age, male gender, race black, obesity, 
and smoking, DM, CAD, HTN, LVH, VHD and AF) were selected for further 
synthesis. Pooled unadjusted and adjusted HRs with 95% CIs are listed in Table 
2.3.  
The details of other factors used in multivariate models of included studies are 
summarized in Table appendix 2.8.  
Chapter 2- Clinical Prediction of Incident HF risk 62 
 
Strength of independent association with incident HF. Further subset meta-
analyses were conducted from 6 studies 60,102,103,116,119,121, where each of 7 risk 
variables was mutually adjusted in models within each study. The strength of 
independent association for incident HF was highest for CAD (2.94 [1.36-6.33]) 
followed by DM (2.00 [1.68-2.38]) and age (per 10 years increase) (1.8 [1.13-2.87]) 
(Table 2.4). 
Publication bias, sensitivity and study quality. Egger’s test for pooled adjusted 
risk indicated significant bias for the estimates of BMI, male gender, and atrial 
fibrillation (Table 2.3B), and BMI for mutually adjusted risk estimates (Table 2.4). 
No publication bias was detected for crude estimates (Table 2.3A). Duval and 
Tweedie’s trim and fill results are presented for all risk estimates where at least 
three studies were pooled. The NOS scale 109 for cohort studies is summarized in 
Table appendix 2.9; most studies were of high quality. 
Exploration of study heterogeneity. Meta-regression was performed for each of 
the seven risk factors in the mutually adjusted models; the following study factors 
were examined: follow-up time, cumulative incidence, mean age, male proportion, 
and smoking proportion, mean BMI, DM proportion, HTN proportion, VHD 
proportion, CAD proportion, study quality. Even though the estimates from these 
seven studies were adjusted for smoking, the pooled risk effect of DM increases by 
approximately 10% for each 10% increase in the proportion of smokers in a study, 
implying some interaction between these risks. Likewise, the pooled risk effect of 
male sex increases by 38% for each 10% increase in the proportion of subjects with 
diabetes in a study. 
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Table 2.3 Pooled risk estimates of risk variables (Unadjusted and adjusted) 
A) Unadjusted 
 Pooled  
HR 
95% CI I2 
Study  
(n) 
Q-Chi2 Q-p value 
Eggers  
test 
Trim-fill  
HR[95%CI] 
BMI( 5kg/m2) 1.54 1.21 - 1.95 96.5 4 86.2 <0.001 0.553 1.28 [1.03-1.59] 
Sex (Male) 1.51 1.07 - 2.12 52.5 3 4.2 0.122 0.916 1.51 [1.07-2.12] 
Smoker (yes) 1.82 1.49 - 2.23 48.0 4 5.8 0.123 0.505 2.03 [1.65-2.49] 
Race (Black) 1.78 1.60 - 1.98  1     
Age (10yr) 2.29 2.09 - 2.51 57.2 4 7.0 0.072 0.842 2.29 [2.09-2.51] 
HTN (yes) 3.49 1.25 - 9.74 98.5 4 195.9 <0.001 0.111 8.35 [3.16-22.09] 
Diabetes (yes) 3.27 2.27 - 4.72 93.3 6 74.6 <0.001 0.278 4.49 [3.15-6.39] 
VHD (yes) 3.92 1.85 - 8.31 96.2 2 26.2 <0.001 *  
CAD (yes) 5.07 2.47 - 10.40 97.5 4 120.5 <0.001 0.496 9.63 [4.64-20.00] 
LVH (yes) 4.40 2.25 - 8.58 87.2 5 31.3 <0.001 0.527 3.29 [1.63-6.64] 
AF (yes) 13.77 11.79 - 16.08  1     
B) Adjusted 
 Pooled HR 95% CI I2 Study (n) Q-Chi2 Q-p value Eggers test Trim-fill HR[95%CI] 
BMI( 5kg/m2) 1.21 1.10 - 1.33 94.1 9 134.8 <0.001 0.062 1.05 [0.96-1.16] 
Sex (Male) 1.51 1.32 - 1.72 58.1 8 16.7 0.019 0.020 1.32 [1.14-1.53] 
Smoker (yes) 1.65 1.45 - 1.88 43.3 8 12.3 0.090 0.201 1.56 [1.34-1.82] 
Race (Black) 0.96 0.75 - 1.23 73.3 4 11.3 0.010 0.825 0.91 [0.72-1.16] 
Age (10yr) 1.70 1.33 - 2.16 99.1 9 848.2 <0.001 0.949 1.70 [1.33-2.16] 
HTN (yes) 1.79 1.41 - 2.27 91.9 11 123.7 <0.001 0.533 2.55 [1.92-3.37] 
Diabetes (yes) 1.94 1.71 - 2.19 56.4 11 23.0 0.011 0.400 1.94 [1.71-2.19] 
VHD (yes) 1.74 1.07 - 2.84 92.9 3 28.0 <0.001 0.150 1.74 [1.07-2.84] 
CAD (yes) 2.90 1.85 - 4.54 97.2 9 285.5 <0.001 0.987 2.90 [1.85-4.54] 
LVH (yes) 2.46 1.71 - 3.53 74.1 6 19.3 0.002 0.431 2.17 [1.47-3.19] 
AF (yes) 1.88 1.60 - 2.21 16.2 4 3.6 0.310 0.020 1.99 [1.66-2.39] 
* Eggers test only used if number of studies was three or greater. 
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Table 2.4 Pooled hazard risk estimates for mutually adjusted risk variables  
 Pooled 
HR 
95% CI I2 
Study 
(n)* 
Q-Chi2 
Q-p 
value 
Eggers 
test 
Trim-fill 
HR[95%CI] 
BMI( 5kg/m2) 1.15 1.06 - 1.25 89.8 5 39.34 <0.001 0.039 1.06 [0.96-1.16] 
Male Gender 1.52 1.24 - 1.87 71.5 5 14.05 0.007 0.107 1.27 [1.03-1.56] 
Smoker (yes) 1.60 1.45 - 1.77 0.0 5 2.69 0.611 0.783 1.60 [1.45-1.77] 
HTN (yes) 1.61 1.33 - 1.96 64.1 5 11.14 0.025 0.358 1.41 [1.15-1.73] 
Age (10yrs) 1.80 1.13 - 2.87 99.1 4 331.4 <0.001 0.64 2.41 [1.49-3.91] 
DM (yes) 2.00 1.68 - 2.38 50.6 6 10.12 0.072 0.841 2.00 [1.68-2.38] 
CAD (yes) 2.94 1.36 - 6.33 97.7 6 212.6 <0.001 0.583 6.71 [2.69-16.74] 
* Number of studies included in estimates for each listed risk factor 
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2.1.5 Discussion 
The findings of this systematic review demonstrated 11 common cardiovascular 
and non-cardiovascular risks associated with incident HF. Results from meta-
analysis revealed the independent risk associated with the 7 most common 
comorbidities. Knowledge of the relative effect sizes may facilitate the process of 
risk assessment in a community-based population. The factors most strongly 
independently associated with incident HF were CAD (2.94 [1.36-6.33]) followed 
by DM (2.00 [1.68-2.38]). 
Calculation of HF risk. Although the role of heart failure risk factors has been 
documented in numerous previous publications, the reported level of risk has been 
heterogeneous, so the relative contribution of each factor to the development of 
heart failure remains controversial. To date, three population-based studies have 
sought to integrate risk factors into single estimate of HF risk 78-80. Of these, the 
ARIC HF risk score is a well-validated parsimonious score, whereas concern has 
been expressed regarding the selection of patients into the Framingham Heart 
Failure Risk Score (which is much influenced by ischaemic aetiology), and the 
Health ABC Heart Failure Score requires blood testing that may not be accessible 
at community screening.  
It is paradoxical that while the performance of an echocardiogram is considered 
appropriate in patients with symptomatic HF, its use in the preclinical stage is 
considered inappropriate 122. Perhaps this is the reason that screening for HF has 
not been widely applied, even in at-risk patients such as those with diabetes 
mellitus, hypertension and CAD, despite the wide availability of echocardiographic 
assessment of systolic and diastolic dysfunction. Moreover, LV assessment using 
2D imaging may be hard to reproduce, and although there have been initial reports 
of both in community studies 123, the place of both in community screening is 
undefined. In any case, some clinical definition of risk would still be required.  
Heart failure screening. Stage B HF (SBHF) lies between overt HF (stages C and 
D) and patients with heart failure risk factors (stage A). These asymptomatic 
patients have evidence of LV damage, which may be detected as disturbances of 
LV structure or function, which predispose toward the development of HF 124. 
SBHF is relatively easy to identify in patients with previous myocardial infarction 
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and regional dysfunction, or with reduced ejection fraction. However, nearly 50% 
of HF is of non-ischaemic origin 44, and in this circumstance, the identification of 
SBHF may be difficult in the absence of LVH. 
Although HF may be prevented by control of HF risk factors, early detection of LV 
dysfunction may permit the institution of measures that prevent progression of the 
problem39,125,126. Screening for SBHF is supported by previous studies of 
subclinical LV systolic and diastolic dysfunction. The prevalence of asymptomatic 
EF <50% is 7.2% in those aged 60-69 years and doubles to 14.3% in those aged >80 
years 51. The prevalence of diastolic dysfunction varies with grade among patient 
with different risk groups. In older (>65 years) patients with a diagnosis of 
hypertension or coronary disease, the prevalence of mild diastolic dysfunction is 
36%, moderate or severe is 16% 56. Abnormal myocardial function can be 
documented in 20-30% of patients with obesity and diabetes 58,59.  
The application of any screening test is most effective when the condition is of at 
least moderate prevalence in the population under study. For example, focusing the 
screening effort on those with non-ischaemic risk factors for HF (diabetes, 
hypertension, overweight, metabolic syndrome, cardiotoxic chemotherapy, familial 
cardiomyopathy) would permit restriction of screening tests to the group most likely 
to have a problem. Nonetheless, these HF risks are highly prevalent in general 
population and their relative and additive importance are not well known.  
The consistency of association of various risk factors with heart failure supports the 
concept that heart failure is predictable in many patients. The development of this 
simple risk calculation strategy derived from this study could be used to focus 
resources (e.g. open access echocardiography) on at-risk non-ischaemic patients. 
However, the predictive value of the risk calculation, the benefit of imaging 
surveillance and the cost-effectiveness of screening of stage A HF in the community 
will need to be validated prospectively. We are undertaking this at present in a 
population-based study (http://www.anzctr.org.au/; ACTRN12614000080628) 
2.1.6 Study Limitations 
Like all meta-analyses, this work is limited by variations in the original studies, 
although all involved at-risk individuals. Likewise, the constituent observational 
studies may be limited by biases in the recruitment process. The high levels of I2 
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attest to substantial heterogeneity between studies. The original intention of the 
analysis was to develop a risk score using the available clinical variables. This was 
limited by the heterogeneity in the studies; particularly in the various cohorts used 
in each study and in the variables used for adjustment. Without access to individual-
level data, we can only propose the combined risk measures derived from this study 
be used as a marker of the magnitude rather than as exact risk estimates. 
Furthermore, our primary interest was to identify and quantify the potential HF risks 
in non-ischemic HF. While CAD is ubiquitous in these, the proportion with CAD 
is low (weighted average 2.2%, Table 1).  Moreover, the benefit of a meta-
regression is that we were able to address the role of other factors independent of 
CAD. Finally, this systematic review was not registered prospectively 
2.1.7 Conclusion 
This systematic review and meta-analysis of 456,850 subjects shows that CAD, 
diabetes, age, hypertension, smoking, male gender and increased BMI are 
consistently and independently associated with a higher risk of incident HF. Atrial 
fibrillation, left ventricular hypertrophy and valve heart disease are also strongly 
associated with incident HF. The estimation of HF risk may become useful in 
selection of asymptomatic patients for imaging as sensitive, new imaging and 
biochemical techniques for identification of LV dysfunction become more widely 
available.  
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Appendix Tables and figures 
Table appendix 2.5 -Baseline characteristics of included studies (demographic)  
  Study 
Publish  
(year) 
Trial  
(study name) 
Data Collection 
(year) 
Total  
(n) 
Follow-Up 
(year) 
HF develop  
(n) 
Incident Rate  
(1000 p-yr*) 
Cumulative 
Incident rate (%) 
Age 
(±SD) 
Gender 
(%male) 
1 
Ho KK et al 110 1993 
Framingham and offspring (US) 
1948-1988 9405 ǂ 40ǂ 652ǂ 1.85    
Kannel et al80 1999  
15267 
pe*ǂ 
38ǂ 486ǂ     
Ho J et al60 2013 1981-2008 6340 8  512 5 8.1% 60±12 46% 
2 
Butler et al79 
Kalogeropoulos et al104 
2008 
2009 
Health ABC study (US) 1997-2004 2934 7  258 13.6 8.8% 74±2.9 48% 
3 He et al102 2001 NHANES (US) 1971-1992 13643 19  1382  10.1% 50±15 41% 
4 Agarwal et al78 2012 ARIC (US) 1987-2005 13555 16  1487   11.0% 54±5.8 45% 
5 Goyal et al111 2010 Million P-Yr *(US) 2000-2005 359947 5  4001 3.96 1.1% 38±14 47% 
6 
Bahrami et al112 
Bahrami et al113 
2008 
2008 
MESA (US) 2000-2006 6814 4  79 3.1 1.2% 65±0.7 47% 
7 
Gottdiener et al103 
Mujib et al 108 
2000 
2010 
Cardio Vascular Health (US) 1989-1996 5625 12  597 19.3 10.6% 73±4.5 42% 
8 Chen et al114 1999 EPESE (US) 1982-1992 1749 8  173 12.5 9.9% 74±6.8 41% 
9 Bibbins-Domingo et al115 2009 CARDIA (US) 1985-2006 5115 20  27  0.5% 24±3.5 45% 
10 Ingelsson et al116 2005 ULSAM (Sweden) 1970-2001 2321 29  259 4.5 11.2% 50±0.0 100% 
11 Wang et al117 2010 Kuopio (Finland) 1986-2006 1032 21  303  29.4% 69±2.8 38% 
12 Aronow et al118 1999 Mt Sinai (US) N/A 2902 4  794   27.4% 81±8.0 32% 
13 Smith et al119 2010 MDCS (Sweden) 1991- 5187 14  112  2.2% 58±5.9 41% 
14 Kenchaiah et al120 2009 Physician’s heart (US) 1982-2007 21094 21  1109 2.57 5.3% 53±9.4 100% 
15 Brouwers et al121 2013 Prevend (Netherlands) 1997-2010 8592 12  374  4.4% 49±12 50% 
                        
  Sum 1993-2013 15 studies 1967-2007 456850 198  11467         
  Mean (Weighted)       30457 7  3323 3.75 0.97% 42 49% 
  SD (Weighted)         1.0 811 1.07 0.11% 12.6 9% 
  Maximum       359947 29  4001 19.3 29.36% 81 100% 
  Minimum       1032 4  27 2.57 0.53% 24 32% 
*pe (person exam); p-yr (person year); ǂ duplicated counts from a single study, not included in counts for total and cumulated incidence. 
FHS (Framingham Heart Study); HABC (Health Aging and Body Composite Study); NHANES (National Health Nutrition Examination Survey); ARIC (The Atherosclerosis Risk in Communities); Million P-Y (One Million Person-Year study);  
MESA (Multi-Ethnic Study of Atherosclerosis); CVH (Cardio Vascular Health study); EPESE (Established Population for Epidemiologic Studies of the Elderly program); CARDIA (Coronary Artery Risk Development in Young Adults);  
ULSAM (Uppsala Longitudinal Study of Adult men); Kuopio (Kuopio Finland study); Mt Sinai (Study at Mt Sinai); MDCS (the Malmo diet and Cancer Study in Swedish people); Physician Heart (the Physician heart study);  
Prevend (Prevention of Renal and Vascular End-stage Disease) 
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Table appendix 2.6 -Baseline characteristics of included studies (Risk prevalence)  
Author(s) 
% 
White 
%  
>Hi/Sc* 
% 
F/Hx* 
% 
Smoke 
% 
Alcohol 
BMI 
(mean) 
SBP 
(mean) 
DBP 
(mean) 
% 
Inactive 
% 
DM 
% 
CAD 
% 
LVH 
% 
HTN 
% 
VHD 
% 
Stroke 
or TIA 
% 
Abn 
ECG 
Heart 
rate 
(mean) 
% 
COPD 
% 
AF 
% 
CKD 
Total 
CHOL 
Ho KK et al ; 110                                           
Kannel et al;80                                           
Ho J et al60 100%     22%   27±4 132 77±11   7% 8% 8% 46% 1% 3% 3% 65   2%   213 
Butler et al; 79 
Kalogeropoulos 
et al104 
59% 89%   56%   27±5 136 71±12   15% 17% 12% 43%   7%   65       203 
He et al102 85% 56%   35% 25% 26±5 134   44% 4% 5%   28% 5%             222 
Agarwal et 78al78 74%     25%   28±5 120     10% 4% 2%   1%   3% 67 8%       
Goyal et al111                   3% 1%   12% 1%         0%     
Bahrami et al112 
Bahrami et al113 
39%     49%   28±0.0 127 72±0.2   14%   10% 48%               194 
Gottdiener et 
al103 
Mujib et al 108 
85% 71%   54%     136 71±11   17%     58%   5% 15%   25% 2%   211.9 
Chen et al114 80% 48%   78%           11%     54%   4%             
Bibbins-D et 
al115 
48% 60% 12% 31% 12% 25±5 110 69±9   2%   6% 3%             4%   
Ingelsson et al116       51%   25±3       6% 0% 2% 43%                 
Wang et al117       29% 30% 27±4 157 82±14 25% 17% 7% 31% 26%               254 
Aronow et al118 67%                 25% 44%   46%                 
Smith et al119       27%   26±4 141 87±9   8% 2%   17%           1%     
Kenchaiah et al 
et al120 
      48% 25% 25±1 126 79±7 14% 3% 9%   24%                 
Brouwers et al121 95%     38%   26±4 128 74±10   4% 6%   32%       69   1% 6% 199 
                                            
Sum                                           
Mean 
(Weighted) 
64%     39%   26 128 76 25.5% 4% 2.23% 6% 16% 1% 5% 5.8% 67 13.1% 0.4% 5.2% 210  
SD (Weighted) 5.8%     2.70%   3  16  8 8.1% 1% 0.23% 1% 3% 0.2% 0.6% 1.4% 10 0.9% 0.1% 1.9% 20  
Maximum 100% 89% 12% 78% 30% 28  157  87 44% 25% 44% 31% 58% 5% 7% 15% 69  25% 2% 6% 254  
Minimum 39% 48% 12% 22% 12% 25  110  69 14% 2% 0.3% 1.5% 3.0% 0.5% 2.7% 2.7% 65  8.4% 0.3% 3.5% 194  
*Hi/Sc (high school); F/Hx (family history of cardiac disease); BMI (Body Mass Index); DM (Diabetes Mellitus); CAD (Coronary Artery Disease); LVH (Left Ventricular Hypertrophy); HTN (Hypertension); VHD (Valvular Heart Disease); TIA (Transient Ischaemic Attack); COPD 
(Chronic Obstructive Pulmonary Disease); AF (Atrial Fibrillation); CKD (Chronic Kidney Disease); CHOL (cholesterol) 
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Table appendix 2.7 -Heterogeneity of risk variables reported in studies  
Variables 
Frequen
cy (n)     
(%) FHS 
Health 
ABC 
NHANES ARIC 
Million 
P-Y 
MESA CVH 
EPES
E 
CARDI
A 
ULSAM 
Kuopi
o  
Mt 
Sinai 
MDCS  
Physician  
Heart 
PREV
END 
Hypertension 14 93% + + + + + + + + + + + + +   + 
Diabetes 13 87% + + + + + + + + + +   + +   + 
Age 11 73% + +   + + + + + +     + +   + 
Male Gender 11 73% +   + + + + + + +     + +   + 
Obesity 10 67% +   + +       + + + +   + + + 
Smoking 10 67% + + + +   + +   + +     +   + 
CAD 10 67% + + + + +   +     +   + +   + 
Dyslipidaemia 8 53% +   + +   +     + + +       + 
LVH 7 47% + +   +   + +   + +           
Black Race 6 40%     + +   + +   +     +       
Fasting Glucose 5 33%   +   +     +       +       + 
Valvular 
Disease 
4 27% +   + + +                     
Atrial 
Fibrillation 
4 27% +       +   +               + 
Abnormal ECG 3 20% +     +     +                 
Heart Rate 3 20% + +   +                       
Excessive 
Alcohol 
3 20%     +           +             
CKD 3 20%   +             +           + 
NT-proBNP 3 20%       +                 +   + 
C-Reactive 
Protein 
3 20%       +     +               + 
Albumin 3 20%   +   +     +                 
Creatinine 3 20%   +   +     +                 
Stroke 2 13%             +           +     
Family History 2 13%                 +             
Education 2 13%     +           +             
COPD 2 13%       +     +                 
LVEF (echo) 2 13%             +   +             
Physical 
Inactive 
1 7%     +                         
CAD (Coronary Artery Disease); LVH (Left Ventricular Hypertrophy); AF (Atrial Fibrillation); VHD (Valvular Heart Disease); COPD (Chronic Obstructive Pulmonary Disease); CKD (Chronic Kidney Disease) 
FHS (Framingham Heart Study); HABC (Health Aging and Body Composite Study); NHANES (National Health Nutrition Examination Survey); ARIC (The Atherosclerosis Risk in Communities); Million P-Y (One Million Person-Year study); MESA (Multi-Ethnic Study of 
Atherosclerosis); CVH (Cardio Vascular Health study); EPESE (Established Population for Epidemiologic Studies of the Elderly program); CARDIA (Coronary Artery Risk Development in Young Adults); ULSAM (Uppsala Longitudinal Study of Adult men); Kuopio (Kuopio 
Finland study); Mt Sinai (Study at Mt Sinai); MDCS (the Malmo diet and Cancer Study in Swedish people); Physician Heart (the Physician heart study); Prevend (Prevention of Renal and Vascular End-stage Disease) 
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Table appendix 2.8 -Heterogeneity of risk variables used for adjusted analysis 
  Author 
Study  
(Trial) 
Risk 
rati
o 
Stats 
Model 
used 
Age 
Gende
r 
Smokin
g 
BM
I 
D
M 
CA
D 
LV
H 
HT
N 
VH
D 
H
R 
A
F 
  
1 
Ho KK110         FHS RR CPH +            
Kannel80 FHS OR PLR + + + + + + + + + +   
Ho J #60 FHS HR CPH + + + + + + + + + + + LBBB; HDL; MI 
2 
Butler79 Health ABC HR CPH +  +  + + + +  +  creatinine 
Kalogeropoulos104 Health ABC RR MH   +  + + + +  +  race 
3 He#102 NHANES RR CPH +  + + + +  + +   
education, alcohol, low physical activity, 
cholesterol, 
4 Agarwal78 ARIC HR CPH + +           
5 Goyal111 Million P-Y HR CPH + +   + +  + +  +  
6 Bahrami112 MESA HR CPH + + + + +  + +     
7 
Gottdiener#103 CVH RR CPH + +  + + + + +     
Mujib108 CVH HR CPH + + +  + + + +   + race, stroke, COPD and peripheral arterial dis 
8 Chen YT114 EPESE HR CPH + +  + + +  +     
9 Bibbins-D115 CARDIA HR CPH    +    +    Cholesterol, CKD 
10 Ingelsson#116 ULSAM  HR CPH   + + + + + +    cholesterol 
11 Wang J117 Kuopio HR CPH + + +  +   +    low physical activity, alcohol cholesterol 
12 Aronow118 Mt Sinai HR CPH + +   + +  +     
13 Smith JG#119 MDCS  HR CPH + + + + + +  +    cholesterol, BNP, CRP 
14 Kenchaiah120 
Physician 
Heart 
HR CPH +  +   +      Alcohol, FHx and medication 
15 Brouwers#121 Prevend HR CPH + + + + + +   +     + Cystatine, UAE, CRP, NT-proBNP, hs-TnT 
¶ Variables used for mutually adjusted risk calculation; # Studies included for mutually adjusted risk calculation. 
RF (Risk Factor); HR (Hazard Ratio); OR (Odds Ratio); RR (Relative Risk); FHS (Framingham Heart Study); HABC (Health Aging and Body Composite Study); NHANES (National Health Nutrition Examination Survey); ARIC (The Atherosclerosis Risk in Communities); 
Million P-Y (One Million Person-Year study); MESA (Multi-Ethnic Study of Atherosclerosis); CVH (Cardio Vascular Health study); EPESE (Established Population for Epidemiologic Studies of the Elderly program); CARDIA (Coronary Artery Risk Development in Young 
Adults); ULSAM (Uppsala Longitudinal Study of Adult men); Kuopio (Kuopio Finland study); Mt Sinai (Study at Mt Sinai); MDCS (the Malmo diet and Cancer Study in Swedish people); Physician Heart (the Physician heart study); Prevend (Prevention of Renal and Vascular 
End-stage Disease) 
LBBB (left bundle branch block); HDL (high density lipoprotein); MI (myocardial infarction); CKD (chronic kidney disease); BNP (brain natriuretic peptide); CRP (c-reactive protein); FHx (family history); UAE (urinary albumin excretion); hs-TnT (highly sensitive troponin T. 
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Table appendix 2.9 -Newcastle–Ottawa scale for included studies 
  Author Study (Trial) 
#1_Selecti
on_Repres
entativenes
s of 
exposed  
#2_Sellecti
on_of Non-
exposed 
#3_Selecti
on_Ascerta
inment of 
exposure  
#4_Outcom
e 
demonstrat
ion at start 
(=yes) 
#5_Compa
rability 
#6_Assess
ment of 
Outcome 
#7_Follow-
up Long 
enough for 
outcome to 
occur 
#8_Follow-
up 
adequacy 
Total 
 
1 
Ho KK110 
Kannel80 
Ho J60          
Framingham study   
     
 
 
8 
2 
Butler79 
Kalogeropoulos104 
Health ABC study   
     
  
 
7 
3 He102 NHANES           8 
4 Agarwal78 ARIC           8 
5 Goyal111 Million P-Y            7 
6 
Bahrami112 
Bahrami113 
MESA     
   
 
 
  
 
8 
7 
Gottdiener103 
Mujib108 
Cardio Vascular 
Health 
  
   
 
 
  
 
8 
8 Chen YT114 EPESE            7 
9 Bibbins-D115 CARDIA           7 
10 Ingelsson116 ULSAM           7 
11 Wang J117 Kuopio           8 
12 Aronow118 Mt Sinai            6 
13 Smith JG119 MDCS          9 
14 Kenchaiah120 Physician’s heart           8 
15 Brouwers121 Prevend          8 
Selection: No is given to cohort with men or women only, or with an age selection range; 
Comparability: if risk adjusted for confounders, or with subgroup analysis of age or gender; ☆☆ if adjusted for interim myocardial infarction 
Follow-up length only if ≥ 5 years 
FHS (Framingham Heart Study); HABC (Health Aging and Body Composite Study); NHANES (National Health Nutrition Examination Survey); ARIC (The Atherosclerosis Risk in Communities); Million P-Y (One Million Person-Year study); MESA (Multi-Ethnic Study of 
Atherosclerosis); CVH (Cardio Vascular Health study); EPESE (Established Population for Epidemiologic Studies of the Elderly program); CARDIA (Coronary Artery Risk Development in Young Adults); ULSAM (Uppsala Longitudinal Study of Adult men); Kuopio (Kuopio 
Finland study); Mt Sinai (study at Mt Sinai); MDCS (the Malmo diet and Cancer Study in Swedish people); Physician’s heart (the Physician heart study); Prevend (Prevention of Renal and Vascular End-stage Disease 
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Table appendix 2.10 -Reasons for excluded Studies 
  Reasons for excluded Studies after full text review (n=83+9=92) 
  Author, year Reasons for exclusion 
1 Eriksson, 1989 (Eur Heart J) Risk estimates not meeting inclusion criteria 
2 Wilhelmsen, 2001 (J Intern Med) Risk estimates not meeting inclusion criteria 
3 Ansari,2003 (Am Heart J) risk for CV hospitolization 
4 Kardys, 2006 (Am Heart J) Risk estimates not meeting inclusion criteria 
5 Gurwitz, 2013 (Am J Med) Risk estimates for HFpEF 
6 Wannamethee, 2011 (J Am Coll) Risk estimate not meeting inclusion criteria 
7 Baena-Diez, 2010 (Clinical Cardiology) Risk estimates not meeting inclusion criteria 
8 Britton, 2009 (Eur J Heart Fail) Risk estimates not meeting inclusion criteria 
9 Dunlay,2009 (Am J Med) case matched study 
10 Gupta, 2010 (Am Heart J) No risk effect estimates 
11 Kenchaiah, 2002 (N Engl J Med) Duplication of study population (FHS) 
12 Ebong, 2013 (Obesity) Duplication of study population (MESA) 
13 Vasan, 2003 (Circulation) Duplication of study population (FHS) 
14 Cesari, 2003 (Circulation) Duplication of study population (HABC) 
15 Ingelsson, 2006 Duplication of study population (ULSAM) 
16 Bibbins, 2004 (Circulation) Not an unselected population 
17 Azad, 2011 (Journal of geriatric cardiology) review article 
18 Carr, 2005 (Am J Cardiol) Not an unselected population 
19 De Simone, 2013 (Nutr Metab Cardiovasc Dis) Not an unselected population 
20 Senni, 1999 (Arch Intern Med) risk for mortality 
21 Owan, 2006 (N Engl J Med risk for mortality 
22 Adlam 2005 (European Heart Journal) Not reporting characteristics of inclusion 
23 Arnlov, 2004 (European heart Journal) Not reporting characteristics of inclusion 
24 Arnold, 2005 (J Am Geriatr Soc) Not reporting characteristics of inclusion 
25 Aurigemma, 2001 (JACC) Not reporting characteristics of inclusion 
26 Babb, 2009 (AORN J) review article 
27 Barnard, 2005 (Current Cardiology reports) review article 
28 Belin, 2011 (Am J Clin Nutr) Not reporting characteristics of inclusion 
29 Bertoni, 2004 (Diabetes care) Diabetic population 
30 Bibbins, 2009 (N Engl J Med) Not reporting characteristics of inclusion 
31 Bleumink, 2004 (European Heart J) No risk effect estimates 
32 Brenyo, 2011 (Cardiol J) Not reporting characteristics of inclusion 
33 Bruch, 2006 (J Am Soc Echo) echo and bnp for CV events 
34 Bui, 2011 (Nature reviews) review article 
35 Cabrera, 2012 (Clin Interv Aging) CV events 
36 Campbell, 2003 (MJA) review article 
37 Castagno, 2012 (JACC) Population not meeting inclusion 
38 Chae,2003 (The Am J of Cardiology) Risk estimat not meeting inclusion 
39 Cowie, 1997 (European Heart Journal) review article 
40 Cowie, 1999 (European Heart Journal) No risk effect estimates 
41 Curtis, 2008 (Archives of internal Med) No risk effect estimates 
42 De Simone, 2007 (Diabetes care) Population not meeting inclusion 
43 Desimone, 2010 (Journal of Hypertension) Population not meeting inclusion 
44 Deswal, 2011 (JACC) review article 
45 Dhingra, 2010 (Arterioscler Throm Vasc Biol) Not reporting characteristics of inclusion 
46 Ekundayo, 2009 (Hypertension) Not reporting characteristics of inclusion 
47 Filippatos, 2011 (Eur J of HF) Not reporting characteristics of inclusion 
48 Folsom, 2009 (Circulation, heart failure) Not reporting characteristics of inclusion 
49 Giamouzies, 2011 (J Cardiac Fail) review article 
50 Haass, 2011 (Circulation, heart failure) Not reporting characteristics of inclusion 
51 Hagege, 2010 (Archives of Cardiovascular Dis) Population not meeting inclusion 
52 Hoffman, 1994 (Arch Intern med) Population not meeting inclusion 
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53 Horne, 2010 (European Journal of heart failure) Risk estimate not meeting inclusion criteria 
54 Hsich, 2011 (JACC) Edtorial comment 
55 Jain, 2011 (Circ cardiovasc Imaging) Risk estimate for CV disease 
56 Kaczorowski, 2011 (BMJ) Not reporting characteristics of inclusion 
57 Kalogeropoulos, 2010 (Circ Heart Fail) Not reporting characteristics of inclusion 
58 Kannel, 2000 (Heart Failure Reviews) review article 
59 Kawut, 2012 (Circulation) risk estimates for HF or death 
60 Ketchum, 2011 (Congestive heart failure) review article 
61 Khatibzadeh, 2012 (International journal of cardiology) review article 
62 Krishnan, 2009 (Circ Heart Fail) Not reporting characteristics of inclusion 
63 Lam, 2011 (Circulation) duplication of population (FHS) 
64 Laugsand, 2013 (European Heart journal) Not reporting characteristics of inclusion 
65 Leung, 2009 (Journal of cardiac failure) Diabetic population 
66 Liszka, 2005 (Ann Fam Med) Duplication of study population (NHANESI) 
67 Lloyd-Jones, 2002 (Circulation) Not reporting characteristics of inclusion 
68 Loehr, 2008 (Am J Cardiol) Duplication of study population (ARIC) 
69 Luepker, 1990 (American J of Epidemiology) Not reporting characteristics of inclusion 
70 Marwick, 2006 (JACC) review article 
71 Mostofsky, 2012 (Circulation. Heart failure) review article 
72 Mujib,2012 (Ann Med) Not reporting characteristics of inclusion 
73 Okin, 2011 (Circ Cardiovasc Qual Outcomes) Population not meeting inclusion 
74 Okin, 2012 (Am J Cardiol) Risk estimate not meeting inclusion criteria 
75 Palazzuoli, 2011 (Intern Emerg Med) review article 
76 Pfister, 2012 (European Heart Journal) Not reporting characteristics of inclusion 
77 Redfield, 2012 (Heart failure clinics) review article 
78 Rod, 2011 (Am J epidemiol) Risk estimate not meeting inclusion criteria 
79 Roger, 2004 (JAMA) Risk estimate not meeting inclusion criteria 
80 Roy, 2011 (Am J Cardiol) Propensity matched study in diabetes 
81 Sanderson, 1995 (International Journal of Cardiology) Risk estimates not meeting inclusion criteria 
82 Schnabel, 2013 (European Journal of Heart Failure) Population not meeting inclusion 
83 Senni, 1998 (Circulation) Risk estimates not meeting inclusion criteria 
84 shah, 2011 (J Am Coll Cardiol) Risk estimates not meeting inclusion criteria 
85 Silver, 2003 (Congestive heart Failure) Not reporting characteristics of inclusion 
86 Sprafka, 1990 (Am J Epidemiol) Risk estimates not meeting inclusion criteria 
87 Suzuki, 2008 (Circulation. Heart Failure) duplication of population (CVH) 
88 Varadarajan, 2006 (J Am Soc Echocardiogr) Population not meeting inclusion 
89 Victor, 2004 (Am J Cardiol) Risk estimates not meeting inclusion criteria 
90 Wang, 2011 (Am J Epidemiol) Not reporting characteristics of inclusion 
91 Wang, 2012 (Circulation) duplication of study population (FHS) 
92 Yan, 2011 (JACC) Risk estimates not meeting inclusion criteria 
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2.2 Cardiac Biochemical Markers 
A variety of biochemical tests have been developed as cardiac biomarkers. The levels 
of these markers may reflect various aspects of the pathophysiology of heart failure. 
Cardiac biomarkers can be broadly classified into 1) neurohormonal activation, i.e. 
natriuretic peptides; 2) myocyte injury, i.e. cardiac troponins; 3) extracellular matrix 
remodelling, i.e. collagen products; 4) inflammation, i.e. cytokines and ST2 and CRP; 
and 5) emerging new biomarkers, i.e. adipokines and galectin3127 and soluble micro 
RNA.  
One of the most widely used markers are cardiac natriuretic peptides (BNP and NT-
proBNP). Other emerging and promising but less common markers include soluble 
ST2 (interleukin 1 receptor) and intra and extra cellular non-coding microRNAs 
(miRNA). Although this research did not include any biomarkers for analysis, mainly 
due to cost issues, these three biomarkers commonly related to HF diagnosis and 
management are discussed in the following section. Current evidence about their 
association with subclinical cardiac dysfunction was also summarized accordingly. 
2.2.1 Cardiac biomarker – Natriuretic Peptides 
The cardiac natriuretic peptides consist of three types: atrial natriuretic peptide (ANP), 
brain natriuretic peptide including (BNP)/N-terminal proBNP (NT-proBNP), and C-
type natriuretic peptide128. BNP and NT-proBNP have emerged as important markers 
for HF diagnosis, prognosis, and guiding treatment.  
BNP is a 32 amino acid polypeptide, NT-proBNP is a 76 amino acid N-terminal 
fragment of BNP. These peptides are secreted into the blood stream by cardiac 
myocytes in response to increased ventricular wall stress, hypertrophy, and volume 
overload127,129,130. The physiologic actions of BNP are reduction in systemic vascular 
resistance, central venous pressure and increased natriuresis. These actions cause 
reduction in blood volume, systemic blood pressure and afterload in order to regulate 
and adjust cardiac output. BNP and NT-proBNP levels are abnormally increased in 
patients with HF and has been used as important markers in emergency department as 
well as at primary care setting. Assessment of blood natriuretic peptide levels is 
currently recommended by some guidelines to help in the diagnosis of HF at the time 
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of presentation124,131. Over the last decade, BNP and NT-proBNP have brought 
significant improvement in HF disease management in both acute HF and in primary 
care setting 127,132-134. 
2.2.1.1 BNP and NT-proBNP in symptomatic HF 
In patients with symptoms, BNP and NT-proBNP had good performance for ruling out 
HF135. The level of BNP or NT-proBNP in the plasma directly relates to the severity 
of HF (Figure 2.7)8. When considering differential diagnosis, the common cut-offs 
used for BNP are: HF is unlikely if <100 pg/mL; HF is likely if BNP >400 pg/mL136. 
Cut-offs for NT-proBNP are: HF is unlikely if <300 ng/mL; but likely if >450 pg/mL 
(age< 50 years), or > 900 pg/mL (age: 50-75 years) or > 1800 pg/mL (age > 70 
years)8,137. As the values detected can be confounded by age and gender. Age specific 
cutoff are listed in Table 2.11. Interpretation of test needs clinical 
guidance13,130,134,138,139.1. In addition to being used for the diagnosis of HF, the cardiac 
peptides may also be beneficial in the treatment of patients with HF. 
 
Figure 2.7 BNP level and symptom by NYHA 
Adopted from Weber and Hamm, 2006;92(6):843-849 
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Evidence on the use of BNP to monitor HF patients has been reported previously140. 
The results showed that monitoring HF using the guidance of BNP and/or NT-proBNP 
resulted in fewer cardiovascular deaths and total cardiovascular events than without 
guidance. However, a recent systematic review and meta-analysis showed the benefits 
of therapy guided by this test were present only in patients with HFrEF (Figure 2.8)132. 
 
Figure 2.8 Treatment guided by (NT-pro)BNP 
Adopted from Brunner-La, Eur J Heart Fail. 2015;17(12):1252-1261. 
 
2.2.1.2 BNP and NT-proBNP in asymptomatic SBHF 
In patients without symptoms, the presence of cardiac structural and functional 
impairment (stage B heart failure) was also associated with elevated BNP and NT-
proBNP. The association with systolic dysfunction defined by reduced ejection 
fraction has been reported in a systematic review and meta-analysis139. The test 
Table 2.11 Cut-off values for the diagnosis of HF  
 Rule out:  
HF unlikely 
Rule in: 
HF likely 
BNP (ng/L) 100 
 
400 
500 
NT-proBNP* (ng/L), age<50  300 450 
NT-proBNP* (ng/L), age>50 300 900 
NT-proBNP** (ng/L), age<75 125  
NT-proBNP** (ng/L), age>75 450  
*(Weber and Hamm, 2006)8, ** (Radem, 2005)16 
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sensitivity by various cut-off values is displayed in Table 2.12. The association with 
left ventricular hypertrophy and diastolic dysfunction was also reported 4 46,139,141-144.  
Table 2.12 Test accuracy of BNP for reduced ejection fraction 
 
However, in these asymptomatic “seemingly normal” individuals, what denotes an 
“elevated or abnormal” value can be ambiguous, challenging and difficult. Figure 2.9 
and Figure 2.10 shows the “near normal” values which show variations in age and 
gender specific community individuals with systolic and diastolic dysfunction. 
 
Figure 2.9 BNP and systolic function by reduced EF 
 
  
n 
BNP/NT-proBNP 
Sensitivity Specificity 
Hutcheon et al 2002 
(BNP cut-off 35 
pmoL/l) 
304 
 
0.94 (0.79-1.0) 0.63 (0.57-0.69) 
Hutcheon et al 2002 
(BNP cut-off 49 
pmoL/l) 
304 0.84 (0.66-0.95) 0.69 (0.63-0.74) 
Kruger et al 2004 
(BNP cut-off 23pmol/l) 
66 0.89 (0.79-0.96) 0.56(0.42-0.68) 
Landray et al 2000 
BNP cut-off 5pmol/l) 
126 0.88 0.73-0.96) 0.34 (0.24-0.45) 
Modified from systematic review and meta-analysis by Davenport, Br J Gen Pract. 
2006;56(522):48-56 
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Figure 2.10 BNP levels and diastolic function 
 
2.2.1.3 Issues about this biomarker 
Regardless of whether patients have or don’t have symptoms, the main concern is the 
issue of common confounding factors. The “normal range” can be broad and with 
substantial analytical and biological variabilities. This may not be important when 
tested values are markedly elevated in patients in advanced stages, but critical when 
values are at near “normal” or at upper limit of normal patient without symptoms. A 
few known confounding factors are summarized as follows: 
First, the effect of age and gender. BNP/NT-proBNP levels are significantly higher in 
normal females and significantly increased with age145,146. Although age related 
comorbidities may also be confounders, the several fold differences in apparently 
normal individuals seemed to be physiological145. Age and gender stratified normal 
limits were suggested from the Framingham study (Figure 2.11). The limit of specified 
cut-offs can make clinical interpretation challenging and difficult in the context of 
other comorbidities. 
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Figure 2.11 Proposed normal BNP levels stratified by age and gender 
Thomas J. Wang et al, Am J Cardiology 2002; 90 254-258 
 
Second, BNP/NT-proBNP levels are inversely related to BMI, in particular visceral 
adiposity. This is possibly related to insulin resistance and metabolic 
disturbance142,147,148. Visceral adiposity is highly prevalent in non-ischemic stage B 
heart failure, so the variability of this test is therefore particularly challenging.  
Third, compared with subjects with cardio vascular risk factors, the value of this 
marker was found to be limited in seemly healthy individuals134. This indicates a 
limited value of this test in early disease stage for screening in the general population. 
Fourth, BNP was found not to be an optimal test for mild systolic dysfunction, nor for 
diastolic dysfunction - even with age and sex-specific discriminatory values13. BNP 
was increased to a lesser extent in subjects with diastolic dysfunction than LV 
hypertrophy or LV systolic dysfunction. Individuals with sole diastolic abnormality 
displayed BNP concentrations at the control level130, indicating BNP can be near 
normal in those with evidence of early cardiac dysfunction. Thus, the value of BNP is 
undetermined in early disease stage (SBHF). 
Fifth, head-to-head comparison of BNP and NT-proBNP results suggested BNP to be 
a better indicator than NT-proBNP in population screening for cardiac dysfunction or 
diagnosis of clinical heart failure142. The cause of the difference and the associated 
clinical impact has not been determined. It is unknown whether analytical or biological 
variability is the underlying cause. However, this is an important issue in the context 
of community screening. 
2.2.1.4 Community screening using BNP – current evidence  
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In the hope that this simple and relatively inexpensive but feasible test may be ideal to 
detect cardiac dysfunction in the community, screening using BNP/NT-proBNP for 
reduced EF has been reported in multiple large population studies. These are the 
Framingham study 2, Olmsted County population13,134, the MONICA cohort1, the 
Multi-Ethnic Study of Atherosclerosis (MESA) cohort144 and the Atherosclerosis Risk 
in Communities (ARIC) study cohort149. The overall test performance for diagnosis of 
left ventricular dysfunction was sub-optimal. In a meta-analysis, Ewald142 
systematically assessed the diagnostic performance and characteristics of BNP or NT-
proBNP in thirteen community based studies (Table 2.13).   
Table 2.13 Community screening studies using BNP and/or NT-proBNP 
 
The potential causes of suboptimal performance of natriuretic peptides in community 
screening of stage B heart failure are multiple. As discussed in the previous section, in 
the presence of multiple common confounding factors, the cut-point used was a major 
limit. Besides, reduced LVEF was used as marker of cardiac dysfunction and the 
prevalence of this marker in the community is low. Given the poor test performance, 
there seems to be a concern regarding the value of the test for initial screening for 
subsequent echocardiogram, as it may overwhelm the echo service1,2,13,142. 
 
 
  Author Reference standard Assay Age (SD) % (f) Sen. Spe. DOR 
1 Luchner1  LVFS<28% BNP 58 56 55 86 7 
2 Vassan2 male LVEF <40% BNP 58 0 65 86 11 
 female    100 80 90 36 
3 McDonagh4 LVSD undefined BNP 51(14) 51 77 87 21 
4 Hobbs6 HF BNP  66 (11) 48 80 88 30 
5 Smith9 LVSD undefined BNP 76 (4) n/a 92 65 21 
6 Ng10 Wall motion score>2 BNP 63 44 88 90 68 
7 Groenning11 LVEF<40% NT-proBNP 68 57 76 67 7 
8 Aquilar12 LVEF<50% NT-proBNP 66 54 92 68 22 
9 Redfield13 LVEF<40% BNP 62(11) 52 90 77 29 
  LVDD    44 91 8 
10 Hedberg14,15 LVEF<40% BNP 75 50   29 
11 Hutcheon17 LVSD undefined BNP 79 65 97 38 8 
12 Epshteyn18 LVSD+DD BNP 54(16) 4 75 76 17 
13 Bibbins-D19 EF<45% BNP 69(10) 8 60 47 7 
    EF<55% or DD BNP 69(10) 8 44 53 5 
Modified from Ewald. Internal Medicine Journal 38 (2008)101-113. 
LVFS: left ventricular fractional shortening; LVEF: left ventricular ejection fraction; LVSD: 
left ventricular systolic dysfunction; HF: hear failure; DD: left ventricular diastolic 
dysfunction; DOR: diagnostic odds ratio. 
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The issue of preserved versus reduced ejection fraction in both asymptomatic and overt 
HF further complicates the test performance. In particular, the value of natriuretic 
peptides in guiding therapy in diagnosed HF patients has shown benefit in patients 
with HFrEF but not HFpEF132. However, this is beyond the scope of this research and 
will not be discussed further. A summary of pros and cons of BNP/NT-proBNP test is 
listed in Table 2.14.  
Therefore, considering the current evidences as mentioned above and the potential 
high costs of these tests in our study, we chose not to include these markers in this 
thesis.  
Table 2.14. Pros and cons of BNP/NT-proBNP test 
 
2.2.2 Cardiac biomarker – Soluble ST2 
In addition to natriuretic peptides, new emerging cardiac biomarkers are gaining 
attention for their value in the diagnosis and prognosis of heart failure. Among these, 
ST2 is a soluble protein, a family member of interleukin-1 receptor, expressed by the 
heart in response to myocardial damage. There are two ST2 isoforms: transmembrane 
bound ST2 and soluble, i.e. circulating ST2. Interleukin-33 is the ligand for both 
isoforms, and binding to the transmembrane form of the receptor exerts a protective 
anti-hypertrophic, anti-fibrotic effect on cardiomyocytes150,151. Soluble ST2 (sST2) 
binds and removes interleukin-33 from the circulation, thus decreasing activation of 
 Pros Corns 
Diagnosis 
 
 
Good to rule out HF, especially in 
acute HF. 
Simple test in ED 
Not good to rule in HF.  
Low level cannot exclude HF 
 
Cut point and 
confounding 
factors 
 
 
Manufacturer recommended 
100pg/mL as cut-off to rule out. 
 
 No single cut-point, most authors 
self-defined cut points based on study 
sample  
 Should consider confounders:  
age, gender, obesity, ethnicity, renal 
function and AF 
 Large biological variability, serial 
tests need to consider confounding 
factors  
Predicting 
outcomes: 
 
 Despite the differences in 
baseline models and cut-points, 
lengths of FU, both test show 
predictive value for all 
outcomes 
 High levels relate to severity 
and worse outcome 
Serum levels do not change rapidly 
with changes in disease status 
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the transmembrane receptor and potentially promoting adverse myocardial 
remodelling and fibrosis150,151. According to the approval of the US Food and Drug 
Administration (FDA), the normal cut-off value is >35 ng/mL. 
2.2.2.1 Soluble ST2 in symptomatic patients with HF 
In patients with acute or chronic heart failure, the American College of Cardiology/ 
American Heart Association guidelines recommend measurement of sST2 for additive 
risk stratification152,153. High sST2 levels are associated with an increased risk for HF 
progression, rehospitalisation, heart transplantation and death. These risks are 
independent of traditional and biochemical risk factors including BNP and NT-
proBNP154. The advantage of using sST2 over BNP and NT-proBNP includes the 
following: 1) sST2 is not adversely affected by common confounding factors like age, 
gender, body mass index, atrial fibrillation and has a single cut point.  2) sST2 shows 
good prognostic value regardless of LVEF155. 3) In HF patients with low NT-proBNP 
levels, elevated sST2 was able to stratify the highest risk patients and provided 
prognostic value156. However, in the presence of low sST2, natriuretic peptides did not 
predict mortality156. Comparison of cumulative hazard of death in patients with acute 
HF stratified by sST2 levels and NT-proBNP is summarized in Table 2.15. 4) Serial 
measurement assessing disease progression over time, sST2 provided with a better 
“reference change value” over BNP and NT-proBNP, which is likely to detect true 
disease change rather than biological variability157-159. 
Table 2.15 Mortality rate in acute HF stratified by ST2 and NT-proBNP 
 
2.2.2.2 Soluble ST2 in community asymptomatic patients with SBHF 
Evidence of sST2 in predicting incident HF in the community was evaluated in several 
large population studies including Framingham160, Cardiovascular Health161 and 
FINRISK97162. Findings from these studies showed that, although associated with 
older age, male gender and myocardial injury and other fibrosis markers, the predictive 
NT-proBNP 
Soluble ST2 
Below Median Above Median 
Below median 10% 40% 
Above median 28% 56% 
Cumulative rate at 1 year follow up. Modified from Rehman SU et al, J Am Coll Cardiol 
2008;52(18):1458-1465. 
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value for new HF in the presence of other risk factors and biomarkers was only 
modest161,162. Therefore, sST2 may not be a useful predictor for incident HF and 
cardiovascular outcome in the community160. 
2.2.3 Cardiac biomarker – MicroRNA 
The term “microRNA” (miRNA) was first described in 1993163. After this discovery, 
scientists began to recognize its importance as a regulator in gene expression. MiRNAs 
are small non-coding strands of (approximately 17-25) nucleotides. The main role of 
miRNAs is to regulate gene expression by either initiating translational repression or 
degradation of messenger RNAs (mRNAs)164. The effects of miRNAs on repressing 
mRNA translation take place inside cells. However, in 2008, miRNAs were discovered 
outside cells and in circulating blood165. These extracellular circulating miRNAs are 
remarkably stable and may be used as circulating biomarkers for diseases. Based on 
current knowledge, there are at least 2588 mature human miRNAs identified and listed 
in “miRNBase” (mirbase.org). Currently, circulating miRNAs are emerging as 
important biomarker for cardiovascular diseases including heart failure for their 
diagnosis, prognosis and more importantly as therapeutic targets (Figure 2.12).  
 
Figure 2.12 Micro RNA and Cardiac vascular risk factors and disease 
Adopted from Maegdefessel et al, J Intern Med. 2014;27(6):633-644. 
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In the field of miRNA biomarker assessment, the sets of miRNAs used for evaluation 
are defined as signatures. Combining two or more miRNA biomarkers as a defined set 
can enhance discriminatory power. For instance, in a two-step screening study, Vogel 
et al found a signature of eight miRNAs (miR-520d-5p, miR-558, miR-122, miR-200b, 
miR-622, miR-519e, miR-1231 and miR-1228) can reliably predict the diagnosis of 
HFrEF with an AUC of 0.81166. He also found the most power single miRNA signature 
for HFrEF was miR-558, followed by miR-122 and miR-520d-5p166. 
2.2.3.1 Micro RNA in HFrEF and HFpEF 
Pathophysiologically, HFpEF is the clinical manifestation of LV diastolic dysfunction. 
In order to assess whether circulating miRNAs can be utilized as biomarkers in the 
detection of HFpEF, in a differentiated diagnosis compared to HFrEF, Nair has 
recently found miR-454, miR-500 (both down-regulated) and miR-1246 (up-
regulated) were significantly dysregulated in HFpEF. Their findings indicated that 
circulating miRNAs can serve as biomarkers to identify and possibly to guide therapy 
for this clinically most challenging disease phenotype167. Similarly, Wong et al had 
identified 344 miRNAs dysregulated between HFpEF, HFrEF and healthy controls168. 
These findings has been reported in another recent study by Watson et al in a similar 
study cohort and further validated in a larger data set169. These analyses showed 
various miRNA signatures are useful for HF and also in the differentiation of HFpEF 
from HFrEF170. 
2.2.3.2 Micro RNA in cardiac hypertrophy and fibrosis 
Cardiac remodelling and fibrosis are important factors in the development of 
ventricular wall stiffness with compromised ventricular contractility and compliance. 
The expression of miRNAs is directly linked to the progression of HF. Although 
important, current evidence is largely based on experimental models. Several studies 
reported altered miRNA levels in cardiac hypertrophy and induction of cardiac 
hypertrophy by alterations of specific miRNAs171. Especially miR-1172, miR-21173, 
miR-133173, miR-195174, miR-208175 were proven to be involved in regulation of 
cardiac hypertrophy.  
Cardiac fibrosis is a common phenotype and found in several cardiac diseases 
including myocardial infarction and heart failure. Cardiac fibrosis is characterized by 
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the adverse accumulation of collagens and other extracellular matrix proteins. In a 
transgenic mouse model, miR-21 was discovered as a key regulator of signalling 
pathways in cardiac fibroblasts controlling the extent of cardiac hypertrophy and 
interstitial fibrosis176. Several other miRNAs have been identified as also targeting 
collagens and relating to cardiac fibrosis including miR-24177 and miR-29178. 
2.2.3.3 Long non-coding RNA in cardiovascular disease 
Long non-coding RNA (LncRNA) are currently defined as transcripts greater than 200 
nucleotides without known protein-coding function179. Recent reports have started to 
reveal the importance of LncRNA in cardiac development and their involvement in 
HF. However, the clinical application of this marker is still at an early stage and little 
is known about the specific function of these transcripts Table 2.16. 
Table 2.16 IncRNAs in cardiovascular disease 
 
2.2.3.4 Micro RNA in community cohorts 
There is currently little evidence available in community screening using miRNA as a 
screening tool. The only study of miRNA in a community cohort was performed in the 
Framingham Heart study (FHS) cohort of 2391 participants with measuring 159 
miRNAs. The study was aimed to understand the comparability of cellular and 
extracellular sources of miRNA expression180. Findings from the study showed that 
plasma and blood miRNA levels are divergent and may reflect different biological 
processes and disease associations. 
2.2.3.5. Micro RNA and targeted therapeutics 
Disease IncRNA Patient number Validation 
referenc
e 
Myocardial 
infarction 
 
HIF1A-AS2, 
ANRIL, 
KCNQ1OT1, 
MIAT (STEMI), 
MALAT1 
274 
STEMI/140NSTEMI/86c
ontrol 
Correlation to 
Troponin 
Vausort3 
Heart 
failure 
LIPCAR 
Screening in 15/15 LVM, 
validation in 87 ICM, 
w/139 ICM w/o LVM 
Associated with 
future CV death 
Kumarsw
amy5 
Coronary 
artery 
disease 
CoroMarker 221 CAD/187 control 
Expression analysis 
vs, a variety of other 
CV disease 
Yang7 
Adopted and modified from Busch A et al, Annals of translational medicine. 2016;4(12):236 
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The discovery of circulating miRNAs has provided new windows for novel drug 
development by the administration of extracellular miRNAs. This includes reparative 
miRNA therapies and/or preventative therapies. Low expression levels of miRNAs 
can be restored with miRNA mimics, exogenously using adeno-associated viruses, 
subcutaneously and directly into the circulation181. The outlook for the clinical 
application in heart failure remains promising, with ongoing phase II clinical trials of 
inhibitory molecules has been carried out in non-cardiovascular fields. 
In conclusion, miRNAs are increasingly recognized to play important roles in 
cardiovascular disease, including heart failure. MiRNAs are detected in the circulation, 
and are proposed as potential diagnostic and prognostic biomarkers in HF. However, 
their role and function in the circulation remains to be resolved. 
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2.3 Electrocardiogram  
Electrocardiography (ECG), similarly to biomarkers, is potentially a suitable screening 
tool at primary care level to pre-select individuals for further echocardiography. 
Although the overall diagnostic sensitivity is known to be low for prediction of 
echocardiographic markers182,183, ECG has its unique feature as a feasible and less 
costly diagnostic tool in the community, comparable to bio-markers139.  
The role of ECG markers in the process of community screening will be analysed and 
discussed in Chapter 7 (Association between ECG and echo markers and outcome) 
of this thesis. 
2.4 Hand-Held Echocardiography 
Given the cost and availability of the standard echocardiography, a hand-held 
ultrasound (HHU) system may able to provide a potential substitute. A modern HHU 
device is characteristically lightweight, portable and may fit into a coat pocket. Most 
HHU devices provide B mode grey-scale imaging, some with colour Doppler, but not 
spectral Doppler. HHU can play an important role in structural cardiac evaluation. 
Although there has been growing interest in the role of HHU as a screening tool in the 
community, the main limitations relate to its imaging capabilities relating to evaluation 
of non-ischemic stage B heart failure. Other than assessing LV ejection fraction, the 
current HHU system does not provide assessment of diastolic   functional assessment 
and speckle tracking analysis for early systolic alteration184,185. As these advanced 
imaging modalities, mainly spectral Doppler, tissue Doppler and speckle tracking 
echocardiography, are key elements in the assessment of early cardiac dysfunction, 
this represents an important limitation in the community detection of non-ischemic 
stage B heart failure. Therefore, we did not include the application of HHU in this 
Thesis. 
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Postscript 
Findings from this chapter suggest that a variety of risk factors are known to be 
associated with HF, the strongest association of non-ischaemic factors are diabetes 
followed by age, hypertension, smoking, male gender and increased BMI. Current 
cardiac peptide and other biomarkers may not be suitable in community screening with 
largely near normal cardiac function. 
The next chapter will describe the TasELF study (Tasmanian study of 
echocardiographic detection of stage B heart failure – a population based sample used 
for this thesis. The chapter will also describe the methodology of echocardiography, 
electrocardiography, questionnaires and functional capacity assessment using 6-
minute walk test.
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Chapter 3. Methods 
Introduction 
This thesis aimed to show the benefit of imaging testing by screening at-risk subjects 
from the local community. The screening clinic included comprehensive clinical 
evaluation, standard questionnaires, assessment of functional capacity using 6-minute 
walk test (6MW), a 12 lead electrocardiogram (ECG) and comprehensive 
echocardiography.  
This chapter describes these relevant methodologies accordingly:  
1) Overall study design of Tasmanian Study of Echocardiographic Detection of Left 
Ventricular Dysfunction (TasELF) - a randomized controlled trial with CONSORT 
(Consolidated Standards of Reporting Trials) check list. 
2) Standard echocardiography and relevant imaging modalities. 
3) Standard questionnaires used in this research for the assessment of activity status, 
symptoms and quality of life. 
4) Standard method used for 6-minute walk test.  
More specific methods used for each topic can be found in the respective studies 
presented in the subsequent chapters. 
3.1 TasELF trial 
The Tasmania Study of Echocardiographic Detection 
of Left Ventricular Dysfunction (TasELF) 
No evidence is available about the benefit of early identification and early intervention 
in those at high risk of heart failure patients to delay or to prevent progression to 
clinical overt heart failure. 
3.1.1 Overall Study Design 
Chapter 3- Methods  94 
 
The study was designed as a Randomized Controlled Trial (RCT) of imaging 
modalities. Stage A heart failure patients were recruited from the local community. 
They were randomized into two screening imaging arms. The advanced Imaging arm 
measured global longitudinal strain (GLS) and diastolic function assessment. The 
presence of either one or in combination was used to define the presence of stage B 
heart failure. Conventional imaging involved measurement of left ventricular ejection 
fraction alone, and reduced ejection fraction was defined as the presence of stage B 
heart failure.  
Treatment were advised in the presence of stage B heart failure. The prognostic 
implications were explained in face to face discussion between patient and 
cardiologist. Treatment titration plan and guidance for monitoring were also shared 
with the patient’s general physician. 
Participants were followed regularly according to study protocol for process 
evaluation and for outcome.  
The overall study flow and design are summarized in Figure 3.13
 
Figure 3.13. Study design and patient flow 
Patient selection and randomization to Advanced imaging arm (AE) and Conventional imaging arm (C) 
with subsequent usual care or intervention in stage B patients. 
 
3.1.2 Sample Calculation 
The total sample was calculated to be 800 with 400 in each arm. Sample power 
calculations were based on the following: 1) previously reported 25% cumulative rate 
of incident heart failure (new heart failure) among patients with evidence of stage B 
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heart failure under usual care57; 2) expected minimum follow-up time of 2-years from 
the last recruitment; 3) a 50% reduction of incident heart failure among the treated 
group (n=186) compared with usual care (n=186), to provide two-sided α=0.05 and 
80% power to document benefit of therapy; 4) expected 7.5% annual rate of loss of 
contact; 5) expected abnormal cardiac function present in ~50% of those under 
advanced imaging modality for screening (Table 3.17).  
Table 3.17 Power calculation of study samples. 
 
3.1.3 Target Population 
We studied community individuals at risk of heart failure. Three heart failure risk 
scores are available, the Framingham heart failure risk score80; the Health ABC heart 
failure risk score79 and the ARIC heart failure risk score78. However, each has 
limitations, either due to the population the score was derived or the need of 
biomarkers for calculation. Therefore, the selection of the target population was not 
based on these scores. 
Data from our systematic review and meta-analysis allowed us to quantify and 
compare each stage A heart failure risk levels, but was not able to calculate the absolute 
risk of each individual. We selected patients ≥ 65 years with risk factors for heart 
failure. 
Target population and selection was performed according to American College of 
Cardiology/American Heart Association Guideline for the Diagnosis and Management 
of Heart Failure in Adults)25 (Figure 3.14). We selected the non-ischemic stage A heart 
failure risk factors: hypertension, diabetes, obesity, metabolic syndrome, using 
cardiotoxins and family history of cardiomyopathy. 
3.1.4 Length of Study 
  Heart Failure therapy Usual care 
According to power calculation 186 186 
Drop-outs (7.5% per year x 2 years) 28 28 
Normal Cardiac function 50% 186 186 
 400 400 
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We planned 24-month of recruitment and 24-month of follow-up from the last 
recruitment. The median follow-up time was planned to be 36 months. 
 
Figure 3.14 Stage in the development of heart failure.  
Adopted from Hunt et al. JACC Vol. 53, No. 15, 2009  
 
3.1.5 Means of recruitment 
Recruitment was conducted through announcements in local public places (community 
centres); advertisement in local media (radio/TV); organized community outreach by 
visiting the local Lions/Rotary events. These activities had influences not only on our 
potential participants, but also on their neighbours, friends and family who either 
volunteered or helped to identify at risk subjects. 
3.1.6 Inclusion Criteria 
• Age: at least 65 years of age (≥ 65 years) 
• The presence of at least one of the following 1) Hypertension, based on SBP>140 
mmHg and self-report of HTN including anti-hypertensive medication; 2) type 2 
diabetes mellitus, based on self-report of diagnosis including medication; 3) obesity, 
based on body mass index (BMI) ≥ 30 g/m2; 4) previous potentially cardio-toxic 
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chemotherapy; 5) familial cardiomyopathy; 6) previous history of heart disease (but 
not existing heart failure).  
3.1.7 Exclusion Criteria 
• Unable to provide written informed consent to participate in this study 
• History of previous heart failure, baseline NYHA >2 
• History of coronary artery disease (previous myocardial infarction, myocardial 
revascularization, coronary stents, positive stress test, or echocardiographic screening 
of LVEF<40%.  
• Known history of more than moderate valvular heart disease  
• Systolic BP <110mmHg, pulse <60/minute 
• Serious life-threatening disease (anticipated life expectancy <2 years) 
• Pre-existing treatment with both investigational drugs (ACEi/ARB and Beta blocker) 
classes, or one class at maximum dose 
• Contraindications/Intolerance of either beta blockers or ACEi/ARB,  
• Participating in any other clinical research trial 
• Atrial fibrillation (Unable to determine diastolic function) 
• Inability to acquire interpretable images (identified from baseline echo) 
3.1.8 Recruitment  
Means of recruitment were as follows: 
 Announcement in public places including Lions/Rotary/Men’s shed 
 Recommendation by GP and leaving trial flyers in GP’s office 
 Advertisement and public talk in local media (radio/TV) 
 Facebook web page 
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Recruitment was carried out during September, 2013 – November, 2015. Echo 
screening outreach service were held in 9 community locations: Huonville, Oatlands, 
Burnie, Deloraine, Devonport, Geeveston, Latrobe, Launceston, Longford, Menzies 
(Figure 3.15).  
 
Figure 3.15 TasELF outreach echo clinic locations  
        TasELF clinics held: Huonville, Oatlands, Burnie, Deloraine, Devonport, Geeveston, Latrobe, 
Launceston, Longford, Menzies 
 
The total number of clinic days were 160 and the number echocardiograms performed 
(including baseline screening and partial follow-up scan at 1 year) was 953 (Table 
3.18). The participants were across most areas of the State of Tasmania, covering >97 
postal areas. Many of them had to take a long drive to travel from their home to these 
clinic sites. For instance, participants travelled from Queenstown to Burnie, from King 
Island to Launceston, from St Helens to Launceston, from Swansea to Hobart, from 
Smithton, George Town and Scottsdale to Burnie, Latrobe and Launceston to attend 
clinics. 
Table 3.18 Summary of TasELF clinic days and number of participants 
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3.1.9 Clinical Evaluation 
A total of 1026 potential participants applied to participate. All completed clinical 
screening. All subjects underwent a clinical evaluation for eligibility (Figure 3.16) and 
risk assessment. This included clinical history, medication status and standard 
questionnaire to assess baseline general health status (EQ5D), activity (Duke Activity 
Score Index) and heart failure symptoms (MLHFQ). We excluded 378 participants not 
meeting clinical inclusion criteria, who did not proceed to echocardiography. The 
detailed causes of exclusion are summarized in Figure 3.16.  
 
Figure 3.16 Summary of TasELF recruitment and inclusion 
 
Location Clinic (days) Participants (number) 
Burnie 8 69 
Deloraine 2 20 
Devonport (Latrobe) 11 59 
Geeveston 2 18 
Huonville 2 18 
Launceston 20 167 
Longford 2 17 
Oatlands 2 26 
Menzies 100 559 
Total 149 953 
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3.1.10 Echocardiographic evaluation and inclusion 
Of the 648 (64%) who met clinical inclusion criteria and were eligible for baseline 
echo screening, 30 were found to have previously unknown cardiac conditions (listed 
in Figure 3.16) and were excluded after echocardiography. Left ventricular abnormal 
systolic function (EF <40%) or more than moderate valvular disease were excluded. 
Details of the echocardiographic assessment protocol are discussed in section 3.2. This 
process left 618 eligible for randomization. 
3.1.11 Randomization 
The randomization followed a Prospective Randomized Open Blinded Endpoint 
(PROBE) design186. This approach was adopted in consideration of the safety of 
intervention titration in these elderly participants. The monitoring of potential 
tolerance and side effects were allocated to the patients’ primary care giver. The 
outcomes including new heart failure events, exercise capacity, symptom status, 
general health and heart failure specific quality of life were to be assessed by 
investigators blinded to allocation status.  
Randomization was done using a central web based system at Menzies Data 
Management Centre (using a computerized protocol). The randomization used 
adaptive allocation and was stratified according to baseline diabetes status. The people 
receiving the treatment, the people assessing the outcomes and the persons analysing 
the data and results were masking/blinding at randomization. 
The 618 eligible participants were randomized to two imaging strategies: Imaging 
guided care using advanced imaging markers (AE) versus usual care (UC) arms. 
Advanced imaging was characterised by the inclusion of global longitudinal strain 
(GLS) and diastology evaluation. The presence of a global longitudinal strain < 18%85 
or diastolic dysfunction were used to advise AE participants of LV dysfunction in a 
face to face discussion with a cardiologist and communicated to their GP for initiation 
of treatment and for treatment monitoring as discussed in the following section. 
UC arm was limited to evaluation of left ventricular ejection fraction. All participants 
in this arm had ejection fraction >40%, advice to initiate treatment in this arm was 
based on individual history. Treatment implications of abnormal echo findings were 
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explained in a face to face discussion with a cardiologist and communicated with their 
primary physician. 
3.1.12 Treatment strategy and titration 
Subjects with an abnormal echocardiographic findings were identified as having stage 
B heart failure and only stage B heart failure participants were advised to initiate 
treatment under the supervision of their physician. The physicians were given a 
detailed study protocol, prognostic implications of individual findings according to 
current guidelines, treatment titration plan and guidance for monitoring adverse events 
and severe adverse events according to the study protocol. 
In the presence of stage B heart failure, by protocol, these patients were initially treated 
with Ramipril at dose of 1.25 or 2.5 mg (according to baseline systemic arterial 
pressure), once or twice a day, and gradually up-titrated to 10 mg/day, or to the 
maximal-tolerated dose (Table 3.19). In patients receiving at least 5 mg/day of 
ramipril, metoprolol was started at an initial dose of 12.5 mg/day and progressively 
up-titrated to the maximal dose of 100 mg/day. Additional heart failure therapy 
(diuretics, anticoagulants or antiarrhythmic drugs) were given at the discretion of the 
physician. Treatment records regarding drug accountability were checked by self-
report questionnaires.  
Table 3.19 Medication titration Schedule 
 
3.1.13 Usual Care  
Weeks since starting 
therapy 
0 2 4 6 8 10 12 14 16 
Ramipril (mg/d)* 1.25 2.5 5 5 5 5 5 5 10 
Metoprolol (mg/d) ٭٭   12.5 25 37.5 50 75 100  
*if patient is already on an ACEi or ARB, there no need to change, however, please up-titrate to the 
maximal tolerable dose.  
** if patient is already on another B-Blocker, there is no need to change, please up-titrate to the 
maximal tolerable dose. 
During treatment, patients need to be seen every 2 weeks during the up titration phase. At each of 
these visits, symptoms status (fatigue, dizziness), blood pressure and heart rate need to be obtained. 
If patients complain of side-effects or the heart rate is <50 beats per minute, the dose should be 
reduced to the prior to the last increment. 
Discontinuation criteria: symptoms consistent with cardiac dysfunction (dyspnea, reduced exercise 
capacity), side effects of therapy (fatigue), progression of cardiac dysfunction (EF<50%, dyspnea, 
reduced exercise capacity) 
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Participants with normal left ventricular ejection fraction and free of significant 
valvular abnormalities from conventional imaging arm, or participants with normal 
diastolic function and normal global longitudinal strain were advised to follow their 
current standard care under their general physician. In the case of progression to heart 
failure, referral to cardiologist and on treatment were provided by their general 
physician. 
3.1.14 Safety Evaluations 
Safety evaluations were performed by recording adverse events and serious adverse 
events, and monitoring vital signs and physical examinations. The following cardiac 
and non-cardiac events were considered as adverse or serious adverse events: 
• Sudden death 
• Death resulting from a cardiac cause 
• acute pulmonary oedema 
•Overt heart failure requiring hospitalization 
• Life-threatening arrhythmias requiring treatment 
• Conduction disturbance requiring a permanent pacemaker 
3.1.15 Follow up 
All subjects were tracked by phone calls on the 3rd, 6th- 12th month for possible 
symptoms and intervention related adverse effect.  
At 12 month follow up, potential HF symptoms were assessed through regular follow-
up phone calls, followed by symptom surveillance questionnaires and clinical visits. 
During the process, information on all-cause hospitalization was monitored and 
collected. Possible heart failure signs and symptoms were reviewed by 3 independent 
cardiologists, and heart failure diagnosis was confirmed using the Framingham criteria 
for HF110. 
3.1.16 Endpoints 
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At one year, the primary composite end points were new onset of heart failure and 
death of cardiovascular causes. 
The diagnosis of new heart failure used Framingham criteria. The Framingham 
diagnostic for clinical congestive heart failure was described in chapter 1 and section 
1.2.2 (Table 1.1). 
3.2 Standard Echocardiographic Evaluation 
3.2 Standard Echocardiography 
3.2.1 Standard echo protocol for screening 
Standard transthoracic 2D and Doppler echocardiographic studies were performed 
using standard equipment (Siemens ACUSON SC2000, Siemens Healthcare, 
Mountain View, CA) and transducer (4V1c, 1.25-4.5 MHz; 4Z1c, 1.5-3.5 MHz) in 
accordance with the American Society of Echocardiography (ASE) guidelines 187,188. 
Images were digitally recorded. The standard TasELF echo screening and evaluation 
protocol is summarized in (Table 3.20).  
Table 3.20 Standard TasELF echocardiography screening protocol 
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3.2.2 M-mode assessment  
Standard M-mode assessment was performed in the parasternal long axis, or long axis 
guided parasternal short axis views. The measurements of left ventricle were septal 
wall, internal dimension and posterior wall during end diastole were followed the 
American Society of Echocardiography’s recommendation for cardiac chamber 
quantification187 and for the calculation of left ventricular mass (Figure 3.17). In the 
cases when a perpendicular was impossible, 2-D linear measurement was used for this 
calculation. Echo-LVH was defined as LVMi>115 g/m2 in men and >95 g/m2 in women187. 
 
Figure 3.17 M-mode measurement of left ventricular mass 
 
3.2.3 Two dimensional echo assessment 
3.2.3.1 Assessment of left ventricular volumes and ejection fraction  
Left ventricular volume and ejection fraction were calculated from the apical 4- and 2-
chamber views using the Simpson’s rule method (Figure 3.18). 
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Figure 3.18 Measurement of LV volume (Modified Simpson’s) 
3.2.3.2. Assessment of left atrial volume 
Left atrial volume was calculated from the apical 4- and 2-chamber views using the 
Simpson’s rule method. LA enlargement (LAE) defined as LAVi≥34 ml/m2  (Figure 3.19)187. 
 
Figure 3.19 Measurement of left atrial volume 
 
3.2.4 Standard Doppler assessment of diastolic function. 
Mitral inflow peak early diastolic velocity (E), peak late diastolic velocity (A), E/A 
ratio, E wave deceleration time (DecT) were measured for diastolic function 
assessment. Tissue Doppler mitral annular early diastolic velocity (e’) was assessed at 
septal and lateral annulus and averaged for calculation of E/e’; septal E/e’≥15, lateral 
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E/e’≥13 and averaged ≥14 were defined as abnormal188. Diastolic dysfunction (DD) 
grade was defined as previously described189. 
1) grade I Diastolic dysfunction: E/A <0.8, E/e’<10, pulmonary venous inflow S<D;  
2) grade II DD: 0.8<E/A<1.5, E/e’ > 10 or LAE, or presence of mid diastolic forward 
flow (L wave), or positive Valsalva (> 50% increased of E/A ratio);  
3) grade III DD: E/A> 1.5, DecT<140 ms.  
3.2.5 Speckle Tracking Echocardiography (STE) 
Each segment of myocardium has its own unique speckle pattern. Once the region of 
interest is defined by the operator, imaging software tracks this speckle pattern frame 
by frame throughout the cardiac cycle190. As the tracking is based on grayscale B-mode 
imaging, it is principally angle independent (Figure 3.20). Strain describes the 
deformation of the myocardium and is defined as change in length normalized to the 
original length (Figure 3.21) (Figure 3.22).  
 
Figure 3.20 Speckle tracking echocardiography.  
Modified from Leitman, J Am Soc Echocardiogr. 2004;17(10):1021-1029. 
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Figure 3.21 Measurement of strain  
(Left) long/circumferential/radial axis. (Right) calculation of strain: l0=initial length; l=instantaneous 
length. 
Modified from D’Hooge J, Eur J Echocadiogr. 2000;1(3):154-170  
 
 
Figure 3.22 Measurement of strain from three imaging planes  
(longitudinal, circumferential and radial dimension) speckle tracking and strain.  
Adopted from Mor-Avi V et al. Eur J Echocardiogr. 2011;12(3):167-205. 
 
Previous studies have demonstrated that this semi-automated imaging tool was highly 
feasible and reproducible84,123. The techniques used for this measurement followed 
standard methodology191,192. 
Left ventricular peak longitudinal strain measurements were obtained from grey scale-
recorded images in the apical 4-chamber, 2-chamber and long-axis views. The 
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endocardial border was manually traced in the end-systolic frame for each view, and 
the software subsequently traced the border in the other frames automatically. In the 
segments with poor tracking, the border was readjusted manually until adequate 
tracking was achieved. The cardiac cycle with the best tracking and visually most 
credible strain curves was selected for analysis193. 
Strain was analysed using velocity vector imaging (Syngo VVI, Siemens Medical 
Solutions) (Figure 3.23). GLS was measured on-line by averaging strain from the 
regional of interest in the apical 4-chamber, 2-chamber and long-axis views. Impaired 
GLS was defined using cut-off of <18 %85,192. Global circumferential strain (GCS) was 
measured off line. Global diastolic strain was obtained by averaging of all 18 segment 
strain values and measured according to method published by Ishii et.al194. 
 
Figure 3.23 measurement of strain 
Global longitudinal strain and diastolic strain in apical 2 chamber view 
 
3.2.6 Three dimensional (3D) echocardiography assessment 
 Assessment of LVEF was also performed by acquiring a full- volume dataset using 
4V1c probe and analysed using Syngo AVA proprietary software from Siemens. The 
3-dimensional endocardial shell was constructed using semi-automated contour 
tracing.  The resultant end-diastolic and end-systolic volumes were used to calculate 
3D-left ventricular ejection fraction Figure 3.24.  
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Figure 3.24 Three Dimensional echocardiography 
Three dimensional echocardiography assessment of LV volumes (EDV, ESV) and ejection fraction (EF) 
 
3.3 Standard Electrocardiogram 
A standard 12-lead ECG was recorded at 25 mm/s and 1 mV/cm according to a 
standard protocol. ECG measurements were performed using MUSE software (GE 
Healthcare, Milwaukee, WI, 2USA) including QRS duration and axis, PR, QT and 
heart rate corrected QT intervals (QTc).  
3.3.1 Cornell criteria and Sokolow-Lyon voltage 
Cornell voltage (Cornell-V) was measured as SV3+RaVL and criteria for LVH was 
defined as ≥2.8 mV (28 mm) in men and ≥2.0 mV (20 mm) in women195. Cornell 
product (Cornell-P) was measured as the product of QRS duration times Cornell 
voltage (RaVL+SV3, plus 6 mm in women), and criteria for LVH was defined as ≥ 2440 
mm·ms196. Sokolow-Lyon voltage (SLV) was measured as SV1+RV5 or RV6, and 
criteria for LVH was defined as≥ 3.5 mV (35mm)197. The 75th percentile of gender 
specific cut-offs for Cornell-V, SLV and Cornell-P from the current study population 
were also used as categorical cut-offs for analysis. 
3.3.2 Minimal changes in the lateral leads 
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Digital 12-lead ECG tracings were analysed by computer at midpoint of the ST 
segment on median complexes in leads V5 and V6198. The maximal magnitude of ST 
deviation in these leads was measured. The cut-off for absolute ST segment deviation 
(minSTmV5V6, the midpoint of the ST segment on median complexes in leads V5 
and V6) was defined as <-20uV.  
3.3.3 P wave terminal force 
Abnormal P-wave terminal force in the right precordial lead V1 (PTFV1)199 was 
defined as the product of the negative P-wave deflection from onset of the negative 
deflection to its nadir in lead V1 [uV] and the duration [ms]) (Figure 3.25). The cut-
off used was defined as ≤ -4000 uVms.  
 
Figure 3.25 measurement of p wave terminal force 
 
3.4 Standard Questionnaires   
3.4.1 Duke Activity Status Index.  
The Duke Activity Status Index (DASI) questionnaire is a self-assessment tool that 
was developed to predict an individual’s maximal exercise capacity 200. It includes 12 
activities representative of major aspects of physical function (personal care, 
ambulation, household tasks, sexual function, and recreational activities). A score is 
calculated based on weighted answers from 12 questions related to daily activities of 
living, for which each item is weighted by its known metabolic cost, and weights of 
positive terms are summed to form the individual patient DASI score. The possible 
scores range from 0 (“no” to all answers) to 58.2 (“yes” to all answers) with higher 
scores representing better functional activity. Estimated peak oxygen consumption 
was calculated according the original formula from Hlatky et al 200:  
Peak VO2 (in mL/kg/min) = 0.43xDASI score+9.6 
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Metabolic equivalent (MET) was calculated as 1MET=3.5 mL/kg/min. 
3.4.2 EuroQol 5 Dimensions Index and Visual Analogue Scale.  
The EuroQol 5 Dimensions Index (EQ-5D) and Visual Analogue Scale (EQ-VAS) 201 
have been used to measure general health status in numerous patient populations, 
including patients with heart failure 202. The EQ-5D descriptive system comprises 5 
dimensions: mobility, self-care, usual activities, pain/discomfort and 
anxiety/depression. The response for 5 dimensions can be combined in a 5-digit 
number which then translates to index-based values according to general population 
samples.  
The index (utilities) ranged from 0-1, with higher numbers representing better health 
status. The EQVAS records the respondent’s self-rated health on a vertical visual 
analogue scale from 0 (worst imaginable) to 100 (best imaginable). 
3.4.3 Minnesota Living with Heart Failure Questionnaire (MLHFQ) 
MLHFQ includes the most pertinent questions to assess the impact of frequent physical 
symptoms of HF - shortness of breath, fatigue, peripheral oedema, and difficulty 
sleeping, and psychological symptoms of anxiety and depression. It has 21 questions, 
each ranging from 0 (not at all) to 5 (very much).  
The MLHF is scored from 0 to 105 with lower scores representing better health 203.  
3.4.4 Anxiety and Depression scores (GAD-7) and PHQ-0 
Generalized Anxiety Disorder-7 (GAD-7) and Patient Health Questionnaire-9 (PHQ9) 
PHQ-9 is used for assessing and monitoring depression severity. It has nine items, each 
of which is scored 0 (not at all) to 3 (nearly every day), providing a 0 to 27 severity.  
GAD-7 is an anxiety measure using 7 items, each of which is scored 0 (not at all) to 3 
(nearly every day), providing a 0 to 21 severity score.  
In general, cut points of 5, 10 and 15 represent mild, moderate and severe levels of 
depressive and anxiety symptoms on PHQ-9 and GAD-7, respectively 204. 
3.4.5 SOF Frailty index.  
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The Study of Osteoporotic Fractures (SOF) frailty index 205 is a simple measure using 
3 components 206. The frailty status was defined as robust (0 components), pre-frail (1 
component) and frail (2 or more components). This is a practical index, the 
performance of which is compatible with other frailty markers 207. 
3.4.6 Charlson Comorbidity Score 
Charlson Comorbidity Score is a weighted index that takes into account the number 
and the seriousness of comorbid disease208. This method of classifying comorbidity 
provides a simple, readily applicable and valid method of estimating risk of death from 
comorbid disease for use in longitudinal studies. The assigned weights was “1” for 
myocardial infarction, congestive heart failure, peripheral vascular disease, 
cerebrovascular disease, dementia, chronic pulmonary disease, connective tissue 
disease, ulcer disease, mild liver disease and diabetes. The assigned weight was “2” 
for hemiplegia, moderate or severe renal disease, diabetes with end organ damage, any 
tumour, leukaemia and lymphoma. The assigned weight was “3” for moderate or 
severe liver disease and the assigned weight was “4” for metastatic solid tumour and 
AIDS208.  
3.5 Assessment of Functional Capacity - Six Minute Walk 
Test 
The measurement of sub-maximum functional capacity in this study was a 6-minute 
walk test distance (6MW). 6MW, conducted following a standardized protocol 209. A 
25-meter flat, obstacle-free corridor, with visible markers at each meter interval and 
stop coins placed at either end, was used. Participants were instructed to walk as far as 
possible, turning 180̊ every 25 meters in the allotted time of 6 minutes. They were able 
to rest, if needed, and the time remaining was called out after every lap. The participant 
walked unaccompanied. Verbal encouragement was given to participants. At the end 
of 6 minutes, they were instructed to stop and the total distance covered was measured 
to the nearest meter.  
Functional capacity can be estimated using Metabolic Equivalents (METS) from the 
6MW distance using a validated formula by Ross et al 210) as follows: 
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Mean Peak VO2 (ml/kg/min) =4.948+0.023*Mean 6MW distances (meters) 
In terms of relating to age and gender specific cut-offs of metabolic equivalents 
(METs) for normal male211 and female212, the following formulae were used in this 
thesis: 
For Male: METs=18.0-(0.15*age) 
For female: METs=14.7-(0.13*age) 
Postscript 
In this chapter, we have documented the methodology used in these studies. LV strain 
has a central role. So the next chapter will discuss one the most important issues of 
using strain in routine clinical management – measurement variability. So far, 
measurement variability between vendors has been documented in the literature as one 
of the most important limitations of this new metric. However, with the effort of a joint 
task force of The European Association of Cardiovascular Imaging (EACVI) and the 
American Society of Echocardiography (ASE) in 2011, it may be that standardization 
has had sufficient effect to make strain a standard measurement. 
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Appendix (the questionnaires) 
Duke Activity Status Index 
The Duke Activity Status Index has been removed for copyright 
reasons
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EuroQol 5 Dimensions Index 
The EuroQol 5 Dimensions Index has been removed for copyright 
reasons
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EuroQol5 Visual Analogue Scale 
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Minnesota Living with Heart Failure Questionnaire (MLHFQ) 
The Minnesota Living with Heart Failure Questionnaire (MLHFQ) has 
been removed for copyright reasons
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Generalized Anxiety score (GAD7) 
The Generalized Anxiety score (GAD7) has been removed for copyright 
reasons
Chapter 3- Methods 119 
Patient Health Questionnaire-9 (PHQ9) 
The Patient Health Questionnaire-9 (PHQ9) has been removed for 
copyright reasons
Chapter 3- Methods 120 
SOF frailty index 
Charlson Comorbidity Score 
The SOF frailty index has been removed for copyright reasons
The Charlson Comorbidity Score has been removed for copyright reasons
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Robust Enough? 
 
 
Article “Improvement in Strain Concordance between Two Major 
Vendors after the Strain Standardization Initiative” was published in 
Journal of American Society of Echocardiography 2015;28(6):642-8 
Yang H, Marwick TH, Fukuda N, Oe H, Saito M, Thomas JD, Negishi K 
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Chapter 4. Use of Strain for Screening – is it Robust 
Enough?  
Introduction 
One of the most important aspects of this research is to show the benefit of imaging 
surveillance in the community. In the attempt to compare the feasibility and 
effectiveness of advanced imaging (speckle tracking echocardiography and 
diastology) versus conventional imaging (left ventricular ejection fraction) in the 
community, this chapter addresses the important issue of measurement variability of 
speckle tracking.  
The conventional echocardiographic assessment of left ventricular ejection fraction 
and diastolic functional assessment has been widely used in routine clinical practice 
regardless of their load and operator dependency. Strain is a more sensitive marker and 
semi-automated technique. However, the measurement variability between vendors is 
potentially a major limitation and of concern in our community based trial. It is 
therefore important to assess whether this issue has been improved with the current 
versions of analysis software and whether the current strain measurement variability 
is acceptable and equivalent compared with that of left ventricular ejection fraction. 
The following text in this chapter has been published in the Journal of American 
Society of Echocardiography. JASE 2015; 28 (6):642-8 
Abstract 
Background: Disagreement of strain measurements among different vendors has 
provided an obstacle to the clinical use of strain. A joint standardization task force 
between professional societies and industry was initiated to reduce inter-vendor 
variability of strain. Although feedback from this process has been used in software 
upgrades, little is known about the effects of efforts to improve conformity. We sought 
whether inter-vendor agreement for global longitudinal strain (GLS) has improved 
after standardization initiatives. 
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Methods: Eighty-two subjects (52±21years, 55% male) prospectively underwent two 
sequential examinations using two most common ultrasound systems (Vivid E9 vs. 
iE33). GLS was calculated using proprietary software EchoPAC BT12 (E12) and 
BT13 (E13) versus QLAB 8 (Q8), QLAB 9 (Q9) and QLAB 10 (Q10). Agreements in 
GLS were evaluated with Bland-Altman plots. Coefficients of variation (CVs) were 
compared using Friedman test and compared with CVs of LV volumes and ejection 
fraction (EF). 
Results: Median GLS using E12 was -19.2% (inter-quartile range: -15.2%, -23.2%), 
compared with -19.3% (IQR -14.9%, -23.7%) for E13, -15.7% (-11.4%, -20%) for Q8, 
-19% (-15.7%, -22.3%) for Q9 and -18.7% (-15.7%, -21.7%) for Q10. The CVs of pre-
standardization GLS (12±8% [E12/Q8]; 14±8 [E13/Q8]) were significantly larger than 
EF (5±5) (p<0.001). After standardization, the CVs of GLS have shown improvement 
(6±4) [E12/Q9]; 7±4 [E12/Q10]; 6±4 [E13/ Q9]; 7±4 [E13/Q10]) and are similar to 
those of EF.  
Conclusions: Subsequent to the joint standardization task force, there has been 
improvement in between-vendor concordance in GLS between two leading ultrasound 
manufactures, the variability of which is now analogous to that of LVEF. The removal 
of concerns about measurement variability should allow wider use of GLS. 
4.1 Background 
Measurement of strain using two dimensional speckle tracking echocardiography 
(STE) is a relatively new test for the assessment of cardiac function, especially for the 
quantitative evaluation of global and regional myocardial function 213. STE has largely 
replaced tissue Doppler derived strain, due to reduction of angle- and operator-
dependence, and STE has become an integrated application in most commercially 
available ultrasound systems. However, variations in proprietary software among 
vendors - causing poor inter-vendor agreement in measurements – have become a 
significant limitation on the implementation of STE 86,193,214-217. This limitation has 
raised the concern of STE becoming an acceptable mainstream methodology in daily 
clinical application, especially in laboratories with echocardiographic instruments 
from multiple vendors. In order to achieve a consensus on methodology for the 
quantitative evaluation of cardiac mechanics, the European Association of 
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Cardiovascular Imaging (EACVI) and the American Society of Echocardiography 
(ASE) invited vendors to participate in a concerted effort to reduce inter-vendor 
variability of strain measurement213,218,219. Guidance has been provided about the steps 
necessary to reduce variability, and this information has been used in software 
upgrades, but little is known about the effects of this process. 
4.2 Aim and Objectives 
The aim of this study was to elucidate whether there is an improvement in inter-vendor 
global strain (GLS) agreement using STE after the implementation of standardization 
initiatives. Despite variabilities of LV volumes and ejection fraction (EF) 
measurements, these are used clinically for serial evaluation, so variations in these 
parameters were used as a frame of reference to compare variations in GLS. 
4.3 Material and Methods 
Study population. Adult participants who had clinically indicated echocardiography 
were prospectively recruited in outpatient clinic in Royal Hobart Hospital, Australia 
and Takasaki General Medical Centre, Japan from June 2013 to November 2013. A 
group of adult healthy volunteers was also included in the study. We included patients 
of age >18 years, without atrial fibrillation or flutter. All subjects underwent two 
transthoracic echocardiograms using two ultrasound systems by the same experienced 
sonographers. The study protocol was approved by the relevant Institutional Review 
Boards220.  
Standard echocardiography. Transthoracic echocardiograms were performed using 
commercially available ultrasound systems from two vendors (S5-1 probe, iE33, 
Philips, Andover, MA, USA; M5S probe, Vivid E9 and M4S probe, Vivid 7 
Dimension, GE Medical, and Milwaukee, WI, USA). Each participant first underwent 
an extensive standard assessment of cardiac anatomy and cardiac function according 
to clinical protocol with one ultrasound system. This was repeated using the other 
ultrasound system. Acquisition was obtained at the highest possible frame rate with 
optimization of image depth and sector width. Multiple consecutive cardiac cycles of 
the three standard apical views (A4C, A2C and ALAX views) were acquired and 
digitally stored as raw data for offline analysis. LV end-diastolic and end-systolic 
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volumes were performed using the biplane method of disks 221. The baseline 
assessment included standard 2D, M-mode, color Doppler, pulse wave and continuous 
wave Doppler and tissue Doppler imaging modalities using standard parasternal, 
apical, subcostal and suprasternal windows. 
Measurement of myocardial strain. Measurement of GLS has been previously 
described 193. Briefly, 2-dimensional images from 3 apical views (A4C, A2C and 
ALAX views) were used. Readings were obtained by averaging 6 segments in each 
view. GLS was determined from the average of all 18 segments. Figure 3.1 is a 
schematic description of image acquisition, strain analyses and comparisons using the 
respective three generations of proprietary software packages from the two vendors. 
In the images acquired on Vivid E9 (Figure 4.26A), speckle tracking analyses were 
performed using proprietary software (EchoPAC-PC BT12 [E12, released March 
2012] and BT13 [E13, released May 2013], GE Medical, Milwaukee, WI). After 
tracing of the endocardial border, the region of interest was adjusted to include the 
entire myocardial thickness and avoid the pericardium. The software then selected 
stable speckles within the myocardium and performed speckle tracking on a frame-to-
frame basis throughout the entire cardiac cycle. The adequacy of tracking was verified 
manually. The cardiac cycle with the best tracking and visually most credible strain 
curves was selected for analysis. In segments with poor tracking, the border was 
readjusted manually until optimal tracking was achieved. After adjustment, segments 
with consistently poor tracking were excluded. Final GLS was calculated as the 
averaged value of GLSs from each apical view, using peak negative longitudinal strain 
during the cardiac cycle. 
Since EchoPAC BT11 (E11, released May 2010) cannot analyze the images acquired 
using current Vivid E9 due to lack of compatibility with older versions of software, a 
separate group of normal volunteers was imaged using GE Vivid 7 Dimension (frame 
rate 72±6 Hz) only for the comparison of E11 and E12 (Figure 4.26B). All offline 
measurement with E11, E12 and E13 was performed by a single observer (HY).  
Images acquired on the iE33 were analyzed using proprietary software from before the 
standardization initiative (QLAB version 8.0 [Q8], released April 2010) and after the 
standardization initiative (QLAB version 9.0 [Q9], released February 2012 and version 
10.0 [Q10], released August 2013, Philips Medical, Andover, MA). For each view, 
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endocardial and epicardial borders were manually traced in the end-systolic frame 
using three software versions with the same image view. All three software versions 
were used to trace the borders automatically frame-by-frame throughout the same 
cardiac cycle. Visual inspection of the tracking was carefully performed, and if 
automated tracking was unsatisfactory, manual point-to-point and frame-to-frame 
adjustments were carefully made until satisfactory tracking was achieved. 
Electrocardiographic tracing was used to estimate the timing of end-systole and early 
diastole. All offline measurement with QLAB was performed by the same observer 
(HY). The analyses using QLAB were performed 4 weeks after analysis of EchoPAC, 
and the operator was blinded to the previous measurements.   
Statistical Analysis. Continuous variables are presented as mean ± standard deviation 
(SD). Categorical variables are expressed as percentages. Normality was evaluated 
using the Shapiro-Wilk W-test. As strain was not normally distributed, Spearman’s 
rho was used to express correlation coefficient. The agreements between two vendors 
and with two software versions were studied using Bland-Altman analysis222 to 
quantify a systemic difference (bias) between two techniques and the spread of 
differences of mean bias (limits of agreement [LOA]). Intraclass correlation 
coefficients (ICCs) were also used for the assessment of agreement. The coefficient of 
variation (CV) was calculated for all measurements. The difference of each paired 
variables was also assessed by percentage error. Percentage error was derived by 
dividing the limits of agreement divided by the mean223. The CV of different systems 
among four series of parameters (LV end-diastolic volume [LVEDV], end-systolic 
volume [LVESV], LVEF and GLS) were compared using Friedman test, followed by 
pairwise tests with Bonferroni’ s correction.  
To assess intra-observer variability, the same operator performed measurements after 
an interval of at least two weeks in 20 randomly selected subjects, blinded to previous 
measurements. For the assessment of inter observer variability, a second operator (KN) 
blindly measured the same group of subjects. Intra-observer and inter-observer 
variability values were summarized as the absolute difference, CV, ICC and Bland-
Altman statistics and by calculating the coefficients of variation.  
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Statistical analysis was performed using IBM SPSS statistics (version 20, IBM Corp., 
Armonk, NY, USA) and MedCalc version 12.0.1.0 (MedCalc Software, Mariakerke, 
Belgium). Statistical significance was accepted at a P value of <0.05. 
 
Figure 4.26 Schematic description 
Schematic description of Ultrasound systems, software versions and combinations of comparisons 
A) In the between vendor comparisons, echocardiographic images were acquired with two ultrasound 
systems for each patient. The images were analyzed with vendor specific software versions (E12 and 
E13 for Vivid E9; Q8, Q9 and Q10 for iE33).  
B) A separate group of normal volunteers was imaged using GE Vivid 7 and analyzed and compared 
using E11 and E12. Software release dates were shown in the brackets. 
E11 (EchoPAC version BT11); E12 (EchoPAC version BT12); E13 (EchoPAC version BT13); Q10 
(QLAB version 10); Q9 (QLAB version 9); Q8 (QLAB version 8)  
 
4.4 Results 
Characteristics of study population. Two patients were excluded at time of image 
acquisition due to inadequate and suboptimal image quality, a total of 82 subjects (45 
men, 55%) were included in the main comparison between the vendors (Figure 4.26A). 
Their baseline demographics, conventional echocardiographic parameters and 
indications for echocardiography are summarized in Table 4.21. Among them, 16 
(20%) were healthy volunteers who were free of clinical symptoms and signs. The 
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study population had wide ranges of age (18-95, mean 52±20.3 years) and body mass 
index (16-43, mean 25±6 kg/m2). Their LVEF was 58±12 % (14-72%). Frame rate of 
images acquired by iE33 (60±6 Hz) were significantly higher (p<0.001) than those 
acquired by Vivid E9 (56±6 Hz).  
Measurement of GLS using various software versions. The measurement of GLS 
was feasible with each software version in all cases. The median values of GLS using 
E12 was -19.2% (inter-quartile range [IQR]: -15.2% to -23.2%), compared with -
19.3% (IQR -14.9% to -23.7%) for E13, -15.7% (IQR: -11.4% to -20%) for Q8, -19% 
(IQR: -15.7% to -22.3%) for Q9 and -18.7% (IQR: -15.7% to -21.7%) for Q10. These 
were summarized in Table appendix 4.24. Overall, GLS showed a good correlation 
between EchoPAC versions (E12 and E13) and QLAB versions (Q8; Q9 and Q10). 
However, the bias and LOA were greater between E12 and E13 versus Q8 than 
between E12 and E13 versus Q9 and Q10 (Table 4.22 and Figure appendix 4.29 to 
Figure appendix 4.32).  
Table 4.21 Clinical and Echo characteristics 
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Results of GLS between Q9 (post-standardization) and Q8 (pre-standardization) 
showed association but significant difference (rho=0.68; bias=-2.6%; LOA=5.0%). A 
similar result was observed comparing Q10 (post-standardization) with Q8 (rho=0.67; 
bias=2.2%; LOA=4.9%). Good correlation was observed comparing E12 versus E13 
(rho=0.94; bias=0.1%; LOA=2.0%) and Q9 versus Q10 (rho=0.90; bias=0.4%; 
LOA=2.5%), both were developed after the standardization task force (Table 4.22 and 
Figure appendix 4.29 to Figure appendix 4.32). 
Table 4.22 Analyses of variation between variables 
Clinical Characteristics  N=82 
Age, y 52±20.6 
Male, n (%) 45(55) 
Weight, kg 71±19 
Height, cm 166±11 
Body mass index (BMI), kg/m2 25±6 
Body surface area (BSA), m2 1.78±0.25 
Systolic blood pressure (mmHg) 128±21 
Diastolic blood pressure (mmHg) 72±15 
Heart rate (beats/min) 67±11 
Echocardiographic data   
LVEDV (ml/m2) 54±23 
LVESV (ml/m2) 25±20 
LVSV (ml/m2) 29±7 
LVEF (%) 58±12 
Left atrium volume (ml/m2) 30±11 
Deceleration time (ms) 204±58 
E/A 1.24±0.64 
e' 0.08±0.04 
E/e' 10.3±6.6 
Indications for 
echocardiography 
n (%) 
Ischemic heart disease 11 (13.4) 
Arrhythmia 10 (12.2) 
Heart murmur 7 (8.5) 
Shortness of breath 9 (11.0) 
Heart failure 8 (9.8) 
Cardiomyopathy 7 (8.5) 
Pericarditis 2 (2.4) 
Post Chemotherapy 3 (3.7) 
Systemic disease 4 (4.9) 
Miscellaneous 5 (6.1) 
Normal Volunteer 16 (19.5) 
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GLS was also analyzed and compared using E11 and E12 in a separate group of normal 
volunteers (n=76) (Figure 4.26). The comparability of E11 and E12 showed good 
correlation (rho=0.883; bias=0.1%; LOA=2.0%; Figure 4.26B). The coefficient of 
variance between E11 and E12 was -0.03±0.02, ICC was 0.94 (0.91-0.96).  
Comparison between GLS and LV volumes. Using the Vivid E9, the mean 
LVEDV (95±41 ml), LVESV (43±35 ml) and EF (58.0±11.8%), were largely similar 
compared with those obtained using iE33 (102±48ml, 46±41 ml and 58.1%±11.9%, 
respectively). (Table appendix 4.24). The CV and percentage error of LVEDV, 
LVESV and LVEF between the two machines are summarized in Table 4.22. Using 
the Friedman Test with Bonferroni correction, the CV of LVEF were significantly 
different from that of LVEDV (p<0.001) and LVESV (p<0.001). The CV of LVEDV 
and LVESV showed no significant difference. 
Variables ICC (95% CI) Rho Bias LOA  
Percentage 
error 
LVEDV (GE/Philip) 
(ml) 
0.96 (0.93-0.97) 0.79 -6.4 33.8 0.39±0.12 
LVESV (GE/Philip) 
(ml) 
0.98 (0.96-0.98) 0.77 -2.9 22.8 0.68±0.29 
LVEF (GE/Philip)  0.95 (0.93-0.97) 0.79 -0.1 9.8 0.18±0.08 
GLS (E12_Q8) (%) 0.79 (0.67-0.86) 0.81 -2.7 4.5 -0.28±0.14 
GLS (E13_Q8) (%) 0.78 (0.65-0.86) 0.81 -2.8 4.5 -0.29±0.11 
GLS (E12_Q9) (%) 0.91 (0.86-0.94) 0.81 -0.2 3.5 -0.21±0.08 
GLS (E13_Q9) (%) 0.95 (0.92-0.97) 0.78 -0.2 3.7 -0.22±0.09 
GLS (E12_Q10) (%) 0.95 (0.92-0.97) 0.76 -0.5 3.5 -0.22±0.09 
GLS (E13_Q10) (%) 0.94 (0.91-0.96) 0.74 -0.6 3.7 -0.23±0.09 
GLS (E13_E12) (%) 0.99 (0.98-0.99) 0.94 0.1 2.0 -0.12±0.05 
GLS (Q9_Q10) (%) 0.97 (0.96-0.98) 0.90 0.4 2.5 -0.15±0.06 
GLS (Q9_Q8) (%) 0.75 (0.61-0.84) 0.68 -2.6 5.0 -0.33±0.12 
GLS (Q10_Q8) (%) 0.80 (0.68-0.87) 0.67 2.2 4.9 -0.32±0.12 
GLS* (E11_E12) (%) 0.94 (0.91-0.96) 0.89 0.1 2.0 -0.098±0.01 
LVEDV (End-diastolic volume); LVESV (End-systolic volume); LVEF (Left ventricular ejection fraction); 
GLS (Global longitudinal strain); CV (coefficient of variation); SD (standard deviation); LOA (Limits of 
agreement); ICC (Intraclass correlation); E12 (EchoPAC version BT12); E13 (EchoPAC version BT13); 
Q10 (QLAB version 10); Q9 (QLAB version 9); Q8 (QLAB version 8) 
*A separate group of normal volunteers (n=76) comparing between E11 and E12 only 
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Figure 4.27 Scatter and Bland-Altman Plots 
The comparison between E11 and E12. Left: Scatter plot. Right: Bland-Altman plot. 
 
The CVs of pre-standardization GLS (0.12±0.08 [E12 versus Q8]; 0.14±0.08 [E13 
versus Q8]) were significantly larger than LVEF (0.05±0.05) (p<0.001). Since 
standardization, the CVs of GLS have shown improvement (0.06±0.04) [E12 versus 
Q9]; 0.07±0.04 [E12 versus Q10]; 0.06±0.04 [E13 versus Q9]; 0.07±0.04 [E13 versus 
Q10]). There was no significant difference in the CV of differences in LVEF and that 
of GLS using post-standardization software; E12 versus Q9 (p=0.99); E13 versus Q9 
(p=0.81); E12 versus Q10 (p=0.22) and E13 versus Q10 (p=0.091) (Figure 4.28a, and 
Table appendix 4.25). Figure 4.28b describes comparison of CVs of within vendor 
software versions (Q8 versus Q9; Q8 versus Q10; Q9 versus Q10 and E12 versus E13) 
to CV of LVEF. 
Intraobserver and interobserver variability. The intra-observer and inter-observer 
variability of GLS from E12, E13, Q8, Q9 and Q10 were acceptable (Table 4.23). 
There were no significant differences among the CVs in intra- (p=0.96) and inter- 
(p=0.11) observer variabilities. 
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Figure 4.28 Comparison of coefficient of variance 
A): Comparisons among the coefficients of variance (CVs) from LVEF and between vendor software 
comparisons of GLS (Q8 versus E12, Q8 versus E13, Q9 versus E12, Q9 versus E13, Q10 versus E12, 
Q10 versus E13) Software before standardization: Q8; software after standardization: Q9, Q10, E12, 
and E13. 
B): Comparisons among the CVs of LVEF and within vendor software comparisons of GLS (Q8 versus 
Q9, Q8 versus Q10, Q9 versus Q10, E12 versus E13).  
 
Table 4.23 Reproducibility Analysis 
 
 
Versions Intraobserver reproducibility   
 Absolute Mean difference 
(%) 
CV (SD) ICC (95% CI) 
Bias 
(LOA) % 
E12 0.08±1.03 -0.03±0.03 0.98 (0.97-0.99) 0.10 (2.0) 
E13 -0.09±0.71 -0.02±0.02 0.99 (0.986-0.997) -0.09 (1.4) 
Q8 -0.19±0.71 -0.03±0.02 0.99 (0.98-0.99) -0.20 (1.3) 
Q9 0.37±1.16 -0.04±0.04 0.98 (0.96-0.99) 0.40 (2.3) 
Q10 0.20±0.72 -0.03±0.02 0.99 (0.98-0.99) 0.20 (2.1) 
 
Interobserver 
reproducibility 
   
 
Absolute Mean 
Difference (%) 
CV ICC (95% CI) 
Bias 
(LOA)% 
E12 0.41±1.36 -0.04±0.03 0.98 (0.94-0.99) 0.4 (2.6) 
E13 0.40±0.82 -0.04±0.02 0.99 (0.988-0.998) -0.3(1.1) 
Q8 -0.52±0.7 -0.04±0.03 0.99 (0.94-0.99) -0.5 (1.3) 
Q9 -0.27±2.27 -0.08±0.07 0.94 (0.85-0.98) -0.3 (4.4) 
Q10 0.55±1.30 -0.05±0.05 0.96 (0.91-0.99) -0.7 (2.9) 
GLS (Global longitudinal strain); CV (coefficient of variation); ICC (Intraclass correlation); LOA (Limits of 
agreement); E12 (EchoPAC BT12); E13 (EchoPAC BT13); Q8 (QLAB version 8); Q9 (QLAB version 9); Q10 
(QLAB version 10)  
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4.5 Discussion 
Between-vendor variability is often cited as a limitation of the clinical application of 
strain imaging. The results of this study demonstrate a reduction of variability of GLS 
in earlier- and later-developed software versions between two leading ultrasound 
manufactures, perhaps reflecting the implementation of the consensus process. This 
improvement has made the between-vendor variability of GLS test analogous to that 
of LVEF, which we accept on a daily basis in the clinical setting. 
Improvement of discordance of strain measurement among vendors. Agreements 
in GLS from different vendors in the literature have been controversial. Some reported 
they are similar224-226, while others have demonstrated a difference 193,214,217,227-229 
(Table appendix 4.26). The potential sources of variation in strain measurement are 
from image acquisition, post-processing and hemodynamic status of patients86. 
However, it appears that the predominant source of variation is differences between 
proprietary software 214,216,217,224. Among different types of software, there are many 
differences in post-processing and strain algorithms, including the level of post-
processed images that are used for strain calculation (radio-frequency vs post-
processed data), the location of the region of interest (ROI, endocardial vs myocardial 
tracking), degree of smoothing, and details of strain processing including arithmetic, 
geographical or Gaussian averaging.  The use of vendor independent software may be 
a solution in a multi-vendor laboratory 193. However, this is not always clinically 
feasible, especially for immediate, online measurement.  
Although all ultrasound vendors offer a means of measuring GLS, we sought to 
compare the most widely available. One of the used systems and proprietary software 
in the present study dominates the list of most commonly used vendors and techniques 
for STE analysis in the literature. In a meta-analysis of 24 studies on normal ranges of 
strain85, 20 studies (83%) used this system and its proprietary software, and this system 
was a comparator in 11 of 12 (92%) of published studies comparing vendor 
discordance (Table appendix 4.26). This demonstration of an improvement in the 
concordance is relevant to clinical practice, being based on groups with a wide variety 
of diagnostic characteristics.  
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The temporal evolution of strain software. The change of concordance of software over 
time is the most important message of this paper. This was achieved through step by 
step multiple comparisons between and within vendors. Proprietary software produced 
by one vendor, E11 (a pre-standardization version) performed comparatively well with 
E12 (a post-standardization version), although this comparison needed a separate data 
set due to technical issues. This concordance was maintained in the main data set 
between E12 and E13 (another post-standardization and most updated version). These 
data support within-vendor concordance (E11, E12 and E13 versions), which is 
reassuring for the strain literature, as this vendor has provided the most widely used 
proprietary STE technology over the last 10 years. The concordance process has 
aligned the results of Q10 and E12, with the between-vendor differences becoming 
analogous to differences for standard echocardiographic parameters (Table appendix 
4.26). However, this alignment has been achieved by changes between measurements 
obtained with Q8 (a pre-standardization version), Q9 (a post-standardization version) 
and Q10 (also a post-standardization and most updated version) – with the latter two 
being analogous. No previous studies have reported this comparison of software across 
time. It seems likely that this achievement of convergence over time is reflective of 
the effort of the joint task force. 
Variability in volume measurement as compared to strain. Volume measurements 
using the biplane method of disks are recommended as a standard method for LV 
volume quantification by the American Society of Echocardiography (ASE)’s 
Guidelines and Standards Committee221. However, while left ventricular ejection 
fraction (LVEF) is an important predictor of outcome, and is widely used to monitor 
cardiac systolic function, this measurement has important technical limitations230, as 
well as wide confidence intervals 231 that compromise its ability to detect subtle 
alterations in LV function. 
The identification of the contour of the ventricle and its direction of contraction are 
fundamental to volumetric calculations, and analogous to the importance of 
endocardial tracking in speckle tracking analysis. The common limitations of these 
methods include: 1) geometric assumptions regarding the LV; 2) the impact of 
endocardial dropout; 3) inaccuracy due to foreshortening of the apex. These factors 
are inherent and accepted causes of variations in LV assessment, especially for serial 
follow-up studies. The finding that inter-vendor differences of GLS are analogous to 
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LVEF and less than volume assessment is an important step in the adoption of GLS 
into a routine clinical setting. These results are consistent with a successful outcome 
from the consensus process of EACVI, ASE and industry initiated in 2010, at least in 
the case of two widely-used vendors 219.  
The study population is a strength of this study. To our knowledge, it is the largest data 
set using two ultrasound systems side by side, with wide range of age (18-95), BMI 
(16-43), left ventricular systolic function (EF 14-72), with both normal subjects and 
patients with various cardiac diseases. This approach does provide the limitation of 
comparing measurement on different echo cine clips, with physiological beat to beat 
variation in preload and afterload. Nonetheless, this variation is small (the CV of heart 
rate of the paired beats from the two systems was 0.05). Moreover, the variation in EF 
and volumes (which is a control for this process) was not less than that observed for 
strain.  
Including a wide range of LV function has represented most clinical scenarios. 
Paradoxically, this comparison has provided the most favorable scenario – a wide 
range of contractile function yields higher correlation coefficients than a population of 
normal subjects only, and the variation might be smaller relative to the higher levels 
of strain. 
4.6 Study Limitation 
The main limitation of this study was that we evaluated the agreement among different 
version of software using the images from two widely-used vendor systems, thus our 
results cannot extrapolate to other versions/vendor systems. However, these systems 
are widely used in the literature. We had to use a separate dataset to evaluate the 
concordance among E11, E12 and E13 due to software version incompatibility. 
Although some may argue the use of the images acquired with previous generation 
system for entire comparisons, it does not reflect current concordance status because 
of lower image quality.  Another point is to acknowledge that other relevant STE 
measurements were not analyzed in this study. These include global radial strain 
(GRS), global circumferential strain (GCS), twist/torsion as well as systolic and 
diastolic strain rate - some of which were achievable from conventional views. We 
performed analysis with GCS (data not shown) and found the overall CVs and biases 
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were larger and ICCs and correlation coefficients were lower. As stated by EACVI 
and ASE’s task force 219, our current clinical experience with GCS and GRS are limited 
as compared to GLS. Therefore, the standardization of these measures will await 
success in GLS standardization. Thus, our results should not be extrapolated to other 
parameters than longitudinal strain.   
Improvements in overall image quality and product features are the source of 
consistent effort by all ultrasound manufacturers. As it is difficult to quantify these 
improvements over time for all vendors, we chose the two most widely used ultrasound 
systems in our current study. Although many users might feel that one vendor has 
changed more than the other, the exact changes by each manufacturer are difficult to 
obtain. Our results cannot be directly extrapolated to other vendor systems and 
software versions.  
4.7 Conclusions 
Robust and quantitative information is obtainable with global longitudinal strain. 
There has been an improvement in between-vendor concordance in GLS after the work 
of the joint standardization task force. This effort has made the variability of this test 
analogous with that of EF. The removal of concerns about measurement variability 
should allow wider use of GLS. 
Postscript 
This chapter has documented the robustness of our main assessment tool, GLS. 
Another important aspect is the role of experience and training in GLS measurement 
precision and validity. Negishi et al have extensively studied this in a recent study349. 
They found that interobserver agreement of GLS is better than LV ejection fraction by 
multiple observers. They also found that although experience is important, training 
appears to be of more value in assessment of segmental strain. The precision of GLS 
was high for all groups. Their finding further ensures the robustness of GLS 
measurement. 
The following chapters will present studies that used data from Tasmanian Study of 
Echocardiographic Detection of Left Ventricular Dysfunction (TasELF) trial.  
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Although echocardiography is required to define stage B heart failure, there are several 
other methods that are more feasible and less costly, and potentially can be used as 
initial screening steps before echocardiography. Chapter 7 address the role of ECG in 
its association with echocardiographic features and outcome. Chapter 8 addresses a 
screening strategy using combined clinical risk scores, functional capacity and ECG. 
Chapter 9 examines the role of individual echocardiographic marker and markers in 
combination in predicting new heart failure. Chapter 6 is a cross-sectional analysis to 
examine and understand the two most commonly prevalent non-ischemic risk factors 
– diabetes and hypertension and their association with features of stage B heart failure. 
Chapter 10 examines the intervention response to screening results as randomized 
control trial. 
Another important risk factor is obesity. Overweight and obesity are highly prevalent 
in the community, even in a much younger age group. The next chapter will discuss 
whether childhood adiposity was related to adult cardiac dysfunction, i.e. should this 
have been used as one of our risk factors in screening? 
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Appendix Figures and tables 
Figure appendix 4.29 -comparison between vendor 
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Figure appendix 4.30 -comparison between vendor 
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Figure appendix 4.31 -comparison within vendor 
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Figure appendix 4.32 -comparison within vendor 
 
Table appendix 4.24 -Measurements of volume and strain 
 
 
 
 
 
 Mean (SD) Median (IQR) Range 
EDV (ml)    
GE Vivid E9 95 (41) 87 (25) 35~286 
Philips iE33 102 (48) 89 (38) 48~345 
ESV (ml)    
GE Vivid E9 43 (35) 33.5 (15) 12~224 
Philips iE33 46 (41) 36 (18) 15~256 
LVEF (%)    
GE Vivid E9 58.0 (11.8) 61 (11) 18~75 
Philips iE33 58.1 (11.9) 62 (7) 14~72 
GLS (%)    
Philips Q8 -15.25 (3.58) -15.7 (4.3) -4.4 ~ -23.5 
Philips Q9 -17.91 (4.14) -19.0 (3.3) -5.3 ~ -25.0 
Philips Q10 -17.36 (4.11) -18.7 (3.0) -5.7 ~ -23.7 
GE E12 -17.95 (4.44) -19.2 (4.0) -6.1 ~ -24.0 
GE E13 -18.02 (4.39) -19.3 (4.4) -5.8 ~ -24.3 
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Table appendix 4.25 -Coefficient of variance for each comparison  
 
  
Variables CV (SD) 
EDV (GE/Philip) (ml) 0.10±0.07 
ESV (GE/Philip) (ml) 0.13±0.09 
LVEF (GE/Philip) 0.05±0.05 
GLS (E12_Q8) (%) 0.12±0.08 
GLS (E13_Q8) (%) 0.14±0.08 
GLS (E12_Q9) (%) 0.06±0.05 
GLS (E13_Q9) (%) 0.06±0.04 
GLS (E12_Q10) (%) 0.07±0.04 
GLS (E13_Q10) (%) 0.07±0.04 
GLS (E13_E12) (%) 0.06±0.05 
GLS (Q9_Q10) (%) 0.04±0.04 
GLS (Q9_Q8) (%) 0.14±0.08 
GLS (Q10_Q8) (%) 0.12±0.09 
GLS* (E11_E12) (%) -0.03±0.02 
LVEDV (End-diastolic volume); LVESV (End-systolic volume); LVEF (Left ventricular 
ejection fraction); GLS (Global longitudinal strain); CV (coefficient of variation); SD 
(standard deviation); LOA (Limits of agreement); ICC (Intraclass correlation); E12 
(EchoPAC version BT12); E13 (EchoPAC version BT13); Q10 (QLAB version 10); Q9 
(QLAB version 9); Q8 (QLAB version 8) 
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Table appendix 4.26 -Vendor and software variability  
Study Year (n) Population Acquisition Software Findings 
Bansal et al 
214 
2008 30 
Ischemic heart 
disease 
GE Vivid 7 
EchoPAC 6.0 
(AFI)/VVI 1.0 
AFI has significantly better 
accuracy and 14% higher 
than VVI  
Manovel et 
al 224 
2010 28 Normal subjects 
GE Vivid 7 vs 
Toshiba Artida 
EchoPAC 07/ 2D 
Tracking 
Comparable GLS 
Koopman 
et al225 
2011 34 
With and 
without cardiac 
disease 
GE Vivid 7 vs 
Philips iE33 
EchoPAC07/ QLAB7 
Comparable GLS using VSS 
and VIS 
Biaggi et 
al226 
2011 47 Normal subjects GE Vivid 7  
EchoPAC 6.2.1/ VVI 
2.0 
Comparable GLS 
Nelson et 
al217 
2012 
10
0 
Various cardiac 
conditions 
GE Vivid 7  
TomTec 4.5/ 
EchoInsight 1.5.0 
TomTec differs 
significantly from 
EchoInsight 
Risum et 
al216 
2012 30 
With and 
without cardiac 
disease 
GE Vivid 7 vs 
Philips iE33 
EchoPAC 09/ 
TomTec 4.5 
Comparable GLS using VSS 
and VIS 
Takigiku et 
al227 
2012 
10
00 
Normal subjects 
GE Vivid 7/E9 
vs Philips iE33 
vs Toshiba 
Artida 
EchoPAC 
11/QLAB7/Ultra-
Extend 
Significant difference 
between vendors 
Negishi et 
al193 
2013 45 
With and 
without cardiac 
disease 
GE Vivid E9 vs 
Philips iE33 
EchoPAC 11/ 
QQLAB08QLAB08/ 
TomTec 4.5 
(1.1)/EchoInsight 
1.5.0 
Poor Correlation with VSS, 
fair correlation with VIS 
Sun et al228 2013 52 Normal subjects 
GE Vivid 7 vs 
Philips iE33 
EchoPAC 06/ QLAB 7 
QLAB 7 was 10% higher 
than EchoPAC06  
Costa et 
al229 
2013 50 
With and 
without cardiac 
disease 
GE Vivid E9 vs 
Philips iE33 
EchoPAC 11/ QLAB 9 
AFI was 2% higher than 
QLAB9 
Castel et 
al232 
2014 64 
With and 
without cardiac 
disease 
GE vivid E9 vs 
Philips iE33 
EchoPAC12/QLAB 9 
Similar GLS but different in 
segmental strain 
VIS, vendor independent software; VSS, vendor specific software  
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Chapter 5. Community Screening in Young Age  
Association of Childhood and Adult obesity with Left 
Ventricular Structure and Function   
Introduction 
Heart failure is a disease of the elderly. Risk stratification and prediction are often done 
in the elderly. But cardiac structural and functional disturbances may happen in the 
young and can be detected by advanced imaging modalities. These have not been well 
studied in the literature. The current chapter is from a pilot sample of CDAH 
(childhood determinants of adult health) with 29 years’ follow-up. In this cohort of 
healthy young adults, overweight and obesity is the only known cardiovascular risk. 
This chapter will discuss childhood versus adult overweight and obesity and their 
associations with structural and functional features of stage B heart failure by 
echocardiography.  
The following text has been published in the International Journal of obesity (Lond). 
2017; 41(4):560-568. 
Abstract 
Background: Overweight and obesity are associated with left ventricular (LV) 
dysfunction. We sought whether echocardiographic evidence of abnormal adult 
cardiac structure and function was related to childhood or adult adiposity. 
Methods: This study included 159 healthy individuals aged 7-15 years and followed 
until age 36-45 years. Anthropometric measurements were performed both at baseline 
and follow-up. Cardiac structure (indexed left atrial volume [LAVi], left ventricular 
mass [LVMi]) and LV function (global longitudinal strain [GLS], mitral e’) were 
assessed using standard echocardiography at follow up. Conventional cut-offs were 
used to define abnormal LAVi, LVMi, GLS and mitral annular e’.   
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Results: Childhood body mass index (BMI) was correlated with LVMi (r=0.25, 
p=0.002), and child waist circumference was correlated with LVMi (r=0.18, p=0.03) 
and LAVi (r=0.20, p=0.01), but neither were correlated with GLS. One standard 
deviation (by age and sex) increase in childhood BMI was associated with LV 
hypertrophy (RR: 2.04 [95% CI: 1.09, 3.78]) and LA enlargement (RR: 1.81 [95% CI: 
1.02, 3.21]) independent of adult BMI, but the association was not observed with 
impaired GLS or mitral e’. Cardiac functional measures were more impaired in those 
who had normal BMI as child but had high BMI in adulthood (p<0.03), and not 
different in those who were overweight or obese as a child and remained so in 
adulthood (p>0.33).  
Conclusions: Childhood adiposity is independently associated with structural cardiac 
disturbances (LVMi and LAVi). However, functional alterations (GLS and mitral e’) 
were more frequently associated with adult overweight or obesity, independent of 
childhood adiposity. 
5.1 Background 
The obesity epidemic is a relatively recent health problem, with more than doubling 
of the prevalence of obesity from 1962 to 2000 in the United States and 
worldwide233,234. More than one in three adults in the United States and more than one 
in four in Australia are obese235. The prevalence among children and adolescents has 
also increased and continues to do so235,236. In addition to its impact on childhood 
health, a major concern about childhood obesity is that it may adversely affect health 
in adulthood237. The longitudinal progression of adiposity and associated adult risk of 
cardiovascular disease (CVD) has been established in large population studies238-241, 
which have mainly focused on cardiovascular risk factors and morphologic changes 
including carotid intima-media thickness (IMT) and left ventricular (LV) mass index 
(LVMi). However, the independent relationship between childhood obesity and adult 
CVD risk is controversial. The risk of CVD among overweight or obese children who 
became non-obese by adulthood is similar to those who were never obese242, while 
those who were normal or at the lower end of the weight scale in childhood and became 
obese as an adult have the worst CVD outcome243. Thus, while there is clearly a need 
to control childhood obesity, the development of obesity over the life course also needs 
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attention. Indeed, our previous results suggested that large artery stiffness appeared to 
be dependent primarily on current adiposity and magnitude of adiposity gain from 
childhood244. The importance of the development of obesity is demonstrated in another 
of our previous studies to assess LVMi245. 
In addition to changes in morphology, obesity may cause functional disturbances, 
independent of structural changes246,247, and to which conventional echocardiographic 
measures (eg. left ventricular ejection fraction, LVEF) are insensitive82. Myocardial 
strain is a sensitive and robust echocardiographic marker of myocardial deformation 
that has been used to detect subtle myocardial impairment in patients with 
hypertension248, diabetes97, obesity and metabolic syndrome73 in the presence of 
normal LVEF. As asymptomatic LV dysfunction is associated with progression to 
heart failure (HF), the independent risk of childhood adiposity for cardiac functional 
alterations is a key research question.  
5.2 Aims and Hypothesis 
In the light of our previous work on obesity and LV dysfunction,249 we hypothesized 
that current obesity is the main problem linked with cardiac functional changes. If this 
were the case, early myocardial dysfunction would be likely to be associated more 
with adult adiposity and less by childhood adiposity. We sought to investigate whether 
childhood adiposity was associated with adult subclinical myocardial dysfunction. 
5.3 Methods 
Study population. This work was performed in a follow-up substudy of subjects 
enrolled in the Childhood Determinants of Adult Health (CDAH) study, a prospective, 
nationwide cohort of Australian children aged 7-15 years (n=8498), who participated 
in the 1985 Australian Schools Health and Fitness Survey (ASHFS).250 The sampling 
method has been described elsewhere.251 We completed comprehensive 
echocardiographic assessments in a subset of 159 adult participants who first 
participated in the ASHFS in 1985, by selecting subjects at two sites for detailed 
myocardial function analysis. The study was approved by the Tasmanian Human 
Ethics Committee, and all individuals gave written informed consent. 
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Body size or adiposity. Weight, height, waist and hip circumference were measured 
in childhood and adulthood.252 Body mass index (BMI) was calculated as weight 
(kg)/height (m) 2. Body surface area was measured as [weight (kg) x height 
(cm)/3000]0.5. Waist circumference (WC) in childhood was measured at the level of 
the umbilicus to the nearest 0.1 cm. WC in adulthood was measured at the narrowest 
point between the lower costal border and the iliac crest to the nearest 0.5 cm. Waist-
to-hip and waist-to-height ratios were calculated as waist (cm)/hip (cm) and waist 
(cm)/height (cm) respectively. Childhood body habitus was classified as healthy 
weight, overweight or obese using IOTF (International Task Force) age- and gender-
specific cut-offs.253 Adult adiposity was classified as normal weight (BMI<25 kg/m2), 
overweight (25≤BMI<30 kg/m2) and obese (BMI≥30 kg/m2). Blood pressure was 
measured from the right brachial artery three times using a digital automatic blood 
pressure monitor (Omron HEM907, Omron Healthcare Inc, Japan), after participants 
had been sitting for at least 5 minutes. The mean of the three measurements was used. 
High blood pressure was defined as systolic blood pressure (SBP)/diastolic blood 
pressure (DBP) >140/90 mmHg.  
Echocardiographic study. Standard transthoracic 2D and Doppler echocardiographic 
studies were performed using standard equipment (Siemens SC2000, Siemens 
Healthcare, Mountain View, CA) and transducers (4V1c, 1.25-4.5 MHz; 4Z1c, 1.5-3.5 
MHz) in accordance with the American Society of Echocardiography (ASE) 
guidelines187,188. Left ventricular (LV) dimensions during diastole and systole and wall 
thicknesses were measured according to the recommended criteria. 187 LV mass was 
indexed to body height using LVM/height1.7254. LV hypertrophy (LVH) was defined 
as LVM index >75 g/m1.7 in men and >57 g/m1.7 in women254. LV and left atrial (LA) 
volumes were calculated by the Simpson biplane method187, and LA volume was 
indexed to body surface area, with LA enlargement (LAE) defined as LAVi≥34 
ml/m2187. Mitral inflow peak early diastolic velocity (E), peak late diastolic velocity 
(A), E/A ratio, E wave deceleration time (DecT) were measured for diastolic function 
assessment188. Tissue Doppler mitral annular early diastolic velocity (e’) was assessed 
at septal and lateral, averaged e’ <10 was used as cut-off188. Averaged E/e’>14 was 
defined as cutoff for abnormal188. LV peak longitudinal strain measurements were 
obtained from grey scale-recorded images in the apical 4-chamber, 2-chamber and 
long-axis views. Strain was analysed using velocity vector imaging (Syngo VVI, 
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Siemens Medical Solutions). GLS was measured by averaging strain from the regional 
of interest in the apical 4-chamber, 2-chamber and long-axis views. Impaired GLS was 
defined using cut-off of <18 %85. 
Biomarkers. A 30 ml blood sample was taken from the antecubital vein after at least 
8 hours of fasting. Fasting glucose, triglycerides, high density lipoprotein (HDL) and 
low density lipoprotein (LDL) cholesterol were analysed. C-reactive protein (CRP) 
level was also obtained. Biomarkers were collected only in a subgroup of children at 
baseline. 
Statistical analysis. Child BMI was converted to z-score specific to each sex and year 
of age by subtracting from each measurement the mean for that sex and age category 
and dividing by its standard deviation (SD). Data are presented as mean ±SD after 
testing for normal distribution (Shapiro-Wilk test). Data deviating from normality are 
expressed as median (inter-quartile range [IQR]). Categorical variables are expressed 
as percentages. For differences among groups, the Mann-Whitney U test was used for 
continuous variables and X2 tests or Fisher’s exact test for categorical variables. 
Associations between variables were assessed with Pearson or Spearman correlation 
coefficients. Multi-group comparison was performed by the analysis of variance with 
Bonferroni post hoc analysis when data showed a normal distribution. Otherwise, the 
Kruskal-Wallis test was used for comparison of non-normally distributed variables. 
Linear regression analysis was used to examine the associations between body size or 
adiposity and echo variables. Logistic regression was used to examine the association 
of adult adiposity with abnormal cardiac measures using conventional cut-offs. 
Statistical analyses were performed using a standard statistical software package 
(SPSS software 22.0, SPSS Inc., Chicago, IL). Statistical significance was defined by 
p< 0.05. 
5.4 Results 
Baseline characteristics. The mean follow-up time among the total 159 participants 
(age 40.2±2.8, range 36-45 years, 47% male) was 28.9±0.1 years. Table 5.27 
summarizes the participants’ characteristics at baseline and at follow-up. Men 
generally had higher BMI at baseline and follow-up.  
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Progression of overweight and obesity. According to IOTF age- and gender-based 
cut-offs at baseline, 18 (11.3%) children were classified as ≥overweight and 2 (1.3%) 
was obese. During follow-up, 93 (59%) adults were categorized as ≥ overweight and 
29 (18%) were obese. 55% (78/141) of children of normal weight had progressed to 
either overweight (38%, 53/141), or obese (18%, 25/141) while 94% (15/16) of 
overweight children remained overweight (11/16) or obese (4/16) into adulthood. Of 
the 2 obese child at baseline, one became normal weight and one became overweight 
(Figure appendix 5.36). 
Table 5.27 Participant characteristics at baseline and follow-up 
 
 Female (n=85) Male (n=74) 
Child    
Age, mean ±SD) 10.2±2.8  11.4±2.5  
Age Range 7-15 7-15 
Height (cm) 140.3±14.9  149.4±15.2  
Weight (kg) 35.5±11.3  41.8±12.3  
Body Mass Index (g/m2) 17.5±2.5  18.3±2.3  
Waist (cm) 59.1±7.2  64.6±7.1  
Hip (cm) 73.7±9.6  77.2±9.7  
Waist-Height ratio 0.42±0.04 0.43±0.03 
Waist-Hip ratio 0.80±0.05  0.84±0.04  
Overweight Obese, n (%) 10 (12) 8 (11) 
Adult   
Age, mean ±SD 39.7±2.9 40.9±2.5 
Age Range 36-45 36-45 
Height (cm) 165.5±6.4 179.0±6.9 
Weight (kg) 69.1±14.7 86.1±13.1 
Body Mass Index (g/m2) 25.2±4.9 26.8±3.7 
Waist (cm) 76.8±11.3 89.9±10.4 
Hip (cm) 101.1±10.9 102.7±6.4 
Waist-Height ratio 0.46±0.07 0.50±0.06 
Waist-Hip ratio 0.76±0.05 0.87±0.07 
Overweight, n (%) 41 (48) 52 (70) 
Obese, n (%) 15 (18) 14 (19) 
Systolic blood pressure 108 (9) 123 (13) 
Diastolic blood pressure 68 (7) 74 (10) 
Blood Glucose (mmol/L) 4.6 (4.3-4.8) 4.8 (4.5-5.1) 
Creatinine (mmol/L) 58 (53-63) 77 (69-85) 
C-reactive protein (mg/L) 0.56 (0.16-2.13) 0.63 (0.22-2.97) 
Insulin (mIU/L) 3.0 (2.0-5.0) 5.0 (3.0-7.8) 
Total Cholesterol (mmol/L) 4.8 (4.2-5.4) 5.1 (4.5-5.7) 
Adult Echo characteristics  
Structural measures   
Relative wall thickness 0.38±0.05 0.39±0.04 
Left ventricular volume (ml/m2) 51±9 56±9 
Left ventricular mass index (Ht^1.7) (g/m2) 53±11 60±11 
Left atrial volume index (ml/m2) 27.9±6.4 28.4±6.0 
Functional measures   
Left ventricular ejection fraction (%) 61 (5) 58±5 
Global longitudinal strain (%) 21±2 19±2 
Mitral inflow E/A 1.8±0.6 1.6±0.4 
Mitral Deceleration time (ms) 207±49 208±52 
Mitral annular early diastolic velocity e' (cm/s) 13.4±2.1 12.5±2.0 
Mitral early diastolic flow/annular velocity E/e' 6.1±1.3 5.6±1.4 
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Echocardiographic characteristics. Cardiac structure and function at follow-up are 
summarized in Table 5.27. Using conventional cut-offs, the prevalence of LA 
enlargement (LAE), LV hypertrophy (LVH), impaired GLS and abnormal e’ were 
16%, 19%, 16%, 6.3% respectively. None had abnormal E/e’ by conventional cut-off. 
The detailed correlations of various body size metrics (including height, weight, BMI, 
WC, Hip, Waist-height ratio, Waist-hip ratio) as child and as adult with adult cardiac 
structural (including LAVi, LVMi) and functional (including mitral e’, E/e’ and GLS) 
measures are summarized in Table appendix 5.31. 
Childhood body BMI was correlated with LVMi (r=0.25, p=0.002), and child WC was 
correlated with LVMi (r=0.18, p=0.03) and LAVi (r=0.20, p=0.01), but neither were 
correlated with mitral e’ and E/e’, nor with GLS. Of all adult body size metrics, BMI 
and WC showed stronger association with both structural and functional measures 
including LVMi, mitral e’, E/e’ and GLS (Table appendix 5.32). Figure 5.33 shows 
the correlation of GLS with adult BMI and WC, not with childhood BMI, nor with 
child WC. The relationship of GLS with childhood WC and BMI demonstrated a non-
linear pattern. In addition, the association of adult WC with GLS seemed to be stronger 
(r=-0.362, p<0.001) than that of BMI (r=-0.164, p=0.39) (Figure 5.33).   
Association of change in body habitus with cardiac structure and function. Table 
5.28 shows the estimated response of adult cardiac changes to one standard deviation 
(SD) increase in childhood BMI and WC before and after adjustment of adult BMI and 
WC. Of the structural measures, increase in child BMI was associated with age and 
gender–specific increase of LVMi, independent of adult systolic blood pressure and 
other cardiovascular risk factors including glucose, insulin and blood lipids. However, 
these associations substantially attenuated after adjustment for adult BMI. In contrast, 
adult BMI and WC remained significant associations with or without the presence of 
childhood weight metrics. Of the functional measures, adult BMI and WC were 
significantly associated with adverse diastolic functional measure (e’) independent of 
child BMI and WC. Adult BMI and WC were not associated with systolic functional 
measure (GLS). Childhood WC demonstrated a positive association with e’ and GLS. 
However, in the presence of adult BMI and WC, these positive associations became 
more prominent and statistically significant, suggesting the increased body weight gain 
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from childhood was positively associated with systolic and diastolic functional 
measures (Table 5.29). 
One standard deviation (SD) (by age and gender) increase in childhood BMI (2.4 g/m2) 
was associated with greater risk of adult LAE (RR: 1.81 [95% CI: 1.02, 3.21]) and 
LVH (RR: 2.04 [95% CI: 1.09, 3.78]), one SD (by age and gender) increase of child 
WC (7.6 cm) was associated with greater risk of LAE (RR: 2.05 [1.26, 3.34]) 
independent of adult BMI and WC (Table appendix 5.33). 
 
 
Figure 5.33 Correlations of global longitudinal strain (GLS) with WC and 
BMI 
 
Figure shows: 1) adult adiposity is strongly associated with GLS, more than 
child adiposity. 2) Child weight showed narrow distribution and very few above 
Z score 2, therefore, a positive association if using linear model. 3) Quadratic 
model yields a higher r2 showed a trend of negative relationship beyond Z score 
of 2. 
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Table 5.28 Correlation of child and adult body adiposity with structural and functional cardiac measurements. 
 LAVi LVMi E/e' e' E/A GLS 
 r p value r p value r p value r p value r p value r p value 
Child             
Age -0.045 0.576 0.095 0.232 0.024 0.771 -0.231 0.004 -0.243 0.002 -0.039 0.626 
Height (cm) 0.021 0.794 0.134 0.092 0.045 0.582 -0.242 0.002 -0.268 0.001 -0.035 0.665 
Weight (kg) 0.046 0.568 0.18 0.023 0.091 0.258 -0.197 0.013 -0.234 0.003 0.004 0.961 
Body Mass Index (g/m2) 0.147 0.066 0.246 0.002 0.098 0.223 0.025 0.755 0.049 0.544 0.046 0.562 
Waist circumference (cm) 0.198 0.012 0.177 0.026 0.039 0.630 0.149 0.062 0.112 0.164 0.071 0.374 
Hip (cm) 0.057 0.481 0.174 0.026 0.087 0.283 -0.124 0.122 -0.169 0.036 0.040 0.622 
Waist-Height ratio 0.130 0.104 0.180 0.024 -0.020 0.809 0.207 0.009 0.127 0.115 -0.014 0.862 
Waist-Hip ratio 0.057 0.481 0.140 0.080 -0.133 0.099 0.107 0.184 0.034 0.679 -0.154 0.054 
Adult             
Height (cm) 0.140 0.079 0.224 0.004 -0.136 0.090 -0.153 0.055 -0.127 0.114 -0.324 <0.001 
Weight (kg) 0.026 0.744 0.381 <0.001 0.085 0.294 -0.305 <0.001 -0.275 0.001 -0.313 <0.001 
Body Mass Index (g/m2) -0.055 0.489 0.342 <0.001 0.194 0.016 -0.289 <0.001 -0.257 0.001 -0.164 0.039 
Waist circumference (cm) -0.071 0.489 0.394 <0.001 0.085 0.293 -0.350 <0.001 -0.336 <0.001 -0.362 <0.001 
Hip (cm) -0.019 0.813 0.293 <0.001 0.176 0.029 -0.222 0.005 -0.165 0.041 -0.083 0.298 
Waist-Height ratio -0.135 0.094 0.350 <0.001 0.151 0.062 -0.323 <0.001 -0.316 <0.001 -0.267 0.001 
Waist-Hip ratio -0.076 0.343 0.334 <0.001 -0.016 0.842 -0.345 <0.001 -0.361 <0.001 -0.474 <0.001 
 
r: correlation coefficient; LAVi: left atrial volume index; LVMi left ventricular mass index; e’: mitral annular early diastolic tissue velocity;  
E/e’: mitral inflow peak early diastolic velocity/mitral annular early diastolic tissue velocity; GLS: global longitudinal strain 
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Table 5.29 Association of adult cardiac structural and function in childhood and in adulthood. 
    LAVi     LVMi     e'     GLS   
  R2 β (95% CI) p R2 β (95% CI) p R2 β (95% CI) p R2 β (95% CI) p 
Body Mass Index (BMI)                         
Child BMI only 0.024 0.14 (-0.11, 2.26) 0.08 0.132 0.20 (0.06, 0.41) 0.01 0.082 0.06 (-0.11, 0.25) 0.46 0.258 0.14 (-0.03, 0.33) 0.05 
Child BMI adjusted for adult BMI 0.037 0.19 (0.02, 0.43) 0.03 0.191 0.11 (-0.06, 0.31) 0.19 0.162 0.17 (0.01, 0.39) 0.04 0.281 0.19 (0.06, 0.41) 0.01 
Adult BMI only 0.007 -0.06 (-0.22, 0.10) 0.47 0.181 0.30 (0.16, 0.45) <0.01 0.138 -0.25 (-0.39, -0.09) 0.01 0.248 -0.09 (-0.24, 0.05) 0.18 
Adult BMI adjusted for child BMI 0.037 -0.13 (-0.29, 0.04) 0.14 0.191 0.26 (0.11, 0.42) 0.01 0.162 -0.31 (-0.47, -0.15) <0.01 0.281 -0.17 (-0.31, -0.02) 0.03 
                      
Waist Circumference (WC)                      
Child WC only 0.040 0.19 (0.04, 0.19) 0.02 0.127 0.26 (0.05, 0.47) 0.02 0.101 0.15 (-0.001, 0.32) 0.05 0.254 0.17 (-0.02, 0.37) 0.08 
Child WC adjusted for adult WC 0.063 0.23 (0.08, 0.42) 0.01 0.179 0.14 (-0.08, 0.36) 0.22 0.206 0.24 (0.09, 0.41) 0.002 0.293 0.28 (0.07, 0.48) 0.01 
Adult WC only 0.013 -0.11 (-0.29, 0.07) 0.23 0.170 0.32 (0.15, 0.49) <0.01 0.138 -0.25 (-0.39, -0.09) 0.001 0.260 -0.17 (-0.33, -0.01) 0.04 
Adult WC adjusted for child WC 0.063 -0.18 (-0.37, 0.01) 0.05 0.170 0.28 (0.10, 0.46) 0.002 0.206 -0.38 (-0.56, -0.21) <0.01 0.293 -0.24 (-0.41, -0.08) 0.01 
Each model contains age and gender. 
BMI: body mass index; LAVi: left atrial volume index; LVMi left ventricular mass index; E/e’: mitral early diastolic peak velocity/mitral early diastolic tissue velocity; 
GLS: global longitudinal strain 
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Participants were then divided into three groups according to results of progression of 
BMI status from childhood and adulthood; normal child and adult BMI (Child-/Adult-
, n=63); normal child but high adult BMI (Child-/Adult+, n=78) and high child and 
adult BMI (Child+/Adult+, n=15). Only 3 participants had abnormal child but normal 
adult BMI and were not included for further study. Table 5.29 presents the clinical, 
cardiac and biomarker findings of the three groups. Child-/Adult+ had significantly 
higher blood pressure and more adult hypertension, relatively more impaired cardiac 
functional measures including mitral e’, higher E/e’ and more LVH. Child+/Adult+ 
group had similar functional measures compared to Child-/Adult- but more impaired 
Table 5.30 Echocardiographic and biomarkers in participants cross-classified by 
child and adult BMI status. 
  
Child-/Adult-  
(n=63) 
Child-
/Adult+  
(n=78) 
Child+/Ad
ult+  
(n=15) 
p 
P  
(1-2) 
P  
(1-3) 
P  
(2-3) 
Blood Pressure            
SBP 111±11 119±14 116±14 <0.01 <0.01 0.12 0.42 
  DBP 67±7 74±10 70±9 <0.01 <0.01 0.22 0.11 
Adult HTN, n (%) 1 (1.6) 9 (12) 1 (7) 0.07 0.02 0.35 0.58 
Adult Echo 
characteristics 
       
Left ventricular mass 
(Ht^1.7) (g/m2) 
52±10) 59 (10) 61±13 <0.01 <0.01 0.01 0.57 
Left atrial volume 
index (ml/m2) 
28±7 28±5 28±6 0.86    
Global longitudinal 
strain (%) 
21±3 19±3 21±2 0.14    
Mitral inflow E/A 1.9±0.5 1.6±0.4 1.8±0.5) <0.01 <0.01 0.78 0.03 
e' (cm/s) 13.6±2.2 12.3 (1.9) 13.0 (1.9) <0.01 <0.01 0.36 0.23 
 E/e' 5.6±1.3 6.1±1.3 6.0±1.1 0.04 0.03 0.33 0.71 
Adult Echo characteristics, categorical       
LV hypertrophy, n (%) 4 (6) 19 (24) 6 (40) 0.02 0.01 <0.01 0.21 
Enlarged left atrium 9 (14) 12 (15) 3 (20) 0.86    
Impaired GLS, n (%) 9 (14) 15 (19) 1 (7) 0.43    
Reduced e' (cut-off 10) 3 (5) 7 (9) 0 (0) 0.34    
Biomarkers            
Blood Glucose 
(mmol/L) 
4.5 (4.2-4.8) 
4.8 (4.6-
5.1) 
4.6 (4.4-
4.7) 
<0.01 <0.01 0.40 0.22 
Creatinine (mmol/L) 63 (56-73) 68 (56-81) 66 (58-70) 0.38    
C-reactive protein 
(mg/L) 
0.2 (0.1-0.6) 
1.6 (0.4-
4.1) 
1.0 (0.3-
2.1) 
<0.01 <0.01 0.03 0.13 
Insulin (mIU/L) 3 (2-4) 5 (4-8) 4 (2-6) <0.01 0.01 0.29 0.35 
Total Cholesterol 
(mmol/L) 
4.9 (4.3-5.4) 
5.1 (4.3-
5.7) 
4.8 (4.4-
6.2) 
0.45    
Triglycerides 
(mmol/L) 
0.7 (0.6-0.9) 
1.1 (0.8-
1.6) 
0.8 (0.6-
1.1) 
<0.01 <0.01 0.31 0.13 
HDL (mmol/L) 1.6 (1.4-1.9) 
1.3 (1.0-
1.5) 
1.6 (1.2-
1.7) 
<0.01 <0.01 0.23 0.07 
LDL (mmol/L) 2.9 (2.3-3.3) 
3.1 (2.5-
3.9) 
3.0 (2.2-
3.7) 
0.09 0.03 0.29 0.73 
Child-/adult: normal child/normal adult weight; child-/Adult+: normal child but overweight or obese adult; Child+/Adult+: overweight 
child/overweight or obese adult 
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structural changes. Results of biomarkers were similar between Child-/Adult- and 
Child+/Adult+, but more abnormal in Child-/Adult+.  
To further demonstrate the magnitude of weight gain on cardiac changes, we further 
separated Child-/Adult+ into two subgroups based on overweight (Child-/Adult 
overweight) and obese (Child-/Adult obese) and compared cardiac changes with 
controls (Child-/Adult-) and with (Child+/Adult+). Figure 5.34 emphasizes the role of 
adult overweight and obesity as a driver of LVH and diastolic dysfunction, rather than 
systolic impairment. These findings parallel the presence of metabolic disturbance and 
inflammation in overweight and obese adults (Figure 5.35). 
 
Figure 5.34 Cardiac structure and function cross-classified by child and adult 
BMI 
Among adults of overweight/obesity, no differences were detected in their cardiac structure and function 
between who were normal in childhood versus who were overweight/obese in childhood (labels in red). 
Among those who were normal in childhood, those who became overweight/obese in adulthood had 
structural and function cardiac abnormalities (labels in blue). Abnormal structural (normal functional) 
change was detected in those who were abnormal in childhood as compared to who were normal (labels 
in green).  
Group 1 (open circle, n=63, normal adult, normal child BMI);  
Group 2 (close circle, n=53, overweight adult, normal child BMI);  
Group 3 (close circle, n=25, obese adult, normal child BMI);  
Group 4 (square, n=15, overweight/obese adult, overweight/obese child BMI). 
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Figure 5.35 Biomarkers in participants cross-classified by child and adult BMI  
Comparing group 4 versus 3&2 (red), no differences were observed except for insulin level, indicating 
most biomarker were elevated in overweight/obese adult regardless of their childhood obesity history. 
Comparing group 1 versus the rest (blue), indicating the development of overweight/obese is associated 
with significantly increased biomarkers. Comparing group 1 versus 4 (green), CRP was significantly 
higher in group 4 indicating the presence of inflammatory status although no difference was detected in 
their insulin, glucose and triglyceride levels. Comparing group 2 and 3 (purple), no difference was 
observed between adult overweight versus obese except for obese individual had higher insulin levels. 
Group 1 (open circle, n=63, normal adult, normal child BMI);  
Group 2 (close circle, n=53, overweight adult, normal child BMI);  
Group 3 (close circle, n=25, obese adult, normal child BMI);  
Group 4 (square, n=15, overweight/obese adult, overweight/obese child BMI). 
 
5.5 Discussion 
In this longitudinal study over almost 30 years, we assessed the association of current 
and past adiposity with adult cardiac structure and function. The findings showed: 1) 
adult overweight and obesity were associated with adverse cardiac function 
independent of childhood weight status, 2) childhood adiposity was associated with 
adult structural cardiac disturbances independent of adult adiposity, 3) disturbances of 
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cardiac function were most pronounced in those who had increased adiposity in 
adulthood, and seem to parallel the severity of their metabolic disturbance.  
Association of LV structure and function with obesity. Obesity is linked with 
alterations of LV structure and function in adults255 and children.256,257 Functional 
alterations often precede and accompany structural changes, and may lead to the 
clinical syndrome of obesity cardiomyopathy.  
Studies investigating obesity-related cardiac dysfunction has shown a number of 
features. First, abnormalities of cardiac structure and function do not require morbid 
obesity (BMI >35). Application of new imaging markers including tissue velocity (e’ 
and E/e’) and speckle tracking echocardiography (GLS) have shown myocardial 
alterations in overweight (BMI, 25 to 30) and mildly obese (BMI, 30 to 35) 
individuals,255,258 perhaps because these markers are more sensitive to subtle 
myocardial damages than are conventional markers259. The assessment of subtle 
cardiac dysfunction using tissue Doppler and speckle tracking has mostly been 
performed in cross sectional studies. In contrast, this study uses a longitudinal 
population sample to address the importance of functional alterations because early 
cardiac dysfunction is a precursor stage of overt heart failure and may lead to adverse 
outcome. The longitudinal sample allowed us to assess adiposity change from 
childhood and the magnitude of adiposity gain to be important predictors. Our results 
are in agreement to other studies using tissue Doppler imaging that showed depressed 
diastolic function in obese young adults255,260. In addition, we showed a positive 
association of child BMI and WC with e’ and GLS in the presence of increased adult 
BMI and WC. This suggests that increased gain of adipose tissue is associated with 
both systolic (GLS) and diastolic (tissue Doppler e’) alterations. Second, the effects of 
obesity on the heart varies from asymptomatic LV dysfunction to overt dilated 
cardiomyopathy. These abnormal findings can be found in individuals who are 
otherwise young (<40 year) and healthy260 and with no evidence of hypertension, 
diabetes, metabolic disturbance and inducible coronary artery disease by stress 
testing.255 In the current study cohort of young (≤ 45 year) and healthy individuals with 
no known history of diabetes, hypertension and coronary artery disease, the prevalence 
of structural abnormalities using guideline-recommended cut-offs187 was 16% by 
LAE, 19% by LVH, 16% by impaired GLS and 6.3% by impaired e’. These 
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observations support the notion that depressed LV function is already present in 
relatively young, overweight/obese people even if clinical features of common 
comorbidities and other associated disease are not evident. Third, the effect of weight 
loss on cardiac functional improvement has been variable, which implies that cardiac 
impairment may not be completely reversible. Many factors contribute to outcomes, 
mostly the magnitude and duration of obesity as well as the magnitude and duration of 
cardiac damage, and both may worsen with the development of codominant 
comorbidities.261,262  
The potential implications of change of obesity with time. Obese children are at risk 
of being obese as adults263,264 which leads to an increased risk of cardiac structural and 
functional impairment. The prognostic implications of childhood obesity has been 
studied in large population studies.242 Although most evidence has been based on 
obesity-related metabolic disturbance,240 the impact of childhood obesity in the 
development of adult left ventricular hypertrophy has been demonstrated265,266. 
However, no studies have assessed the impact of childhood obesity on adult cardiac 
function. In our study, there was not enough evidence to demonstrate the independent 
association of childhood body size. We suspect a few possible contributing factors: 1) 
a relatively “healthy childhood population” with only 11.3% overweight and 1.3% 
obese children; 2) a possible non-linear relationship between childhood BMI and 
functional measures; 3) adult cardiac functional changes are more associated with 
adult body adiposity and characteristics. Cardiac functional impairment in adulthood 
is an indication of adverse outcome and disease progression.  
Whether childhood obesity is an independent predictor of adverse adult outcome has 
been challenged in the recent literature. In a systematic review by Lloyd, evidence 
indicated that children with low BMI but overweight in adulthood243 had the highest 
risk of CVD. In another systematic review and meta-analysis, Llewellyn and 
Simmonds challenged the conventional view of using childhood BMI predicting adult 
morbidity.267 264 The authors concluded that childhood obesity is associated with 
moderately increased risk of adult morbidity but that the association was not strong 
enough to predict outcome. This was due to the fact that most weight-related 
morbidities occurred in individuals who were of healthy weight as a child. In our study, 
after adjustment for adult body size, the magnitude of adiposity change seemed to be 
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associated with alteration of both GLS and e’. It likely that the duration of obesity is 
an important determinant of cardiac function changes and subsequent adverse 
outcomes, but we were unable to gather this information in our study268. Further 
research is needed to explore the effects of the time course of weight change. 
The mechanism of cardiac dysfunction and metabolic disturbance. The 
progression of cardiac dysfunction in obese individuals is influenced by a variety of 
determinants including genetic and environmental influences.269  In adulthood, obesity 
often coexists with weight-related comorbidities, mostly diabetes and hypertension, 
which further complicates the cardiac manifestations. First, cardiac preload is 
increased in obese individuals due to increased metabolic demand270,271. In the absence 
of myocardial dysfunction, this may explain the observation of increased or 
supernormal LV ejection fraction.249 Second, cardiac afterload is also increased due to 
alterations of arterial resistance and stiffness.249 Obesity related insulin resistance 
plays an important role by causing arterial wall smooth muscle cell damage (which 
alters stiffness and resistance), and myocardial cell apoptosis and cardiac 
dysfunction.272 Third, a combination of inflammatory, metabolic and neurohormonal 
changes lead to myocardial fibrosis, causing both cardiac systolic and diastolic 
dysfunction.73 The presence of metabolic disturbance in this cohort is demonstrated by 
the subgroup of child-/adult+, who had the highest insulin, glucose and triglyceride 
levels (Figure 5.35). C-reactive protein was significantly higher in all three groups 
with increased adult weight as compared with normal adult weight, reflecting the 
inflammatory process associated with obesity. Functional measures in child+/adult+ 
were relatively preserved and similar to those of child-/adult- (Figure 5.34), suggestive 
of functional cardiac changes are associated with adiposity gain. Interestingly, this 
subgroup had lower levels of metabolic and inflammatory markers than other obese 
and overweight patients (Figure 5.35), indicating that adiposity gain may be the key 
determinant. 
 
5.6 Study Limitation 
This study has several limitations. First, it comprises a small study population, 
obtained from two sites (Tasmania and Victoria), which we thought likely to be 
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representative of the rest. The influence of progression of body weight at populational 
level, i.e. social economical and environmental factors cannot be excluded. 
Echocardiographic assessment of cardiac function needs to be further explored in the 
full cohort in all sites. Second, at baseline in 1985, this study cohort was relatively 
healthy, only 11% classified as overweight and 0.6% obese. This has limited our ability 
to track changes of cardiac function in relation to their weight status. Third, 
echocardiography was not performed at baseline. Fourth, the duration of obesity and 
adiposity gain was not available. Fifth, baseline blood pressure and biochemistry was 
not adjusted as potential confounders due to the limited data points available at follow-
up. These are potential independent risk factors affecting adult cardiac function, and 
the potential impact needs to be further explored. 
5.7 Conclusion 
Childhood adiposity is independently associated with structural cardiac disturbance 
(LVMi and LAVi). However, cardiac functional alterations (abnormal GLS and mitral 
e’) were more frequently associated with adult overweight/obese independent of 
childhood adiposity. 
Postscript 
Findings from this study suggested future studies needs to focus on the following: 1) 
Tracking changes from overweight/obese children with cardiac dysfunction into 
adulthood and association with outcome. 2) Understanding the duration and magnitude 
of adiposity gain and the duration of cardiac dysfunction and association with cardiac 
dysfunction.   
Next chapter is a cross-sectional analysis to examine and understand the two most 
commonly prevalent non-ischemic risk factors – diabetes and hypertension and their 
association with features of stage B heart failure. 
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Appendix Figures and tables 
 
Figure appendix 5.36 -Tracking weight status from childhood to adulthood 
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Figure appendix 5.37 -Correlation of waist circumference with cardiac structure 
Child waist circumference (WC) correlates with increased LV mass and LA volume. Adult waist 
circumference (WC) correlates with LV mass but not LA volume. 
 
 
Figure appendix 5.38 -Correlation of waist circumference with cardiac function 
Child waist circumference does not correlate with GLS, not with mitral e’ 
Adult waist circumference correlates with both GLS and mitral e’ 
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Table appendix 5.31 -Correlation of child and adult body adiposity with cardiac structural and function 
Body mass index and waist circumference showed stronger association with cardiac structural and functional measures. 
  LAVi LVMi  E/e' e'  E/A GLS  
  r p value r p value r p value r  p value r p value r p value 
Child                         
Age -0.045 0.576 0.095 0.232 0.024 0.771 -0.231 0.004 -0.243 0.002 -0.039 0.626 
Height (cm) 0.021 0.794 0.134 0.092 0.045 0.582 -0.242 0.002 -0.268 0.001 -0.035 0.665 
Weight (kg) 0.046 0.568 0.18 0.023 0.091 0.258 -0.197 0.013 -0.234 0.003 0.004 0.961 
Body Mass Index (g/m2) 0.147 0.066 0.246 0.002 0.098 0.223 0.025 0.755 0.049 0.544 0.046 0.562 
Waist circumference (cm) 0.198 0.012 0.177 0.026 0.039 0.630 0.149 0.062 0.112 0.164 0.071 0.374 
Hip (cm) 0.057 0.481 0.174 0.026 0.087 0.283 -0.124 0.122 -0.169 0.036 0.040 0.622 
Waist-Height ratio 0.130 0.104 0.180 0.024 -0.020 0.809 0.207 0.009 0.127 0.115 -0.014 0.862 
Waist-Hip ratio 0.057 0.481 0.140 0.080 -0.133 0.099 0.107 0.184 0.034 0.679 -0.154 0.054 
Adult             
Height (cm) 0.140 0.079 0.224 0.004 -0.136 0.090 -0.153 0.055 -0.127 0.114 -0.324 <0.001 
Weight (kg) 0.026 0.744 0.381 <0.001 0.085 0.294 -0.305 <0.001 -0.275 0.001 -0.313 <0.001 
Body Mass Index (g/m2) -0.055 0.489 0.342 <0.001 0.194 0.016 -0.289 <0.001 -0.257 0.001 -0.164 0.039 
Waist circumference (cm) -0.071 0.489 0.394 <0.001 0.085 0.293 -0.350 <0.001 -0.336 <0.001 -0.362 <0.001 
Hip (cm) -0.019 0.813 0.293 <0.001 0.176 0.029 -0.222 0.005 -0.165 0.041 -0.083 0.298 
Waist-Height ratio -0.135 0.094 0.350 <0.001 0.151 0.062 -0.323 <0.001 -0.316 <0.001 -0.267 0.001 
Waist-Hip ratio -0.076 0.343 0.334 <0.001 -0.016 0.842 -0.345 <0.001 -0.361 <0.001 -0.474 <0.001 
r: correlation coefficient; LAVi: left atrial volume index; LVMi left ventricular mass index; e’: mitral annular early diastolic tissue velocity;  
E/e’: mitral inflow peak early diastolic velocity/mitral annular early diastolic tissue velocity; GLS: global longitudinal strain 
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Table appendix 5.32 -Relative risk of increased body size 
Body size measured as (every one standard deviation change of body mass index [BMI] and Waist circumference [WC]) abnormal cardiac structure and function using 
conventional cut-offs. 
  LA enlargement (34)  LV hypertrophy  Abnormal mitral e'    Impaired GLS   
  R2 RR (95%CI) p R2 RR (95%CI) p R2 RR (95%CI) p R2 RR (95%CI) p 
Body mass index (BMI)             
Child BMI (adjusted for adult BMI) 0.073 1.81 (1.02, 3.21) 0.04 0.300 2.04 (1.09, 3.78) 0.02 0.140 0.52 (0.22, 1.25) 0.14 0.285 0.46 (0.24, 0.89) 0.02 
Adult BMI (adjusted for child BMI) 0.073 0.53 (0.29, 0.97) 0.04 0.300 1.77 (1.13, 2.76) 0.01 0.140 1.31 (0.62, 2.75) 0.48 0.285 1.18 (0.68, 2.08) 0.56 
Waist circumference             
Child waist (adjusted for adult waist) 0.141 2.05 (1.26, 3.34) <0.01 0.253 1.52 (0.94, 2.48) 0.09 0.192 0.35 (0.13, 0.94) 0.04 0.260 0.59 (0.33, 1.08) 0.09 
Adult waist (adjusted for child waist) 0.141 0.37 (0.17, 0.80) 0.01 0.253 2.01 (1.18, 3.38) 0.01 0.192 1.71 (0.79, 3.66) 0.17 0.260 1.33 (0.76, 2.31) 0.31 
Each model contains age and gender  
Cut-offs for LA enlargement: ≥34 ml/m2; LV hypertrophy >95 female, >115 male; Abnormal mitral e’: averaged e’<10 cm/s; Impaired GLS <18%. 
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Baseline Cross Sectional Analyses – 
Association of Aetiology and 
Pathophysiology 
 
 
Article “Pathophysiological effects of different risk factors of heart 
failure” was published in 
Open Heart 2016;3(1): e000339 
Hong Yang, Ying Wang, Kazuaki Negishi, Mark Nolan, Thomas H 
Marwick 
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Chapter 6. Baseline Cross Sectional Analyses  
Pathophysiological Effects of Different Risk Factors 
for Heart Failure 
Introduction 
Among the listed stage A heart failure risk factors, not all are equal. The two main 
non-ischemic risk factors are hypertension and type 2 diabetes and highly prevalent in 
the community, with 54% having type 2 diabetes and 82% hypertension in the TasELF 
cohort. As will be described in the following section, many had suboptimal control of 
their primary risk factors, i.e. >50% hypertensive patients were poorly controlled by 
their current medication. The early detection of coronary artery disease has a relatively 
different pathway as most will present with chest pain or angina, therefore the early 
intervention for cardioprotection of these patients is relatively well defined. Unlike 
coronary artery disease, the underlying cardiac damage may not be identified, as 
echocardiography is not indicated in this population. It is unknown whether the 
underlying cardiac changes are related to etiology. This chapter assessed whether there 
was association between different risk factors and related pathophysiology.  
The following text of this chapter has been published in Open Heart 2016;3(1): 
e000339. 
Abstract 
Background. Hypertension and type 2 diabetes mellitus (T2DM) are important causes 
of non-ischemic heart failure (HF). Understanding the pathophysiology of early HF 
may guide screening. We hypothesized that the underlying physiology differed 
according to etiology. 
Methods. In this cross-sectional study of 521 asymptomatic community-based 
subjects >65 years with >1 HF risk factors, 187 subjects (36%) had both T2DM and 
hypertension (T2DM+/HTN+), 109 (21%) had T2DM with no hypertension 
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(T2DM+/HTN-), and 72 (14%) had neither T2DM nor hypertension (T2DM-/HTN-). 
In 153 (29%), clinic blood pressure was ≥140/90 mmHg, defined as active 
hypertension (T2DM-/HTN+). All underwent a comprehensive echocardiogram, 
including conventional parameters for systolic and diastolic function as well as global 
longitudinal strain (GLS), diastolic strain (DS) and diastolic strain rate (DSR). A six-
minute walk test (6MW) was used to assess functional capacity. 
Results. GLS in T2DM-/HTN+ group (-18.9±2.7%) was similar to that in T2DM-
/HTN- group (-19.4±2.4%), and greater than T2DM+/HTN- (-18.0±2.8%, p=0.005). 
DS in T2DM-/HTN- (0.47±0.15%) exceeded that in T2DM-/HTN+ (0.43±0.14%) and 
T2DM+/HTN- (0.43±0.13%). 6MW distance was preserved in T2DM-/HTN+ 
(482±85m) and reduced in T2DM+/HTN- (469±93, p<0.001). Those with T2DM and 
active hypertension had worst GLS, DS, DSR and shortest 6MW distance (p<0.002). 
In multivariable analysis, GLS was associated with T2DM but neither active 
hypertension nor a history of hypertension. Diastolic markers and LV mass were 
associated with hypertension and T2DM. Thus, subjects with HF risk factors show 
different functional disturbances according to aetiology.  
Conclusion. Patients with hypertension had relatively less impaired GLS and 
preserved 6MW distance but more impaired diastolic function.   
6.1 Background 
The aetiology and pathophysiology of heart failure (HF) is undergoing a transition. 
With the decline of coronary artery disease (CAD), hypertension and type 2 diabetes 
mellitus (T2DM) have become the most common aetiologies of incident HF. Among 
these preclinical individuals with stage A HF25, the risk of incident HF with 
hypertension is known to be relatively lower than CAD and T2DM 273, the role of 
hypertension as the leading cause of HF274 reflects its prevalence in the community. In 
contrast, the risk of incident HF is nearly twice as high in those with T2DM 273. Both 
conventional echocardiographic measures of diastolic dysfunction and myocardial 
strain analysis have been well studied in T2DM and are early markers of diabetic 
cardiomyopathy275 57,58. Unfortunately, the conventional echocardiographic 
assessment of diastolic function in hypertension often provides inconsistencies 276 
which may compromise its use to screen for preclinical HF. A screening and early 
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treatment process could limit the progression to HF arising from the heavy burden of 
hypertension and T2DM in the community. However, it is not clear whether strain or 
conventional diastolic measures would be optimal for this purpose, whether they are 
analogous, or indeed if the underlying ethology has a differential effect on either 
marker. 
6.2 Aims and Hypothesis 
An understanding of the pathophysiologic differences of different causes of preclinical 
HF might guide screening for early intervention and disease prevention. We 
hypothesised that the optimal cardiac markers vary with the underlying aetiology, and 
that the degree of underlying cardiac dysfunction correlates with their functional 
capacity measured by six-minute walk test distance (6MW) – a simple measure of the 
functional status of patients and as a predictor of morbidity and mortality in LV 
dysfunction 277.  
6.3 Methods 
Patient selection. Asymptomatic individuals >65 years old with HF risk factors were 
recruited through local media advertising based on the presence of >1 of the following 
HF risk factors: (1) hypertension (based on self-report of diagnosis including 
medication); (2) T2DM (based on self-report of diagnosis including medication); (3) 
obesity (body mass index [BMI] >30); (4) previous chemotherapy; (5) family history 
of HF; (6) previous history of heart disease (but not existing HF). The exclusion 
criteria were subjects with: (1) a history of previous HF; (2) a history of coronary artery 
disease CAD (3) a history (or evidence on baseline echocardiogram) of >moderate 
valvular heart disease; (4) left ventricular ejection fraction <40% on baseline 
echocardiogram; (5) inability to acquire interpretable images for speckle tracing 
imaging analysis at baseline. This study was performed in accordance with a research 
protocol approved by the Tasmanian Human Research Ethics Committee. A written 
informed consent was obtained from each participant after explained the nature and 
purposes, complexity and level of risk of the study. 
Data collection. Data were collected prospectively at facilities in the community, from 
all participants enrolled in the study. All completed standard questionnaires relating to 
Chapter 6 – Cross sectional analyses of aetiology and pathophysiology 174 
 
health status (EuroQol 5-dimension index, EQ5D), functional capacity (Duke Activity 
Score Index, DASI), frailty (Study of Osteoporotic Fractures frailty index (SOF)), 
symptom status (Minnesota Living with HF Questionnaire, MLHFQ). Anthropometric 
measurements were obtained and body mass index was calculated. Waist and hip 
measurements were obtained. Standard serial blood pressure measurements, standard 
12 lead electrocardiogram (ECG) and a comprehensive transthoracic echocardiogram 
including speckle tracing imaging was performed. A six-minute walk test (6MW) was 
used to assess submaximal functional capacity.  
Other collected data included socioeconomic indicators, complete medical history, 
family history, cardiovascular risk factors, heart rate and patient-reported outcome 
measures. 
Blood pressure measurements: Peripheral and derived aortic blood pressure readings 
were obtained using a validated technique 278, with a commercially available pulse-
wave analysis system (Mobil-O-Graph PWA, IEM, Stolberg, DE). Serial 
measurements were conducted after a 10-minute rest in a quiet room, with readings 
were obtained twice in a seated position at rest and immediately after 6MW. To define 
active hypertension, an averaged (at least two) sitting systolic blood pressure 
(SBP) >140 mmHg or diastolic blood pressure (DBP) >90 mmHg were used as cut-
off 279,280. 
Standard echocardiographic study. Standard transthoracic 2D and Doppler 
echocardiographic studies were performed using a commercial system (Siemens 
ACUSON SC2000, 4V1c and 4Z1c probes, Siemens Healthcare, Mountain View, CA) 
in accordance with the American Society of Echocardiography guidelines 187,281. Left 
ventricular (LV) dimensions during diastole and systole and wall thicknesses were 
measured from parasternal long-axis views according to the recommended criteria. LV 
mass was calculated according to guidelines and indexed for body surface area (BSA) 
(g/m2). LV hypertrophy (LVH) was defined as LV mass index (LVMi) >115 g/m2 in 
men and >95 g/m2 in women 187. LV and left atrial (LA) volumes were calculated by 
the Simpson biplane method, and indexed to body surface area (LAVi). Abnormal 
LAVi was defined as >34 ml/m2 187. For diastolic function assessment, mitral inflow 
peak early diastolic velocity (E), peak late diastolic velocity (A), E/A ratio, E wave 
deceleration time (DT) were measured; E/A<0.8 identified delayed relaxation. Tissue 
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Doppler mitral annular early diastolic velocity (e’) was assessed at septal and lateral 
walls and averaged for calculation of E/e’; an average E/e’>15 was considered 
consistent with raised filling pressure.  
Myocardial strain. Speckle tracking was used for measurement of global longitudinal 
strain (GLS), from 3 standard apical views, using commercial software (Syngo VVI, 
Siemens Medical Solutions). After manual tracing of LV endocardial border during 
end-systole, this was automatically tracked throughout the cardiac cycle. GLS was 
obtained by averaging all 18 segment strain values from the three standard views; 
abnormal GLS is defined as >-18% 85. Global diastolic strain was obtained by 
averaging of all 18 segment strain values and measured according to method published 
by Ishii et.al. 282. Calculation of diastolic strain was determined as (A-B)/A * 100% 
(A= the systolic value of strain at closure of aortic valve; B= the value of strain at the 
one-third point of diastole duration) (Figure 6.39). Diastolic strain rate was determined 
from the average of 18 segments of early diastolic strain rate. 
 
Figure 6.39 Measurement of GLS and diastolic strain (DS) 
 
Functional capacity assessment. A 6-minute walk test distance (6MW) was used for 
the measurement of sub-maximal functional capacity in this study. 6MW was 
conducted following a standardized protocol 209. 
Statistical analysis. Data are presented as mean ± standard deviation (SD) after testing 
for normal distribution with the Kolmogorov-Smirnov test. Data deviating from 
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normality are expressed as median and inter-quartile range (IQR). Categorical 
variables are expressed as percentages. Multi-group comparison was performed by the 
analysis of variance (ANOVA) with Bonferroni post hoc analysis when data showed 
a normal distribution. Otherwise, the Kruskal-Wallis test was used for comparison of 
non-normally distributed variables. Linear regression analysis was used to examine 
the associations between clinical, echocardiographic and functional variables before 
and after adjustment for age, gender and other clinical variables. Logistic regression 
analysis was used to examine the association of low functional capacity and abnormal 
GLS. Statistical analysis was performed using a standard statistical software package 
(SPSS software 22.0, SPSS Inc., Chicago, IL). Statistical significance was defined by 
p <0.05. 
6.4 Results 
Population characteristics. There were 535 community individuals potentially 
eligible for assessment during the study period. After exclusion of 14 after the baseline 
echo screening due to valvular pathology and poor LV ejection fraction, the final 
number of individuals included in this study was 521 (age 71±5 [IQR: 67-74]) years, 
49% of whom were men. All had completed assessment according to the standard 
protocol. The listed HF risk factors were present in all of these subjects, with self-
reported hypertension being the most common (82%), T2DM (54%) and obesity 
(47%), previous chemotherapy (9.2%), family history of heart disease at young age 
(36%) and a known cardiac condition without overt HF (10%). All had normal LVEF 
(>50%). A total of 340 out of 521 subjects (65%) met the criteria of active hypertension 
(SBP >140 mmHg and or DBP > 90 mmHg).  
Four groups were derived according to the status of T2DM and the presence of 
hypertension, named T2DM+/HTN-; T2DM/HTN+; T2DM+/HTN+; T2DM-/HTN-. 
These four etiologic groups were studied to test the individual effect of hypertension 
versus T2DM and combined effect of T2DM+hypertension (Table 6.33). There was 
no difference in age and gender between T2DM-/HTN+ and T2DM+/HTN-. Other risk 
factors including obesity, chemotherapy, family history, history of heart disease were 
also similar between the two groups (Table 6.33). However, compared to T2DM-
/HTN+, T2DM+/HTN- had significantly higher prevalence of dyslipidaemia 
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(p<0.001) and higher ARIC and FHS scores (p<0.001). The T2DM+/HTN+ group had 
significantly greater body mass index (BMI) and dyslipidaemia. Baseline medication 
history (including beta blocker (BB), angiotensin-converting enzyme inhibitor 
(ACEi), angiotensin receptor blocker (ARB), diuretics and calcium antagonists) was 
similar. A greater percentage of participants with T2DM+/HTN+ were on statin 
therapy than other groups. 
Echocardiographic assessment. Baseline echocardiographic measures stratified by 
the four etiologic groups are summarized in Table 6.34. LVMi was higher in 
hypertensive groups (T2DM-/HTN+ and T2DM+/HTN+), but LVEF, LVEDV and 
RWT were similar among the groups. Of the conventional diastolic parameters, mitral 
annular e’ (average of medial and lateral) was lower and E/e’ (average of medial and 
lateral) was higher in T2DM-/HTN+ and T2DM+/HTN+ than T2DM+/HTN-. Using 
E/e’ >15 as cut-off, the percentage of abnormal E/e’ in the groups was different 
(p=0.049).  T2DM+/HTN+ had the highest prevalence of diastolic dysfunction (82%) 
according to the current recommendations of the American Society of 
Echocardiography 281, although this was not statistically significant among the groups. 
Echocardiographic assessment using speckle tracking analysis is also summarized in 
Table 6.34. GLS was significantly lower in T2DM+/HTN- and T2DM+/HTN+. Using 
-18% as cut-off, abnormal GLS was present in 42% of the whole cohort, most 
commonly in those with T2DM (T2DM+/HTN- and T2DM+/HTN+). Diastolic strain 
and diastolic strain rate were reduced in T2DM-/HTN+, T2DM+/HTN- and 
T2DM+/HTN+. Comparison of conventional and STE analysis measures among and 
between four groups are shown in Figure 6.40 A-H.   
Association of hypertension and T2DM with cardiac changes. The association 
between abnormal functional parameters and T2DM and hypertension were tested 
using univariable analysis, followed by two multivariable models to test the 
independent association between T2DM, a history of hypertension and active 
hypertension (the latter two being entered into each model separately (Table 6.35). 
When modelled with age, gender, BMI and HR, reduced GLS was independently 
associated with T2DM but not hypertension (either history or active). In contrast, 
diastolic parameters were generally associated with active hypertension as well as 
T2DM. 
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Table 6.33 Baseline demographic and clinical characteristics by etiology 
  
Total 
(n=521) 
T2DM-/HTN+  
(n=153) 
p (HTN-
contrl) 
T2DM+/HTN-  
(n=109) 
p (T2DM-
contrl) 
p (HTN-
T2DM) 
T2DM+/HTN+  
(n=187) 
p 
(Both-
contrl) 
p (Both-
HTN) 
p (Both-
T2DM) 
T2DM-/HTN-  
(n=72) 
p 
(total) 
Age (years) 71 (5) 71 (5)  71 (4)   71 (5)    71 (5) 0.742 
Gender male, n (%) 256 (49) 65 (43) 0.478 59 (54) 0.028 0.063 105 (56) 0.007 0.012 0.736 27 (38) 0.010 
Heart rate (bpm) 67 (59-75) 66 (58-74) >0.99 68 (60-76) 0.102 0.324 68 (61-75) 0.162 0.530 >0.99 64 (59-72) 0.035 
SBP (mmHg) 146 (18) 156 (15) <0.001 130 (8) >0.99 <0.001 154 (14) <0.001 0.460 <0.001 128 (10) <0.001 
DBP (mmHg) 82 (11) 90 (11) <0.001 74 (7) >0.99 <0.001 84 (10) <0.001 0.315 <0.001 74 (7) <0.001 
Pulse pressure (mmHg) 64 (15) 67 (15) <0.001 55 (8) >0.99 <0.001 69 (15) <0.001 0.324 <0.001 54 (12) <0.001 
Mean artery pressure 108 (12) 114 (13) <0.001 99 (7) >0.99 <0.001 111 (9) <0.001 0.149 <0.001 100 (9) <0.001 
Central SBP (mmHg) 149 (20) 158 (20) <0.001 131 (13) 0.947 <0.001 154 (18) <0.001 0.451 <0.001 138 (15) <0.001 
Central DBP (mmHg) 83 (10) 87 (11) <0.001 78 (6) >0.99 <0.001 85 (9) <0.001 0.215 <0.001 77 (9) <0.001 
∆SBP (pre-post 6MW) 18 (20) 18 (24)  20 (19) 0.392 <0.001 18 (19)    16 (16) 0.722 
Body Mass Index (g/m2) 29 (26-33) 29 (26-32) >0.99 28 (26-32) >0.99 >0.99 31 (27-34) 0.005 0.050 0.032 28 (25-31) 0.002 
HF risk factors             
ARIC risk (4yr) (%) 6.2 (3.6-11.4) 4.2 (2.5-7.3) 0.104 7.3 (4.6-11.9) <0.001 <0.001 9.2 (6.2-14.9) <0.001 <0.001 0.048 3.2 (1.8-4.9) <0.001 
FHS risk (4yr) (%) 4.0 (2.0-6.5) 3.0 (2-4) 0.186 4.0 (3-10) <0.001 <0.001 5.0 (3-14) <0.001 <0.001 1.000 2.5 (1.8-3) <0.001 
T2DM, n (%) 296 (57) 0 (0) n/a 109 (100) <0.001 <0.001 187 (100) <0.001 <0.001 n/a 0 (0) <0.001 
Obesity, n (%) 245 (47) 67 (44) 0.197 46 (42) 0.313 0.798 107 (57) 0.001 0.014 0.013 25 (35) 0.003 
History HTN, n (%) 421 (81) 134 (88) 0.556 75 (67) 0.015 <0.001 151 (81) 0.457 0.089 0.020 61 (85) 0.002 
Chemotherapy, n (%) 46 (9) 13 (9) 0.529 7 (6) 0.263 0.533 18 (10) 0.722 0.719 0.339 8 (11) 0.701 
Family History, n (%) 184 (35) 63 (41) 0.944 44 (40) 0.862 0.895 47 (25) 0.009 0.002 0.006 30 (42) 0.004 
History heart dis, n (%) 47 (9) 21 (14) 0.011 9 (8) 0.131 0.171 15 (8) 0.127 0.089 0.943 2 (3) 0.049 
Dyslipidaemia, n (%) 284 (55) 60 (41) 0.580 64 (63) <0.001 <0.001 121 (72) 0.018 <0.001 0.159 39 (56) <0.001 
Charlson score 1.0 (0.0-2.0) 0 (0-1) 1.000 1.0 (1-3) <0.001 <0.001 1.0 (1-2) <0.001 <0.001 1.000 0 (0-1) <0.001 
Medication, n (%)             
Beta blocker 38 (7) 12 (7.8)  11 (10)   10 (5.3)    5 (6.9) 0.495 
ACEi/ARB 360 (69) 104 (68)  69 (63)   137 (73)    50 (69) 0.344 
Diuretics 67 (13) 22 (16)  11 (11)   21 (13)    13 (19) 0.432 
Calcium antagonist 115 (22) 26 (19)  24 (25)   47 (28)    18 (27) 0.273 
Lipid Lowering Meds 287 (55) 57 (41) 0.580 75 (76) <0.001  125 (75) <0.001 <0.001 0.933 30 (45) <0.001 
Anti-platelet 193 (37) 44 (32) 0.163 41 (41) 0.961   80 (49) 0.334 0.003 0.246 28 (42) 0.031 
Functional Capacity            
6MW (meter) 463 (101) 482 (85) >0.99 469 (93) >0.99 >0.99 438 (119) 0.019 <0.001 0.067 479 (81) <0.001 
Patient reporting outcome measure            
DASI MET 8.3 (1.0-8.9) 8.9 (7.6-9.0) >0.99 8.0 (6.6-9.0) 0.036 0.053 7.7 (6.6-9.0) <0.001 <0.001 >0.99 8.9 (8.0-9.0) <0.001 
EQ5D 0.84 (0.74-1.0) 0.84 (0.77-1.0) >0.99 0.84 (0.72-1.0) 0.144 0.177 0.81 (0.73-1.0) 0.039 0.027 >0.99 0.88 (0.77-1) 0.004 
EQ VAS 80 (70-90) 85 (70-93) >0.99 80 (70-90) 0.029 0.202 80 (70-90) 0.024 0.179 >0.99 88 (79-95) 0.005 
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MLHF 1.0 (0.0-9.0) 1.0 (0-7)   1.0 (0-9.5)     1.0 (0-12)       1.0 (0-6.8) 0.971 
Continuous variables are listed either: mean (SD) or median (low quartile-upper quartile); Categorical variables are listed: number (%); ACEi: angiotensin converting enzyme inhibitor; ARB: angiotensin receptor 
blockers ARIC: The Atherosclerosis Risk in communities; Both=HTN+/T2DM+; Contrl=HTN-/T2DM-; DASI MET: Duke Activity score index with metabolic equivalent task; DBP: diastolic blood pressure; EQ5D: 
European Quality of Life-5 dimensions; EQVAS: European Quality of Life visual analogue scale; FHS: Framingham Heart Study; HTN: hypertension; MLHF: Minnesota Living with Heart Failure score; PROMs: 
patient reporting outcome measures; SBP: systolic blood pressure; T2DM: type 2 diabetes mellitus; 6MW: six-minute walk test 
 
Table 6.34 Echocardiographic characteristics of patients 
Echocardiographic characteristics of patients with stage A heart failure, categorized by aetiology 
  
Total  
(n=521) 
T2DM-/HTN+  
(n=153) 
p (HTN-
Contrl) 
T2DM+/HT
N-  
(n=109) 
p 
(T2DM-
Contrl) 
p (HTN-
T2DM) 
T2DM+/HT
N+  
(n=187) 
p (Both-
contrl) 
P 
(HTN-
both) 
p 
(T2DM-
both) 
T2DM-
/HTN-  
(n=72) 
p 
(total) 
LVIDd 4.6 (0.6) 4.6 (0.6)  4.6 (0.5)   4.6 (0.6)    4.5 (0.5) 0.376 
LVEDV (2D) (ml) 88 (26) 88 (22)  85 (25)   91 (27)    86 (28) 0.189 
LVEF (%) 63 (6) 64 (6)  64 (6)   63 (7)    65 (6) 0.115 
RWT 0.43 (0.1) 0.43 (0.1)  0.43 (0.1)   0.44 (0.1)    0.42 (0.1) 0.289 
GLS (%) -18.3 (2.7) -18.9 (3) >0.99 -18.0 (3) 0.005 0.056 -17.4 (3) <0.01 <0.01 0.436 -19.4 (2) <0.01 
Abnormal GLS, n (%) 220 (42) 50(33)  51 (47)   102 (55)    17 (24) <0.01 
DD (Grade_0), n (%) 102 (20) 32 (21)  23 (21)   30 (16)    17 (24) 
0.649 DD (Grade_I), n (%) 298 (57) 87 (57)  58 (53)   116 (62)    37 (51) 
DD (Grade_II), n (%) 100 (19) 27 (18)  21 (19)   36 (19)    16 (22) 
E/A  0.8 (0.2) 0.80 (0.2)  0.82 (0.21)   0.78 (0.20)    0.83 (0.18) 0.203 
DT (ms) 249 (51) 247 (54)  248 (53)   253 (52)    245 (39) 0.597 
e' (cm/s) 7.7 (1.6) 7.6 (1.6) 0.170 7.9 (1.7) >0.99 >0.99 7.5 (1.5) 0.013 1.000 0.160 8.2 (1.6) 0.010 
E/e' 10.1 (3) 10.1 (3.2) 0.135 10.0 (2.7) 0.279 >0.99 10.6 (3.2) 0.003 0.817 0.731 9.1 (2.6) 0.006 
Preclinical HF (E/e'15) 
(n, %) 
70 (13) 22 (14)  11 (10)   33 (20)    4 (6) 0.049 
Diastolic Strain (%) 0.41 (0.15) 0.43 (0.15) 0.278 0.43 (0.13) 0.411 >0.99 0.39 (0.15) 0.003 0.417 0.411 0.47 (0.15) 0.006 
Diastolic SR (1/s) 0.96 (0.26) 0.97 (0.26) 0.280 0.97 (0.27) 0.278 >0.99 0.91 (0.25) 0.001 0.117 0.297 1.05 (0.25) 0.001 
LAVi (ml/m2) 31 (10) 31 (10)  31 (10)   33 (10)    30 (10) 0.148 
LVMi (g/m2) 93 (24) 96 (22) 0.023 88 (21) >0.99 0.033 96 (26) 0.017 >0.99 0.024 86 (21) 0.001 
Preclinical HF (LVH) 
(n, %) 
143 (27) 58 (38)  16 (15) 
  
58 (31)   
 
11 (15) <0.01 
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Continuous variables are listed as mean (SD); Categorical variables are listed as number (%). 
Both=HTN+/T2DM+; Contrl=HTN-/T2DM-; HTN: hypertension; T2DM: type 2 diabetes mellitus; 
LVIDd: left ventricular internal dimension during end diastole; LVEDV: left ventricular end diastolic volume; LVEF: left ventricular ejection fraction; RWT: relative wall thickness; GLS: global longitudinal strain; 
DD: diastolic dysfunction grading according to ASE recommendation; LAVi: left atrium volume index; LVMi left ventricular mass index; LVH: left ventricular hypertrophy  
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Association of exercise capacity with cardiac changes in hypertension and T2DM. 
The 6MW test distance in the entire cohort correlated with GLS (r=-0.11, p=0.01) and 
E/e’ (r=-0.10, p=0.03), but not other diastolic parameters or LV mass. 6MW distance 
in subgroups is shown in Figure 6.40H. Compared with T2DM-/HTN-, T2DM-/HTN+ 
had preserved 6MW distance, while T2DM+/HTN-had a non-significant reduction and 
those T2DM+/HTN+ had significantly lower 6MW distance (p=0.019). Multivariable 
analysis showed T2DM was independently associated with reduced 6MW in both 
models (history of hypertension and active hypertension). In contrast, active or history 
of hypertension was associated with preserved 6MW after adjustment for age, gender, 
height, SBP and heart rate (Table 6.36). 
Lastly, Table 6.37 summarizes the association of 6MW distance with abnormal cardiac 
functional parameters, after adjusting for age, gender, height, HR and SBP. 6MW was 
independently associated with GLS, DS and LVMi, not with other diastolic 
parameters. In multivariable logistic analysis using GLS (-18% cut-off) and 6MW 
(lower quartile distance: 410 cut-off), those with 6MW distance <410 meters were 
associated with abnormal GLS with an odds ratio of 1.69 (95% CI: 1.09- 2.60, p=0.02).  
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Abnormal strain (2A) but not EF (2B). Diastolic markers (2C-F), LV mass (2G) and exercise capacity (2H) were impaired in the 
presence of both hypertension and T2DM. 
Figure 6.40 Association of LV function with hypertension and T2DM. 
 
 
 
Control vs HTN: p=0.170
Control vs DM: p=1.000
Control vs Both: p=0.013
HTN vs DM: p=1.000
HTN vs Both: p=1.000
DM vs Both: p=0.160
Figure 2c. Mitral e’ (overall p=0.010) Figure 2d. Mitral E/e’ (overall p=0.006)
Control vs HTN: p=0.135
Control vs DM: p=0.279
Control vs Both: p=0.003
HTN vs DM: p=1.000
HTN vs Both: p=0.817
DM vs Both: p=0.731
P=1.000
P=1.000
P=1.000
P=0.013
P=0.160
P=0.170
P=0.160
P=0.279
P=0.817
P=0.731
P=1.000
P=0.003
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Table 6.35 Association of T2DM and hypertension with cardiac function 
  GLS DS DSR e' E/e' E/A LVMi 
  ß (95% CI) p ß (95% CI) p ß (95% CI) p ß (95% CI) p ß (95% CI) p ß (95% CI) p ß (95% CI) p 
Univariate analysis              
T2DM 1.383 (0.922, 1.845) <0.001 -0.031 (-0.056, -0.01) 0.017 -0.068 (-0.11, -0.022) 0.004 -0.002 (-0.005, 0.001) 0.191 0.603 (0.073, 1.134) 0.026 -0.015 (-0.051, 0.020) 0.396 0.097 (-3.99, 4.19) 0.963 
History HTN -0.156 (-0.755, 0.443) 0.608 -0.007 (-0.040, 0.025) 0.649 -0.012 (-0.07, 0.046) 0.679 -0.002 (-0.006, 0.001) 0.214 0.689 (0.021, 1.357) 0.043 0.011 (-0.034, 0.057) 0.622 5.82 (0.695, 10.94) 0.026 
Active HTN 0.463 (-0.031, 0.957) 0.066 -0.033 (-0.06, -0.007) 0.014 -0.063 (-0.11, -0.016) 0.009 -0.005 (-0.007, -0.002) 0.002 0.711 (0.160, 1.262) 0.012 -0.037 (-0.074, 0.001) 0.053 8.72 (4.53, 12.92) <0.001 
Model with history of HTN*                      
T2DM 0.972 (0.522, 1.423) <0.001 -0.021 -0.043, 0.000) 0.054 -0.062 (-0.11, -0.015) 0.010 -0.003 (-0.006, -0.001) 0.020 0.764 (0.229, 1.298) 0.005 -0.000 (-0.025, 0.035) 0.996 -1.553 (-5/43, 2.321) 0.431 
History HTN -0.025 (-0.578, 0.529) 0.931 -0.015 (-0.042, 0.012) 0.275 -0.016 (-0.073, 0.042) 0.590 -0.002 (-0.006, 0.001) 0.164 0.742 (0.086, 1.399) 0.027 0.011 (-0.032, 0.055) 0.615 4.26 (-0.493, 9.02) 0.098 
Model with active HTN*                      
T2DM 1.00 (0.56, 1.45) <0.001 -0.022 (-0.04, -0.001) 0.044 -0.064 (-0.11, -0.02) 0.010 -0.003 (-0.006, -0.001) 0.017 0.726 (0.19, 1.26) 0.007 -0.003 (-0.04, 0.03) 0.848 -1.564 (-5.375, 2.247) 0.421 
Active HTN 0.408 (-0.05, 0.86) 0.079 -0.035 (-0.06, -0.013) 0.002 -0.059 (-0.11, -0.013) 0.013 -0.005 (-0.007, -0.002) 0.001 0.691 (0.151, 1.23) 0.012 -0.033 (-0.069,0.032) 0.848 7.029 (3.144, 10.91) <0.001 
* adjusted for age, male gender, BMI, HR 
GLS: global longitudinal strain; DS: diastolic strain; DSR: diastolic strain rate; LVMi: left ventricular mass index; T2DM: type 2 diabetes mellitus; HTN: hypertension 
 
Table 6.36 Association of 6MW distance with hypertension and T2DM status 
    Univariable analysis   
Model with history of 
hypertension 
    
Model with active 
hypertension 
 r2 ß (95% CI) p value ß (95% CI) r2 p value ß (95% CI) p value r2 
Age 0.090 -6.314 (-8.06, -4.56) <0.001  
0.182 
   
0.181 
Male gender 0.023 30.8 (13.4, 48.1) 0.001     
BMI 0.050 2.274 (1.41, 3.14) <0.001     
SBP 0.017 -0.742 (-1.24, -0.25) 0.003     
HR 0.029 -1.559 (-2.345, -0.773) <0.001     
T2DM 0.024 -31.66 (-49.1, -14.2) <0.001 -34.5 (-51.2, -17.8) <0.001 -35.29 (-51.8, -18.7) <0.001 
History HTN 0.000 2.72 (-19.44, 24.88) 0.810 7.056 (-13.9, 28.0) 0.508  0.687  
Active HTN 0.005 -15.14 (-33.56, 3.28) 0.107     -4.88 (-28.7, 18.9)   
SBP: systolic blood pressure; HR: heart rate; T2DM: type 2 diabetes mellitus; HTN: hypertension 
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Table 6.37 Association of 6MW with echocardiographic measures 
  r2 ß (95% CI) p value 
GLS* 0.142 -0.281 (-0.52, 0.04) 0.002 
DS* 0.339 -0.015 (-0.03, 0.004) 0.010 
DSR* 0.052 -0.001 (-0.03, 0.02) 0.930 
e'* 0.125 -0.001 (-0.003, 0.0001) 0.072 
E/e'* 0.083 0.002 (-0.28, 0.28) 0.988 
E/A* 0.109 -0.005 (-0.02, 0.01) 0.610 
LVMi* 0.171 -1.826 (-3.58, -0.08) 0.041 
*adjusted with age, gender, height, HR, SBP. 
Beta as per 100 meter distance of 6MW test. 
 
 
6.5 Discussion 
This study demonstrated that in individuals with non-ischemic stage A HF risks, 
T2DM is associated with more impaired cardiac function and reduced exercise 
capacity than is present in those with hypertension. Although patients with both well- 
and poorly-controlled blood pressure showed abnormal diastolic function, it appears 
that abnormal GLS is an independent marker for diabetic cardiomyopathy rather than 
hypertensive heart disease. Poor BP control is associated with more impaired cardiac 
function with or without the presence of diabetes. 
Combined effect of T2DM and hypertension on LV function. Diabetes and 
hypertension constitute two powerful independent risk factors for cardiovascular 
disease. T2DM is known to be a strong predictor of incident HF, independent of other 
concomitant risk factors 57,65,283-286. Subclinical diastolic dysfunction and systolic 
impairment assessed using global longitudinal strain (GLS) are believed to be early 
markers of diabetic cardiomyopathy 58,65. However, hypertension is present in 40-80% 
of patient with longstanding diabetes 287 and most of these studies were performed in 
populations with a high prevalence of hypertension, and therefore reflect the combined 
impact of hypertension and T2DM. In our study, patients with mixed T2DM and 
hypertension had a 20% prevalence of E/e’>15, analogous to a 23% prevalence in 
another community-based study of 1760 T2DM patients with an 86% of hypertension 
and 36% of prevalence of coronary artery disease (CAD). Follow-up of that group 
showed that the hazard ratio (HR) of hypertension (HR 4.27, 95%CI 1.92-12.15) for 
subsequent HF was almost double that of CAD (HR 2.2, 95% CI 1.62-3.01). The 
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negative synergistic effect of hypertension and diabetes was likely the cause of high 
prevalence of impaired diastolic and systolic dysfunction and associated adverse 
outcome 288 57,65. However, the exact underlying pathophysiology of this combined 
impact is unclear. Diabetes is a metabolic disorder characterized by intracellular 
accumulation of toxic fatty acid intermediates 289. This change also affects cardiac 
mitochondrial resulting in contractile dysfunction 290. There is a well-recognized 
tendency to develop diastolic dysfunction even in the absence of significant 
hypertension, however, the presence of hypertension may accelerate the adverse 
changes and cause end organ damage 291. Quantitative measure using fibrosis score 
showed the degree of myocardial and interstitial fibrosis contributes to the pathological 
involvement 292. The score was found to be lowest for hypertensive, midrange for 
diabetic and highest for hypertensive-diabetic. It is presumed that fibrosis and 
metabolic consequences of myocyte in diabetes leading to impaired both systolic and 
diastolic function, while chronic afterload causing interstitial fibrosis lead to a more 
impaired diastolic than systolic function in hypertension. The coexisting hypertension 
exacerbates functional changes by producing larger amount of fibrosis. Another 
observation was described that abnormal GLS and diastolic dysfunction were not 
analogous to each other. As an early marker, diastolic function was documented in 
47% of patients with T2DM, Ernande showed abnormal strain in 28% of those with 
normal diastolic function 58. In multivariable analysis, a history of hypertension but 
not T2DM was associated with diastolic parameters. This relationship was mirrored in 
our study, in which the prevalence of diastolic dysfunction was 72% in those with 
T2DM with abnormal strain in 47% of them (Table 6.34) – a higher prevalence found 
in our study was likely due to older age (71±5 vs 52±5 years) and higher prevalence 
of history of hypertension (67% vs 38%). A history of hypertension but controlled 
blood pressure was associated with increased E/e’, which may represent a combined 
impact. The findings parallel the finding that hypertension (either historical or high 
blood pressure at the time of the echocardiogram) was independently associated with 
e’ and E/e’ and diabetes was associated with E/e’ 288.  
It needs to be noted that our finding of GLS was consistently associated with diabetes 
but not hypertension in the multivariable analysis should not be interpreted as a normal 
GLS in this population. Influence of afterload on left ventricular causing reduced 
global longitudinal strain in early disease stage has been describe in both animal model 
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and human studies 248,293,294. Understanding these difference would be important and 
beneficial to guide effective screening and early intervention in the community as 
hypertension and diabetes are the two leading etiology of preclinical HF in this 
population.  
Effects of controlled and uncontrolled hypertension on LV impairment. 
Hypertension has been shown to precede the development of HF in both men and 
women 295. Although there have been improvements in the overall management of 
hypertension, there remain a significant number of hypertensive patients who remain 
untreated or fail to achieve optimal control296,297. Of the 82% with a known history of 
hypertension in our study, 92% of them were on anti-hypertensive therapy, but only 
33% had good control of blood pressure (Table 6.33). Our study demonstrated 
uncontrolled blood pressure was independently associated with more severe cardiac 
dysfunction including abnormal e’, E/e’, diastolic strain, diastolic strain rate and LV 
mass. However, GLS appeared to be relatively preserved in those with hypertension 
as compared to those with neither hypertension and nor T2DM. These findings are 
inconsistent with previous work in a small group of younger (46±14 years) 
hypertensive subjects with controlled blood pressure showing lower peak strain and 
strain rate at rest, with blunting of strain increment during exercise248. The dependence 
of myocardial strain on hemodynamic conditions has been reported in both 
hypertension298 299 and valve disease300.  
Assessment of exercise capacity using 6MW. Impaired exercise capacity and 
functional changes during exercise were known to be early markers of subclinical LV 
dysfunction in patients with hypertension and diabetes 70,301,302. However, a standard 
exercise testing protocol is not feasible in community-based screening for subclinical 
LV dysfunction. Due to its simplicity and inexpensiveness, the 6MW test is often used 
to estimate submaximal functional capacity in this setting; the predictive value of 
6MW for peak oxygen uptake is of moderate accuracy 303. In our study, 6MW distance 
correlated with subclinical cardiac dysfunction, and was significantly reduced in those 
with T2DM+/HTN+ individuals, but relatively preserved in those with hypertension 
alone. 
6.6 Study Limitations 
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The present analysis was based on a cross-sectional sample from a clinical trial 
population of ≥65-year-old participants with at least one of the listed non-ischemic 
SAHF risks. The control group without T2DM or hypertension had other HF risks 
(mainly obesity), but there were no age-matched controls without HF risk factors. 
Another important limitation of this study was the concomitant presence of coronary 
artery disease (CAD) was not assessed. Our intention and focus was on non-ischemic 
population with a very low prevalence of known CAD (<5%). However, diabetic 
cardiomyopathy and hypertensive heart disease are both known as part of 
atherosclerosis process, which make their heart susceptible to ischemia coronary 
changes. Some of the functional changed may be caused by underlying ischemic and 
non-ischemic pathophysiologic changes. A possible approach to address this limitation 
would be a stress test to identify those with underlying CAD, but we could not perform 
this in the context of a community-based study. 
6.7 Conclusions 
Hypertension is associated with less impairment of GLS and exercise capacity than is 
T2DM. Those with both well- and poorly-controlled blood pressure showed abnormal 
diastolic functional markers, and more severely impaired cardiac function was 
associated with worse BP control. However, GLS appears to be associated with 
diabetic cardiomyopathy rather than hypertensive heart disease in this population at 
risk of HF. 
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Postscript 
Findings from this chapter suggest early markers for isolated hypertension and 
diabetes may be different although these two often coexist. In the community setting, 
individuals with both comorbidities had more impaired cardiac function.  
Next chapter will discuss the role of ECG in screening. ECG is widely used in primary 
setting. However, it is not sensitive to subtle cardiac changes. We will discuss the role 
of new ECG markers in relation to echo features and outcome. 
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Chapter 7. Association between ECG and echo 
markers and outcome  
Role of electrocardiography (ECG) technique in 
Screening 
Introduction 
The main concern of community screening using echocardiography is test feasibility 
and cost. ECG has been widely used as the first line diagnostic tool in primary care to 
assess cardiac rhythms and ischemic cardiac disease. The potential role of the ECG to 
screen for non-ischemic stage B heart failure is the focus of this chapter. The TasELF 
cohort excluded patients with a previous history of valvular disease, coronary artery 
disease and atrial fibrillation. It was assumed that the main ECG changes would relate 
to left ventricular hypertrophy, abnormal left atria, QRS duration and minor ST 
changes. The availability of automated measurement of all ECG markers would also 
facilitate a comprehensive and multi-marker approach for efficient and effective 
screening.  
The following text in this chapter has been published in ESC Heart Failure 2017; 
DOI:10.1002/ ehf2.12151. 
Abstract 
Aims. The detection of non-ischemic stage B heart failure (SBHF) may facilitate the 
recognition of those at risk of progression to overt HF and HF prevention. We sought 
the relationship of specific electrocardiographic (ECG) markers of SBHF to 
echocardiographic features of SBHF and their prognostic value for development of 
HF. The ECG markers were Cornell Product (Cornell-P), P wave terminal force in lead 
V1 (PTFV1), ST depression in lead V5 V6 (minSTmV5V6) and increased heart rate. 
Echocardiographic assessment of SBHF included left ventricular hypertrophy (LVH), 
impaired global longitudinal strain (GLS), and diastolic dysfunction (DD). 
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Method and results – Asymptomatic subjects ≥65 years without prior cardiac history, 
but with HF risks, were recruited from the local community. At baseline, they 
underwent clinical assessment, 12-lead ECG and comprehensive echocardiography. 
New HF was assessed clinically at mean follow-up of 14±4 months, and 
echocardiography was repeated in subjects with HF. Of the 447 subjects (age 71±5, 
47% men), SBHF was present in 13% by LVH, 31% by impaired GLS and 62% by ≥ 
grade I DD. Forty were lost to follow-up. Clinical HF developed in 47 of 407, of whom 
20% had echocardiographic LVH, 51% abnormal GLS, and 76% DD at baseline. 
Baseline LVH and abnormal GLS (not grade I DD) were independently associated 
with outcomes (clinical HF and cardiovascular death). Cornell-P and heart rate (not 
minSTmV5V6 nor PTFV1) were independently associated with LVH, impaired GLS 
and DD. Cornell-P and minSTV5V6 (not heart rate nor PTFV1) were independently 
associated with outcomes. More ECG abnormalities improved sensitivity, but ECG-
markers were not independent of or incremental to echocardiographic markers to 
predict HF in SBHF. 
Conclusion – In this elderly study population, ECG markers showed low diagnostic 
sensitivity for non-ischaemic SBHF and low prognostic value for outcomes. Cornell-
P and minSTmV5V6 had predictive value for outcomes in non-ischaemic SBHF 
independent of age, gender, and common comorbidities but were not incremental to 
echocardiography. 
7.1 Background 
Stage B heart failure (SBHF) is an early stage with no symptoms despite evidence of 
cardiac structural or functional impairment25,70. Most often it is due to loss of 
functioning myocytes from myocardial infarction, valvular disease or left ventricular 
hypertrophy (LVH) secondary to hypertension25. Randomized trials have shown that 
early intervention can prevent or delay the onset of overt HF in patients with reduced 
left ventricular ejection fraction (LVEF) in the ischaemic population 37,40. However, 
evidence is missing in the non-ischaemic population with preserved LVEF about 
utility of early diagnosis and treatment. Using echocardiography, SBHF may be 
detected by LVH, diastolic dysfunction (DD), or impaired global longitudinal systolic 
strain (GLS)70. The assessment of left ventricular (LV) function has been strengthened 
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by speckle-tracking echocardiography. This semi-automated method is highly 
sensitive for the detection of subtle myocardial impairment, provides incremental 
prognostic value over LVEF65 and can be a functional marker of SBHF 70,307.  
However, the cost and feasibility of current echocardiographic techniques are a barrier 
to community-based screening for SBHF. A selective screening strategy of identifying 
high-risk individuals based on the use of simpler tools that are more feasible could 
improve the efficiency of a screening approach.  
The association of abnormal electrocardiographic (ECG) markers and incident HF has 
been reported in the literature, including abnormal QRS duration304, abnormal P-wave 
terminal force in lead V1(PTFV1)199, ST changes 198 and various markers in 
combination 305, 343. ECG-LVH has been associated with abnormal cardiac function 
and has predictive value for incident HF independent of echocardiographic LVH 306. 
ECG-LVH by Cornell product (Cornell-P) criteria is strongly associated with DD 309, 
and in a larger cohort of hypertensive patients, ECG-LVH was associated with 
increased risk of LV systolic dysfunction 310, especially when combined with ST 
depression in the lateral precordial leads (V5-V6), even in the absence of coronary 
disease 198, 344.  ECG markers [Cornell-P, PTFV1, minimal ST deviation at m point of 
leads V5 and V6 (minSTmV5V6), and abnormally increased heart rate] may reflect 
underlying structural changes in the heart. Their associations with outcome have not 
been well studied. 
7.2 Aims and Objectives 
Accordingly, we aimed to evaluate the performance of commonly utilized ECG 
markers to predict echocardiographic features of SBHF70 and to compare the 
prognostic and incremental value of these ECG markers with echocardiographic 
indices for HF in this community population at risk of HF. 
7.3 Methods 
Study Population. Participants were enrolled through local media advertising. Data 
were prospectively collected from subjects ≥65 years old and living in the community. 
Inclusion was based on the presence of one or more of HF risk factors: 1) hypertension 
(based on SBP >140 mmHg and/or self-report of anti-hypertensive medication); 2) 
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type 2 diabetes mellitus (T2DM, based on self-report of diagnosis including 
medication); 3) obesity (body mass index [BMI] ≥30); 4) previous potentially cardio 
toxic chemotherapy; 5) family history of heart failure; 6) previous history of heart 
disease (but not existing heart failure). Exclusion was based on subjects with: 1) 
symptoms or a known history of HF; 2) known coronary artery disease (CAD) 
including history of myocardial infarction and coronary artery by-pass graft; 3) more 
than moderate valvular heart disease; 4) reduced LVEF (<40%) on baseline 
echocardiography; 5) atrial fibrillation (AF); 6) inability to acquire interpretable 
images at baseline. This study was performed in accordance with a research protocol 
approved by the Tasmanian Human Research Ethics Committee (HREC), and 
registered with the Australian and New Zealand Clinical Trials Registry 
(http://www.anzctr.org.au/ ; ACTRN12614000080628). Individual written informed 
consent was obtained from participants  
Data collection. Data were prospectively collected at facilities in the community, from 
all participants enrolled in the study. All underwent a physical examination and 
symptom questionnaire. Anthropometric measurements were obtained and body mass 
index (BMI) was calculated (body weight [kg]/height2 [m2]). Blood pressure was 
measured twice after 10-minutes of rest. Data were also collected on socioeconomic 
indicators, complete medical history, and family history. Charlson comorbidity score 
index was used for comorbidity assessment311. 
Electrocardiogram (ECG). A standard 12-lead ECG was recorded at 25 mm/s and 1 
mV/cm according to standard protocol. ECG measurements were performed using 
MUSE software (GE Healthcare, Milwaukee, WI, USA) including QRS duration and 
axis, PR, QT and heart rate. Cornell voltage (Cornell-V) was measured as SV3+RaVL 
and criteria for LVH was defined as ≥2.8 mV (28 mm) in men and ≥2.0 mV (20 mm) 
in women310. Criteria for LVH using the Cornell product (Cornell-P, the product of 
QRS duration times Cornell voltage [RaVL+SV3] plus 6 mm in women) was defined 
as ≥ 2440 mm·ms310, and the 75th percentile of gender specific cut-offs for Cornell-P 
from the current study population were also used as categorical cut-off. Sokolow-Lyon 
voltage (SLV) was measured as SV1+RV5 or RV6, and criteria for LVH was defined 
as ≥3.5 mV (35 mm) 197. The cut-off for absolute ST segment deviation 
(minSTmV5V6, the midpoint of the ST segment on median complexes in leads V5 
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and V6) was defined as <-20uV. Abnormal P-wave terminal force in the right 
precordial lead V1 (PTFV1; the product of the negative P-wave deflection from onset 
of the negative deflection to its nadir in lead V1 [uV] and the duration [ms]) was 
defined as ≤ -4000 uVms 199. An abnormal ECG was defined as the combination of ≥1 
of the following: 1) resting heart rate ≥80 bpm; 2) 75th percentile of Cornel-P; 3) 
abnormal minSTmV5V6 and 4) abnormal PTFV1. 
Echocardiographic study. Standard transthoracic 2D and Doppler echocardiographic 
studies were performed using standard equipment (Siemens ACUSON SC2000, 
Siemens Healthcare, Mountain View, CA) and transducer (4V1c, 1.25-4.5 MHz; 4Z1c, 
1.5-3.5 MHz) in accordance with the American Society of Echocardiography (ASE) 
guidelines187. LV dimensions during diastole and systole and wall thicknesses were 
measured according to the recommended criteria, and LV mass (LVMi) was calculated 
accordingly 187. Echo-LVH was defined as LVMi>115 g/m2 in men and >95 g/m2 in 
women. LV and left atrial (LA) volumes were calculated by the Simpson biplane 
method 187 indexed to body surface area. LA enlargement (LAE) defined as LAVi≥34 
ml/m2. Mitral inflow peak early diastolic velocity (E), peak late diastolic velocity (A), 
E/A ratio, E wave deceleration time (DecT) were measured for diastolic function 
assessment188,189. Tissue Doppler mitral annular early diastolic velocity (e’) was 
assessed at septal and lateral and averaged for calculation of E/e’; septal E/e’≥15, 
lateral E/e’≥13 and averaged ≥14 were defined as abnormal188. Diastolic dysfunction 
(DD) grade was defined as previously described as188, 281: 
-Grade I DD: E/A <0.8, E/e’<10, pulmonary venous inflow S<D;  
-Grade II DD: 0.8<E/A<1.5, E/e’ > 10 or LAE, or presence of mid diastolic forward 
flow (L wave), or positive Valsalva (> 50% increase of E/A ratio);  
- Grade III DD: E/A> 1.5, DecT<140 ms.  
LV peak longitudinal strain measurements were obtained from grey scale-recorded 
images in the apical 4-chamber, 2-chamber and long-axis views. Strain was analysed 
using velocity vector imaging (Syngo VVI, Siemens Medical Solutions). GLS was 
measured on-line by averaging strain from the region of interest in the apical 4-
chamber, 2-chamber and long-axis views. Impaired GLS was defined using cut-off of 
<18 %85. Global circumferential strain (GCS) was measured off line. Global diastolic 
strain was obtained by averaging all 18 segment strain values and measured according 
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to method published by Ishii 282. Functional capacity was assessed using a 6-min walk 
test distance following a standardized protocol 209. 
Follow-up and primary end-point. Potential HF symptoms were assessed through 
regular follow-up phone calls, followed by symptom surveillance questionnaires and 
clinical visits. Possible heart failure signs and symptoms were reviewed by 3 
independent cardiologists, and heart failure diagnosis was confirmed using the 
Framingham criteria for HF110. The primary composite end-point was defined as new-
onset of HF and death of cardiovascular (CV) causes. Follow-up echocardiographic 
assessment of LVEF was performed to classify the patients with HF with reduced 
(HFrEF, LVEF<40%), mid-range (HFmrEF, LVEF 40-49%) or preserved EF 32. 
Statistical analysis. Data are presented as mean (±standard deviation [SD]) after 
testing for normal distribution (Shapiro-Wilk test). Data deviating from normality are 
expressed as median (inter-quartile range [IQR]). Categorical variables are expressed 
as percentages. Correlation between variables was assessed with Pearson or Spearman 
correlation coefficients. For differences among groups, Mann-Whitney U test or t-test 
were used for continuous variables. Pearson’s X2 tests or Fisher’s Exact test were used 
for categorical variables. Logistic regression analysis was used to examine the 
association of ECG markers and abnormal echocardiographic features of SBHF. The 
primary outcome of time to event was examined with univariable and multivariable 
Cox proportional hazards models. Receiver operator characteristic analysis was used 
to examine the discriminative ability of variables for outcome. Comparisons of AUCs 
was performed with the method suggested by Hanley and McNeil. Survival analysis 
was performed using the Kaplan-Meier method, and the differences in survival 
between groups were assessed by the log-rank test. Net Reclassification Improvement 
(NRI) was based on quartile boundaries of probability calculated from the 
multivariable logistic regression for incremental value of ECG markers over clinical 
and echocardiographic measures for outcome. Statistical analyses were performed 
using a standard statistical software package (SPSS software 22.0, SPSS Inc., Chicago, 
IL). Statistical significance was defined by p< 0.05. 
7.4 Results 
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Patient selection Baseline ECG and echocardiography were obtained in 447 
individuals from the community (age 71±5 years, 47% men) who met the inclusion 
criteria. HF risk factors were present in all – most commonly hypertension (81%), 
T2DM (54%) and obesity (45%); 81% had more than one of the listed risk factors. 
Echocardiographic markers of SBHF were LVH (13%), DD (65% by ≥ grade 1 DD 
and 10% by ≥ grade 2 DD), and impaired GLS (32%). The median (IQR) for Cornell-
V was 9.8 (6.8-13.6) mm; SLV 18.0 (14.1-22.7) mm, Cornell-P 1090 (786-1500) 
mm·ms. The mean (±SD) of minSTV5V6 was 3.1±39 and PTFV1 -2918±3532. Using 
the conventional cut-off values, ECG-LVH was present in 1.6% by SLV, 2% by 
Cornell-V and 3.1% by Cornell-P. Abnormal PTFV1 was present in 35%, abnormal 
minSTmV5V6 in 27% and increased heart rate in 13%.  
Association of ECG markers with echocardiographic feature of SBHF. Baseline 
demographic, electrocardiographic and echocardiographic characteristics are listed in 
Table 7.38, stratified according to the presence SBHF features. Subjects with LVH 
and DD were older but impaired GLS was unrelated to age. However, more men had 
impaired GLS than women. Mean BMI was not different among groups. Hypertension 
and obesity were more prevalent in subjects with LVH; T2DM and obesity were more 
prevalent in subjects with impaired GLS. Functional capacity by 6MW was lower in 
those with diastolic dysfunction (DD) (p=0.02). 
Using continuous measures, both Cornell-V and Cornell-P were significantly higher 
in groups with echocardiographic LVH (Echo-LVH), DD and impaired GLS 
(p≤0.023). SLV showed no differences among the groups. The overall prevalence of 
ECG evidence of LVH (ECG-LVH) by the listed criteria was the greatest by Cornell-
P criteria - detected in 8.6% of Echo-LVH, 4.5% of DD and 6.3% of impaired GLS. 
By SL voltage and Cornell-V criteria, only 5.2% and 3.4% in Echo-LVH were 
abnormal, respectively. The 75th percentile gender specific cut-off of Cornell-P for 
LVH from the current cohort was 1442 mm·ms for men and 1518 mm·ms in women; 
this cut-off detected 45% of those with Echo-LVH, but also detected 22% of those 
with no Echo-LVH as being abnormal. As ECG markers are gender dependent, we 
further assessed their correlation with each SBHF feature stratified by gender (Table 
appendix 7.42). In general, correlation between men was better than women. There 
was significant correlation of Cornell-V and Cornell-P with LVMi, with better 
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correlation using Cornell product than voltage. Correlation with GLS and e’ were 
similarly better with Cornell Product. SLV showed insignificant correlation. 
MinSTmV5V6 showed significant correlation with LVMi and GLS. The overall 
discriminative ability of 4 ECG markers for SBHF features is displayed by receiver 
operating characteristic (ROC) curve in Figure 7.41.  
 
The independent associations of ECG markers with SBHF features are summarized in 
Table 7.39. Cornell-P and resting heart rate were associated with Echo-LVH, DD and 
impaired GLS independent of age, gender, SBP, BMI, Charlson comorbidity score and 
other ECG markers. One standard deviation of the mean increased Cornell-P (635 
mm·ms) was associated with an odds ratio was 1.48 for Echo-LVH, 1.39 for DD and 
1.37 for impaired GLS (p<0.012) independent of clinical variables. In multivariable 
analysis with all four ECG markers, the independent association of Cornell-P and 
increased resting heart rate remained significant, with similar effect size (p<0.047) 
(Table 7.39). 
Predefined cut-offs of the four abnormal ECG markers were assessed for diagnostic 
characteristics for echo features of SBHF. The diagnostic characteristics including 
sensitivity and positive predictive value (PPV) for detection of echocardiographic 
LVH, DD and impaired GLS are summarized in Table 7.40. Sensitivity was overall 
low using single marker, which improved slightly using combined markers with the 
expected loss of specificity from including multiple variables.  
 
Figure 7.41 ROC analysis of ECG vs Echo features 
Receiver operating characteristic (ROC) curve shows common ECG markers for discriminative 
characteristics for echocardiographic LVH, impaired global longitudinal strain (GLS) and for ≥ 
grade I diastolic dysfunction. 
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Association of ECG markers with primary outcome. After a median interval of 
14±4 months, 40 individuals were lost to follow-up or alive but unable to attend 
follow-up. This group was no different from the remaining 407 individuals who 
completed follow-up (Table appendix 7.43). New HF symptoms developed in 47 
patients and 4 died (2 of CV causes). The primary composite end-point of new-onset 
of HF and CV death occurred in 49 (12%) of the entire cohort - an annualized event-
rate of 10%. Of the entire cohort, 66% had at least one abnormal ECG markers, 29% 
had two and 7% had all three. Figure 7.42 shows adverse outcome was proportional to 
the number of abnormal ECG markers.  
 
 
Figure 7.42 Kaplan Meier plot of outcome vs abnormal ECG 
markers 
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 Table 7.38 Baseline characteristics  
Baseline clinical and echocardiographic characteristics stratified by LVH, diastolic dysfunction and impaired GLS. 
  
LVH (-) 
(n=389) 
LVH (+) 
(n=58) 
P  
value 
Normal diastolic 
(n=158) 
DD* 
(n=289)  
P  
value 
Normal GLS 
(n= 305) 
Impaired GLS** 
(n=142)  
P  
value 
Clinical characteristics          
Age (years) 70 (67-74) 71 (68-77) 0.019 69±4 72±5 <0.001 71±5 71±5 0.787 
Male, n (%) 188 (48) 20 (35) 0.049 83 (53) 125 (43) 0.060 119 (39) 89 (63) <0.001 
SBP (mmHg) 139±16 146 ±19 0.001 137±14 141±17 0.009 139±15 141±19 0.321 
DBP (mmHg) 81±10 84 (±10) 0.078 80±9 82±11 0.057 80±10 84±11 <0.001 
Body mass index (g/m2) 30±5 30 (±5) 0.458 29±5 30±6 0.332 29±5 30±6 0.078 
Charlson Score 1.0 (0-2.0) 1.0 (0-2.0) 0.744 1 (0-2) 1 (0-2) 0.138 1.0 (0-2.0) 1.0 (0-2.0) 0.177 
Type2 Diabetes, n(%) 205 (53) 36 (62) 0.182 76 (48) 165 (57) 0.068 141 (46) 100 (70) <0.001 
Obese, n(%) 167 (43) 36 (62) 0.006 66 (42) 137 (47) 0.253 125 (41) 78 (55) 0.006 
Hypertension, n(%) 309 (79) 53 (91) 0.031 126 (80) 236 (82) 0.622 248 (81) 114 (80) 0.796 
6-minute-walk (meter) 469±101 444 (±99) 0.066 481±98 457±100 0.019 470±96 456±108 0.171 
ECG characteristics          
Heart rate (beat/min) 68±11 66±10 0.172 65±11 69±11 <0.001 67±10 70±12 0.002 
QRS duration (ms) 82 (76-90) 86 (78-95) 0.047 82 (76-90) 84 (76-92) 0.489 82 (76-90) 84 (76-94) 0.147 
Cornell voltage (mm) 9.5 (6.8-13.2) 11.4 (7.5-16.3) 0.006 9.1 (6.4-12.2) 10.4 (7.3-14.3) 0.015 9.1 (6.4-12.8) 11.2 (7.4-15.2) 0.001 
SL voltage (mm) 18 (14-23) 18 (13-24) 0.851 18.7 (14.1-23.1) 17.7 (14.0-22.6) 0.515 17.9 (14.1-22.9) 18.2 (14.0-22.6) 0.920 
Cornell product (mm·ms) 1062 (769-1440) 1431 (1093-1821) <0.001 1020 (724-1320) 1123 (849-1558) 0.001 1079 (776-1451) 1132 (825-1637) 0.096 
minSTmV5V6 (uV) 4 (-20, 29) -10 (-40, 19) 0.021 9 (-20, 30) 0 (-24, 24) 0.166 4 (-20, 29) -5 (-25, 19) 0.035 
PTFV1 (uVms) -3153 (-4864, -1328) -2322 (-4193, -846) 0.189 -2844 (-4541, -1152) -3185 (-4767, -1328) 0.479 -3139 (-4696, -1291) -3042 (-5164, -1116) 0.738 
Echo characteristics continuous         
LV mass index (BSA) 79±14 112±13 <0.001 81±17 45±11 0.044 82±16 87±19 0.004 
LAVolmlm2 29±8 37 ±11 <0.001 30±8 30±9 0.808 30±9 30±9 0.901 
LV ejection fraction (%) 64±6 62±7 0.035 64±5 63±6 0.079 65±5 61±7 <0.001 
GLS (%) 18.6±2.5 18.0±2.7 0.103 19.0±2.4 18.3±2.6 0.004 19.9±1.6 15.6±1.6 <0.001 
GCS (%) 29.4±5.6 28.9±5.1 0.466 29.6±5.6 29.2±5.5 0.404 30±5 28±6 <0.001 
Mitral E/A 0.81±0.21 0.81±0.27 0.983 0.95±0.13 0.73±0.23 <0.001 0.8±0.2 0.8±0.3 0.821 
DecT (ms) 249±49 258±54 0.265 231±41 261±51 <0.001 252±49 247±52 0.374 
E/e' (average) 8.8±2.5 9.9±3.1 0.003 8.29±1.76 9.29±2.88 <0.001 8.9±2.6 9.1±2.5 0. 44 
Diastolic Strain (%) 0.42±0.14 0.37±0.16 0.026 0.48±0.12 0.28±0.14 <0.001 0.43±2.62 0.38±0.16 <0.001 
Diastolic Strain ate (1/s) 0.97±0.25 0.87±0.22 0.007 1.06±0.25 0.89±0.23 <0.001 1.02±0.2 0.82±0.2 <0.001 
Echo characteristics categorical          
LV hypertrophy - -  15 (9.5) 43 (14.9) 0.105 35 (12) 23 (16) 0.167 
Dilated LA (cut-off 34) 101 (26) 32 (55) <0.001 42 (27) 91 (32) 0.296 90 (30) 43 (31) 0.832 
Abnormal E/e' (>13) 42 (11) 12 (21) 0.031 3 (2) 51 (18) <0.001 36 (12) 18 (13) 0.792 
Abnormal GLS (<18%) 119 (31) 23 (40) 0.167 43 (27) 99 (34) 0.126 - -  
Diastolic dysfunction>I 246 (63) 43 (74) 0.105 - -  190 (62) 99 (70) 0.126 
Data expressed as mean ±SD or median (IQR) for continuous variables. N (%) for categorical variables 
*Presence of more than grade I diastolic dysfunction. ** Impaired GLS: GLS<18%. Abbreviations: DD: diastolic dysfunction; EDV: end diastolic volume; GLS: global longitudinal strain; GCS: global circumferential 
strain; LVH: left ventricular hypertrophy; LV: left ventricle; LA: left atrium; LVEF: LV ejection fraction; 6MW: 6-minute walk test. 
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Table 7.39 Association between ECG and echo markers of SBHF 
    
Left Ventricular 
hypertrophy 
    
Diastolic 
dysfunction  
    
Impaired GLS 
(<18%) 
  
  R2 OR (95% CI) p value R2 OR (95% CI) p value R2 OR (95% CI) p value 
Models with each of following*          
Heart Rate (11 bpm) 0.083 0.730 (0.54, 0.99) 0.044 0.181 1.408 (1.13, 1.76) 0.003 0.136 1.538 (1.24, 1.91) <0.001 
Cornell product (635 mm·ms) 0.101 1.475 (1.14, 1.90) 0.003 0.175 1.385 (1.08, 1.78) 0.012 0.116 1.372 (1.11, 1.69) 0.003 
minSTmV5V6 (39 uV) 0.080 0.747 (0.55, 1.01) 0.058 0.157 0.917 (0.74, 1.13) 0.420 0.098 0.843 (0.68, 1.04) 0.843 
PTFV1 (3532 uVms) 0.075 1.239 (0.94, 1.64) 0.136 0.156 0.933 (0.75, 1.15) 0.521 0.091 0.982 (0.79, 1.21) 0.866 
Model with all following          
Heart Rate (11 bpm) 
0.134 
0.72 (0.53, 0.99) 0.047 
0.199 
1.388 (1.10, 1.75) 0.005 
0.158 
1.522 (1.22, 1.90) <0.001 
Cornell product (635 mm·ms) 1.490 (1.13, 1.96) 0.004 1.390 (1.05, 1.84) 0.021 1.310 (1.04, 1.65) 0.021 
minSTmV5V6 (39 uV) 0.869 (0.63, 1.19) 0.379 1.019 (0.81, 1.29) 0.872) 0.920 (0.73, 1.16) 0.492 
PTFV1 (3532 uVms) 1.236 (0.92, 1.67) 0.166 0.979 (0.78, 1.23) 0.853 1.061 (0.85, 1.33) 0.606 
* value as per standard deviation 
Each model contains age, gender, heart rate, SBP, BMI, Charlson Comorbidity score; LIFE: using cut-offs from LIFE study as stated in methods 
Table 7.40 Diagnostic characteristics 
Diagnostic characteristics- comparison of ECG markers using conventional cut-offs, gender specific upper quartile cut-offs for detection of stage B heart failure 
  Left ventricular hypertrophy    Impaired Global Longitudinal strain Diastolic Dysfunction (≥ stage I)   
  
#LVH/ total# at risk 
(PPV) 
#LVH/total# LVH 
(Sensitivity) 
p 
#AbnGLS/ 
total# at risk 
(PPV) 
#AbnGLS/total# 
AbnGLS 
(Sensitivity) 
p 
#DD/ total# at 
risk (PPV) 
#DD/total# DD 
(Sensitivity) 
p 
Single ECG marker and cut-off                
Cornell Product 75th (m>1442, f>1518) 26/111 (23%) 26/58 (45%) <0.001 42/111 (38%) 42/142 (30%) 0.113 85/111 (77%) 85/289 (29%) 0.002 
Abnormal-PTFV1 (≤-4000uV·ms) 17/156 (11%) 17/58 (29%) 0.338 48/156 (31%) 48/142 (34%) 0.740 105/156 (67%) 105/289 (36%) 0.390 
Abnormal-minSTmV5V6(≤-20uV) 19/119 (16%) 19/58 (32%) 0.257 45/119 (38%) 45/142 (32%) 0.098 80/119 (67%) 80/289 (28%) 0.493 
Abnormal-Heart Rate(≥80bpm) 5/57 (9%) 5/58 (9%) 0.312 26/57 (46%) 26/142 (18%) 0.016 45/57 (79%) 45/289 (16%) 0.016 
Combined ECG markers                
Presence of ≥ 1 abnormal ECG 44/296 (15%) 44/58 (76%) 0.096 96/296 (32%) 96/142 (68%) 0.672 205/296 (69%) 205/289 (71%) 0.004 
Presence of ≥ 2 abnormal ECG 17/115 (26%) 17/58 (29%) 0.503 48/115 (42%) 48/142 (34%) 0.008 83/115 (72%) 83/289 (29%) 0.050 
Presence of ≥ 3 abnormal ECG 5/29 (17%) 5/58 (9%) 0.480 15/29 (52%) 15/142 (11%) 0.017 24/29 (83%) 24/289 (8%) 0.035 
PPV= positive predictive value 
#=number of participants 
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The independent and incremental predictive value of common ECG markers for 
primary outcome was examined using continuous (per SD) in univariable as well as 
series of multivariable Cox regression models. In univariable analysis, Cornell-V (not 
SLV), Cornell-P, minSTmV5V6 (not PTFV1), LVMi and GLS (not DD) were 
significant predictors for outcome. The 75th percentile of Cornell-P showed predictive 
value and this association remained significant after adjusting for clinical variables 
(Table 7.41).  
The four ECG markers (Cornell-P, minSTmV5V6, PTFV1 and heart rate) were 
moderately correlated (correlation coefficient: -0.01 to -0.42). When they were entered 
into the models together with Charlson comorbidity score, only Cornell-P showed 
significant association. In the subsequent analyses with echocardiographic markers, 
the association of either Cornell-P or minSTmV5V6 became insignificant with the 
presence of either LVMi or GLS (Table 7.41). 
The incremental value of ECG markers over clinical measures (with and without 
echocardiographic features) was examined using Net Reclassification Improvement 
(NRI) analysis. Addition of one or two abnormal ECG to clinical information (model 
I), clinical + any one echo marker (model II) and any two echo markers did not 
demonstrate any significant incremental value for outcome with better performance of 
adding 2 ECG markers than 1 (NRI=-0.01 to 0.11, p>0.065) (Table appendix 7.44) 
).  
Figure 7.43 demonstrates the association of abnormal ECG (ECG+) with outcome in 
the presence of one (Figure 3a), two (Figure 3b) and all three (Figure 3c) abnormal 
echo markers. Results showed that in patients with mild cardiac abnormalities (one 
abnormal echo), the presence of abnormal ECG is significantly associated with 
outcome (Hazard ratio: 2.2, 1.04-4.68, p=0.04) regardless of echo status.  
Abnormal ECG appeared to have prognostic value in those with mild disturbances of 
cardiac structure and function by echocardiography, although generally, more 
prognostic information appeared to be obtainable from echocardiography. Abnormal 
ECG did not add incremental value to clinical and echocardiographic assessment 
(Figure 7.44). 
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Table 7.41 Cox regression association of ECG for outcome 
  Univariable Cox regression 
Models I* (Clinical+ each 
ECG and Echo marker) 
  Model II**   Model III**     
Variables HR (95% CI) P HR (95% CI) P 
C 
statistic 
HR (95% CI) P  
C 
statistic 
HR (95% CI) P  
C 
statistic 
Age (years) 1.07 (1.01, 1.13) 0.02      
0.701 
(0.72) 
 
1.06 (0.99, 1.12) 0.07 
0.682 
(p=0.94) 
Male, n (%) 1.41 (0.80, 2.49) 0.23      1.41 (0.78, 2.57) 0.26 
Charlson Score 1.21 (1.10, 1.33) <0.01    1.23 (1.12, 1.36)  
<0.0
1  
  
ECG markers (per SD)            
Heart Rate (per 11 bpm) 0.81 (0.59, 1.11) 0.19 0.85 (0.61, 1.18) 0.34 0.704(0.92) 0.73 (0.53, 1.03) 0.08   
SL voltage (mm) 0.97 (0.93, 1.01) 0.13          
Cornell voltage (mm) 1.07 (1.01, 1.13) 0.02          
Cornell product (per 635 mm·ms) 1.41 (1.10, 1.82) 0.01 1.36 (1.06, 1.76) 0.02 0.715 (0.93) 1.33 (1.01, 1.77) 0.04 1.13 (0.82, 1.54) 0.45 
minSTmV5V6 (per 39 uV) 0.69 (0.51, 0.96) 0.03 0.68 (0.49, 0.94) 0.02 0.695 (0.89) 0.78 (0.57, 1.09)  0.14 0.76 (0.55, 1.07) 0.12 
PTFV1 (per 3532 uVms) 0.97 (0.72, 1.29) 0.83 0.87 (0.64, 1.18) 0.37 0.695 (0.33)  0.92 (0.66, 1.22) 0.54    
75th Cornel-P(m≥1442;f≥1581) 1.84 (1.00, 3.85) 0.05 1.89 (1.03, 3.51) 0.04 0.704 (0.85)       
Echo markers (per SD)            
LV mass (per 17 g/m2) 1.68 (1.31, 2.16) <0.01 1.63 (1.26, 2.12) <0.01 0.724 (0.36)   1.48 (1.12, 1.96) 0.01 
Abnormal GLS (per 2.6%) 0.64 (0.49, 0.83) 0.001 0.74 (0.56, 0.97) 0.03 0.761 (0.03)       
Diastolic dysfunction≥ grade I 1.47 (0.76, 2.84) 0.25 1.15 (0.58, 2.28) 0.69 0.703 (0.23)           
* Model Is, each line is a model with Clinical (age, gender Charlson comorbidity Score) and each ECG and Echo marker. C-statistic for clinical=0.699 
** Model II contains all 4 ECG markers: Heart rate, Cornell-P, minSTmV5V6 and PTFV1 with Charlson score;  
*** Model III contains age, gender, Cornell product, minSTmV5V6 and LV mass 
 
 
 
 
 
Chapter 7 – How to screen – role of ECG in screening 204 
 
 
Figure 7.43 Echo features of SBHF vs abnormal ECG 
The presence of echo features of SBHF with/without abnormal ECG and associated outcome.  
Abnormal ECG was defined as presence of any two abnormal ECG marker (Cornel-P, minSTmV5V6, PTFV1 and baseline HR). Abnormal echo was defined as the presence 
of any one (3a), any two (3b) or all three (3c) of LVH, impaired GLS (18% cutoff) and diastolic dysfunction. 
Abnormal ECG and normal echo (ECG+/Echo-, coded red triangle) is associated with worst outcome in mild SBHF by presence of 1 echo marker. 
Moderate cardiac impairment (defined by any 2 echo marker) is associated with worse outcome regardless of their ECG status. 
Severe cardiac impairment (if presence of all 3 echo marker) is associated with worse outcome regardless of their ECG status 
Chapter 7 – How to screen – role of ECG in screening 205 
 
 
7.5 Discussion 
In this heterogeneous community cohort with known non-ischemic HF risks and preserved EF, 
we did not find ECG markers to be of value in screening for SBHF because of low prevalence, 
low sensitivity, and low predictive value, compared with echocardiographic features of SBHF. 
However, a number of associations between ECG and new indices of LV dysfunction and 
outcome were identified. Cornell-P and increased resting heart rate were independently 
associated with echocardiographic SBHF features. Cornell-P and minSTmV5V6 were 
 
Figure 7.44 Incremental value of abnormal ECG 
Incremental value of abnormal ECG over clinical and abnormal echocardiographic markers of stage B 
Heart Failure  
Clinical was defined as age, gender and Charlson comorbidity score;  
Abnormal ECG was defined as the presence of any one or more of (75th percentile of Cornell product; 
minSTmV5V6, PTFV1 and heart rate) 
Abnormal echo was defined as the presence of any one or more of (LVH, impaired GLS and diastolic 
dysfunction). 
Figure shows: the presence of more abnormal ECG markers had relative incremental value over clinical 
information only and when only one abnormal echo marker was present. 
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associated with primary outcome independent of clinical measures but not independent of or 
incremental to echocardiographic measures.  
Stage B heart failure is defined as a condition with asymptomatic structural and/or functional 
changes in the heart. The clinical recognition of early HF can be difficult, and the prevalence 
of incident HF may vary broadly depending on the diagnostic criteria 345, 346. A recent meta-
analysis reported that incident HF diagnosis in 8 out of 15 included studies was based on a non-
standardized clinical description273. Differences in the diagnostic criteria for HF may have 
impact on the outcome assessment in these studies. Among four commonly used HF diagnostic 
criteria (Framingham, Boston, Gothenburg, and European Society of Cardiology (ESC) 
criteria)312, there were significant differences in predicting clinically relevant outcomes 
including incident hospital admission. The absolute 3-year risk of hospital admission following 
a Framingham HF diagnosis was 6.1% (odds ratio 2.4, 95% CI 0.8-6.8, p=0.022)312, there were 
significant differences in predicting clinically relevant outcomes including incident hospital 
admission. The Framingham criteria seems to correlate best with echocardiography, which the 
gold standard to diagnose HF 312. Accordingly, we selected the Framingham HF criteria to select 
subjects with HF. Echocardiography was performed in the subjects with HF to evaluate LVEF. 
Although we excluded any known and possible HF at baseline, the annualized rate of incident 
HF was 10%. A higher proportion of stage C1 at baseline may partially explain this 44. 
Individuals in stage C1 had a significantly worse outcome than SBHF. A high incidence rate 
was observed in another community study of a cohort with combined diabetes and 
hypertension57, in whom E/e’ > 15 (detected in 23%) was used to categorized stage B HF. In 
our cohort, the prevalence of increased E/e’ was lower in entire cohort (12%) but was similar 
in those with both HTN and T2DM (20%).  
In this study, we provided a comprehensive assessment of early markers of myocardial damage 
(DD and strain imaging) in addition to assessment of structural cardiac changes. In the non-
ischemic population with preserved LVEF, impaired GLS and diastolic dysfunction have a 
comparable effect on functional capacity to LVH.70 The current guidelines have recommended 
that strain could be used in asymptomatic subjects at risk of HF for early detection of preclinical 
myocardial dysfunction 32. Indeed, this is feasible in the community – several community-based 
studies have used strain, including the Northern Manhattan study 288, Framingham study 347, the 
CARDIA study 348, and others. Previous studies in a different population, with a significant 
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proportion of ischemic disease have demonstrated the association of ECG changes of LVH with 
DD.309 The association of ECG features of LVH with systolic function is based on LV mid-
wall shortening, which is likely to be affected by LV geometry.310 Using speckle tracking 
echocardiography (STE), a sensitive imaging marker for early myocardial damage, which has 
been linked to outcomes 65. This study confirmed the association of ECG markers with early 
systolic changes by GLS, and these associations were independent of clinical measures 
including blood pressure, BMI and comorbidities such as diabetes and hypertension. The 
potential mechanisms linking abnormal ECG markers and depressed systolic function are 
multiple. Ischemia could be an important contributor, and is hard to exclude in a cohort with a 
high prevalence of hypertension and diabetes.310 Myocardial interstitial fibrosis is another 
possible and important link.  
Screening for SBHF in the non-ischemic population is challenging, due to a lack of feasible and 
effective markers. LVH is widely used as an important feature of SBHF, and can be diagnosed 
by ECG or echocardiography. The association of ECG-LVH with risk of incident HF has been 
widely recognized in a recent meta-analysis273. ECG-LVH and echocardiographic LVH were 
found to be equally predictive of incident HF in a community study after follow-up of 12 
years306. Thus, ECG-LVH has been used as established risk component in two widely-used HF 
risk scores79,80. Other studies have proposed an independent and incremental prognostic 
significance of ECG-LVH over echocardiography313,314. However, the prevalence of ECG-LVH 
is known to be low, varies from 0.6-40%, with an average of 18% only if using combined 
multiple diagnostic criteria 315. In the process of screening, a single ECG marker may be 
insufficiently effective due to its low sensitivity and positive predictive value316. In a 
community based study, Gencer studied predictive value of combined multiple ECG makers. 
He found combined abnormal ECG markers were present in up to 34% of population and were 
significantly incremental to clinical measures305. Given its safety, low cost and wide availability 
and a first-line routine examination, the ECG has an important role in the primary care. 
Computerized measurement facilitated a comprehensive and multi-marker approach for 
screening. In our study, a combination of four commonly used ECG measures had slightly 
improved screening sensitivity over one marker. However, its prognostic value over echo 
showed benefit only in those with early cardiac changes and the incremental value over 
echocardiogram has not been established. Thus, the relative merits of ECG or echocardiography 
are still controversial.  
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An effective screening program needs more than a feasible screening test. Screening at the 
primary care level faces major challenges relating to the feasibility. First, the approach to 
screening for SBHF is influenced by the scope of target for prevention. The intervention 
strategy for non-ischemic SBHF has not been well defined. It is unknown whether the presence 
of increased risk would justify intervention without evidence of HF. Second, traditional SBHF 
based on structural remodelling (LVEF and LVH) needs to be supplemented by more functional 
parameters,70 which are more sensitive and can detect myocardial impairment prior to the onset 
of structural remodelling. Although clinical risk-based and ECG could serve to select higher 
risk individuals, echocardiography is still needed for guiding intervention. Third, the use of 
biochemical marker and hand held ultrasound devices. The sensitivity of BNP may be a 
particular issue in screening of non-ischemic HF, due to the effects of obesity on BNP levels.148. 
Plasma natriuretic peptides have been better markers for heart failure than they are for LV 
dysfunction as they reflect cardiac wall stress, which can be expected to be normal until there 
is an increment of filling pressure. In asymptomatic individuals, findings from studies have 
been heterogeneous. The sensitivity and positive predictive values of natriuretic peptides have 
been low – for example, the sensitivity was reported to be 30% against LVH by cardiac MRI.317 
Despite this inverse relationship, NT-proBNP was reported to provide significant prognostic 
information in a population study with 21 years of follow up149. Given the limited availability 
and relative cost of standard echocardiography, a hand-held ultrasound (HHU) system may able 
to provide a potential substitute. HHU can play an important role in structural cardiac 
evaluation. Although there has been growing interest in its role as a screening tool in the 
community, the main limitations relate to its imaging capabilities - other than assessing LVEF, 
the current HHU system does not provide assessment of DD or GLS.  
7.6 Study Limitations 
The present study was based on a community clinical trial. There are several limitations. First, 
because the follow-up period was short, the outcome assessment may be limited. Second, 
relatively high rate of incident HF in this cohort may suggest the presence of unrecognized HF 
at baseline. As previously reported, the possibility of high prevalence of stage C1 in this cohort 
may explain their rapid progress to new HF44. Third, the lack of protection of clinical outcome 
by treatment may indicate confounding by indication (i.e. the most at risk patients were treated 
in primary care, but were more likely to have events. Fourth, we did not obtain biomarkers (e.g. 
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brain natriuretic peptides), as previous work showed these were more effective in symptomatic 
rather than asymptomatic dysfunction.142. Moreover, the test performance of BNP is 
constrained by increasing patient age, obesity and insulin resistance.142,148 although recently 
published data showed controversial results149. Fifth, the concomitant presence of CAD was not 
investigated. Atherosclerosis may co-exist with diabetic cardiomyopathy and hypertensive 
heart disease and may cause LV dysfunction because of CAD. We sought to exclude patients 
with a history consistent with CAD, but we cannot exclude an ischaemic contribution to the 
reported cardiac functional changes. Recruitment was partly through newspaper advertising and 
this may result in a population selection bias.  
7.7 Conclusions  
Although standard ECG markers showed low sensitivity and low positive predictive value for 
SBHF, Cornell-P and abnormally increased heart rate were independently associated with LVH, 
impaired GLS and DD. Cornell-P and ST changes showed prognostic value for clinical HF, and 
death of CV causes independent of clinical measures but were not incremental to 
echocardiography. However, ECG abnormalities were associated with poor outcome in those 
with early and mild echocardiographic features of impairment. 
Postscript 
The results of this chapter suggest that in the non-ischemic population, ECG changes were 
associated with cardiac remodelling, were of predictive of outcome and were not suitable for 
initial screening. In chapter 8, rather than being used alone, ECG is used in combination with 
clinical information and with functional capacity.  
Next chapter will address an effective screening strategy using combined clinical risk scores, 
functional capacity and ECG.  
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Appendix tables 
Table appendix 7.42 -Correlation between ECG and echo markers 
Correlation between ECG markers and cardiac structural and functional measures in men and women 
  LVMi GLS e' E/e' Diastolic strain Diastolic strain rate 
  rho P value rho P value rho P value rho P value rho P value rho P value 
Male             
Cornell Voltage 0.394 <0.001 -0.218 0.002 -0.171 0.013 0.05 0.471 -0.197 0.004 -0.301 <0.001 
SL Voltage 0.047 0.499 0.097 0.161 0.002 0.976 -0.027 0.698 0.098 0.158 0.024 0.734 
Cornell product  0.403 <0.001 -0.196 0.005 -0.19 0.006 0.047 0.497 -0.196 0.005 -0.273 <0.001 
minSTmV5V6 -0.301 <0.001 -0.152 0.028 0.114 0.102 -0.055 0.427 0.065 0.348 0.126 0.069 
PTFV1 0.097 0.164 -0.060 0.387 -0.083 0.234 -0.011 0.870 0.054 0.438 -0.095 0.171 
Female             
Cornell Voltage 0.183 0.004 -0.131 0.043 -0.249 <0.001 0.047 0.466 -0.144 0.026 -0.132 0.042 
SL Voltage 0.018 0.784 0.017 0.798 0.042 0.516 0.012 0.848 0.118 0.069 0.120 0.065 
Cornell product 0.263 <0.001 -0.159 0.014 -0.211 0.001 0.079 0.221 -0.109 0.092 -0.126 0.053 
minSTmV5V6 -0.178 0.006 0.123 0.058 0.067 0.300 0.099 0.128 0.128 0.048 0.169 0.009 
PTFV1 0.026 0.686 0.098 0.132 0.134 0.039 -0.023 0.728 0.212 0.001 0.116 0.073 
GLS: global longitudinal strain; DS: diastolic strain; DSR: diastolic strain rate 
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Table appendix 7.43 -characteristics (completed follow-up) 
  
Completed follow-up Unable to follow-up  p  
(n=406) (n=40) value 
Age (year) 71±5 71±5 0.627 
Gender male 196 (48) 12 (30) 0.028 
Body Mass Index (g/m2) 30±5 31±6 0.234 
Type 2 Diabetes mellitus 218 (54) 23 (58) 0.634 
Obese (BMI≥30 g/m2) 182 (45) 21 (53) 0.346 
Hypertension 333 (82) 29 (73) 0.152 
Previous Chemotherapy 36 (9) 5 (12) 0.445 
Family history 147 (36) 13 (33) 0.649 
Previous heart condition 29 (7) 6 (15) 0.077 
Charlson Comorbidity score 1 (0-2) 1 (0-2) 0.595 
LV Ejection fraction  64±6 64±7 0.770 
GLS 18.6±2.5 18.0±2.9 0.404 
Mitral E/A 0.8±0.2 0.8±0.2 0.752 
Mitral e' (cm/s) (averaged) 0.08±0.02 0.08±0.02 0.399 
E/e' (averaged) 8.9±2.6 9.0±2.5 0.768 
Left atrium volume (ml/m2) 30±9 30±9 0.431 
LV mass (g/m2) 84±18 82±16 0.521 
Diastolic dysfunction 265 (65) 24 (60) 0.519 
Abnormal E/e', (13) 49 (12) 5 (13) 0.932 
LV hypertrophy (echo) 53 (13) 5 (13) 0.925 
LA enlargement (34) 124 (31) 9 (23) 0.289 
Abnormal GLS, cut-off 18 129 (32) 13 (33) 0.917 
Cornell Voltage (mm) 9.9 (7.0-13.7) 8.2 (4.6-12.9) 0.115 
Sokolow-Lyon L voltage (mm) 17.9 (13.9-22.9) 18.9 (14.3-22.5) 0.763 
Cornell Product (mm·ms) 1093 (783-1513) 1036 (807-1409) 0.627 
minSTmV5V6 (uV) 2.2±39 11.6±35 0.234 
PTFV1 (uVms) -2856±3539 -3546±3438 0.178 
LV hypertrophy by SL voltage 7 (2) 0 (0) 0.403 
LV hypertrophy by Cornell voltage 7 (2) 2 (5) 0.159 
Continuous variable as: mean ±SD or median (IQR). Categorical variable as: n(%), GLS: global longitudinal strain; LA: left atrium; LV left ventricle 
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Table appendix 7.44 -Net reclassification Improvement (NRI)  
Examine the incremental value of ECG over clinical (Model I), ECG marker over Clinical +1 echo (Model II) and ECG marker over Clinical +2 echo markers (Model 
III) 
  Model I (Clinical + ≥ 2 abnormal ECG marker)   
Increased 
Risk 
Decreased 
Risk 
 Net correctly reclassified 
% 
(Clinical) 
Composite endpoints 
(n=49) 
Quartile 1 
(<6.24%) 
Quartile 2 (6.24-
9.57%) 
Quartile 3 (9.57-
15.6%) 
Quartile 4 
(≥15.69%) 
n n % 
Quartile 1 (<6.24%) 5 0 0 0 
6 1 10.2 
Quartile 2 (6.24-9.57%) 1 6 0 0 
Quartile 3 (9.57-15.6%) 0 0 10 6 
Quartile 4 (≥15.69%) 0 0 0 21 
        
     Increased 
Risk 
Decreased 
Risk 
Net correctly reclassified 
%  
No event (n=358) 
Quartile 1 
(<6.24%) 
Quartile 2 (6.24-
9.57%) 
Quartile 3 (9.57-
15.6%) 
Quartile 4 
(≥15.69%) 
n n % 
Quartile 1 (<6.24%) 81 13 0 0 
38 44 0.3 
Quartile 2 (6.24-9.57%) 16 66 14 0 
Quartile 3 (9.57-15.6%) 0 18 61 11 
Quartile 4 (≥15.69%) 0 0 10 67 
  Net reclassification improvement =0.11            0.105 
  p=0.065               
Clinical=age, gender, Charlson score 
 
 
  Model II (Clinical + 1 Echo +≥1 abnormal ECG)   
Increased 
Risk 
Decreased Risk  Net correctly reclassified % 
(Clinical + 
1Echo) 
Composite endpoints 
(n=49) 
Quartile 1 
(<6.32%) 
Quartile 2 (6.32-
9.42%) 
Quartile 3 (9.42-
15.87%) 
Quartile 4 
(≥15.99%) 
n n % 
Quartile 1 (<6.32%) 4 0 0 0 
4 0 8.2 
Quartile 2 (6.32-
9.42%) 
3 5 0 0 
Quartile 3 (9.42-
15.87%) 
0 0 11 4 
Quartile 4 (≥15.99%) 0 0 0 22 
     Reclassified  
     Increased 
Risk 
Decreased Risk Net correctly reclassified %  
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No event (n=358) 
Quartile 1 
(<6.32%) 
Quartile 2 (6.32-
9.42%) 
Quartile 3 (9.42-
15.87%) 
Quartile 4 
(≥15.99%) 
n n % 
Quartile 1 (<6.32%) 83 11 0 0 
37 38 0.3 
Quartile 2 (6.32-
9.42%) 
18 64 14 0 
Quartile 3 (9.42-
15.87%) 
0 12 68 12 
Quartile 4 (≥15.99%) 0 0 8 62 
  
Net reclassification improvement 
(NRI)=0.085  
          0.085 
  p=0.074               
  
 
 
 
 
      
  Model II (Clinical + 2 Echo +≥1 abnormal ECG)   
Increased 
Risk 
Decreased Risk  Net correctly reclassified % 
(Clinical + 2 
Echo) 
Composite endpoints 
(n=49) 
Quartile 1 
(<5.69%) 
Quartile 2 (5.69-
9.42%) 
Quartile 3 (9.42-
15.76%) 
Quartile 4 
(≥15.76%) 
n n % 
Quartile 1 (<5.69%) 5 0 0 0 
1 4 -6.1 
Quartile 2 (5.69-
9.42%) 
1 5 0 0 
Quartile 3 (9.42-
15.76%) 
0 1 7 1 
Quartile 4 (≥15.76%) 0 0 2 27 
     Reclassified  
     Increased 
Risk 
Decreased Risk Net correctly reclassified %  
No event (n=358) 
Quartile 1 
(<5.69%) 
Quartile 2 (5.69-
9.42%) 
Quartile 3 (9.42-
15.76%) 
Quartile 4 
(≥15.76%) 
n n % 
Quartile 1 (<5.69%) 84 11 0 0 
23 40 4.7 
Quartile 2 (5.69-
9.42%) 
15 75 8 0 
Quartile 3 (9.42-
15.76%) 
0 17 71 4 
Quartile 4 (≥15.76%) 0 0 8 63 
  
Net reclassification improvement (NRI) =-
0.014 
          -0.014 
Clinical=age, gender, Charlson score 
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Article “Community Screening for Nonischemic Cardiomyopathy in 
Asymptomatic Subjects ≥ 65 Years with Stage B Heart Failure” was published 
in 
American Journal of Cardiology 2016; 117 (12): 1959-65 
Hong Yang, Ying Wang, Mark Nolan, Kazuaki Negishi, Peter M Okin, Thomas 
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Chapter 8. Screening strategy-role of Risk scores ECG and 
6MW  
Community Screening for Non-Ischemic Cardiomyopathy 
in Asymptomatic Subjects ≥ 65 Years with Stage B Heart 
Failure  
Introduction 
The estimation of heart failure risk is a critical step in appropriate selection of patients for 
imaging. Findings from the systematic review (chapter 2) suggested the relative magnitude of 
the common non-ischemic risks, but did not provide an appropriate risk calculation algorism 
due to the heterogeneity of the studies. In this chapter, we aimed to apply and compare the 
common available risk scores of heart failure, combining ECG and baseline functional capacity. 
The intention was that clinical information, ECG and 6-minute walk test might be readily 
available in the community setting before echocardiography. If an effective screening strategy 
is possible, this could be used to select the highest risk individuals for echocardiography.  
The following text in this chapter has been published in the American Journal of Cardiology 
2016; 117 (12): 1959-65 
Abstract 
A process to identify and target a selected population at risk of heart failure (HF) could facilitate 
screening and prevention. We sought to develop an effective screening process from clinical 
characteristics, functional capacity and electrocardiogram (ECG). Asymptomatic subjects≥65 
years, with ≥1 HF risks were recruited from the community. Individuals with valvular disease, 
ejection fraction <40% and atrial fibrillation were excluded. All underwent clinical evaluation 
including assessment of HF risk using Framingham HF (FHS) and Atherosclerosis Risk in 
Communities (ARIC) scores, ECG, echocardiography and 6-minute walk (6MW) test. After 
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14±4months, new HF was assessed using Framingham criteria. A randomly selected derivation 
cohort was used to integrate ARIC score and 6MW in a classification and regression tree 
(CART) analysis, with the remaining population used for validation. Of 419 subjects (age 70±5; 
48% men), 52 developed HF. ARIC was more effective than the FHS score (AUC 0.65 vs 0.53, 
p=0.01). CART selected ARIC (>9.5%) and 6MW (<501m) as cut-offs to define low-, 
intermediate- and high-risk groups. Abnormal ECG further divided the intermediate group into 
high and low risk. The 134 individuals identified as high risk by a combined clinical and ECG 
strategy showed more echocardiographic features of cardiac dysfunction including LV mass, 
mitral e’, mitral E/e’ and longitudinal strain (p<0.01). New HF was significantly more frequent 
than in the remaining patients (20% vs 9%, p=0.003; HR 2.08 [95% CI, 1.21-3.57], p=0.008). 
Thus, initial clinical risk and ECG assessment facilitate effective HF screening by identifying 
a high risk group.  
8.1 Background 
The prevalence and costs of congestive heart failure (HF) remain high and are predicted to 
further increase318. Previous randomized trials have shown that early intervention can delay or 
prevent the onset of overt HF in patients with reduced left ventricular ejection fraction 
(LVEF)36. However, the epidemiology of HF is changing, with increasing numbers of patients 
with normal LVEF. In these patients, features of stage B HF (SBHF) may be detected by left 
ventricular hypertrophy (LVH), abnormal diastolic function or impaired global longitudinal 
systolic strain (GLS)70. However, community-wide screening using echocardiography has not 
been justified47. An alternative would be a selective screening strategy of defining “at risk” 
individuals by simple clinical evaluation with subsequent echocardiography. Several 
community-based HF risk scores have been developed78-80. The Framingham HF risk (FHS) 
and Atherosclerosis Risk in Communities (ARIC) scores are based on clinical information that 
is readily available in primary care settings. Likewise, the six minute walk test (6MW) is a 
simple and feasible test with previous work showing improved risk assessment in SBHF319. 
8.2 Aims and Hypothesis 
We hypothesized that the combination of clinical and functional variables would 1) correlate 
with the degree of underlying cardiac dysfunction as shown by echocardiography, and 2) predict 
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HF better with than without functional capacity. We sought to explore these hypotheses in a 
community-based study of ≥65-year-old individuals with risk factors but no symptoms of HF. 
8.3 Methods 
Patient selection. Participants were voluntarily enrolled through presentations to local 
community groups and media advertising. Data were collected prospectively from subjects ≥65 
years old, living in the community, based on the presence of >1 HF risk factors: (1) hypertension 
(HTN, based on SBP >140 mmHg and self-report of HTN including anti-hypertensive 
medication; (2) type 2 diabetes mellitus (T2DM, based on self-report of diagnosis including 
medical management); (3) obesity (body mass index [BMI] ≥30); (4) previous chemotherapy; 
(5) family history of heart failure; and (6) previous history of heart disease (but not existing 
heart failure). We excluded subjects with: (1) symptoms or a known history of HF; (2) known 
coronary artery disease (CAD); (3) more than moderate valvular heart disease; (4) reduced 
LVEF (<40%) on baseline echo; (5) atrial fibrillation (AF); and (6) inability to acquire 
interpretable images at baseline. This study was performed in accordance with a research 
protocol approved by the Tasmanian Human Research Ethics Committee. Individual written 
informed consent was obtained from participants after explanation of the nature and purpose, 
complexity and level of risk of the study. 
Data collection. Data were collected prospectively at facilities in the community, from all 
participants enrolled in the study. All underwent a physical examination and symptom 
questionnaire. They also underwent a standard 12 lead electrocardiogram (ECG), a 
comprehensive transthoracic echocardiogram and 6MW test. Blood pressure was measured 
twice after 10-minutes of rest in the supine position. Data were also collected on socioeconomic 
indicators, complete medical history, and family history of HF.  
Quantification of heart failure risks. The FHS and ARIC risk scores were used to calculate 
the absolute risk of HF for all individuals. Calculation of FHS score (4-year probability of HF) 
was performed using 9 common clinical variables including age, sex, prevalence of CAD, 
diabetes and valve disease, LV hypertrophy (LVH) on ECG, systolic blood pressure (SBP), 
heart rate, and body mass index (BMI)80. For the ARIC score, we adopted the on-line ARIC 
Heart Failure Risk Calculator, which uses the 10 most common clinical variables including age, 
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race, sex, SBP, current use of blood pressure-lowering medication, smoking status, heart rate 
and BMI, prevalent CAD and diabetes.320 We made minor modifications (using open source 
code) to permit quantification of risk at four years.  
Functional capacity. Functional capacity was measured in the community using 6MW 
following a standardized protocol209. A 25-meter flat, obstacle-free corridor was used, with 
visible markers at each meter interval and stop coins placed at either end. Participants were 
instructed to walk at the best of their effort and walked unaccompanied. Mean peak VO2 was 
estimated using an established equation210. Age- and gender-adjusted functional capacity were 
estimated according to nomogram based metabolic equivalents in men211 and women212. 
Electrocardiogram. A standard 12-lead ECG was recorded at 25 mm/s and 1 mV/cm according 
to standard protocol. ECG measurements were performed using MUSE software (GE 
Healthcare, Milwaukee, WI, USA). Cornell product (CP), defined as the product of QRS 
duration times Cornell voltage (RaVL+SV3, plus 6 mm in women), was measured in all and the 
reference value was derived from the 75th percentile of the study population, analogous to 
derivation in the LIFE study196. In this work, a CP >1498 mm ms was used to deemed abnormal. 
Echocardiographic study. Standard transthoracic 2D and Doppler echocardiographic studies 
were performed using standard equipment (Siemens ACUSON SC2000, Siemens Healthcare, 
Mountain View, CA) and transducer (4V1c, 1.25-4.5 MHz; 4Z1c, 1.5-3.5 MHz) in accordance 
with the American Society of Echocardiography (ASE) guidelines187,281. LV dimensions during 
diastole and systole and wall thicknesses were measured from parasternal long-axis views 
according to the recommended criteria, and LV mass (LVM) was calculated accordingly187. 
LVH was defined as LVM index (LVMi) >115 g/m2 in men and >95 g/m2 in women. LV and 
left atrial (LA) volumes (LAV) were calculated by the Simpson biplane method. LAV ≥34 
ml/m2 was used as abnormal cutoff187. Mitral inflow peak early diastolic velocity (E), peak late 
diastolic velocity (A), E/A ratio, E wave deceleration time (DT) were measured for diastolic 
function assessment281. E/A ratio <0.8 was used as cut-off to designate delayed relaxation 
(Stage 1). Tissue Doppler mitral annular early diastolic velocity (e’) was assessed at septal and 
lateral and averaged for calculation of E/e’; an average E/e’≥13 was used to designate raised 
filling pressure281. LV peak longitudinal strain measurements were obtained from grey scale-
recorded images in the apical 4-chamber, 2-chamber and long-axis views. Strain was analysed 
offline using velocity vector imaging (Syngo VVI, Siemens Medical Solutions). After manual 
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tracing of the LV endocardial border during end-systole, this was automatically tracked 
throughout the cardiac cycle. LV global longitudinal strain (GLS) was obtained by averaging 
strain from the regional of interest in the apical 4-chamber, 2-chamber and long-axis views. 
Follow-up. Potential HF symptoms were assessed through regular follow-up phone calls, 
followed by symptom surveillance questionnaires and clinical visits. During the process, 
information on all-cause hospitalization was monitored and collected. Possible heart failure 
signs and symptoms were reviewed by 3 independent cardiologists, and heart failure diagnosis 
was confirmed using the Framingham criteria for HF110. The primary composite endpoint was 
defined as new HF and cardiovascular death. 
Statistical analysis. Data are presented as mean (±SD) after testing for normal distribution 
(Shapiro-Wilk test). Data deviating from normality are expressed as median (inter-quartile 
range [IQR]). Categorical variables are expressed as percentages. For differences among risk 
groups, the Mann-Whitney U test and the Kruskal-Wallis test were used for continuous variable 
and X2 tests for categorical variables. Associations between variables were expressed with 
Pearson or Spearman correlation coefficients. The area under the receiver operating 
characteristic (ROC) curve was used to test predictive accuracy of variables, and statistical 
differences between the areas under the curves (AUCs) were performed with the method 
suggested by Hanley & McNeil321. Survival function was estimated by Kaplan-Meier method 
and the difference in survival between groups were assessed by the log-rank test. 
Classification and Regression Tree (CART) analysis is a non-parametric and nonlinear method 
based on the repeated partitioning of a sample into subgroups by pre-defined criteria322. This 
relatively infrequently-used method provides an approach to identify at risk patients without 
the effects of data distribution, multi-collinearity, outliers and/or missing data, and interactions 
that impact other approaches323. The decision-tree model based on ARIC score combining 
6MW distance for the prediction of new HF and cardiac death was built as follows. The main 
study cohort was split into a derivation (1/2) and validation cohort by random selection. The 
tree model was then built from the derivation cohort, whereby patients were split into binary 
groups with the highest contrast for outcome. In each level of the tree, the variable with the 
strongest relationship to the endpoint was selected and the optimal cut-off was used. The 
McNemar X2 test was used to test paired data (e.g. discordance in sensitivity and specificity in 
dichotomous ARIC and 6MWscores). Subsequent CART validation was performed in the 
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validation cohort, with the expectation of showing a similar proportion of correctly classified 
cases for each category of outcome for the derivation and validation datasets. Based on risk 
stratification of CART model, we further tested the discrimination ability to predict the outcome 
in the entire cohort. The predicted risk groups were related to echocardiographic evidence of 
cardiac dysfunction.  
The CART model was built using commercially-available software (DTREG predictive 
modelling software 10.8.0, Brentwood TN, USA). Statistical analysis was performed using 
standard software (SPSS software 22.0, SPSS Inc., Chicago, IL) and significance was defined 
by p<0.05.  
8.4 Results 
Of 822 individuals from the community who were potentially eligible and volunteered for 
assessment, 344 were excluded due to failure to meet the clinical inclusion criteria and 42 were 
excluded after baseline echo screening, leaving 438 patients (median age 70 years [IQR: 67-
74], 52% women) who underwent baseline testing (Figure appendix 8.49). HF risk factors were 
present in all – most commonly hypertension (82%), diabetes mellitus (55%) and obesity 
(45%); 80% had more than one of the listed risk factors. The FHS and ARIC scores were 
calculated in all subjects, and the median 4 year FHS and ARIC HF risks were 3.0% (IQR: 2.0-
6.5%) and 5.8% (IQR: 3.4-10.4%) respectively.  
After a median interval of 14±4 months, 19 of 438 participants (4%) were lost to follow-up or 
alive but unable to attend follow-up. This group was no different from the remaining 419 who 
completed follow-up (Table appendix 8.49). New HF symptoms developed in 52 patients (2 
were admitted to hospital with HF) and 4 died (2 of cardiovascular causes). The primary 
composite end-point (events) of new-onset HF and cardiovascular death occurred in 54 (12.8%) 
of the entire cohort, and annualized event-rate of 11%. Participants with events were older and 
greater prevalence of diabetes, higher Charlson comorbidity score and total number of stage A 
HF risk factors (p<0.01). Patient report outcome measures showed the general (EurQoL-5D) 
and HF specific health status (Minnesota Living with HF score) were poor (p<0.02), Activity 
status (Duke Activity Score Index score) was lower (p<0.01). 
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Compared with those remaining asymptomatic, the 54 individuals who reached the composite 
end-point had higher ARIC score (p<0.01), but did not show significant differences in FHS 
scores (p=0.08). ROC analysis showed the AUC of FHS and ARIC were 0.53 (95% CI: 0.45-
0.62, p=0.415) and 0.65 (0.57-73, p<0.01), respectively. The difference between AUC was 0.12 
(95%CI 0.03-0.21, p=0.01). The discriminative ability of ARIC was significantly better than 
that of FHS. 
Of the 419 individuals, 209 were randomly selected and defined as the derivation cohort for 
building the decision tree, and the rest of the cohort (n=210) was defined as validation cohort. 
Baseline clinical and echocardiographic characteristics of the two cohorts are shown in Table 
8.45. No difference was observed in clinical and echocardiographic characteristics except for a 
difference in BMI. There were 25 events (12%) in the derivation cohort and 29 in the validation 
cohort (13%) (p=0.57).  
The decision process was built from the derivation cohort using the ARIC score and 6MW 
distance. The score of importance was 100.0 for ARIC and 42.2 for 6MW. Maximum depth of 
the full tree was 9 and total number of group splits was 20 with 21 terminal nodes. The relative 
error value was 1.083 with a standard error of 0.045. From a three-level tree (Figure appendix 
8.50), the best cut-point was ARIC risk of 9.5%, which corresponds to the top 29th percentile 
of all ARIC levels. The optimal cut-point for 6MW was 501 meters, corresponding to the lower 
40th percentile of all 6MW distances.  
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ARIC score and 6MW distance were modestly correlated (rho=0.40, p<0.01). As a categorical 
variable, low risk by ARIC (≤9.5) was associated with preserved exercise capacity (6MW≥ 
501) in 48% and high risk (ARIC>9.5) was associated with reduced exercise capacity 
(6MW<501) in 78%. In the 54 patients with events, ARIC was >9.5% in 26 (48%) and 6MW 
was <501 meters in 43 (80%, p=0.001). However, in the 365 who remained asymptomatic, 
ARIC was ≤ 9.5% in 271 (74%) and 6MW was ≥501 in 159 (44%, p<0.001). The additional 
predictive effect of categorical 6MW to ARIC was further analysed in the entire cohort using 
ROC analyses. Figure 8.45 showed significant improvement with the addition of 6MW. 
The combination of ARIC and 6MW defined three risk groups - low, intermediate and high – 
with respective event rates of 4.5%, 14% and 18%. The validation of the tree (in the validation 
cohort and entire cohort) is summarized in Figure 8.46.  
Table 8.45 Baseline characteristics of derivation vs validation cohort 
 Derivation cohort Validation cohort 
  (n=209) (n=210) 
Age (year) 70 (67-74) 70 (67-74) 
Gender male, n (%) 109 (52) 91 (43) 
Body Mass Index (g/m2) 29 (27-33) 28 (25-32) 
ARIC risk score (%) 6.2 (3.6-11.2) 5.6 (3.2-9.6) 
FHS risk score (%) 3.0 (2.3-5.0) 4.0 (2.0-7.0) 
T2DM, n (%) 125 (59) 107 (51) 
Obese, n (%) 96 (46) 94 (45) 
Hypertension, n (%) 166 (79) 178 (85) 
Previous Chemotherapy, n (%) 19 (9) 19 (9) 
Family history, n (%) 81 (39) 73 (35) 
Previous heart condition, n (%) 20 (10) 13 (6) 
Charlson score 1 (0-2) 1 (0-2) 
LV Ejection fraction (%) 64 (60-68) 63 (60-68) 
GLS (%) 18.4 (16.9-20.3) 18.8 (16.9-20.4) 
Mitral E/A 0.79 (0.67-0.92) 0.75 (0.65-0.91) 
Mitral e' (cm/s) (averaged) 7.6 (6.4-8.5) 7.5 (6.4-8.9) 
E/e' (averaged) 8.7 (7.2-10.5) 8.3 (6.9-10.3) 
Left atrium volume (ml/m2) 30 (24-36) 29 (24-36) 
LV mass (g/m2) 83 (72-97) 80 (69-94) 
Abnormal E/e', cutoff 13, n (%) 28 (13) 24 (11) 
LVH, n (%) 31 (15) 26 (12) 
Dilated LA, n (%) 68 (33) 62 (30) 
Abnormal GLS, cutoff 18, n (%) 122 (58) 131 (62) 
6MW (meters) 485 (411-531) 479 (425-529) 
Adjusted Functional capacity (%) 0.71 (0.62-0.80) 0.73 (0.63-0.83) 
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For further analysis of appropriate combinations, tables were created by combining low and 
intermediate (Table 8.46a), versus combining intermediate and high risk groups (Table 8.46b). 
The latter showed higher sensitivity (89%), low false negative rate (11%) and high negative 
predictive value (96%). The exclusion of low risk subjects would allow savings in the cost of 
echocardiography, with a low risk of missing HF. Although restriction of screening to only high 
risk individuals (Table 8.46a) would limit the need for echocardiography to a smaller group 
(<25% of the total) but would miss more than half of the patients developing HF. The exclusion 
of low risk subjects and identification of high risk subjects would facilitate further screening 
and prevention. Individuals in intermediate risk group (n=182) were further assessed by ECG 
analysis using the Cornell product cut-off for separation. Of the total 182, 39 were abnormal, 
which were subsequently combined with CART high risk (n=95) to form a final 134 individuals 
as a result of screening by CART and ECG and recommended for further echocardiography. 
 
Figure 8.45 ROC of ARIC and with 6MW 
Receiver operator characteristic (ROC) curves. The area under the curve is a marker of 
the discriminant capability of the ARIC score and its combination with 6MW. 
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The combination of CART and ECG strategies showed a 53% sensitivity for HF in the high 
risk group, and positive predictive value of 20% (Table 8.46c). 
 
 
 
Figure 8.46 Incident rate in derivation, validation cohort entire 
Low risk patients have <5% risk, intermediate risk patients have approximately 15% risk, and 
high risk patients have approximately 20% risk.  
Table 8.46 Validation of new heart failure 
Validation of new heart failure in entire cohort of three risk groups derived from CART analysis 
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Parameters measured by conventional and speckle tracking echocardiographic (STE) analysis 
were compared in two risk groups derived from the combination of clinical and ECG screening 
process (Table 8.47). There were significant differences in most systolic and diastolic measures. 
Individuals with high risk had significantly impaired GLS, diastolic strain and diastolic strain 
rate but with preserved global circumferential strain (GCS). These findings provide evidence 
to justify the use of echocardiography in these high risk subjects. The prevalence of SBHF 
features categorized by risk groups and entire cohort are shown in Figure 8.47. This increased 
risk is associated with worse outcome (Figure 8.48). 
 
 
Table 8.47 Baseline characteristic in high and low risk group 
Baseline Echocardiographic characteristics in high and low risk group defined by CART and ECG 
 Total  
(n=419)  
Low risk  
(n=270*) 
High risk  
(n=134) 
p  
(MWU**) 
Age 70 (67-74) 69 (67-72) 73 (69-77) <0.001 
Gender (male %) 200 (48) 131 (49) 61 (46) 0.57 
Body Mass Index 29 (26-32) 28 (26-31) 31 (27-35) <0.001 
Heart rate 67 (59-75) 65 (58-72) 71 (64-77) <0.001 
SBP 139 (128-149) 138 (127-147) 143 (132-151) <0.001 
DBP 82 (75-88) 82 (75-87) 81 (74-90) 0.916 
Echo (continuous), median (IQR)    
Left ventricular volume (ml) 85 (71-103) 45 (38-51) 43 (38-53) 0.721 
Relative wall thickness 0.47 (0.41-0.52) 0.46 (0.41-0.51) 0.47 (0.43-0.53) 0.029 
Left ventricular mass (g/m2) 81 (71-95) 79 (69-92) 85 (75-101) <0.001 
LVEF (%)(Mean±SD) 64 (±6) 65 (±6) 62 (±7) 0.001 
GLS (%)(Mean±SD 18.5 (±2.5) 18.9 (±2.3) 17.7 (±2.7) <0.001 
GCS (%) 28.9 (25-33) 29.3 (25.9-32.9) 28.5 (24.5-31.8) 0.062 
E/A 0.77 (0.66-0.91) 0.80 (0.69-0.92) 0.73 (0.61-0.85) 0.001 
DT (ms) 246 (219-283) 244 (219-274) 249 (218-288) 0.313 
e' (cm/s) (Mean±SD) 7.6 (±1.6) 7.8 (±1.5) 7.1 (±1.64) <0.001 
E/e' averaged (Mean±SD) 8.9 (±2.6) 8.5 (±2.4) 9.8 (±2.9) <0.001 
Diastolic Strain (%) 0.42 (0.32-0.52) 0.44 (0.36-0.53) 0.36 (0.28-0.47) <0.001 
Diastolic SR (1/s) 0.93 (0.79-1.10) 0.95 (0.81-1.13) 0.85 (0.72-1.05) <0.001 
LAVI (ml/m2) 29 (24-36) 29 (24-36) 30 (25-37) 0.084 
Echo (categorical), n (%)     
LV hypertrophy 57 (14) 25 (9) 30 (22) <0.001 
Abnormal GLS (cutoff 18)  165 (40) 91 (34) 65 (49) 0.004 
Abnormal GLS (cutoff 16)  69 (17) 32 (12) 35 (26) <0.001 
Abnormal E/e' (13) 52 (12) 23 (9) 27 (20) 0.001 
≥ Diastolic dysfunction 
Grade_I  
273 (65) 159 (59) 104 (78) <0.001 
LA enlargement (34) 130 (31) 83 (31) 43 (32) 0.783 
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Figure 8.47 prevalence of SBHF in risk groups 
Proportion of subjects with features of stage B heart failure in each risk group 
Prevalence of stage B heart failure on the basis of abnormal E/e’, LV hypertrophy, LA 
enlargement and GLS <18%. Depending on the criteria, subclinical LV disease is identified 
in between 9-34% of low risk patients and 12-40% of high risk patients. 
 
Figure 8.48 Event free survival in high versus low risk 
groups 
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8.5 Discussion 
In this study, we demonstrated a risk quantification strategy using clinical characteristics and 
functional capacity, followed by ECG abnormalities to define low and high risk groups for new 
HF. The risk-level of these groups corresponds to abnormal cardiac findings and outcome at 
one year follow up. Findings from this study could facilitate HF screening in the community by 
an initial clinical and ECG screening to quantify risk, followed by echocardiography in selected 
(32%) high risk individuals. 
Definition of new HF. Heart failure is a clinical diagnosis. Unfortunately, the clinical 
recognition can be difficult and the prevalence estimates vary broadly, depending on the 
diagnostic criteria. In a recent meta-analysis, HF diagnosis in 8 out of 15 included studies was 
based on a non-standardized clinical description273. Differences in the diagnostic criteria for HF 
may impact on the outcome assessment in these studies. Four commonly used HF diagnostic 
criteria were compared by Di Bari including Framingham, Boston, Gothenburg, and European 
Society of Cardiology (ESC) criteria312. There were significant differences between the four in 
predicting clinically relevant outcomes including incident hospital admission for HF. The 
absolute 3-year risk of hospital admission following a Framingham HF diagnosis was 6.1% and 
odds ratio of 2.4 (95% CI 0.8-6.8, p=0.022)312. Additionally, disturbances of structural and 
functional characteristics at baseline were best predicted using the Framingham HF criteria.312 
Accordingly, we selected the Framingham criteria for identification of new HF in our study. 
Although we excluded any possible and known HF at baseline, the annualized rate of incident 
HF was 11%. This finding is in line with recent reports of progression of SBHF 324, and like 
other studies, could reflect the inclusion of stage C1 at baseline – Framingham criteria may not 
capture mild or early HF (stage C1) in individuals with atypical symptoms44. The diagnosis of 
this subgroup is helped by the addition of functional assessment and echocardiographic 
findings, and the group has a significantly worse outcome than stage B HF. A similar high 
incidence rate was observed in another community study of a cohort with combined diabetes 
and hypertension57, in whom E/e’>15 (detected in 23%) was used to categorize stage B HF. In 
our study, the prevalence of increased E/e’ was lower in the entire cohort (12%) but similar in 
the high risk group (22%). However, our findings are that abnormal GLS may be a better marker 
in the high and intermediate risk groups. 
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Heart failure prediction using risk algorithms. The optimal screening strategy to identify 
asymptomatic individuals at risk for incident HF is undefined. Multi-marker risk scores have 
been developed to facilitate the process,78-80 but with limited external validation data, their 
discriminative ability for overt HF remains controversial325. The Framingham HF score (FHS) 
80 was developed in a select population with known CAD, valvular disease and hypertension, 
which may explain its sub-optimal predictive performance in our study with mostly non-
ischemic etiology and with insignificant valvular diseases. Although predictive power can be 
enhanced by the inclusion of biomarkers, this process limits the feasibility of community 
screening and generates additional cost.  
Functional assessment is an important component to be considered in the evaluation of HF. 
6MW reflects a patient’s ability to perform submaximal activities and this objective measure is 
of prognostic value in HF 277. Although 6MW is modestly correlated with ARIC in the 
prediction of HF, we anticipated that a risk stratification combining clinical characteristics and 
functional capacity would be valuable in the screening process. To our knowledge, our study is 
the first to combine 6MW into risk calculation, and may help in the selection of a subgroup for 
echocardiography. 
Clinical implications. Risk scores for incident HF are designed to target subjects for HF 
prevention. The identification of low risk group (34%) suggests that further screening may not 
be needed in these individuals, as 96% of them will have a low probability of developing 
clinical HF. Their clinical management should be targeted to treating risk factors. On the other 
hand, the identification of high risk (23%) suggests that echocardiography is likely to show 
abnormal findings and these individuals are likely to benefit from cardio-protective treatment. 
The identification of intermediate risk accounts for nearly half of the entire population, and our 
findings suggest that 50% of HF comes from this group, so echocardiographic screening is 
recommended. 
8.6 Study Limitations 
The present analysis was based on a community based clinical trial and had several limitations. 
First, HF is a progressive disorder along the continuum of asymptomatic to symptomatic states. 
The possibility of high prevalence of stage C1 in this cohort (i.e. patients with mild symptoms 
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who failed to meet Framingham HF criteria)44, may explain their rapid progress to new HF – 
an observation that is in line with findings from others44,324. Second, we did not obtain 
biomarkers (e.g. brain natriuretic peptides), as previous work showed these were more effective 
in symptomatic rather than asymptomatic dysfunction142. Moreover, the test performance of 
BNP is constrained by increasing patient age, obesity and insulin resistance142,148 although 
recently published data showed controversial results149. Third, findings from this study only 
provide a pre-screening strategy, an echocardiogram is needed for further screening. Previous 
evidence did not support LVEF-based community-wide screening as EF was insufficiently 
sensitive for detecting early myocardial disease to justify its cost47. However, the 
miniaturization and automation of echocardiography may permit new parameters to help where 
other failed before. Lastly, the recruitment was partly through newspaper advertising, and this 
may result in a population selection bias.  
8.7 Conclusion 
An initial quantitative clinical risk assessment of HF improves the effectiveness of screening 
by identifying groups at high- and intermediate-risk on clinical grounds. The sensitivity and 
negative predictive value of screening appear to be optimal if intermediate risk individuals are 
included. 
Postscript 
It needs to be noted that the ARIC score is a powerful risk predicting tool. In fact, we only 
adopted the simple online version with only 10 clinical variables, in the interest of sampling 
feasibility and controlling cost. The inclusion of biomarkers would improve the area under the 
receiving operational curve of ARIC, but its feasibility would reduce and cost would increase. 
Results from this study suggest a well-defined screening strategy using readily available clinical 
information and functional assessment. However, the presence of 40% of intermediate risk is a 
main concern, it means we would either screen these patients with significant additional cost or 
we would have missed half of the new heart failure cases within this group, were we not to 
screen them. 
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In a community cohort with multiple contributing factors, including the magnitude and duration 
of the primary disease and the degree of how well were treated and controlled. Selection for 
echocardiography continued to be challenging. No other single test is as useful as 
echocardiography. 
The next chapter will discuss echocardiographic screening in this community cohort. 
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Appendix figures and tables 
 
 
 
Figure appendix 8.49 -Flow chart of the recruitment of participants 
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Figure appendix 8.50 -CART for new HF in derivation cohort 
Classification tree for new HF based on derivation cohort discriminating low, intermediate and high 
risk groups 
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Figure appendix 8.51 -comparison of AUC of ARIC and FHS 
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Table appendix 8.48 -Baseline characteristics of eligible participants 
 Completed 
follow-up 
Unable to 
follow-up 
P 
value  
  (n=419) (n=19)  
Age (year) 70 (67-74 69 (67-70 0.265 
Gender male, n (%) 200 (47) 7 (37) 0.352 
Body Mass Index (g/m2) 29 (26-32) 28 (26-33) 0.782 
ARIC risk score (%) 5.8 (3.4-10.4) 5.4 (2.8-13.7) 0.914 
FHS risk score (%) 3.0 (2.0-6.5) 3.0 (3.0-6.5) 0.596 
T2DM, n (%) 232 (55) 9 (47) 0.493 
Obese, n (%) 190 (45) 7 (37) 0.466 
Hypertension, n (%) 344 (82) 14 (74) 0.353 
Previous Chemotherapy, n (%) 38 (9.1) 1 (5.3) 0.569 
Family history, n (%) 154 (37) 6 (32) 0.647 
Previous heart condition, n (%) 33 (8) 2 (10) 0.677 
Charlson score 1 (0-2) 1 (0-3) 0.283 
LV Ejection fraction (%) 64 (60-68) 64 (62-67) 0.952 
GLS (%) 18.5 (16.9-20.2) 18.9 (15.1-19.6) 0.553 
Mitral E/A 0.77 (0.66-0.91) 0.76 (0.64-0.96) 0.655 
Mitral e' (cm/s) (averaged) 7.6 (6.4-8.7) 7.9 (7.1-9.2) 0.174 
E/e' (averaged) 8.5 (7.0-10.3) 8.3 (7.6-9.0) 0.862 
Left atrium volume (ml/m2) 29 (24-36) 27 (24-37) 0.46 
LV mass (g/m2) 81 (71-95) 72 (70-91) 0.296 
Abnormal E/e', cutoff 13, n (%) 52 (12) 2 (11) 0.807 
LVH, n (%) 57 (14) 2 (11) 0.701 
Dilated LA, n (%) 130 (31) 5 (26) 0.659 
Abnormal GLS, cutoff 18, n (%) 166 (40) 7 (37) 0.809 
6MW (meters) 482 (423-530) 462 (401-500) 0.135 
Adjusted Functional capacity (%) 0.72 (0.62-0.81) 0.71 (0.56-0.81) 0.408 
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Chapter 9. Echocardiographic Screening – Best Echo 
Predictors  
Introduction 
The previous chapter focused on screening strategy using clinical scores and 6-minute walk test 
as initial steps in the screening process to select individuals at highest risk to undergo 
echocardiography, however, we found it possible to select out only the lowest risk patients, as 
the diagnoses of stage B heart failure requires echocardiography. This chapter will focus on 
performance of various echocardiographic markers to predict the primary outcomes in the 
TasELF study. 
The following text in this chapter has been published in the European J Heart Fail. 2016; 
18:1331-9. 
Abstract 
Background. Incident heart failure (HF) continues to pose a common and serious problem. We 
sought to examine the value of echocardiographic predictors of new HF in a community-based 
elderly population at risk for HF, independent of and incremental to clinical evaluation.  
Method. Asymptomatic patients≥65 years, with≥1 HF risk (hypertension, type 2 diabetes, 
obesity) were recruited from the community; patients with valve disease, reduced ejection 
fraction (EF) and atrial fibrillation (AF) were excluded. Patients underwent standard clinical 
evaluation including calculation of Charlson comorbidity score and a comprehensive 
echocardiography including global longitudinal strain (GLS). Functional capacity was assessed 
by 6 minute-walk test (6MW). New HF and cardiovascular (CV) death were assessed after a 
mean follow-up of 14±4 months by 3 independent cardiologists using Framingham criteria.  
Results. Of 410 subjects (age 70±5 years; 48% men), the prevalence of Stage B HF was 13% 
(by LVH), 12% (by abnormal E/e’), 33% (by impaired GLS) and 31% (by enlarged LA, LAE). 
New HF symptoms developed in 49 and 2 died of CV causes, giving an event-rate of 104/1000 
Chapter 9 – Best screening tools – role of echo predictors versus outcome 240 
 
person-years. These patients were older (p=0.012), had higher Charlson score (p<0.001), larger 
LV mass and LA, higher E/e’ and lower GLS (p<0.05). LAE, LVH, abnormal GLS and E/e’ 
were independent predictors of new HF. In sequential models, LV mass and GLS added 
incremental information to clinical parameters. GLS significantly reclassified individuals 
(p=0.002), but no reclassification improvement was identified using LVMi, E/e’ and LAVi. 
Conclusion – Echocardiographic assessment (especially GLS and LV mass) provides 
incremental value in predicting incident HF. 
9.1 Background 
The prevalence and cost of congestive heart failure (HF) remain a common and serious problem 
in the community21. Treatment of known risk HF risk factors (stage A HF, SAHF), with more 
intensive targeting of its preclinical stages of asymptomatic left ventricular (LV) damage (stage 
B HF, SBHF) may be an effective strategy to prevent or delay the onset of HF25. Previous 
studies in ischemic SBHF patients with reduced LV ejection fraction (LVEF) have shown that 
early intervention can delay or prevent the onset of overt HF34. However, the recognition of 
these asymptomatic stage B patients requires imaging guidance, so choosing the right test for 
community screening is an important step. An ideal screening marker needs to be safe, accurate 
and cost-effective. Previous evidence did not support LVEF-based community-wide screening 
as it was insufficiently sensitive for detecting early myocardial disease to justify its cost82. 
However, recent technological developments have led to the availability of new imaging 
markers that are sensitive to mild LV impairment. 
Among the increasing numbers of patients with non-ischemic SBHF and normal LVEF, 
increased LV mass326, increased left atrial (LA) size327, LV diastolic dysfunction and impaired 
global longitudinal systolic strain (GLS) 57,97have been reported to predict new onset HF. While 
the extension of echocardiographic features of SBHF from reduced LVEF and/or LV 
hypertrophy (LVH) to impaired GLS and abnormal diastolic function has been investigated 
with reference to functional capacity70, no previous comparison of these imaging markers in 
relation to subsequent incident HF has been reported in the literature. 
9.2 Aims and Hypothesis 
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We aimed to compare the prediction of incident HF with common echocardiographic markers 
of SBHF including LV mass index (LVMi), GLS, LA volume index (LAVi) and diastolic 
function in a community elderly cohort with non-ischemic SAHF. We hypothesized that GLS 
would be the optimal screening marker for community detection of non-ischemic Stage B heart 
failure. 
9.3 Methods 
Patient selection. Participants were voluntarily enrolled through local media advertising. Data 
were prospectively collected from subjects ≥65 years old and living in the community. Inclusion 
was based on the presence of one or more of HF risk factors: 1) hypertension (HTN, based on 
SBP >140 mmHg and self-report of HTN including anti-hypertensive medication); 2) type 2 
diabetes mellitus (T2DM, based on self-report of diagnosis including medication); 3) obesity 
(body mass index [BMI] ≥30); 4) previous potentially cardio toxic chemotherapy; 5) family 
history of heart failure; 6) previous history of heart disease (but not existing heart failure). We 
excluded subjects with: 1) symptoms or a known history of HF; 2) known coronary artery 
disease (CAD) including history of myocardial infarction, coronary artery by-pass graft and 
coronary stenting; 3) more than moderate valvular heart disease; 4) reduced LVEF (<40%) on 
baseline echo; 5) atrial fibrillation (AF); 6) inability to acquire interpretable images at baseline. 
This study was performed in accordance with a research protocol approved by the Human 
Research Ethics Committee of participating centres in Australia and New Zealand 
(ACTRN12614000080628). Individual written informed consent was obtained from 
participants after explanation of the nature and purpose, complexity and level of risk of the 
study. 
Data collection. Data were prospectively collected at facilities in the community, from all 
participants enrolled in the study. All underwent a physical examination and symptom 
questionnaire. They also underwent a comprehensive transthoracic echocardiogram and 6MW 
test. Anthropometric measurements were obtained and body mass index (BMI) was calculated 
(body weight [kg]/height2 [m2]). Blood pressure was measured twice after 10-minutes of rest. 
Data were also collected on socioeconomic indicators, complete medical history, and family 
history. The Charlson comorbidity score was used for comorbidity assessment311. 
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Echocardiographic study. Standard transthoracic 2D and Doppler echocardiographic studies 
were performed using standard equipment (Siemens ACUSON SC2000, Siemens Healthcare, 
Mountain View, CA) and transducer (4V1c, 1.25-4.5 MHz; 4Z1c, 1.5-3.5 MHz) in accordance 
with the American Society of Echocardiography (ASE) guidelines187,281. LV dimensions during 
diastole and systole and wall thicknesses were measured according to the recommended criteria, 
and LVMi was calculated accordingly 187. LV hypertrophy (LVH) was defined as LVMi>115 
g/m2 in men and >95 g/m2 in women. LV and LA volumes were calculated by the Simpson 
biplane method 187, and LA volume was indexed to body surface area, with LA enlargement 
(LAE) defined as LAVi≥34 ml/m2.  
Mitral inflow peak early diastolic velocity (E), peak late diastolic velocity (A), E/A ratio, E 
wave deceleration time (DecT) were measured for diastolic function assessment281. Tissue 
Doppler mitral annular early diastolic velocity (e’) was assessed at septal and lateral and 
averaged for calculation of E/e’; an averaged E/e’≥13 was defined as abnormal281. 
LV peak longitudinal strain measurements were obtained from gray scale-recorded images in 
the apical 4-chamber, 2-chamber and long-axis views. Strain was analyzed using velocity 
vector imaging (Syngo VVI, Siemens Medical Solutions). GLS and GLS rate (GLSR) were 
measured on-line in the community setting by averaging strain from the regional of interest in 
the apical 4-chamber, 2-chamber and long-axis views. Complete analysis (in all views) was 
possible due to our baseline exclusion of patients with poor apical images. Impaired GLS was 
defined using cut-off of <18 %85. Global circumferential strain (GCS) and GCS rate (GCSR). 
Global circumferential strain (GCS) and GCS rate (GCSR) were measured off-line. Standard 
echocardiographic screening protocol is shown in supplementary material Table S3. 
Definition of stage B heart failure. Evidence of SBHF required the presence of at least one of 
the following: 1) LVH; 2) LAE; 3) Abnormal E/e’; 4) Impaired GLS. 
Functional capacity. Functional capacity was assessed using a 6-minute walk test (6MW) 
distance following a standardized protocol209. Mean peak VO2 was estimated using an 
established equation210 for calculation of age and gender adjusted functional capacity. 
Follow-up. Potential HF symptoms were assessed through regular follow-up phone calls, 
followed by symptom surveillance questionnaires and clinical visits. During the process, 
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information on all-cause hospitalization was monitored and collected. Possible heart failure 
signs and symptoms were reviewed by 3 independent cardiologists, and heart failure diagnosis 
was confirmed using the Framingham criteria for HF110. The primary composite end-point was 
defined as new-onset of HF and CV death. 
Statistical analysis. Data are presented as mean (±standard deviation [SD]) after testing for 
normal distribution (Shapiro-Wilk test). Data deviating from normality are expressed as median 
(inter-quartile range [IQR]). Categorical variables are expressed as percentages. For differences 
among groups, Mann-Whitney U test was used for continuous variables and X2 tests for 
categorical variables. Associations between variables were assessed with Pearson or Spearman 
correlation coefficients. The primary outcome of time to event was examined with univariable 
and multivariable Cox proportional hazards models. The independent predictive value of 
continuous echo variables was assessed by adding each of LVMi, LAVi, and E/e’ and GLS to 
an initial model based on clinical variables. The incremental value of categorical SBHF features 
was assessed in nested Cox models by sequential addition of LVH, LAE, abnormal E/e’ and 
abnormal GLS. The performance of each model was compared using the Akaike’s Information 
Criterion (AIC), and C statistic. Net Reclassification Improvement (NRI) was based on quartile 
boundaries of each model probability calculated from the multivariable logistic regression for 
incremental value of SBHF features over clinical measures328. Receiver operator characteristic 
analysis was used to examine the discriminative ability of variables for outcome. Comparisons 
of AUCs was performed with the method suggested by Hanley and McNeil321. 
A decision–tree model based on the four categorical SBHF markers for the prediction of events 
was built using classification and regression tree (CART) analysis. In each level of the tree, the 
variable with strongest relationship to the events was selected. The CART model was built 
using commercial available software (DTREG 10.8.0, Brentwood TN, USA). Other statistical 
analyses were performed using a standard statistical software package (SPSS software 22.0, 
SPSS Inc., Chicago, IL). Statistical significance was defined by p< 0.05. 
9.4 Results 
Patient selection. Of 822 individuals from the community who were potentially eligible and 
volunteered for assessment, 352 were excluded due to failure to meet the baseline clinical 
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inclusion criteria and 42 were excluded after baseline echo screening, leaving 428 patients 
(median age 70 years [IQR:67-74], 48% men) who underwent baseline testing. HF risk factors 
were present in all – most commonly HTN (81%), T2DM (56%) and obesity (46%), which 
were present in isolation or in combination in 414 out of 428 (97%) of the entire cohort. More 
than one of the listed risk factors was present in 81%.  
Follow-up. After a median interval of 14±4 months (492 person-years) of follow-up, 18 of 428 
participants (4%) were lost to follow-up or alive but unable to attend follow-up. This group was 
no different from the remaining 410 individuals who completed follow-up (Table appendix 
9.51). New HF symptoms developed in 49 patients, (2 were admitted to hospital with HF) and 
4 died (2 of CV causes). The primary composite end-point of new-onset of HF and CV death 
occurred in 51 (12.4%) of the entire cohort - an event-rate of 104 per 1000 person-years. 
Characteristics of individuals with and without events. Table 9.49 shows the baseline 
demographic, clinical characteristics of individuals with and without composite endpoint 
(events). Participants with events were older, had higher BMI, and greater prevalence of T2DM 
and higher Charlson comorbidity score. There is no difference in medication history and age 
and gender adjusted functional capacity. 
Echocardiographic characteristics. Conventional systolic and diastolic echocardiographic 
characteristics are also summarized in Table 9.49. Baseline LVEF were preserved in all subjects 
(≥40%) and showed no differences in those with events (p=0.22). Indexed LV sizes were similar 
(p=0.19-0.32). Diastolic function grading according to ASE recommendation did not show 
difference but individuals who had events had higher prevalence of increased E/e’ and LAE. 
Comparisons of the median of LVMi, E/e’, GLS and LAVi between individuals with and 
without events are displayed in Figure appendix 9.56. According to conventional cut-offs of the 
4 markers, the prevalence of SBHF was 13% (by LVH), 12% (by abnormal E/e’), 33% (by 
impaired GLS) and 31% (by LAE) in the entire population. Of the 51 individuals having events, 
25 (49%) had impaired GLS, 26 (51%) had LAE, 12 (24%) had abnormal E/e’ and only 10 
(20%) had LVH. The annualized incident rate was 16% in LVH, 20% in abnormal E/e’, 16% 
in impaired GLS and 17% in LAE.  
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Table 9.49 Baseline characteristics 
Baseline clinical and echocardiographic characteristics of individuals who developed new HF or 
cardiovascular (CV) death 
  
No Event Event¶ HR   p  
(n=359) (n=51) (95% CI) value 
Demographic clinical characteristics and medication history 
Age (years) 70 (67-74) 72 (68-76) 1.070 (1.02, 1.13) 0.012 
Gender male (%) 167 (47) 30 (59) 1.567 (0.89, 2.74) 0.115 
Body Mass Index (g/m2) 29 (26-32) 30 (27-35) 1.080 (1.03, 1.13) 0.001 
Heart rate (BPM) 67 (60-75) 65 (57-75) 0.977 (0.95, 1.01) 0.119 
Systolic blood pressure (mmHg) 139 (128-149) 138 (128-147) 0.995 (0.98, 1.01) 0.526 
Diastolic blood pressure (mmHg) 82 (75-87) 81 (73-87) 0.983 (0.96, 1.01) 0.202 
Current smoker, n (%) 6 (2) 2 (4) 1.608 (0.39, 6.64) 0.511 
Ever Smoker, n (%) 181 (50) 26 (51) 0.791 (0.45, 1.38) 0.410 
Type 2 diabetes, n (%) 194 (54) 34 (67) 3.001 (1.65, 5.48) <0.001 
Obese, n (%) 156 (44) 30 (59) 2.353 (1.30, 4.25) 0.004 
Hypertension, n (%) 289 (81) 46 (90) 1.450 (0.57, 3.67) 0.433 
Previous Chemotherapy, n (%) 35 (10) 3 (6) 0.594 (0.18, 1.91) 0.383 
Family History of cardiac disease, n (%) 137 (38) 13 (26) 0.534 (0.28, 1.00) 0.051 
Past cardiac History (not HF/CAD), n (%) 18 (5) 6 (11) 1.903 (0.81, 4.49) 0.143 
Total # risk factors 3 (3-4) 4 (3-4) 1.466 (1.12, 1.91) 0.005 
Charlson comorbidity score 1.0 (0-2) 2.0 (1-4) 1.213 (1.11, 1.33) <0.001 
Beta blocker 21 (6) 4 (8) 1.911 (0.68, 5.34) 0.217 
ACEi/ARB 242 (67) 40 (78) 1.345 (0.69, 2.63) 0.385 
Diuretics 45 (14) 6 (13) 0.792 (0.33, 1.88) 0.596 
Calcium Ant 72 (23) 15 (33) 1.338 (0.72, 2.49) 0.358 
Lipid Lowering Meds 190 (59) 32 (69) 1.887 (1.00, 3.55) 0.049 
Antiplatelet 129 (40) 19 (41) 1.159 (0.64, 2.09) 0.623 
Functional Capacity     
6MW test distance 485 (427-535) 454 (387-493) 0.996 (0.99, 0.999) 0.006 
Functional Capacity (adjusted) 0.72 (0.63-0.82) 0.65 (0.59-0.75) 0.980 (0.96, 1.00) 0.061 
Echocardiographic continuous variables, median(IQR)   
LVEDV index (ml/m2) 44 (38-51) 46 (38-57) 1.013 (0.99, 1.04) 0.317 
LVESV index (ml/m2) 16 (13-19) 17 (14-23) 1.034 (0.98, 1.09) 0.185 
Relative Wall Thickness 0.47 (0.42-0.52) 0.47 (0.40-0.52) 2.448 (0.08, 79.4) 0.614 
LV mass index (g/m2) 81 (70-95) 90 (76-105) 1.028 (1.01, 1.04) <0.001 
LVEF (%) 64 (61-68) 63 (57-67) 0.972 (0.93, 1.02) 0.220 
GLS (%) 18.7 (17.1-20.4) 17.8 (15.7-19.3) 0.841 (0.76, 0.93) 0.001 
GLSR (1/s) 1.3 (1.2-1.5) 1.4 (1.2-1.5) 0.746 (0.17, 3.29) 0.699 
GCS (%) 28.9 (25.5-32.9) 29.1 (24.6-31.7) 0.991 (0.94, 1.05) 0.741 
GCSR (1/s) 2.5 (2.1-2.9) 2.5 (2.2-2.7) 1.228 (0.83, 1.82) 0.304 
Mitral E/A 0.77 (0.66-0.91) 0.75 (0.66-0.92) 0.609 (0.16, 2.39) 0.477 
DecT (ms) 244 (219-276) 258 (227-306) 1.002 (0.99, 1.01) 0.464 
e' (cm/s) (averaged) 7.6 (6.5-8.9) 7.1 (6.1-8.4) 0.885 (0.74, 1.06) 0.186 
E/e' (averaged) 8.4 (7.0-10.3) 8.9 (6.9-11.6) 1.099 (1.00, 1.21) 0.050 
Diastolic Strain (%) 0.42 (0.32-0.51) 0.42 (0.30-0.54) 0.871 (0.12, 6.16) 0.890 
Diastolic Strain rate (1/s) 0.94 (0.79-1.11) 0.89 (0.71-1.02) 0.581 (0.19, 1.75) 0.335 
Left atrial volume (ml/m2) 29 (24-35) 34 (26-40) 1.038 (1.01, 1.06) 0.003 
Echo categorical variables, n (%)     
LV Hypertrophy (yes) 45 (13) 10 (20) 1.017 (1.01, 1.03) 0.003 
Diastolic dysfunction >=grade I (yes) * 229 (64) 37 (73) 1.339 (0.72, 2.49) 0.356 
Diastolic dysfunction >=grade II 36 (10) 6 (12) 1.047 (0.45, 2.46) 0.916 
Abnormal E/e' (cutoff, 13) (yes) 39 (11) 12 (24) 2.236 (1.16, 4.29) 0.016 
Abnormal GLS (cutoff 18) (yes)  109 (30) 25 (49) 2.204 (1.27, 3.83) 0.005 
LA Enlargement (cutoff 34) (yes) 103 (29) 26 (51) 2.351 (1.35, 4.10) 0.003 
Presence of any SBHF features (yes)¥ 212 (59) 42 (82) 3.169 (1.54, 6.53) 0.002 
¶Event=primary composite end-point (new HF and death of cardiovascular causes); *Diastolic function grading according ASE recommendation; 
¥ the presence of at least one of the following: LVH, GLS<18, E/e'>13, LAE. Abbreviation: ACEi: angiotensin 
converting enzyme; ARB: angiotensin receptor blockers; DecT: mitral inflow deceleration time; EDV: end diastolic 
volume; ESV: end systolic volume; GLS: global longitudinal strain; GLSR: global longitudinal strain rate; GCS: 
global circumferential strain; GCSR: global circumferential strain rate; LV: left ventricle; LA: left atrium; LVEF: 
LV ejection fraction; 6MW: 6-minute walk test. 
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Of the entire cohort, 62% had ≥1 of any SBHF features. 41% had one, 15% had two, 5% had 
three and 1% had all four. The Hazard ratio of events was 3.17 (95% CI: 1.5-6.5, p=0.002) in 
those ≥1 of any SBHF features. Figure 9.52 illustrate the distribution of events according to 
 
 
 
Figure 9.52 Distribution of event among SBHF features  
Cases among patients with LVH, abnormal GLS, and LAE (top 1A) or abnormal E/e’ (bottom 1B). Most 
patients with events have abnormal strain. 
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features of SBHF. This level of risk increased in proportion to increasing number of SBHF 
features (Figure 9.53).  
 
Independent and incremental value of SBHF features to predict outcome. The independent 
and incremental predictive value of 4 SBHF markers for outcome was examined using both 
continuous and categorical measures using series of Cox regression models. Based on 
univariable analysis (Table 9.50), age, gender and Charlson comorbidity score were selected as 
the variables comprising the initial clinical model for subsequent analysis. In this model, age 
and Charlson score (but not male gender) were independent predictors. In subsequent models 
by adding each of the 4 SBHF markers (as continuous variables), LVMi, GLS and LAVi were 
predictive of outcome, independent of clinical evaluation. However, only LVMi and GLS (not 
LAVi and E/e’) were independent predictors when all measures were combined (Table 
appendix 9.53). Nested models were also used to assess the measures as categorical variables; 
LAE and impaired GLS (p<0.038) but not LVH and E/e’ (p>0.09) were independent and 
incremental to clinical parameters (Figure 9.54).  
 
 
Figure 9.53 Comparison of outcome vs SBHF features 
Comparison of outcomes between patients with one (left) or multiple markers of SBHF (right). There 
is increasing risk with increasing numbers of echocardiographic abnormalities. 
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Using receiver operating characteristic (ROC) analysis, the discriminatory ability of LVMi, 
LAVi, E/e’ and GLS without clinical variables showed AUC of LVMi, GLS and LAVi were 
superior to E/e’ (Figure appendix 9.57A). The discriminatory ability of clinical variables (age, 
gender, BMI and Charlson score) with addition of GLS (AUC: 0.72, p<0.01) exceeded that with 
LVMi, LAVi and E/e’ (Figure appendix 9.57B). Comparison of AUC showed borderline 
improvement with the addition of GLS to clinical model (p=0.05), but no improvement with 
the addition of LVMi, LAVi and E/e’ (p>0.14). The incremental value of each SBHF feature 
over clinical parameters was further examined as net reclassification improvement (NRI). GLS 
significantly reclassified individuals into a higher risk over clinical risks (NRI: 26%, p=0.002) 
(Table 9.51), while no NRI improvement was observed using LVMi, E/e’ and LAVi (p=0.08-
0.09) (Table appendix 9.54 to 9.56). 
 
 
Figure 9.54 Incremental value of SBHF vs clinical 
Incremental value of SBHF (categorical) over clinical parameters for composite outcome. LAE and GLS 
showed incremental value. 
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Table 9.50 Net Reclassification (Clinical characteristics +GLS)  
  (Clinical + GLS)   
Increased 
Risk 
Decreased 
Risk 
 Net correctly 
reclassified % 
(Clinical) 
Composite endpoints 
(n=51) 
Quartile 1 
(<6.29%) 
Quartile 2 (6.29-
9.55%) 
Quartile 3 (9.55-
15.8%) 
Quartile 4 
(≥15.8%) 
n n % 
Quartile 1 (<6.29%) 4 2 0 0 
12 3 17.6 
Quartile 2 (6.29-
9.55%) 
2 1 1 1 
Quartile 3 (9.55-
15.8%) 
0 0 7 8 
Quartile 4 (≥15.8%) 0 0 1 24 
     Reclassified  
          
Increased 
Risk 
Decreased 
Risk 
Net correctly 
reclassified %  
No event (n=359) 
Quartile 1 
(<6.29%) 
Quartile 2 (6.29-
9.55%) 
Quartile 3 (9.55-
15.8%) 
Quartile 4 
(≥15.8%) 
n n % 
Quartile 1 (<6.29%) 85 11 1 0 
51 82 8.64 
Quartile 2 (6.29-
9.55%) 
34 42 19 2 
Quartile 3 (9.55-
15.8%) 
4 24 42 18 
Quartile 4 (≥15.8%) 0 2 18 57 
 Net reclassification improvement (NRI)          26.24 
  p=0.002             
Clinical characteristics include: age, gender, body mass index, and Charlson comorbidity score. GLS: global longitudinal strain 
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In a decision tree based on the four SBHF markers, LAE was the strongest predictor followed 
by impaired GLS and abnormal E/e’, defining three risk groups – low, intermediate and high- 
risk. This model proposed that LAE should be evaluated first, with GLS applied to patients with 
normal LA size, and E/e’ to those with normal LA and GLS (Figure 9.55). 
9.5 Discussion 
The results of this study of SBHF, outcome events (mainly new HF) were associated with 
structural (LVH, LAE) as well as functional (GLS, E/e’) changes. Of the 4 common SBHF 
markers, the presence of any marker is associated with a 3-folder higher risk for events. GLS 
and LVMi were independent predictors, but only GLS was associated with significant 
incremental value.    
Definition of new HF. Heart failure is a clinical diagnosis. Patients in SBHF may minimize or 
deny their symptoms in the early phases, and clinical recognition can be difficult. The 
prevalence estimates may vary broadly depending on the diagnostic criteria. A recent meta-
analysis reported that incident HF diagnosis in 8 out of 15 included studies was based on a non-
standardized clinical description273. Differences in the diagnostic criteria for HF may have 
 
Figure 9.55 Echo screening for stage B heart failure and risk stratifications 
Chapter 9 – Best screening tools – role of echo predictors versus outcome 251 
 
impact on the outcome assessment in these studies. Among four commonly used HF diagnostic 
criteria (Framingham, Boston, Gothenburg, and European Society of Cardiology (ESC) criteria) 
312, there were significant differences in predicting clinically relevant outcomes including 
incident hospital admission. The absolute 3-year risk of hospital admission following a 
Framingham HF diagnosis was 6.1% (odds ratio 6.9, 95% CI 1.3-36.1, p=0.022) 312, and 
disturbances of cardiac structural and functional characteristics at baseline were best predicted 
using the Framingham HF criteria 312. Accordingly, we selected the Framingham HF criteria to 
adjudicate events in our study. It needs to be noted, although we excluded any known and 
possible HF at baseline, the annualized rate of incident HF was 11%. This may partially be 
explained by a higher proportion of stage C1 at baseline – it is known that Framingham criteria 
may not capture mild or early HF (stage C1) in individuals with atypical symptoms44, and the 
diagnosis of this subgroup may be helped by the addition of functional assessment and 
echocardiographic findings. Individuals in stage C1 had a significantly worse outcome than 
SBHF. A high incidence rate was observed in another community study of a cohort with 
combined diabetes and hypertension57, in whom E/e’ > 15 (detected in 23%) was used to 
categorized stage B HF. In our cohort, the prevalence of increased E/e’ was lower in entire 
cohort (12%) but was similar in those with both HTN and T2DM (20%).  
Markers of SBHF. The progression of HF is a continuum from hemodynamic disturbance to 
functional and structural remodeling that precede the onset of symptoms. The conventional non-
valvular markers of SBHF are reduced LVEF and LVH25, which have been found to be 
insensitive for early disease changes64; in this study, LVMi was unrelated to events (Figure 
9.52). Thus, not only structural markers but also systolic and diastolic dysfunction might be 
considered components of SBHF70. However, little is known about which marker(s) may 
symbolize the earliest changes of stage B heart failure. Ernande showed both diastolic and strain 
imaging are early markers58, and these measurements are often discordant. It is unclear whether 
these differences reflect different disease entities of SBHF; in our study, of the 51 individuals 
who had events, 21 had one of four markers; 9 had impaired GLS, 3 had abnormal E/e’, 9 had 
LAE, and none had LVH alone (Figure 9.52). Markers of SBHF result from underlying causes 
which often co-exist, including hypertension, diabetes286,329, obesity330 and aging331; different 
combinations may explain some differences in their structural responses. In our analysis, GLS 
was consistently associated with outcome, but the CART model supports consideration of 
simpler measures (LAE and GLS) as the primary steps for screening, with E/e’ adding most 
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when these parameters are normal. This has improved screening efficacy by capturing majority 
of those with events (82%) 86. 
In community screening, the balance between the prevalence of a disease and that of abnormal 
screening markers to be used are important determinants for screening efficacy. In a community 
screening study for SBHF, Mureddu used NT-proBNP and ECG screening comparing against 
echocardiogram as gold standard 332. NT-proBNP screening was only sensitive in detecting 
those with reduced LVEF (prevalence: 1.5%), which may partially explain authors’ conclusion 
about the inadequacy of this test in the community. The prevalence of LVEF≤50% in the local 
community trials was 5-6%49, compared to 16-19% for LVH53; 6-7% for increased E/e’189 and 
46% for LAE (≥32 ml/m2)327. The prevalence of impaired GLS in our study was 33% using a 
GLS cutoff of 18% and 17% with a GLS cutoff of 16%. In contrast to previous reported 
prevalence of 43% SBHF44, in our study group of >65 year old subjects with HF risk factors, 
62% had SBHF if any of the four markers was present, and this captured 42 out of 51 events 
(82%).  
Clinical implications. The identification of SBHF in non-ischemic individuals is difficult, 
because echocardiography is not currently indicated for routine management. Clearly, an echo 
screening strategy is most efficient if it is restricted to a high-risk population. A previous echo 
screening study by Mureddu et al included 19% with known CAD and 7.4% with known valve 
disease; our approach to these patients have been to exclude them from screening on the basis 
that their disease warrants therapy. In contrast to our work, follow-up for incident HF was not 
defined in this study. Our findings provide evidence to justify the use of echocardiography for 
the prediction of adverse outcomes. Using LAE and impaired GLS, markers reflecting the 
burden of diastolic dysfunction and early myocardial alteration, 31% were classified as high 
(>20%) and intermediate risk (10-20%). In those with normal LAVi and GLS, abnormal E/e’ 
further identified 10% of subjects who belonged to the intermediate risk group, which 
accounted for 46% of subjects otherwise deemed to be of low risk.  
Given the recognized adverse outcome of SBHF, further effort should be made not only to 
identify this problem but also to monitor and potentially stop disease progression by preventive 
treatment. Previous trials of SBHF management were largely based on ischemic etiology with 
reduced LVEF34, but effective management of non-ischemic SBHF awaits further evidence. 
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9.6 Study Limitations.  
The present analysis was based on a community-based clinical trial and has several limitations. 
First, a relatively high rate of incident HF in this cohort may suggest the presence of 
unrecognized HF at baseline. As previously reported, the possibility of high prevalence of stage 
C1 in this cohort may explain their rapid progress to new HF44. Second, the concomitant 
presence of coronary artery disease (CAD) was not investigated. Diabetic cardiomyopathy and 
hypertensive heart disease may co-exist with atherosclerosis, which may cause LV dysfunction 
due to CAD. We sought to exclude patients with a history consistent with CAD, but we cannot 
exclude an ischemic contribution to the reported cardiac functional changes. Third, inclusion 
of individuals with T2DM based on self-report rather than blood results (due to feasibility and 
cost constraints, and may thereby underestimate the true prevalence of this disease in the 
community. Fourth, the lack of protection of clinical outcome by treatment may indicate 
confounding by indication (i.e. the most at risk patients were treated in primary care, but were 
more likely to have events. Fifth, we used strain rather than tissue Doppler imaging systolic 
component (S’) for the detection of subclinical systolic dysfunction because of a desire to avoid 
systolic translational movement. However, it might be considered that tissue velocity is more 
widely available than speckle tracking. Last, recruitment from the community through self-
selection inherently carries a risk of population selection bias and a relative short follow-up 
period is an important limitation of the current study. 
9.7 Conclusion 
Echocardiographic assessment provides incremental value in predicting incident HF. Impaired 
GLS and LVMi were independent predictors; however, impaired GLS was a more sensitive 
marker with significant incremental value for prediction of HF. The presence of any SBHF 
feature is associated with more than 3-folder higher risk. 
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Postscript 
Findings from this chapter confirmed our hypothesis of GLS to be superior in its prognostic 
and incremental value over other echo markers. The uniqueness of this study was 1) a 
community elderly population with the mixture of multiple comorbidities. 2) GLS is compared 
side by side with other echo markers (LVMi, LAVi and E/e’) over clinical information in this 
population of non-ischemic etiology. 3) In this community population, a multiple marker for 
diagnoses of SBHF maybe more effective, and the presence of any abnormal echo is associated 
with a 3-folder higher risk of new heart failure. 
Although the detection of stage B heart failure is facilitated by GLS and diastology. Its value 
in improving outcome is predicated by treatment, which will be discussed in the next chapter. 
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Appendix Figures and tables  
 
 
Figure appendix 9.56 -Baseline SBHF features in patients with and without HF 
Comparison of baseline SBHF features in patients with and without HF. Incident HF was 
associated with significant differences in all markers other than E/e’.  
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Figure appendix 9.57 -ROC Analysis SBHF vs clinical information 
Receiver operating characteristic curves for events, discriminatory ability of each of GLS, 
LVMi, LAVi, E/e’ (A) and in combination (B) 
Clinical variable: age, gender, BMI, charlson;  
LVMi: left ventricular mass index; LAVi: left atrial volume index; GLS: global longitudinal strain. 
 
 
 
 
 
Table appendix 9.51 -Baseline characteristics of eligible participants 
  
Completed 
follow-up 
Unable to follow-
up 
 p  
(n=410) (n=18) value 
Age (year) 70 (67-74) 69 (67-70) 0.213 
Gender male, n (%) 197 (48) 7 (39) 0.446 
Body Mass Index (g/m2) 29 (26-32) 28 (27-34) 0.616 
T2DM, n (%) 228 (56) 8 (44) 0.351 
Obese, n (%) 186 (45) 7 (39) 0.589 
Hypertension, n (%) 335 (82) 13 (72) 0.312 
Previous Chemotherapy, n (%) 38 (9) 1 (6) 0.592 
Family history, n (%) 150 (37) 6 (33) 0.779 
Previous heart condition, n (%) 24 (6) 1 (6) 0.958 
Charlson comorbidity score 1.0 (0-2) 0.5 (0-1.5) 0.187 
LV Ejection fraction (%) 64 (60-68) 63 (61-67) 0.915 
GLS (%) 18.6 (16.9-20.3) 18.9 (15.1-19.7) 0.671 
Mitral E/A 0.77 (0.66-0.91) 0.79 (0.67-0.98) 0.459 
Mitral e' (cm/s) (averaged) 7.6 (6.4-8.7) 8.0 (7.1-9.2) 0.203 
E/e' (averaged) 8.5 (7.0-10.3) 8.3 (7.6-9.2) 0.880 
Left atrium volume (ml/m2) 29 (24-36) 27 (24-37) 0.622 
LV mass (g/m2) 81 (71-95) 73 (69-91) 0.452 
Abnormal E/e', cut-off 13, n (%) 51 (12) 2 (11) 0.867 
LV Hypertrophy, n (%) 55 (13) 2 (11) 0.778 
LA Enlargement, n (%) 129 (32) 5 (28) 0.736 
Abnormal GLS, cu-toff 18, n (%) 126 (31) 5 (28) 0.790 
Adjusted Functional capacity (%) 0.71 (0.62-0.81) 0.67 (0.56-0.79) 0.235 
GLS: global longitudinal strain; LA: left atrium; LV: left ventricle; T2DM: type 2 diabetes mellitus 
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Table appendix 9.52 -Nested sequential model 
Independent associations of SBHF features with new heart failure and Cox regression models (clinical, clinical + each and combined SBHF markers) 
  Model I (Clinical)   Model II (Clinical + LVMi)  Model III (Clinical +LAVi)  Model IV (Clinical +E/e') Model V (Clinical+ GLS) Model VI (all) 
Chi-square 27.69   39.95  34.43   30.75  31.91   44.38  
c statics 0.708   0.73  0.742   0.725  0.767   0.771  
AIC 492   482   489   452   490   480   
  HR (95%CI) p HR (95%CI) p HR (95%CI) p HR (95%CI) p HR (95%CI) p HR (95%CI) p 
Age 1.067 (1.01, 1.13) 0.019 1.054 (1.00, 1.11) 0.05 1.051 (0.99, 1.11) 0.071 1.056 (0.99, 1.12) 0.059 1.063 (1.01, 1.12) 0.029 1.036 (0.98, 1.09) 0.231 
Gender 1.574 (0.89, 2.76) 0.112 1.284 (0.73, 2.27) 0.391 1.499 (0.86, 2.62) 0.157 1.612 (0.92, 2.82) 0.095 1.296 (0.72, 2.33) 0.387 1.142 (0.63, 2.06) 0.659 
Charlson 1.210 (1.11, 1.33) <0.001 1.223 (1.11, 1.34) <0.001 1.213 (1.11, 1.33) <0.001 1.208 (1.10, 1.32) <0.001 1.191 (1.08, 1.31) <0.001 1.210 (1.10, 1.33) <0.001 
LVMi     1.027 (1.01, 1.04) <0.001           1.021 (1.00, 1.04) 0.019 
LAVi       1.033 (1.01, 1.06) 0.015       1.010 (0.98, 1.04) 0.533 
E/e'           1.084 (0.98, 1.19) 0.117     1.056 (0.96, 1.17) 0.289 
GLS                 0.884 (0.79, 0.99) 0.028 0.877 (0.78, 0.99) 0.027 
Clinical model: age, gender and Charlson comorbidity score 
AIC: Akaike information criterion; E/e’ mitral early diastolic peak velocity/mitral annular tissue velocity; GLS: global longitudinal strain; HR: hazard ratio; LAVi: left atrial volume 
index; LVMi: left ventricular mass index. 
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Table appendix 9.53 -Net Reclassification (Clinical characteristics +LVMi) 
  (Clinical + LVMi)   
Increased 
Risk 
Decreased 
Risk 
 Net correctly 
reclassified % 
(Clinical) 
Composite endpoints 
(n=51) 
Quartile 1 
(<5.38%) 
Quartile 2 (5.39-
9.49%) 
Quartile 3 (9.49-
16.01%) 
Quartile 4 
(≥16.01%) 
n n % 
Quartile 1 (<5.38%) 2 1 1 0 
8 6 3.92 
Quartile 2 (5.39-9.49%) 1 5 1 0 
Quartile 3 (9.49-
16.01%) 
0 4 6 5 
Quartile 4 (≥16.01%) 0 0 1 24 
     Reclassified  
          
Increased 
risk 
Decreased 
Risk 
Net correctly 
reclassified %  
No event (n=359) 
Quartile 1 
(<5.38%) 
Quartile 2 (5.39-
9.49%) 
Quartile 3 (9.49-
16.01%) 
Quartile 4 
(≥16.01%) 
n n % 
Quartile 1 (<5.38%) 60 12  0 
51 82 8.64 
Quartile 2 (5.39-9.49%) 40 59 21 3 
Quartile 3 (9.49-
16.01%) 
1 21 54 15 
Quartile 4 (≥16.01%) 0 1 19 55 
 Net reclassification improvement (NRI)          12.56 
  p=0.1141             
Clinical= age, gender, Charlson and BMI 
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Table appendix 9.54 -Net Reclassification (Clinical characteristics +LAVi) 
      Reclassified  
  
(Clinical + LAVi)   
Increased 
Risk 
Decreased 
Risk 
 Net correctly 
reclassified % 
(Clinical) 
Age, gender, 
BMI, 
Charlson 
Composite endpoints (n=54) 
Quartile 1 
(<7.39%) 
Quartile 2 (7.39-
11.04%) 
Quartile 3 (11.04-
17.04% 
Quartile 4 
(≥17.05%) n n % 
Quartile 1 (<7.39%) 3 2 1 0 
7 10 -5.56 
Quartile 2 (7.39-11.04%) 1 3 3 0 
Quartile 3 (11.04-17.04% 0 4 12 1 
Quartile 4 (≥17.05%) 0 0 5 19 
 
    Increased 
Risk 
Decreased 
Risk 
Net correctly 
reclassified %  
No event (n=365) 
Quartile 1 
(<7.39%) 
Quartile 2 (7.39-
11.04%) 
Quartile 3 (11.04-
17.04% 
Quartile 4 
(≥17.05%) n n % 
Quartile 1 (<7.39%) 87 12 0 0 
43 75 8.77 
Quartile 2 (7.39-11.04%) 28 53 12 3 
Quartile 3 (11.04-17.04% 0 19 54 16 
Quartile 4 (≥17.05%) 0 1 27 53 
NRI=0.0321       0.0321 
P=0.6951     
Clinical= age, gender, Charlson and BMI 
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Table appendix 9.55 -Net Reclassification (Clinical characteristics +E/e’) 
      Reclassified  
  
(Clinical + E/e’)   
Increased Risk 
Decreased 
Risk 
 Net correctly 
reclassified % 
(Clinical) Age, 
gender, BMI, 
Charlson 
Composite endpoints 
(n=54) 
Quartile 1 
(<7.39%) 
Quartile 2 (7.39-
11.04%) 
Quartile 3 (11.04-
17.04% 
Quartile 4 
(≥17.05%) n n % 
Quartile 1 (<7.39%) 6 0 0 0 
5 8 -5.56 
Quartile 2 (7.39-11.04%) 1 5 1 0 
Quartile 3 (11.04-17.04% 0 2 11 4 
Quartile 4 (≥17.05%) 0 0 5 19 
 
    
Increased Risk 
Decreased 
Risk 
Net correctly 
reclassified %  
No event (n=365) 
Quartile 1 
(<7.39%) 
Quartile 2 (7.39-
11.04%) 
Quartile 3 (11.04-
17.04% 
Quartile 4 
(≥17.05%) n n % 
Quartile 1 (<7.39%) 90 9 0 0 
26 51 6.85 
Quartile 2 (7.39-11.04%) 18 69 9 0 
Quartile 3 (11.04-17.04% 0 17 64 8 
Quartile 4 (≥17.05%) 0 0 16 65 
NRI=0.0129       0.0129 
P=0.86       
Clinical= age, gender, Charlson and BMI 
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Chapter 10. Intervention Responses to Screening  
Introduction 
The previous chapters focused on possible screening tools and the most effective screening 
strategy. However, it is unknown whether a screening program would be effective in reduction 
of heart failure even if the efficacy of screening for stage B heart failure was demonstrated75,77. 
One of the major challenges needed to justify an effective screening programs is “Do persons 
with positive screening comply with advice and interventions” 75. This chapter sought to 
evaluate the effectiveness of imaging guided care compared to usual care in improving outcome 
in TasELF study. 
The following text in this chapter has been published in JACC. Cardiovascular imaging 10(3): 
217-226. 
Abstract 
Background. The detection of non-ischemic stage B heart failure (SBHF) has been facilitated 
by advanced echocardiographic imaging modalities. However, improved outcomes have not 
been proven as they are predicated on benefit of treatment.  
Objectives. The purpose of the study was to evaluate the benefit of care guided by the detection 
of SBHF using advanced echocardiography for the reduction of new HF in the community. 
Method. Between 9/2013 and 11/2015, 618 asymptomatic community-based patients with HF 
risks (age 71±5 years) were randomized to care guided by advanced echocardiography (AE; 
myocardial deformation and detailed diastolic function) versus usual care (UC). Evidence of 
SBHF led to advice to the patient and their primary physician to initiate treatment with 
angiotensin converting enzyme inhibition and beta adrenoceptor blockade. The trial followed 
Prospective Randomized Open Blinded Endpoint design. Participants were followed for 1 year 
for the primary composite endpoint of death from cardiovascular causes and new HF. 
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Results. AE identified 219 as having SBHF and treatment was advised. Over a mean follow-
up of 13±6 months, 67 reached the primary end-point. The incidence rate of HF was no different 
between the two arms (p=0.47), likely because only 43% initiated therapy, and only 9% 
achieved target dose. Among subjects needing therapy on the basis of imaging and adherent to 
therapy, imaging guided care showed a 77% lower hazard for the primary outcome (p=0.04).  
Conclusion. The detection of SBHF from strain and diastolic function evaluation was 
associated with a higher incidence of incidence HF and death. The efficacy of pharmacological 
intervention with angiotensin converting enzyme inhibition and beta-adrenoceptor blockade is 
limited by its uptake, and alternative strategies should be considered. 
10.1 Background 
Stage B heart failure (SBHF), has been defined in the American College of 
Cardiology/American Heart Association (ACC/AHA) guidelines to include asymptomatic 
patients with abnormal left ventricular (LV) structure or function 25. Patients with SBHF are at 
higher risk for developing overt heart failure (HF)44. In contrast to Stage A HF (SAHF, i.e. HF 
risk factors) 333, where therapy is directed towards the control of cardiovascular (CV) risk 
factors, cardio-protective therapies are recommended in SBHF 25, on the basis of trials showing 
pharmacological interventions to delay and reduce the burden of HF in the SBHF population 
40,41. The difference between SAHF and SBHF is a problem, because although highly prevalent, 
non-ischemic SBHF requires an effective screening strategy for its recognition. While modern 
imaging techniques may be able to provide this strategy, their incorporation into routine care 
needs evidence that management will be altered.  
10.2 Aims and Hypothesis 
Accordingly, we developed a community-based screening program in elderly patients for 
detection of SBHF using echocardiography and subsequent cardio-protection. Our primary 
aims were: 1) to assess whether imaging guided cardio-protective therapy, when added to usual 
care, would reduce the rate of incident heart failure, 2) to assess the feasibility of coupling an 
effective community screening program with interventional treatment in high risk 
asymptomatic elderly individuals with SBHF. 
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10.3 Methods 
Study design. The Tasmanian Study of Echocardiographic Detection of LV Dysfunction 
(TasELF) is a community based screening and interventional program. The study followed a 
Prospective Randomized Open Blinded Endpoint (PROBE) design 186. Individuals were 
randomized to either undergo an imaging guided screening strategy for early detection and 
treatment of SBHF or to continue with usual care 334. The data were collected at various clinical 
sites within the State of Tasmania, Australia. 
Patient selection. Asymptomatic community-based patients (≥65 years old) with HF risks 
volunteered for enrolment through local community presentations and media advertising. 
Patients with stage A HF risk factors were eligible for inclusion25, including hypertension 
(HTN, based on blood pressure ≥140/90 mmHg and self-report of HTN including anti-
hypertensive medication); type 2 diabetes mellitus (T2DM, based on self-report of diagnosis 
including medical management); obesity (body mass index [BMI] >30); previous 
chemotherapy; family history of heart failure; previous history of heart disease (but not existing 
heart failure). We excluded subjects with: symptoms or a known history of HF; known coronary 
artery disease (CAD); more than moderate valvular heart disease; reduced left ventricular 
ejection fraction (LVEF) (<40%) on baseline echo; already taking both trial medication, beta-
blocker (BB) and angiotensin converting enzyme inhibitor (ACEi)/Angiotensin Receptor 
Blocker (ARB), at baseline and contraindication of BB and/or ACEi and ARB. We also 
excluded those in whom we were unable to acquire interpretable images from baseline 
echocardiography (inclusion and exclusion in Table appendix 10.59). 
End-point. The primary composite endpoints were incident HF and death from CV causes. 
Potential HF symptoms were assessed through regular follow-up phone calls, followed by 
symptom surveillance questionnaires and clinical visits. New onset HF was adjudicated by a 
blinded end-point committee using Framingham criteria at 1 year. Loss to follow-up was 
defined as not having replied for evaluation in ≥2 months. 
Sample size. Sample size was calculated based on the following: 1) an expected prevalence of 
abnormal cardiac function in ~50% using advanced echocardiographic imaging, 2) an expected 
7.5% annual rate of loss to follow-up, 3) a previously reported 12% annualized rate of incident 
heart failure among patients with evidence of SBHF under usual care 57, 4) assumption of a 
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50% reduction of events with intervention compared with usual care. A sample size of 400 in 
each randomized group would provide 80% power to document benefit of therapy at a two 
sided α=0.05.  
The trial was monitored by a Data and Safety Monitoring Board (DSMB) with termination 
guidelines for futility (if conditional probability of rejecting the null hypothesis was unlikely to 
achieve statistical significance) and feasibility (if recruitment or other aspects of its conduct 
were unable to fulfil requirements due to unforeseen circumstances. 
Randomization. Randomization was done using central web-based program with adaptive 
allocation stratified by diabetes status. The eligible participants were randomized to advance 
echocardiographic imaging (AE, involving measurement of global longitudinal strain and 
diastolic function), versus usual care (UC, continuing with their usual care treatment for 
primary risk factors such as hypertension and diabetes). The randomization list and intervention 
list were prepared by assigned persons who were blinded to details of the investigations. 
Patient report outcome measures (PROMs) and functional capacity. All participants 
enrolled in the study underwent a physical examination and standard PROMs questionnaires 
relating to health status (EuroQol 5 Dimensions Index, EQ5D), activity status (Duke Activity 
Score Index, DASI), symptom status (Minnesota Living with HF Questionnaire, MLHFQ), 
depression (Patient Health Questionnaire-9, PHQ9) and anxiety (generalized anxiety disorder 
questionnaire, GAD7). 
Functional capacity was assessed using a 6-minute walk test (6MW) distance following a 
standardized protocol 209.  
Echocardiographic study. Standard transthoracic 2D and Doppler echocardiographic studies 
were performed using standard equipment (Siemens ACUSON SC2000, Siemens Healthcare, 
Mountain View, CA) and transducer (4V1c, 1.25-4.5 MHz; 4Z1c, 1.5-3.5 MHz) in accordance 
with the American Society of Echocardiography (ASE) guidelines187. Diastolic function was 
assessed by measuring mitral inflow peak early diastolic velocity (E), peak late diastolic 
velocity (A), E/A ratio, E wave deceleration time (DecT)188,189,281. Echo left ventricular 
hypertrophy (LVH), left atrial enlargement (LAE) was assessed according to recommended 
cutoffs 187. Diastolic dysfunction (DD) grade was defined as previously described189,281. Grade 
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I: E/A <0.8, E/e’<10, pulmonary venous inflow S<D. Grade II: 0.8<E/A<1.5, E/e’ > 13 or LAE, 
or presence of mid diastolic forward flow (L wave), or positive Valsalva (> 50% increase of 
E/A ratio). Grade III: E/A> 1.5, DecT<140 ms. LV peak longitudinal strain measurements were 
obtained from gray scale-recorded images in the apical 4-chamber, 2-chamber and long-axis 
views. Strain was analysed using velocity vector imaging (Syngo VVI, Siemens Medical 
Solutions). GLS was measured on-line by averaging strain from the region of interest in three 
apical views. Impaired GLS was defined using cut-off of <18 % 85. All echocardiographic 
measurements were obtained on-line before participants left clinic. Echocardiographic 
definition of SBHF was: 1) Impaired GLS (<18%) and/or 2) ≥grade I diastolic dysfunction. 
Cardio-protective treatment for SBHF. The treatment protocol was a combination of ramipril 
(starting with 1.25 and up titrate to 10 mg/day) with the addition of Metoprolol (start 12.5 and 
up to 100 mg/day) (titration plan in Appendix T2). Cardioprotection was initiated by the 
patient’s general physicians (GP), under guidance by the investigators. The titration plan and 
guidance for monitoring was proposed to subjects with evidence of SBHF who required 
treatment in AE arm and their physicians. As some patients were already on one of the two 
agents (at submaximal dose) at recruitment, any pre-existing ACEi/ARB or BB, other than 
ramipril and Metoprolol, were up-titrated to the maximal tolerable dose (Table appendix 10.60). 
General guidance regarding risk reduction was shared with all subjects, and a report (including 
clinical and imaging information, according to randomization arms) was shared with all patients 
and their physicians.  
Medication adherence. The primary analysis involved comparison on an intention to treat 
basis, in the belief that this would provide direct evidence of the clinical effectiveness of 
screening for SBHF.  
Those who required treatment based on results of AE were notified of this at the screening visit 
and re-contacted within 4-6 weeks to reinforce the need to follow-up with their GP.  
A process evaluation was performed within a period of 3 months, to allow reasonable time for 
up titration. Adherence to protocol was defined on the basis of treatment initiation and dose 
maximization. 
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Statistical analysis. Data are presented as mean (± standard deviation [SD]) after testing for 
normal distribution (Shapiro-Wilk test). Data deviating from normality are expressed as median 
(inter-quartile range [IQR]). Categorical variables are expressed as percentages. All analyses 
were performed on an intention to treat basis. The comparability of baseline characteristics in 
the two arms was assessed by chi-square tests for categorical variables and the Mann-Whitney 
U test for continuous variables. Cox proportional hazard regression model with time-dependent 
covariates was used to assess the relative risk of primary outcome of individuals under usual 
care versus those under imaging guided care. Survival analysis was performed using the 
Kaplan-Meier method, and the differences in survival between groups were assessed by the log-
rank test. Statistical analyses were performed using a standard statistical software package 
(SPSS software 22.0, SPSS Inc., Chicago, IL). Statistical significance was defined by p<0.05.  
This report follows the recommendations of the 2010 Consolidated Standards of Reporting 
Trials Statement 335. This study was performed in accordance with a research protocol approved 
by the Tasmanian Human Research Ethics Committee (HREC), and registered with the 
Australian and New Zealand Clinical Trials Registry (http://www.anzctr.org.au/; 
ACTRN12614000080628). Individual written informed consent was obtained from participants 
after explanation of the nature and purpose, complexity and level of risk of the study.  
10.4 Results 
Patient selection and characteristics. Between September 2013 and November 2015, a total 
of 1026 self-referred community participants at or over the age of 65 years, and with non-
ischemic HF risk factors, volunteered in response to advertising through community 
organizations and local media. After clinical and echocardiographic screening for eligibility, 
618 (age: 71±5 years, 48% men) met inclusion criteria. The most common HF risk factors were 
hypertension (79%), diabetes mellitus (51%) and obesity (44%), 79% of individuals having ≥2 
of the listed risk factors. Of the total, 6.5% of participants were already taking BB and 67% 
were on ACEi or ARB treatment at baseline; none were taking both at baseline and none were 
at maximal doses. 
Of these 618 individuals who underwent randomization, 308 were assigned to the advanced 
echocardiography-guided care arm (AE). The remaining 310 were assigned to the usual care 
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(UC) arm (Figure 10.58). There were no differences in the demographic, clinical, socio-
economic features, nor were the patient reported symptoms and activity status between the two 
groups (Table 10.56). There were 23 patients who were in AF at baseline, 12 in AE arm and 11 in UC 
arm. Of the 12 in AE arm, all had abnormal GLS and treatment was required based on abnormal GLS. 
None of 11 AF of UC arm required treatment for abnormal EF. 
Screening results and pharmacological intervention. Comprehensive echocardiograms were 
performed in all subjects. Of the 308 individuals in AE arm, evidence of SBHF was found in 
219 (71%) defined by abnormal GLS or DD, with abnormal GLS present in 113 (37%) and 
diastolic dysfunction in 211 (69%); 83 individuals (27%) had both. Patients with abnormal 
function were older and had significantly higher Atherosclerosis Risk in Communities (ARIC) 
HF risk score and Charlson comorbidity score compared with the remaining AE patients 
(p<0.002). Treatment advice with titration plan were proposed to these 219 as well as their GP. 
There were 18 patients in the AE group who had a mid-range EF (40-53%), of whom 17 required 
treatment on the basis of abnormal GLS or DD. Of the 310 individuals in UC arm, no treatment 
was advised based on GLS and DD criteria. However, 5 individuals were started on treatment 
based on mild reduction of left ventricular ejection fraction (LVEF 40-53%); none had LVEF 
<40%. 
Side-effects. Side-effects were self-reported in a total of 31 individuals, but there was no 
reported syncope or other severe adverse effects. The most common side-effects were dry cough 
from Ramipril and bradycardia and lethargy from beta blocker. Side-effects led to 
discontinuation of the medication in 4% in the AE arm and none in the UC arm, with most 
continuing with minor adjustment of medication. Side-effects were also reported in individuals 
in usual care group. These are summarized in Table 10.58. 
Intention-to-treat analysis. At the last follow-up clinic (March 2016), 23 (11 from AE) 
participants were contactable but unable to attend the follow-up assessment. Contact was lost 
with 8 participants (1.3%) - 4 from the AE arm. At 13±6 months, a total of 22 (4%) participants 
(18 from the AE arm and 4 from the UC group) had withdrawn from the study because of 
reluctance to attend further follow-up, unwillingness to take additional medication, but in only 
3 due to side-effects. Therefore, follow-up for this outcome assessment was 91% complete (275 
vs 290/618) (Figure 10.58).  
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There were 5 deaths (2 of cardiovascular causes). New HF symptoms developed in 65 patients. 
The primary composite end-point of new HF and CV death occurred in 67 (11.8%) with an 
annualized incidence rate of 10.9%. The three deaths from non-CV causes were in both arms 
while the two CV deaths were both in the AE group. The incidence of the primary end point 
was 13% (37/275) in the AE arm and 10.3% (30/290) in the UC arm (p=0.25). There was no 
difference in event free survival using Kaplan-Meier analysis between two arms (Log rank Chi-
square=0.53, p=0.47) (Figure 10.58). 
Initiation and up-titration of medication. Medication initiation and up-titration was assessed 
using self-reporting questionnaires and telephone calls. Almost all patients - 307 of 308 in the 
AE arm and 309 of 310 from the UC arm - responded to our evaluation. Figure 10.60 
summarizes medication status in the entire cohort. An increment of medical therapy 
(determined by initiation or up-titration) was achieved in total of 146 individuals across both 
arms. In the AE arm, an adjustment of medication was achieved in 94 out of the 219 (43%) 
SBHF patients with abnormal imaging (Figure 10.60). Of these 219 subjects, 20 (9%) had 
achieved recommended target dose, and 64 had initiated one or both medications without dose 
increments because of concern about reduction of BP or other potential sources of intolerance. 
The cut-offs dose as target dose were: Ramipril 10 mg/day; Enalapril 20 mg/day, Perindopril 
10 mg/day. Irbesartan: 300 mg/day; Candesartan 32 mg/day; Valsartan 160 mg/day; 
Metoprolol: 100 mg/day. For other reasons (generally blood pressure control) an adjustment of 
medication was also achieved in 15% of the UC arm, and in 7 subjects in the AE arm without 
evidence of SBHF.  
The DSMB stopped the trial in November 2015, on the basis of poor therapeutic adherence 
(~40%) in both initiation and up-titration of medication. 
Protocol analysis. The potential clinical benefit of screening guided care was evaluated in Cox 
proportional hazard model and with the adjustment of number of subjects who required 
treatment. Given the fact that a low medication adherence (43%), the model was also adjusted 
for subjects who were actually adherent to treatment (Treatment up-titration). 
Echocardiographic imaging guided care was associated with 77% lower risk for primary 
outcome at one year, hazard ratio 0.23 (95% CI 0.06-0.98, p=0.047) (Table 10.58).  
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In the absence of treatment protection, individuals with abnormal GLS, diastolic dysfunction 
and the presence of both was associated with worse outcome (Figure 10.61). No treatment 
benefit were observed in subgroups with Abnormal GLS, DD and the presence of both (p>0.4). 
 
 
Figure 10.58 Consort diagram 
CONSORT chart describing patient allocation. Patients were randomized to imaging guided 
care, advanced echocardiography (AE) or usual care (UC), guidance was given based on the 
findings of echocardiography. 
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Table 10.56 Baseline characteristics 
Clinical, social economical and echocardiographic characteristics of two 
randomized groups - “usual care, UC” versus “advanced echocardiography, AE”.  
  
UC  
(n=310) 
AE  
(n=308) 
p 
value 
Demographic and clinical characteristics    
Age (year) 70 (67-74) 70 (67-74 0.22 
Age>75 year, n (%) 54 (17) 54 (18) 0.97 
Gender male, n (%) 140 (45) 152 (49) 0.29 
Body Mass Index (g/m2) 29 (26-32) 29 (26-33) 0.89 
Systolic blood pressure (mmHg) 140 (128 (150) 140 (129-149) 0.88 
Diastolic blood pressure (mmHg) 82 (75-89) 81 (75-88) 0.58 
Ever Smoking, n (%) 152 (49) 150 (49) 0.93 
ARIC score (%) 5.8 (3.7-10.7) 6.3 (3.4-11.9) 0.67 
T2DM, n (%) 158 (51) 155 (50) 0.87 
Obese, n (%) 139 (45) 135 (44) 0.8 
Hypertension, n (%) 243 (78) 243 (79) 0.88 
Previous Chemotherapy, n (%) 32 (10) 43 (14) 0.17 
Family history, n (%) 107 (35) 117 (38) 0.37 
Previous heart condition, n (%) 25 (8) 26 (8) 0.87 
Charlson score 1.0 (0-2) 1.0 (0-2) 0.52 
ACEi, n (%) 208 (67) 208 (68) 0.91 
Beta-blocker, n (%) 19 (6.1) 14 (4.5) 0.38 
Calcium Antagonists, n (%) 60 (21) 70 (25) 0.32 
Diuretics, n (%) 44 (15) 35 (12) 0.31 
Lipid lowing medication, n (%) 166 (58) 149 (52) 0.19 
Anti-platelets, n (%) 107 (37) 105 (37) 0.94 
6 minute walk distance (meters) 485 (432-546) 480 (410-530) 0.19 
Patient report outcome measures (PROMs)    
Duke activity score index (MET) 8.3 (7.3-8.9) 8.3 (7.0-8.9) 0.94 
General Health utility (EQ5D) 0.84 (0.74-1.0) 0.84 (0.77-1.0) 0.62 
General Health utility (EQVAS) 80 (70-90) 80 (70-90) 0.82 
Minnesota Living with HF score 1 (0-8.3) 1 (0-8.0) 0.62 
Depression status (PHQ9) 2 (0-4) 1 (0-3) 0.24 
Anxiety status (GAD7) 1 (0-3) 0 (0-2.8) 0.26 
Socio-economic determinants    
Social economical index for areas (ranking 1-10) 4 (2-6) 4 (2-6) 0.48 
Education level ≥ high school, n (%) 245 (83) 247 (82) 0.76 
Living alone, n (%) 90 (30) 107 (36) 0.12 
Private Health insured n (%) 216 (72) 211 (71) 0.79 
Total Number of medication pills /day 5 (3-8) 5 (3-8) 0.46 
Baseline echocardiographic characteristics    
Valve disease*, n (%) 11 (3.5) 13 (4.2) 0.67 
Left ventricular ejection fraction (%) 64 (60-68) 64 (60-68) 0.75 
GLS (%) 18.5 (16.7-20.3) 18.4 (16.8-20.1) 0.67 
E/e' (average) 8.4 (7.1-10.3) 8.4 (7.1-10.3) 0.66 
Abnormal GLS (18 cutoff), n (%) 103 (33) 113 (37) 0.37 
Diastolic dysfunction (≥ grade I), n (%) 206 (67) 211 (69) 0.58 
Diastolic dysfunction (≥ grade II), n (%) 43 (14) 41 (13) 0.92 
Left ventricular hypertrophy, n (%) 42 (14) 39 (13) 0.74 
Left atrial enlargement, n (%) 117 (38) 104 (34) 0.29 
Abnormal E/e', n (%) 39 (13) 34 (11) 0.55 
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Figure 10.60 Medication status at follow up 
In the AE arm, an increment of medication was achieved in 84 out of the 219 (43%) SBHF 
patients with abnormal imaging (shown in red). In addition, 7 subjects in the AE arm 
(labelled in blue) had cardioprotective medications started for control of hypertension, 
without evidence of SBHF. An increment of medication was also achieved in 14% of the 
UC arm, 
 
 
 
 
 
Figure 10.59 Kaplan-Meier analysis of event free survival 
between two arms 
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Figure 10.61 Kaplan-Meier analysis of outcome between GLS vs DD 
Table 10.57 Clinical effect of screening for primary outcome 
 
 Crude   Adjusted**   
No. of endpoints/ 
total assessed* 
(%) 
HR (95% CI) 
 p 
value 
HR (95% CI) 
 p 
value 
New HF and CV death       
      
Advanced Imaging (AE) versus 37/275 (13%) 
1.22 (0.75, 1.97) 0.43 0.23 (0.05, 0.95) 0.04 
Usual care (UC) 30/290 (10%) 
      
SBHF identified by imaging 
versus 
35/219 (16%) 
1.99 (1.23, 3.23) 0.01 7.01 (1.65, 29.9) 0.01 
SBHF not identified or 
unknown 
32/346 (9%) 
      
Treatment up-titration (+) 
versus 
24/143 (17%) 
1.51 (0.91, 2.49) 0.11 1.09 (0.64, 1.86) 0.75 
Up-titration (-) 43/422 (10%) 
* A total of 565 out of 618 were assessed for primary outcome at 1 year follow up  
**Adjusted for (in the model as binary variables): randomization status + SBHF by imaging + Treatment up-titration   
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10.5 Discussion 
The results of this study show that among individuals in the community ≥65 years old, with 
mainly multiple HF risk factors, evidence of SBHF was identified in 71% with the use of 
advanced echocardiography, and these showed an annualized event-rate of 10.9%. Despite the 
prognostic information from imaging, the trial emphasizes the difficulties in providing cardio-
protection in asymptomatic elderly individuals at risk of HF. Pharmacological intervention was 
unsuccessful in intention to treat analysis, although there may have been potential benefits from 
imaging-guided care in adherent patients.  
Definition of new HF. Heart failure is a clinical diagnosis, and patients may minimize or deny 
their symptoms in the early phases, making clinical recognition difficult. Prevalence estimates 
may vary broadly depending on the diagnostic criteria; a recent meta-analysis reported that 
incident HF diagnosis in 8 of 15 included studies was based on a non-standardized clinical 
description 273.  
Differences in the diagnostic criteria for HF may also impact the outcome assessment in these 
studies. Among four commonly used HF diagnostic criteria (Framingham, Boston, Gothenburg, 
and European Society of Cardiology (ESC) criteria) 312, there were significant differences in 
predicting clinically relevant outcomes including incident hospital admission. As disturbances 
Table 10.58 Medication side effects and alterations 
 
  
AE 
arm 
UC 
arm 
total 
ACEi/ARB    
no change in dose 7 2 9 
reduce dose 0 0 0 
ceased but stay on trial 2 0 2 
ceased and wish to withdraw 1 0 1 
    
Beta blocker    
no change in dose 8 1 9 
reduce dose 2 2 4 
ceased but stay on trial 2 1 3 
ceased and wish to withdraw 3 0 3 
total  25  6 31 
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of cardiac structural and functional characteristics at baseline were best predicted using the 
Framingham HF criteria 312, we selected the Framingham HF criteria to adjudicate events in 
our study. However, although the absolute 3-year risk of hospital admission following a 
Framingham HF diagnosis was 6.1% (odds ratio 6.9, 95% CI 1.3-36.1, p=0.022) 312, the 
annualized rate of incident HF in our study was 10.3%. This likely reflects the high clinical risk 
of these subjects, most of whom had multiple HF risk factors. In addition, although we excluded 
symptomatic HF at entry, Framingham criteria may not capture mild or early HF (stage C1) in 
individuals with atypical symptoms44. Moreover, a high rate of incident HF was observed in a 
similar community study of a cohort with combined diabetes and hypertension 57, in whom 
E/e’ > 15 (detected in 23%) was used to categorized stage B HF. In our cohort, the prevalence 
of increased E/e’ was similar in those with both HTN and T2DM (20%).  
Diagnosis and management of SBHF. Imaging screening for SBHF is based on the concept 
that this stage is a precursor of overt clinical HF, and has been advocated in practice guidelines 
336 because SBHF is associated with a 5-fold greater risk of symptomatic HF 82. Imaging by 
echocardiography is generally believed to be a safe and accurate for the diagnosis SBHF. 
Although EF as the only functional feature in the conventional criteria for SBHF 152, both strain 
and diastolic dysfunction are associated with adverse outcome and impaired functional capacity 
70.  
Of course, the accuracy and prognostic value of diagnostic tests have no direct effect on patient 
outcomes unless indirectly by influencing the therapeutic pathway. The evidence to date for 
pharmacological therapy in SBHF is largely based on EF. This supports ACEi as the foundation 
of management of SBHF 34, with the improvements in all-cause mortality, recurrent 
cardiovascular events and progression to HF 37,88. In the Heart Outcomes Prevention Evaluation 
study (HOPE) 42, ACEi also significantly reduced the rate of death, myocardial infarction, and 
stroke, and reduction of HF admission and death was reported after treatment in a similar 
population with SAHF 337. Evidence also supports the use of beta blockers in asymptomatic 
patients 34. In the Survival and Ventricular Enlargement (SAVE) and Studies of Left Ventricular 
Dysfunction (SOLVD) trials, concomitant use of beta blocker therapy was associated with 
reductions in cardiovascular death and heart failure 37,88.  
In this study, we sought to gather evidence on the benefit of early detection of SBHF using new 
functional markers to guide management. We assessed this by randomizing subjects to either 
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screening strategy or usual care and comparing their outcomes, using an “intention to treat” 
approach 334. This design allows assessment of the benefit of early detection, as well as 
recognition of potential risks associated with diagnostic procedures, including false positives 
resulting in over treatment. In addition, our intention was also to determine whether an 
intervention works among a community screening population. Unfortunately, the negative 
results of the current study were attributable to lack of effectiveness 338 in medication delivery 
following imaging screening. Side-effects were uncommon, and the main causes were 
reluctance of patients and physicians to initiate and up-titrate therapy in the presence of a 
normal EF and the absence of symptoms.  
10.6 Study Limitation 
This study has several limitations. The follow-up time was only one year. The method adopted 
for assessment of medication use was self-report rather than pill counts and rate of prescription 
refills. However, there is no optimal means of achieving this 339, and self–report is simple and 
feasible in the context of community screening and has been strongly associated with adverse 
cardiac events 340.  
We excluded patients with EF <40% because previous clinical trials showed a benefit from 
therapy (30). The study did not incorporate the analysis of HF with mid-range EF, a category 
that has been recently proposed in the guidelines (31), and only one patient was in this category 
in the absence of abnormal GLS. 
AF was not excluded in the initial design, because the optimal management of this important 
subgroup in non-ischemic stage B HF is unclear. However, the numbers of patients with AF 
was small, and they were equally distributed among the groups. Of the 12 in AE arm, all had 
abnormal GLS and treatment was required based on abnormal GLS. None of the 11 AF patients 
in the UC arm required treatment for abnormal EF. 
10.7 Conclusion 
The application of advanced echocardiographic markers is feasible in the community diagnosis 
of SBHF, and predicts incident HF. Despite their risk levels, the adherence to intervention in 
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this asymptomatic group with a normal EF was poor. Subsequent attempts with this study 
design might include a disease management program to ensure adherence with therapy. 
 
Clinical Perspectives: 
Competency in Medical Knowledge. Patients of >65 years old with heart failure risk factors have a 
high prevalence of stage B heart failure, evidenced by LV hypertrophy, LV diastolic or systolic 
dysfunction. These patients are at risk of early development of clinical heart failure. 
Competency in Patient Care. The appropriate therapeutic response to the detection of stage B heart 
failure is undefined. This study showed no benefit from screening for stage B heart failure, but uptake 
of cardioprotective therapy and dose titration were both inadequate. 
Translational Outlook. A strategy to identify stage B heart failure seems unlikely to alter the 
progression to heart failure in the absence of an integrated disease management program. 
 
Postscript 
In the TasELF study, we proved that non-ischemic stage B heart failure is highly prevalent in 
the community. We also proved that an effective screening strategy in the community is 
feasible. However, we have not proven the benefit of imaging surveillance using advanced 
imaging tools. Poor compliance of patient to medication is the direct cause of premature 
cessation of this trial. The introduction of cardio-protection in asymptomatic individuals has 
potential system-, patient- and provider-level barriers. Previous studies have shown that about 
half of all patients prescribed antihypertensive medication stopped taking them within a year350. 
The non-adherence rate in HF patients is reported as 21% for ACEi, 35% for beta-blockers, 
44% for spironolactone and 17% for statins351. The preparedness to initiate treatment is a barrier 
at provider-level. This includes perceived patient attitude, concerns over patient age, gender, 
comorbidity and clinical uncertainty352. These “soft” reasons to avoid management 
intensification are the main components of clinical inertia. At system level, problems in 
adherence may be ameliorated by increasing the involvement of the specialist in supporting 
primary care givers (e.g. disease management programs). The program can involve case 
managers and patient care teams353, emphasis of evidence-based guidelines in flow sheets to 
monitor therapy, and improving the measurement of medication adherence354.  
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Appendix Figures and tables 
 
Table appendix 10.59 -Inclusion and Exclusion 
Inclusion criteria  
- Age: at least 65 years of age (≥ 65 years) 
- The presence of at least one of the following 1) Hypertension, based on 
SBP>140 mmHg and self-report of HTN including anti-hypertensive 
medication; 2) type 2 diabetes mellitus, based on self-report of diagnosis 
including medication; 3) obesity, based on body mass index (BMI) ≥ 30 g/m2; 
4) previous potentially cardio-toxic chemotherapy; 5) familial 
cardiomyopathy; 6) previous history of heart disease (but not existing heart 
failure).  
Exclusion Criteria 
- Unable to provide written informed consent to participate in this study 
- History of previous heart failure, baseline NYHA >2 
- History of coronary artery disease (previous myocardial infarction, 
myocardial revascularization, Coronary stents, positive stress test. Or 
echocardiographic screening of LVEF<40%. (These are either known 
coronary artery disease or underlying coronary artery disease) 
- Known history of more than moderate valvular heart disease  
- Systolic BP <110mmHg, pulse <60/minute 
- Serious life-threatening disease (anticipated life expectancy <2 years) 
- Pre-existing treatment with both investigational drug (ACEi/ARB and Beta 
blocker) classes or one class at maximum dose 
- Contraindications/Intolerance of either beta blockers or ACEi/ARB,  
- Participating in any other clinical research trial 
- Inability to acquire interpretable images (identified from baseline echo) 
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Table appendix 10.60 -medication titration schedule 
Weeks from start 0 2 4 6 8 10 12 14 16 
Ramipril (mg/d)* 1.25 2.5 5 5 5 5 5 5 10 
Metoprolol (mg/d) ٭٭   12.5 25 37.5 50 75 100  
*If patient is already on an ACEi or ARB, there no need to change, however, please up-titrate to the 
maximal tolerable dose. 
** If patient is already on another B-Blocker, there is no need to change, please up-titrate to the 
maximal tolerable dose. 
 
During treatment, patients need to be seen every 2 weeks during the up titration phase. At each of 
these visits, symptoms status (fatigue, dizziness), blood pressure and heart rate need to be obtained. 
If patients complain of side-effects or the heart rate is <50 beats per minute, the dose should be reduced 
to the prior to the last increment. 
Discontinuation criteria: symptoms consistent with cardiac dysfunction (dyspnea, reduced exercise 
capacity), side effects of therapy (fatigue), progression of cardiac dysfunction (EF<50%, dyspnea, 
reduced exercise capacity) 
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Chapter 11. Summary future direction and conclusion 
11.1 Summary of background 
Heart failure is a major burden to the health care system and the community due to the cost of 
care and poor quality of life. The prevention of heart failure might be possible with early 
identification and early intervention to reduce the disease burden. 
Stage B heart failure is the precursor stage of clinical heart failure. However, causes of stage B 
heart failure are heterogeneous as are the underlying pathophysiological changes. Previous 
clinical trials have provided us evidence in the ischemic population using pharmacological 
intervention. However, the majority of the Stage B heart failure in the community is now of 
non-ischemic aetiology.  
Asymptomatic stage B heart individuals in the community could be detected with an effective 
screening strategy based on modern imaging modalities. However, a screening program in the 
community is not only about the identification of the disease, but also about provision of a 
management service, including medical treatment and monitoring of these with positive test 
results. Medication adherence poses additional challenge for good communication to convey 
the prognostic impact of abnormal cardiac function in these seemly health individuals. 
11.2 Summary of results 
Speckle tracking imaging is a reliable imaging modality in the community. Being semi-
automated and highly feasible for point of care assessment. Multiple echo markers provide 
incremental prognostic value over clinical information. Global longitudinal strain was a 
superior predictor of outcome to left ventricular mass, left atrial volume and mitral E/e’. 
Second, in this elderly cohort at risk of heart failure, stage B heart failure was highly prevalent. 
The prevalence of any abnormal echocardiographic marker was 60-70%. The presence of this 
stage B is associated with 3-fold higher risk of new heart failure at one year follow-up. 
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Third, the screening for SBHF using echocardiography can be facilitated by an effective pre-
screening strategy. Among those with the presence of stage A heart failure risk factors, 
calculation of risk can be obtained from clinical information and a 6-minute walk test at 
baseline. About 20% would be classified as high risk and echocardiography is indicated, and 
40% will be classified as low risk and usual care would be advised. In the significant 
intermediate risk group of 40%, evaluation might involve ECG, but if resources allowed, 
echocardiogram may be beneficial, as half of the new heart failure came from this group.  
Fourth, at one year follow-up, the incident rate of new heart failure was high, 104 per 1000-
person year. Effective intervention in these community dwelling individuals is important.  
Fifth, despite a high incident rate of new heart failure at one year, pharmacological intervention 
was not being successful in this trial. By process evaluation, only 9% of that requiring treatment 
had reached target dose, 34% initiated their therapy according to titration plan.  Adherence was 
only 43% if based on the initiation or optimization of the titration plan. 
Sixth, a semi quantitative process evaluation by questionnaire and telephone showed subjective 
unwillingness from both the participants and their physician seemed to be the main barrier to 
medication adherence. 22% of the entire cohort experienced some degree of financial pressures 
in paying their medical bills and this percentage was higher (34%) in non-adherents. Difficulties 
in obtaining medication were recorded in 7.5% overall, and 22% (p=0.008) in non-adherents. 
Non-adherence was not associated with age, gender, clinical characteristics and their societal 
economic factors in this cohort. 
Last, subclinical cardiac dysfunction is also present in otherwise healthy but overweight and 
obese young adults. While cardiac structural changes are associated with their childhood weight 
status, cardiac dysfunction was mostly associated with their current weight status and the 
magnitude of weight gain from childhood. Future studies may explore the duration and 
magnitude of weight change with events as well as the association of their subclinical cardiac 
dysfunction with future events. 
 
11.3 Strengths and Limitations 
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To our knowledge, this is the first study in the literature; on community screening and cardio-
protection for non-ischemic stage B heart failure. It is also the first intervention study using 
advanced imaging (strain imaging and comprehensive diastology) modality in the community.  
The main limitations of this trial have been discussed in each relevant chapter and as follows:  
1). Recruitment through self-selection inherently carries a risk of population selection bias. 
2). Short follow-up time. This is an on-going study; more results will be provided. 
3). A relatively high event rate at one year, suggesting possible unrecognized symptoms at 
baseline by participants as they are non-specific and not meeting heart failure definition.   
4). Non-ischemic status was based on self-report of history, but a stress test was not performed 
due to the feasibility in the community, we cannot exclude an ischemic contribution to the 
cardiac changes. 
5). The lack of protection of clinical outcome by treatment may indicate confounding by 
indication (most at risk patients were treated in primary care, but were more likely to have 
events. 
6). Medication history and adherence were mainly self-reported as compared to pill counts and 
assessment of prescription refills. 
7). We did not obtain biomarkers, although recent evidence in the literature showed 
controversial results on its performance. 
8). Lack of intensive monitoring of the participants under treatment and intensive 
communication with their primary physician to reinforce adherence with specialist support. A 
preventive strategy may be successful with the implication of a disease management program 
(DMP). 
9). Finally, the study samples in chapter 6, 7, 8, 9 and 10 were from TasELF population, there 
are some discrepancies in study samples in each chapter. One reason is that not all studies were 
conducted at same time the period of recruitment. Another important reason is the hypothesis 
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in each chapter varies.  Figure 11.62 is a general flow chart explaining the difference in patient 
selection in each chapter of this thesis. 
 
Figure 11.62 General flow chart of sample selection in chapter 6,7,8,9, and 10. 
. 
11.4 Future directions 
First, although echocardiographic markers including advanced imaging markers are powerful 
predictors of clinical outcome, their value in improving clinical outcome is predicated on 
treatment change. This has not been proven. Ensuring treatment adherence will be an important 
step to determine whether imaging guided treatment is efficacious and beneficial. To improve 
treatment adherence, effort may be made at the following levels: 1) At participant level, to 
provide a more individualized risk assessment including the absolute as well as relative risk 
with or without treatment. 2) At provider level, to provide a disease management program to 
facilitate management of elderly individuals with multiple comorbidities, medication 
intolerance and side effects. 
Second, once prove an efficacious treatment, the cost-effective analysis of a community 
screening and early intervention program versus long term reduction of new heart failure 
incidence and reduction of heart failure hospitalization and management are important next 
steps. 
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Third, evidence on treatment and disease regression has been reported using echocardiographic 
markers, including reduction of left ventricular mass341, left atrial volume342 and improved 
global longitudinal strain72. These are important intermediate endpoints although these trials 
were performed in highly selected population with specific phenotype. These intermediate 
endpoints can be further assessed in this cohort and their association with heart failure and other 
cardio and non-vascular outcomes. 
11.5 Conclusion 
Diagnosis of SBHF need advanced imaging markers. Although advanced imaging markers are 
powerful predictors of clinical outcome in SBHF, the value of these markers in improving 
clinical outcome has not been proven, because it is predicated on treatment change. This is the 
critical first step - ensuring treatment adherence is important to determine that treatment is 
efficacious and beneficial. Once we prove an efficacious treatment, its cost to provide 
improvements in the short term and long term outcome need cost-effectiveness analysis. 
The best strategy could be to use pre-screening using clinical information and feasible 
functional assessment to select high-risk individuals for echocardiography. Once abnormal 
cardiac function is detected, these individuals will be guided for treatment. 
The whole screening process may be best accomplished in a disease management program, 
including trained nurses, sonographers, general physicians and specialist cardiologists to ensure 
treatment adherence, safety and screening effectiveness. 
Heart failure prevention is important in the community. We have proved that an effective 
screening strategy in the community is feasible. We have also shown the high prevalence of 
stage B heart failure in the community. However, the benefit of imaging surveillance using 
GLS on therapy has not been proven. 
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